{"1eb183f9e1afa9f0bdfd7768e1d684f8944cdde3": [["Neutron star mergersThe neutron star merger GW170817 marked the begin ning of multi messenger astronomy because it was the first gravitational wave event with a recorded electro magnetic counterpart 1 .", [["GW170817", "CHEMICAL", 44, 52]]], ["As the neutron stars merged, they released a short flash of gamma rays, followed by electro magnetic radiation from different processes including the radioactive radiation emitted in the formation of heavy elements -a fireworks show known as a kilonova.", [["heavy elements", "DNA", 200, 214], ["a short flash of gamma rays", "PROBLEM", 43, 70], ["electro magnetic radiation", "TREATMENT", 84, 110], ["the radioactive radiation", "TREATMENT", 146, 171], ["radioactive radiation emitted", "OBSERVATION", 150, 179], ["heavy elements", "OBSERVATION", 200, 214]]], ["Less than 2 s after the merger was detected by LIGO and Virgo, the Fermi Gamma ray Burst Monitor independently detected the gamma ray burst.", [["the Fermi Gamma ray Burst Monitor", "TEST", 63, 96]]], ["Telescopes around the world started looking for the electro magnetic radiation and neutrinos, with more than 50 teams of astronomers mobilized for the task.", [["Telescopes", "TREATMENT", 0, 10], ["the electro magnetic radiation", "TREATMENT", 48, 78]]], ["\"It was majestic science, but also a very intense experience, \" says Mansi Kasliwal, principal investigator of GROWTH (Global Relay of Observatories Watching Transients Happen), an international collabo ration studying fast changing events (transients) such as supernovae, neutron stars or black hole mergers using a network of telescopes around the world.", [["an international collabo ration", "TREATMENT", 178, 209], ["black hole mergers", "TREATMENT", 290, 308]]], ["The amount of data recorded kept scientists busy for months with the full analysis.", [["the full analysis", "TEST", 65, 82], ["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["But already by October 2017 more than 30 papers had been published in various journals includ ing varied results such as a new measurement of the Hubble constant 2 and the confirmation that heavy ele ments are created in such neutron star mergers through the rapid neutron capture process 3 .Neutron star mergersA different beast GW190425 was different and surprising.", [["GW190425", "CHEMICAL", 330, 338], ["GW190425", "CHEMICAL", 330, 338], ["heavy ele ments", "PROBLEM", 190, 205], ["the rapid neutron capture process", "TREATMENT", 255, 288], ["neutron capture", "OBSERVATION", 265, 280]]], ["The combined mass of this binary sys tem (about 3.4 solar masses) is much larger than was expected from the known galactic neutron star bina ries 4 .", [["The combined mass of this binary sys tem", "PROBLEM", 0, 40], ["3.4 solar masses", "PROBLEM", 48, 64], ["combined", "OBSERVATION_MODIFIER", 4, 12], ["mass", "OBSERVATION", 13, 17], ["3.4 solar", "OBSERVATION_MODIFIER", 48, 57], ["masses", "OBSERVATION", 58, 64], ["much", "OBSERVATION_MODIFIER", 69, 73], ["larger", "OBSERVATION_MODIFIER", 74, 80], ["galactic neutron", "OBSERVATION", 114, 130]]], ["Interestingly, the event was detected only by the Livingston interferometer, because the Hanford detector was temporarily offline at the time and the Virgo data had a low signal to noise ratio.", [["the Virgo data", "TEST", 146, 160], ["a low signal to noise ratio", "PROBLEM", 165, 192]]], ["GW190425 left astronomers reassessing the existing theories of how neutron star pairs are formed.", [["GW190425", "CHEMICAL", 0, 8], ["left", "ANATOMY_MODIFIER", 9, 13], ["astronomers", "OBSERVATION", 14, 25]]], ["More data and new simulations are needed to solve the puzzle of the unexpectedly high mass of the merger.Public alertsIn general, in the first and second operating runs no infor mation about gravitational wave events was made available to the wider scientific community before the full analysis had been completed.", [["gravitational wave events", "PROBLEM", 191, 216], ["the full analysis", "TEST", 277, 294], ["high", "OBSERVATION_MODIFIER", 81, 85], ["mass", "OBSERVATION", 86, 90]]], ["However, some alerts were sent to astronomers when events were detected with a high con fidence level.", [["a high con fidence level", "PROBLEM", 77, 101]]], ["In O3, things changed completely with the debut of the new public alert system.", [["O3", "CHEMICAL", 3, 5], ["O3", "CHEMICAL", 3, 5], ["O3", "SIMPLE_CHEMICAL", 3, 5]]], ["This automated sys tem sends an alert within minutes of the detection of a grav itational wave event.", [["This automated sys tem", "TEST", 0, 22], ["the detection", "TEST", 56, 69], ["a grav itational wave event", "PROBLEM", 73, 100]]], ["Not all alerts survive closer scrutiny and some are retracted.", [["retracted", "OBSERVATION", 52, 61]]], ["However, the public alerts allow astronomers to respond swiftly with multi messenger hunts for an electromagnetic counterpart.Public alertsThe public alerts are exciting for astronomers and the general public alike, with smart phone apps developed to enable on the go access to the latest information about gravitational wave detections.", [["gravitational wave detections", "TEST", 307, 336]]], ["\"It is great that many pupils and students, and members of the general publicIulia GeorgescuAs the third LIGO-Virgo operating run (O3) finishes earlier than planned owing to the COVID-19 pandemic, we look at the ups and down of the past 12 months.Iulia Georgescuwww.nature.com/natrevphys have downloaded the app, \" says Alberto Vecchio, direc tor of the Institute for Gravitational Wave Astronomy at the University of Birmingham, UK, whose students developed the app called Chirp.", [["Gravitational Wave Astronomy", "TREATMENT", 368, 396], ["great", "OBSERVATION_MODIFIER", 7, 12]]], ["But at the same time he stresses that the public alerts \"only provide a very limi ted amount of information, essentially the key infor mation that allows astronomers to point telescopes at the right region of the sky at the right time. \"", [["right", "ANATOMY_MODIFIER", 193, 198], ["region", "ANATOMY_MODIFIER", 199, 205], ["right", "ANATOMY_MODIFIER", 224, 229]]], ["To confirm the nature of an event and characterize it, a full ana lysis is required and that can take months of rigorous examination of the data.An exciting possibilityOne candidate event in the O3 caught everyone's eyes: the merger detected on 14 August 2019, named in the public alert system as S190814bv (the GW naming is given only after the full analysis has been completed).", [["eyes", "ANATOMY", 216, 220], ["O3", "CHEMICAL", 195, 197], ["O3", "SIMPLE_CHEMICAL", 195, 197], ["eyes", "ORGAN", 216, 220], ["a full ana lysis", "TREATMENT", 55, 71], ["rigorous examination of the data", "TEST", 112, 144], ["the full analysis", "TEST", 342, 359], ["possibility", "UNCERTAINTY", 157, 168]]], ["This event is possibly a neutron star-black hole merger, although that has yet to be confirmed.", [["possibly", "UNCERTAINTY", 14, 22]]], ["Although there have been other hints, such an event would be a first to be detected, and could have an associated electro magnetic counterpart.", [["an associated electro magnetic counterpart", "PROBLEM", 100, 142]]], ["\"We found a tantalizing counterpart called DG19wxnjc which photo metrically showed all the hallmark signatures of a kilo nova, \" says Kasliwal.", [["DG19wxnjc", "DNA", 43, 52]]], ["What's next At the time of writing, the future is uncertain and not only for gravitational wave astronomy.", [["gravitational wave astronomy", "PROBLEM", 77, 105]]], ["The implications of the COVID19 pandemic have yet to be grasped, but they likely mean a delay for the upgrades planned to start by 2021.", [["the COVID19 pandemic", "TREATMENT", 20, 40]]], ["For the next operating run, O4, scheduled for late 2021 or early 2022, the plan was to use these upgrades to increase the sensitivity of the LIGO inter ferometers by as much as 60% for Hanford and 40% for Livingston.Ups and downsAt the moment, KAGRA has just restarted after a brief commissioning break to improve its sensitivity.", [["O4", "CHEMICAL", 28, 30], ["O4", "SIMPLE_CHEMICAL", 28, 30], ["these upgrades", "TREATMENT", 91, 105], ["Livingston", "TREATMENT", 205, 215], ["KAGRA", "TREATMENT", 244, 249]]], ["GEO600 might also continue observations.", [["GEO600", "CHEMICAL", 0, 6], ["GEO600", "SIMPLE_CHEMICAL", 0, 6]]], ["After all detectors stop, data analysis will continue for months: interesting, and perhaps unexpected, results are in store.", [["data analysis", "TEST", 26, 39]]]], "PMC7430102": [["IntroductionIn January 2020, a new coronavirus was found in Wuhan, Hubei, China.", [["coronavirus", "DISEASE", 35, 46], ["coronavirus", "ORGANISM", 35, 46], ["a new coronavirus", "PROBLEM", 29, 46]]], ["The coronavirus research group of the International Committee for the Classification of viruses named it severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1 The World Health Organization calls the pneumonia caused by the coronavirus COVID-19.2 Due to the characteristics of human-to-human transmission, COVID-19 has become popular all over the world and caused tens of thousands of deaths.", [["acute respiratory syndrome coronavirus", "DISEASE", 112, 150], ["pneumonia", "DISEASE", 208, 217], ["COVID-19", "CHEMICAL", 314, 322], ["deaths", "DISEASE", 393, 399], ["coronavirus", "ORGANISM", 232, 243], ["human", "ORGANISM", 285, 290], ["human", "ORGANISM", 294, 299], ["COVID-19", "CELL", 314, 322], ["coronavirus", "SPECIES", 232, 243], ["human", "SPECIES", 285, 290], ["human", "SPECIES", 294, 299], ["severe acute respiratory syndrome coronavirus", "SPECIES", 105, 150], ["SARS-CoV-2", "SPECIES", 154, 164], ["human", "SPECIES", 285, 290], ["human", "SPECIES", 294, 299], ["viruses", "PROBLEM", 88, 95], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 105, 150], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162], ["the pneumonia", "PROBLEM", 204, 217], ["the coronavirus COVID", "TEST", 228, 249], ["viruses", "OBSERVATION", 88, 95], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["respiratory syndrome", "OBSERVATION", 118, 138], ["pneumonia", "OBSERVATION", 208, 217]]], ["Now it is a public health emergency of international concern over the global outbreak of novel coronavirus.3 At present, the National Health Commission of China has published the corresponding guidelines for diagnosis, treatment, prevention, and control of COVID-19.4,5 It is mentioned that medical institutions should set up isolation wards.", [["coronavirus", "DISEASE", 95, 106], ["COVID", "DISEASE", 257, 262], ["coronavirus", "ORGANISM", 95, 106], ["novel coronavirus", "PROBLEM", 89, 106], ["treatment", "TREATMENT", 219, 228], ["prevention", "TREATMENT", 230, 240], ["COVID", "TEST", 257, 262]]], ["The suspected or confirmed patients of COVID-19 were placed in the isolation ward first, and then pathogen or serological examination was performed.", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["COVID", "TEST", 39, 44], ["serological examination", "TEST", 110, 133]]], ["If evidence of COVID-19 infection is found, the patient will be transferred to a targeted treatment unit to continue treatment.", [["infection", "DISEASE", 24, 33], ["COVID-19", "GENE_OR_GENE_PRODUCT", 15, 23], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["COVID-19 infection", "PROBLEM", 15, 33], ["treatment", "TREATMENT", 117, 126], ["infection", "OBSERVATION", 24, 33]]], ["At present, COVID-19 mainly infects adults, especially some elderly men.6,7 There are relatively few cases of infection in children.", [["infection", "DISEASE", 110, 119], ["adults", "ORGANISM", 36, 42], ["children", "ORGANISM", 123, 131], ["children", "SPECIES", 123, 131], ["COVID", "TEST", 12, 17], ["infection", "PROBLEM", 110, 119], ["relatively", "OBSERVATION_MODIFIER", 86, 96], ["few", "OBSERVATION_MODIFIER", 97, 100], ["infection", "OBSERVATION", 110, 119]]], ["In this study, the clinical characteristics of children in isolation ward during the COIVID-19 epidemic were analyzed retrospectively, to provide basis for isolation and timely diagnosis of diseases in children.", [["children", "ORGANISM", 47, 55], ["children", "ORGANISM", 202, 210], ["children", "SPECIES", 47, 55], ["children", "SPECIES", 202, 210], ["this study", "TEST", 3, 13], ["the COIVID", "TEST", 81, 91], ["isolation", "TREATMENT", 156, 165], ["diseases", "PROBLEM", 190, 198], ["diseases", "OBSERVATION", 190, 198]]], ["It is conducive to the scientific investigation of COVID-19 and provides an effective basis for COVID-19 prevention and control methods.MethodBecause of the nature of this retrospective study, the Medical Ethics Committee of Hubei Maternal and Child Health Hospital approved the research plan and waived patient consent.", [["COVID-19", "CHEMICAL", 51, 59], ["COVID-19", "CELL", 51, 59], ["patient", "ORGANISM", 304, 311], ["patient", "SPECIES", 304, 311], ["COVID", "TEST", 51, 56], ["COVID-19 prevention", "TREATMENT", 96, 115], ["control methods", "TREATMENT", 120, 135], ["this retrospective study", "TEST", 167, 191]]], ["The children in the pediatric isolation ward of our hospital from January 1, 2020, to February 29, 2020, were selected as the object of study.", [["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12]]], ["The basic data, epidemic history, symptoms, blood analysis, liver function, myocardial enzyme spectrum, chest computed tomography (CT) results, electrocardiogram (ECG) results, SARS-CoV-2 nucleic acid test results, hospitalization days, and hospitalization expenses of all the children in the isolation ward were collected.MethodData processing was done by SPSS 25 statistical software.", [["blood", "ANATOMY", 44, 49], ["liver", "ANATOMY", 60, 65], ["myocardial", "ANATOMY", 76, 86], ["nucleic acid", "CHEMICAL", 188, 200], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["liver", "ORGAN", 60, 65], ["myocardial", "MULTI-TISSUE_STRUCTURE", 76, 86], ["children", "ORGANISM", 277, 285], ["children", "SPECIES", 277, 285], ["The basic data", "TEST", 0, 14], ["symptoms", "PROBLEM", 34, 42], ["blood analysis", "TEST", 44, 58], ["liver function", "TEST", 60, 74], ["myocardial enzyme spectrum", "TEST", 76, 102], ["chest computed tomography", "TEST", 104, 129], ["CT)", "TEST", 131, 134], ["electrocardiogram", "TEST", 144, 161], ["ECG", "TEST", 163, 166], ["SARS", "TEST", 177, 181], ["CoV", "TEST", 182, 185], ["nucleic acid test", "TEST", 188, 205], ["MethodData processing", "TEST", 323, 344], ["liver", "ANATOMY", 60, 65], ["chest", "ANATOMY", 104, 109]]], ["The counting data are described statistically by n (%).", [["The counting data", "TEST", 0, 17]]], ["The measurement data of nonnormal distribution are described statistically by median and quartile [M(P25, P75)].ResultFrom January 1, 2020, to February 29, 2020, we collected data of 66 cases in the isolation ward.", [["The measurement data", "TEST", 0, 20]]], ["There were 37 males (56.1%) and 29 females (43.9%), and the male-to-female ratio was 1.28:1.", [["female", "ORGANISM", 68, 74], ["females", "TEST", 35, 42]]], ["There were 35 children without definite exposure history (53%).", [["children", "ORGANISM", 14, 22], ["children", "SPECIES", 14, 22]]], ["There were 17 children (25.8%) with suspected COVID-19 at home, and the children were in close contact with them.", [["children", "ORGANISM", 14, 22], ["children", "ORGANISM", 72, 80], ["children", "SPECIES", 14, 22], ["children", "SPECIES", 72, 80]]], ["Only 14 patients (21.2%) had close contact with the confirmed COVID-19 patients.", [["COVID", "DISEASE", 62, 67], ["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 71, 79]]], ["All the children in the isolation ward had different symptoms before admission.", [["children", "ORGANISM", 8, 16], ["children", "SPECIES", 8, 16], ["different symptoms", "PROBLEM", 43, 61]]], ["Among them, 55 cases (83.3%) had fever, 48 cases had cough (72.7%), 21 cases had stuffy nose (31.8%), and 24 cases had runny nose (36.4%; see Table 1).ResultThe age of the children ranged from 1 month to 13 years, with an average of 4.3 years.", [["nose", "ANATOMY", 88, 92], ["fever", "DISEASE", 33, 38], ["cough", "DISEASE", 53, 58], ["runny nose", "DISEASE", 119, 129], ["nose", "ORGAN", 88, 92], ["children", "ORGANISM", 172, 180], ["children", "SPECIES", 172, 180], ["fever", "PROBLEM", 33, 38], ["cough", "PROBLEM", 53, 58], ["stuffy nose", "TEST", 81, 92], ["runny nose", "PROBLEM", 119, 129]]], ["The number of children of school age was the largest, with 18 cases (27.3%).", [["children", "ORGANISM", 14, 22], ["children", "SPECIES", 14, 22], ["largest", "OBSERVATION_MODIFIER", 45, 52]]], ["There were 17 cases (25.8%) of infancy.", [["infancy", "PROBLEM", 31, 38]]], ["There were 14 cases of early childhood (21.2%), 11 cases of preschool age (16.6%), and 6 cases of puberty (9.1%; see Table 2).ResultIn the course of collecting case data, we found that not all children had data of the pathogen.", [["puberty", "DISEASE", 98, 105], ["children", "ORGANISM", 193, 201], ["children", "SPECIES", 193, 201], ["puberty", "TEST", 98, 105], ["collecting case data", "TEST", 149, 169], ["the pathogen", "PROBLEM", 214, 226]]], ["Among them, the largest number of children were infected with Mycoplasma pneumoniae, 17 cases (25.8%), followed by SARS-CoV-2 infection, 14 cases (21.2%).", [["Mycoplasma pneumoniae", "DISEASE", 62, 83], ["SARS-CoV-2 infection", "DISEASE", 115, 135], ["children", "ORGANISM", 34, 42], ["Mycoplasma pneumoniae", "ORGANISM", 62, 83], ["SARS-CoV-2", "ORGANISM", 115, 125], ["children", "SPECIES", 34, 42], ["Mycoplasma pneumoniae", "SPECIES", 62, 83], ["CoV-2", "SPECIES", 120, 125], ["Mycoplasma pneumoniae", "SPECIES", 62, 83], ["SARS-CoV-2", "SPECIES", 115, 125], ["Mycoplasma pneumoniae", "PROBLEM", 62, 83], ["SARS", "TEST", 115, 119], ["CoV", "TEST", 120, 123], ["2 infection", "PROBLEM", 124, 135], ["largest", "OBSERVATION_MODIFIER", 16, 23], ["Mycoplasma pneumoniae", "OBSERVATION", 62, 83]]], ["There were 6 children with respiratory syncytial virus (9.1%).", [["respiratory syncytial virus", "DISEASE", 27, 54], ["children", "ORGANISM", 13, 21], ["respiratory syncytial virus", "ORGANISM", 27, 54], ["children", "SPECIES", 13, 21], ["respiratory syncytial virus", "SPECIES", 27, 54], ["respiratory syncytial virus", "PROBLEM", 27, 54]]], ["Only 2 cases (3%) were infected with Epstein-Barr virus (see Table 3).ResultFrom the laboratory test data, we found that white blood cells level was normal in 44 cases (66.7%), increased in 15 cases (22.7%), and decreased in 7 cases (10.6%).", [["white blood cells", "ANATOMY", 121, 138], ["Epstein-Barr virus", "DISEASE", 37, 55], ["Epstein-Barr virus", "ORGANISM", 37, 55], ["white blood cells", "CELL", 121, 138], ["white blood cells", "CELL_TYPE", 121, 138], ["Epstein-Barr virus", "SPECIES", 37, 55], ["Epstein-Barr virus", "TREATMENT", 37, 55], ["the laboratory test data", "TEST", 81, 105], ["white blood cells level", "TEST", 121, 144], ["decreased", "OBSERVATION_MODIFIER", 212, 221]]], ["The number of lymphocytes (LYM) was normal in 21 cases (31.8%), increased in 19 cases (28.8%), and decreased in 26 cases (39.4%).", [["lymphocytes", "ANATOMY", 14, 25], ["LYM", "ANATOMY", 27, 30], ["lymphocytes", "CELL", 14, 25], ["LYM", "CANCER", 27, 30], ["lymphocytes", "CELL_TYPE", 14, 25], ["LYM", "CELL_TYPE", 27, 30], ["lymphocytes", "OBSERVATION", 14, 25], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["decreased", "OBSERVATION_MODIFIER", 99, 108]]], ["C-reactive protein level was increased in 23 cases (34.8%).", [["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["C-reactive protein", "PROTEIN", 0, 18], ["C-reactive protein level", "TEST", 0, 24], ["reactive protein", "OBSERVATION", 2, 18]]], ["In the liver function of children, alanine aminotransferase was increased in 11 cases (16.7%) and aspartate aminotransferase was increased in 25 cases (37.9%).", [["liver", "ANATOMY", 7, 12], ["alanine", "CHEMICAL", 35, 42], ["aspartate", "CHEMICAL", 98, 107], ["alanine", "CHEMICAL", 35, 42], ["aspartate", "CHEMICAL", 98, 107], ["liver", "ORGAN", 7, 12], ["children", "ORGANISM", 25, 33], ["alanine", "AMINO_ACID", 35, 42], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 43, 59], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 98, 124], ["aspartate aminotransferase", "PROTEIN", 98, 124], ["children", "SPECIES", 25, 33], ["alanine aminotransferase", "TEST", 35, 59], ["aspartate aminotransferase", "TEST", 98, 124], ["liver", "ANATOMY", 7, 12]]], ["In the myocardial enzymes, lactate dehydrogenase was increased in 37 cases (56.1%), CK-MB was increased in 36 cases (54.5%), and creatine kinase was increased in only 7 cases (10.6%).", [["myocardial", "ANATOMY", 7, 17], ["lactate", "CHEMICAL", 27, 34], ["creatine", "CHEMICAL", 129, 137], ["lactate", "CHEMICAL", 27, 34], ["creatine", "CHEMICAL", 129, 137], ["myocardial", "MULTI-TISSUE_STRUCTURE", 7, 17], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 27, 48], ["CK-MB", "GENE_OR_GENE_PRODUCT", 84, 89], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 129, 144], ["myocardial enzymes", "PROTEIN", 7, 25], ["lactate dehydrogenase", "PROTEIN", 27, 48], ["creatine kinase", "PROTEIN", 129, 144], ["the myocardial enzymes", "TEST", 3, 25], ["lactate dehydrogenase", "TEST", 27, 48], ["CK-MB", "TEST", 84, 89], ["creatine kinase", "TEST", 129, 144], ["myocardial", "ANATOMY", 7, 17]]], ["All the children in the isolation ward had tests for the detection of SARS-CoV-2 nucleic acid, and 14 of them were positive (21.2%; see Table 4).ResultAll the children in the isolation ward had had chest CT at the time of admission.", [["chest", "ANATOMY", 198, 203], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 70, 93], ["children", "ORGANISM", 8, 16], ["children", "ORGANISM", 159, 167], ["children", "SPECIES", 8, 16], ["children", "SPECIES", 159, 167], ["SARS-CoV", "SPECIES", 70, 78], ["tests", "TEST", 43, 48], ["the detection", "TEST", 53, 66], ["SARS", "TEST", 70, 74], ["CoV", "TEST", 75, 78], ["nucleic acid", "TEST", 81, 93], ["chest CT", "TEST", 198, 206], ["chest", "ANATOMY", 198, 203]]], ["Among them, there were 8 cases without obvious abnormality (12.1%), 28 cases (42.4%) had speckled or patchy shadow, 6 cases (9.1%) had strip shadow, and 19 cases (28.8%) had ground glass opacity (GGO).", [["GGO", "DISEASE", 196, 199], ["obvious abnormality", "PROBLEM", 39, 58], ["cases", "TEST", 71, 76], ["speckled or patchy shadow", "PROBLEM", 89, 114], ["cases", "TEST", 118, 123], ["strip shadow", "TEST", 135, 147], ["cases", "TEST", 156, 161], ["ground glass opacity", "PROBLEM", 174, 194], ["patchy", "OBSERVATION_MODIFIER", 101, 107], ["shadow", "OBSERVATION_MODIFIER", 108, 114], ["ground glass opacity", "OBSERVATION", 174, 194]]], ["A total of 4 cases (6.1%) were found to have atelectasis, and only 1 case (1.5%) had pleural effusion (see Table 5).ResultThrough the study of the ECG of the children, it was found that 27 cases showed sinus rhythm (40.9%) and 28 cases showed sinus tachycardia (42.4%), but we found that 11 cases showed sinus arrhythmia (16.7%; see Table 6).ResultBased on the statistical analysis of the hospitalization days of all the children in the isolation ward, it was found that the median and quartile of hospitalization days were 8 (7, 10) days, and the hospitalization cost was CNY 9269.32 (8168.2, 11204.33).DiscussionCoronavirus is a RNA virus that exists in nature.", [["pleural", "ANATOMY", 85, 92], ["sinus", "ANATOMY", 243, 248], ["sinus", "ANATOMY", 304, 309], ["atelectasis", "DISEASE", 45, 56], ["pleural effusion", "DISEASE", 85, 101], ["sinus rhythm", "DISEASE", 202, 214], ["sinus tachycardia", "DISEASE", 243, 260], ["sinus arrhythmia", "DISEASE", 304, 320], ["pleural", "ORGAN", 85, 92], ["children", "ORGANISM", 158, 166], ["children", "ORGANISM", 421, 429], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 614, 625], ["children", "SPECIES", 158, 166], ["children", "SPECIES", 421, 429], ["atelectasis", "PROBLEM", 45, 56], ["pleural effusion", "PROBLEM", 85, 101], ["the study", "TEST", 130, 139], ["the ECG", "TEST", 143, 150], ["sinus rhythm", "TEST", 202, 214], ["sinus tachycardia", "PROBLEM", 243, 260], ["sinus arrhythmia", "PROBLEM", 304, 320], ["CNY", "TEST", 573, 576], ["Coronavirus", "PROBLEM", 614, 625], ["a RNA virus", "PROBLEM", 629, 640], ["atelectasis", "OBSERVATION", 45, 56], ["pleural", "ANATOMY", 85, 92], ["effusion", "OBSERVATION", 93, 101], ["sinus tachycardia", "ANATOMY", 243, 260], ["sinus", "ANATOMY", 304, 309], ["arrhythmia", "OBSERVATION", 310, 320]]], ["It can be divided into 4 subtypes: \u03b1, \u03b2, \u03b3, and \u03b4.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 35, 36], ["\u03b2", "GENE_OR_GENE_PRODUCT", 38, 39], ["\u03b3", "GENE_OR_GENE_PRODUCT", 41, 42], ["\u03b1, \u03b2, \u03b3, and \u03b4.", "CELL_LINE", 35, 50]]], ["SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), which can cause serious respiratory diseases, belong to type \u03b2 coronavirus.8 The genome sequence of SARS-CoV-2 was matched with that of type \u03b2 coronavirus, but it was different from that of SARS-CoV and MERS-CoV.", [["respiratory", "ANATOMY", 94, 105], ["SARS", "DISEASE", 0, 4], ["Middle East respiratory syndrome coronavirus", "DISEASE", 13, 57], ["respiratory diseases", "DISEASE", 94, 114], ["type \u03b2 coronavirus", "DISEASE", 126, 144], ["SARS", "DISEASE", 260, 264], ["SARS-CoV", "ORGANISM", 0, 8], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 13, 57], ["MERS-CoV", "ORGANISM", 59, 67], ["type \u03b2 coronavirus", "ORGANISM", 126, 144], ["SARS-CoV-2", "ORGANISM", 170, 180], ["type \u03b2 coronavirus", "ORGANISM", 206, 224], ["SARS-CoV", "ORGANISM", 260, 268], ["MERS-CoV", "ORGANISM", 273, 281], ["SARS-CoV", "SPECIES", 0, 8], ["Middle East respiratory syndrome coronavirus", "SPECIES", 13, 57], ["MERS-CoV", "SPECIES", 59, 67], ["type \u03b2 coronavirus", "SPECIES", 126, 144], ["SARS-CoV-2", "SPECIES", 170, 180], ["type \u03b2 coronavirus", "SPECIES", 206, 224], ["SARS-CoV", "SPECIES", 260, 268], ["MERS-CoV", "SPECIES", 273, 281], ["SARS", "PROBLEM", 0, 4], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 13, 57], ["serious respiratory diseases", "PROBLEM", 86, 114], ["type \u03b2 coronavirus", "PROBLEM", 126, 144], ["SARS", "PROBLEM", 170, 174], ["type \u03b2 coronavirus", "PROBLEM", 206, 224], ["CoV", "OBSERVATION_MODIFIER", 5, 8], ["Middle", "ANATOMY_MODIFIER", 13, 19], ["respiratory syndrome", "OBSERVATION", 25, 45], ["serious", "OBSERVATION_MODIFIER", 86, 93], ["respiratory diseases", "OBSERVATION", 94, 114]]], ["At present, some of the physical and chemical properties of SARS-CoV-2 refer to the studies of SARS-CoV and MERS-CoV.DiscussionAt present, our diagnosis of COVID-19 is mainly based on the Diagnosis and Treatment of New Coronavirus Pneumonia (Trial Version 7) issued by the National Health Committee of the People\u2019s Republic of China.4 It is mentioned that the diagnosis of suspected cases requires any one of the epidemiological history and conforms to any 2 of the clinical manifestations.", [["SARS", "DISEASE", 60, 64], ["SARS", "DISEASE", 95, 99], ["Pneumonia", "DISEASE", 231, 240], ["SARS-CoV", "ORGANISM", 95, 103], ["MERS-CoV", "ORGANISM", 108, 116], ["SARS-CoV", "SPECIES", 95, 103], ["MERS-CoV", "SPECIES", 108, 116], ["the studies", "TEST", 80, 91], ["COVID", "TEST", 156, 161], ["Treatment", "TREATMENT", 202, 211], ["New Coronavirus Pneumonia", "PROBLEM", 215, 240], ["the clinical manifestations", "PROBLEM", 462, 489], ["New", "OBSERVATION_MODIFIER", 215, 218], ["Coronavirus", "OBSERVATION_MODIFIER", 219, 230], ["Pneumonia", "OBSERVATION", 231, 240]]], ["If there is no clear history of epidemiology, it is necessary to comply with 3 of the clinical manifestations.", [["the clinical manifestations", "PROBLEM", 82, 109], ["no", "UNCERTAINTY", 12, 14]]], ["Due to the age limitation, infections in most of the children are spread by family gatherings, and some of them have no obvious exposure history, which may lead to misdiagnosis or missed diagnosis, and finally bring difficulties to epidemic prevention and control.DiscussionBecause COVID-19 is highly infectious, in order to screen suspected cases of COVID-19 and prevent the spread of the epidemic, the inpatient department has set up an isolation ward, which aims to make Infectious Diseases get early detection, early diagnosis, early isolation, and early treatment.", [["infections", "DISEASE", 27, 37], ["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["infections", "PROBLEM", 27, 37], ["epidemic prevention", "TREATMENT", 232, 251], ["COVID", "TEST", 282, 287], ["COVID", "TEST", 351, 356], ["early isolation", "TREATMENT", 532, 547], ["early treatment", "TREATMENT", 553, 568], ["infections", "OBSERVATION", 27, 37], ["infectious", "OBSERVATION", 301, 311]]], ["Some patients with potential COVID-19 infection were further screened in the isolation ward in order to provide new clinical basis for the prevention and control of COVID-19 in the future.DiscussionIn this study, by summarizing the clinical characteristics of children in the isolation ward, it was found that the male-to-female ratio was 1.28:1 in the isolation ward, and the percentage of male was higher than that of female.", [["infection", "DISEASE", 38, 47], ["COVID-19", "CHEMICAL", 165, 173], ["COVID-19", "CHEMICAL", 165, 173], ["patients", "ORGANISM", 5, 13], ["COVID-19", "ORGANISM", 29, 37], ["children", "ORGANISM", 260, 268], ["female", "ORGANISM", 322, 328], ["patients", "SPECIES", 5, 13], ["children", "SPECIES", 260, 268], ["potential COVID-19 infection", "PROBLEM", 19, 47], ["COVID", "TEST", 165, 170], ["this study", "TEST", 201, 211], ["infection", "OBSERVATION", 38, 47]]], ["However, there is no sufficient evidence to prove that male children are more susceptible, which needs to be confirmed by further epidemiological investigation.", [["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["further epidemiological investigation", "TEST", 122, 159], ["no sufficient evidence to prove", "UNCERTAINTY", 18, 49]]], ["There are 31 cases of children who had a history of exposure (47%), but only 14 cases (21.2%) were in close contact with COVID-19 patients.", [["children", "ORGANISM", 22, 30], ["patients", "ORGANISM", 130, 138], ["children", "SPECIES", 22, 30], ["patients", "SPECIES", 130, 138]]], ["However, we also found that some children with COVID-19 had no clear history of exposure.", [["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["COVID", "TEST", 47, 52]]], ["It is suggested that COVID-19 cannot be excluded completely in children without definite epidemic history, and it may be judged comprehensively by combining other symptoms or examination results.", [["children", "ORGANISM", 63, 71], ["children", "SPECIES", 63, 71], ["combining other symptoms", "PROBLEM", 147, 171], ["examination results", "TEST", 175, 194]]], ["Most of the symptoms in the isolation ward were fever and cough, and some children had stuffy nose and runny nose.9 But these symptoms have no obvious specificity compared with other pneumonia.", [["nose", "ANATOMY", 94, 98], ["fever", "DISEASE", 48, 53], ["cough", "DISEASE", 58, 63], ["pneumonia", "DISEASE", 183, 192], ["children", "ORGANISM", 74, 82], ["nose", "ORGANISM_SUBDIVISION", 94, 98], ["nose", "ORGANISM_SUBDIVISION", 109, 113], ["children", "SPECIES", 74, 82], ["the symptoms", "PROBLEM", 8, 20], ["fever", "PROBLEM", 48, 53], ["cough", "PROBLEM", 58, 63], ["stuffy nose", "PROBLEM", 87, 98], ["runny nose", "PROBLEM", 103, 113], ["these symptoms", "PROBLEM", 120, 134], ["other pneumonia", "PROBLEM", 177, 192], ["runny nose", "OBSERVATION", 103, 113], ["pneumonia", "OBSERVATION", 183, 192]]], ["At present, some of COVID-19 are asymptomatic infection,10,11 which suggests that it is not only from the clinical symptoms to judge whether the children should be admitted to the isolation ward.", [["infection", "DISEASE", 46, 55], ["children", "ORGANISM", 145, 153], ["children", "SPECIES", 145, 153], ["COVID", "TEST", 20, 25], ["asymptomatic infection", "PROBLEM", 33, 55], ["the clinical symptoms", "PROBLEM", 102, 123], ["asymptomatic", "OBSERVATION_MODIFIER", 33, 45], ["infection", "OBSERVATION", 46, 55]]], ["We found that the children in the isolation ward had not only SARS-CoV-2 infection but also Mycoplasma pneumoniae and respiratory syncytial virus infection.", [["infection", "DISEASE", 73, 82], ["Mycoplasma pneumoniae", "DISEASE", 92, 113], ["respiratory syncytial virus infection", "DISEASE", 118, 155], ["children", "ORGANISM", 18, 26], ["SARS-CoV-2", "ORGANISM", 62, 72], ["Mycoplasma pneumoniae", "ORGANISM", 92, 113], ["respiratory syncytial virus", "ORGANISM", 118, 145], ["children", "SPECIES", 18, 26], ["Mycoplasma pneumoniae", "SPECIES", 92, 113], ["respiratory syncytial virus", "SPECIES", 118, 145], ["SARS-CoV-2", "SPECIES", 62, 72], ["Mycoplasma pneumoniae", "SPECIES", 92, 113], ["respiratory syncytial virus", "SPECIES", 118, 145], ["SARS", "PROBLEM", 62, 66], ["CoV-2 infection", "PROBLEM", 67, 82], ["Mycoplasma pneumoniae", "PROBLEM", 92, 113], ["respiratory syncytial virus infection", "PROBLEM", 118, 155], ["Mycoplasma pneumoniae", "OBSERVATION", 92, 113], ["respiratory", "ANATOMY", 118, 129], ["syncytial virus", "OBSERVATION", 130, 145]]], ["Previous studies have shown that the differential diagnosis of COVID-19 is Mycoplasma pneumonia and bronchiolitis.12 This is consistent with our findings.DiscussionThe number of LYM decreased in 39.4% of the children in the isolation ward.", [["COVID", "DISEASE", 63, 68], ["Mycoplasma pneumonia", "DISEASE", 75, 95], ["bronchiolitis", "DISEASE", 100, 113], ["LYM", "CANCER", 178, 181], ["children", "ORGANISM", 208, 216], ["children", "SPECIES", 208, 216], ["Previous studies", "TEST", 0, 16], ["COVID", "TEST", 63, 68], ["Mycoplasma pneumonia", "PROBLEM", 75, 95], ["bronchiolitis", "PROBLEM", 100, 113], ["Mycoplasma", "OBSERVATION_MODIFIER", 75, 85], ["pneumonia", "OBSERVATION", 86, 95], ["bronchiolitis", "OBSERVATION", 100, 113], ["consistent with", "UNCERTAINTY", 125, 140]]], ["This may be related to the fact that the virus inhibits LYM production or kills LYM.13 Lactate dehydrogenase and CK-MB were increased in more than half of the children, which may be caused by different degrees of myocardial cell damage caused by infection.", [["myocardial cell", "ANATOMY", 213, 228], ["LYM", "CHEMICAL", 56, 59], ["Lactate", "CHEMICAL", 87, 94], ["myocardial cell damage", "DISEASE", 213, 235], ["infection", "DISEASE", 246, 255], ["Lactate", "CHEMICAL", 87, 94], ["LYM", "GENE_OR_GENE_PRODUCT", 56, 59], ["LYM", "GENE_OR_GENE_PRODUCT", 80, 83], ["Lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 87, 108], ["CK-MB", "GENE_OR_GENE_PRODUCT", 113, 118], ["children", "ORGANISM", 159, 167], ["myocardial cell", "CELL", 213, 228], ["LYM", "PROTEIN", 56, 59], ["LYM", "PROTEIN", 80, 83], ["Lactate dehydrogenase", "PROTEIN", 87, 108], ["CK", "PROTEIN", 113, 115], ["children", "SPECIES", 159, 167], ["the virus", "PROBLEM", 37, 46], ["Lactate dehydrogenase", "TEST", 87, 108], ["CK-MB", "TEST", 113, 118], ["myocardial cell damage", "PROBLEM", 213, 235], ["infection", "PROBLEM", 246, 255], ["may be related to", "UNCERTAINTY", 5, 22], ["virus", "OBSERVATION", 41, 46], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["may be caused", "UNCERTAINTY", 175, 188], ["different degrees", "OBSERVATION_MODIFIER", 192, 209], ["myocardial cell damage", "OBSERVATION", 213, 235], ["infection", "OBSERVATION", 246, 255]]], ["This is similar to what Mugosa et al14 found in his study of influenza A (H1N1) virus.", [["influenza A (H1N1) virus", "DISEASE", 61, 85], ["influenza A (H1N1) virus", "ORGANISM", 61, 85], ["influenza A (H1N1", "SPECIES", 61, 78], ["influenza A (H1N1) virus", "SPECIES", 61, 85], ["his study", "TEST", 48, 57], ["influenza A (H1N1) virus", "PROBLEM", 61, 85]]], ["A total of 21.2% of the children in the isolation ward were SARS-CoV-2 nucleic acid positive, and the infection rate was high, which also suggested the necessity of screening children for COVID-19 in the isolation ward.DiscussionIn the isolation ward, 87.9% of the patients had abnormal chest CT, including 28 cases with speckled or patchy shadow, 6 cases with stripe shape, and 19 cases with GGO.", [["chest", "ANATOMY", 287, 292], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 60, 83], ["infection", "DISEASE", 102, 111], ["GGO", "DISEASE", 393, 396], ["children", "ORGANISM", 24, 32], ["children", "ORGANISM", 175, 183], ["patients", "ORGANISM", 265, 273], ["children", "SPECIES", 24, 32], ["children", "SPECIES", 175, 183], ["patients", "SPECIES", 265, 273], ["SARS-CoV", "SPECIES", 60, 68], ["SARS", "TEST", 60, 64], ["CoV", "TEST", 65, 68], ["nucleic acid", "TEST", 71, 83], ["the infection rate", "TEST", 98, 116], ["COVID", "TEST", 188, 193], ["abnormal chest CT", "TEST", 278, 295], ["speckled or patchy shadow", "PROBLEM", 321, 346], ["stripe shape", "TEST", 361, 373], ["GGO", "PROBLEM", 393, 396], ["infection", "OBSERVATION", 102, 111], ["chest", "ANATOMY", 287, 292], ["patchy", "OBSERVATION_MODIFIER", 333, 339], ["shadow", "OBSERVATION_MODIFIER", 340, 346]]], ["However, the current study found that the CT image of COVID-19 is complex and changeable, mainly manifested as multiple GGO of both lungs.", [["lungs", "ANATOMY", 132, 137], ["lungs", "ORGAN", 132, 137], ["COVID-19", "DNA", 54, 62], ["the current study", "TEST", 9, 26], ["the CT image", "TEST", 38, 50], ["COVID", "TEST", 54, 59], ["multiple", "OBSERVATION_MODIFIER", 111, 119], ["GGO", "OBSERVATION", 120, 123], ["both", "ANATOMY_MODIFIER", 127, 131], ["lungs", "ANATOMY", 132, 137]]], ["This may be related to telangiectasia and hyperemia of alveolar septum, fluid exudation in alveolar cavity, and interstitial congestion of interlobular septum.15 This shows that the abnormality of chest CT is an important reference for children to enter the isolation ward.DiscussionThrough the study of the ECG of the children, it was found that 16.7% of the ECG of the children showed sinus arrhythmia.", [["alveolar septum", "ANATOMY", 55, 70], ["fluid", "ANATOMY", 72, 77], ["alveolar cavity", "ANATOMY", 91, 106], ["interstitial", "ANATOMY", 112, 124], ["interlobular septum", "ANATOMY", 139, 158], ["chest", "ANATOMY", 197, 202], ["sinus", "ANATOMY", 387, 392], ["telangiectasia", "DISEASE", 23, 37], ["hyperemia", "DISEASE", 42, 51], ["sinus arrhythmia", "DISEASE", 387, 403], ["alveolar septum", "TISSUE", 55, 70], ["alveolar cavity", "MULTI-TISSUE_STRUCTURE", 91, 106], ["interstitial congestion", "PATHOLOGICAL_FORMATION", 112, 135], ["interlobular septum", "MULTI-TISSUE_STRUCTURE", 139, 158], ["chest", "ORGAN", 197, 202], ["children", "ORGANISM", 236, 244], ["children", "ORGANISM", 319, 327], ["children", "ORGANISM", 371, 379], ["sinus", "MULTI-TISSUE_STRUCTURE", 387, 392], ["children", "SPECIES", 236, 244], ["children", "SPECIES", 319, 327], ["children", "SPECIES", 371, 379], ["telangiectasia", "PROBLEM", 23, 37], ["hyperemia of alveolar septum", "PROBLEM", 42, 70], ["fluid exudation in alveolar cavity", "PROBLEM", 72, 106], ["interstitial congestion of interlobular septum", "PROBLEM", 112, 158], ["the abnormality", "PROBLEM", 178, 193], ["chest CT", "TEST", 197, 205], ["the study", "TEST", 291, 300], ["the ECG", "TEST", 356, 363], ["sinus arrhythmia", "PROBLEM", 387, 403], ["may be related to", "UNCERTAINTY", 5, 22], ["telangiectasia", "OBSERVATION", 23, 37], ["hyperemia", "OBSERVATION", 42, 51], ["alveolar septum", "ANATOMY", 55, 70], ["fluid exudation", "OBSERVATION", 72, 87], ["alveolar cavity", "ANATOMY", 91, 106], ["interstitial", "ANATOMY_MODIFIER", 112, 124], ["congestion", "OBSERVATION", 125, 135], ["interlobular septum", "ANATOMY", 139, 158], ["chest", "ANATOMY", 197, 202], ["sinus", "ANATOMY", 387, 392], ["arrhythmia", "OBSERVATION", 393, 403]]], ["This may also be related to cardiac hypoxia and cardiomyocyte damage caused by infection.", [["cardiac", "ANATOMY", 28, 35], ["cardiomyocyte", "ANATOMY", 48, 61], ["cardiac hypoxia", "DISEASE", 28, 43], ["cardiomyocyte damage", "DISEASE", 48, 68], ["infection", "DISEASE", 79, 88], ["cardiac", "ORGAN", 28, 35], ["cardiomyocyte", "CELL", 48, 61], ["cardiac hypoxia", "PROBLEM", 28, 43], ["cardiomyocyte damage", "PROBLEM", 48, 68], ["infection", "PROBLEM", 79, 88], ["may also be related to", "UNCERTAINTY", 5, 27], ["cardiac", "ANATOMY", 28, 35], ["hypoxia", "OBSERVATION", 36, 43], ["cardiomyocyte", "ANATOMY", 48, 61], ["damage", "OBSERVATION", 62, 68], ["infection", "OBSERVATION", 79, 88]]], ["This also suggests that we should pay attention to protect the heart function in the treatment of children in the isolation ward.DiscussionWhen the children were hospitalized in the isolation ward, we found that the hospitalization days were relatively long and the hospitalization costs were relatively high.", [["heart", "ANATOMY", 63, 68], ["heart", "ORGAN", 63, 68], ["children", "ORGANISM", 98, 106], ["children", "ORGANISM", 148, 156], ["children", "SPECIES", 98, 106], ["children", "SPECIES", 148, 156], ["heart", "ANATOMY", 63, 68]]], ["This may be related to the need for multiple SARS-CoV-2 nucleic acid tests.", [["nucleic acid", "CHEMICAL", 56, 68], ["multiple SARS", "TEST", 36, 49], ["CoV-2 nucleic acid tests", "TEST", 50, 74], ["may be related to", "UNCERTAINTY", 5, 22]]], ["Therefore, if we can rule out the risk of infectious diseases in the isolation ward as soon as possible, we can transfer the child to the general ward for further treatment, which can shorten the hospitalization time and treatment cost of the child.DiscussionAlthough nucleic acid detection is the gold standard for the diagnosis of COVID-19, due to the influence of many factors on the specimen, it is easy to have false negative.16 Therefore, we can comprehensively judge some suspected children with COVID-19 by clinical symptoms, history of epidemiology, number of LYM, myocardial zymogram, chest CT, and ECG.", [["specimen", "ANATOMY", 387, 395], ["myocardial", "ANATOMY", 574, 584], ["infectious diseases", "DISEASE", 42, 61], ["nucleic acid", "CHEMICAL", 268, 280], ["child", "ORGANISM", 243, 248], ["children", "ORGANISM", 489, 497], ["myocardial", "MULTI-TISSUE_STRUCTURE", 574, 584], ["children", "SPECIES", 489, 497], ["infectious diseases", "PROBLEM", 42, 61], ["further treatment", "TREATMENT", 155, 172], ["nucleic acid detection", "TEST", 268, 290], ["COVID", "TEST", 333, 338], ["COVID", "TEST", 503, 508], ["clinical symptoms", "PROBLEM", 515, 532], ["myocardial zymogram", "TEST", 574, 593], ["chest CT", "TEST", 595, 603], ["ECG", "TEST", 609, 612], ["infectious", "OBSERVATION", 42, 52], ["myocardial", "ANATOMY", 574, 584], ["chest", "ANATOMY", 595, 600]]], ["We can first put the suspected children with COVID-19 into the isolation ward for treatment, and then transfer them to the general ward for treatment after excluding COVID-19.", [["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["COVID", "TREATMENT", 45, 50], ["treatment", "TREATMENT", 82, 91], ["treatment", "TREATMENT", 140, 149], ["COVID", "TEST", 166, 171]]], ["In this way, it can play a certain role in the prevention and treatment of COVID-19.", [["COVID-19", "CHEMICAL", 75, 83], ["COVID", "TEST", 75, 80]]], ["As this study belongs to a single-center study, and the sample size is small, there are some limitations, which may not reflect the actual situation of the disease.", [["this study", "TEST", 3, 13], ["a single-center study", "TEST", 25, 46], ["the sample size", "TEST", 52, 67], ["the disease", "PROBLEM", 152, 163], ["size", "OBSERVATION_MODIFIER", 63, 67], ["small", "OBSERVATION_MODIFIER", 71, 76], ["some", "OBSERVATION_MODIFIER", 88, 92], ["may not reflect", "UNCERTAINTY", 112, 127], ["disease", "OBSERVATION", 156, 163]]], ["Therefore, further research is needed with a larger sample size and at multiple locations.Author ContributionsJZ contributed to acquisition, analysis, or interpretation of data, and drafted the manuscript.", [["analysis", "TEST", 141, 149], ["larger", "OBSERVATION_MODIFIER", 45, 51], ["size", "OBSERVATION_MODIFIER", 59, 63]]], ["YW substantially contributed to conception or design and critically revised the manuscript for important intellectual content.", [["important intellectual content", "PROBLEM", 95, 125]]]], "e76dee3d98158375c02db9f9651aff610b3906a5": [["IntroductionThe National Pulmonary Embolism Response Team (PERT) Consortium, the largest organization in the world specifically dedicated to improving outcomes in PE and advancing the science around this disease, recently published consensus recommendations for the diagnosis, treatment and follow-up for patients with acute PE.", [["Pulmonary Embolism", "DISEASE", 25, 43], ["PE", "DISEASE", 163, 165], ["PE", "DISEASE", 325, 327], ["patients", "ORGANISM", 305, 313], ["patients", "SPECIES", 305, 313], ["PE", "PROBLEM", 163, 165], ["this disease", "PROBLEM", 199, 211], ["treatment", "TREATMENT", 277, 286], ["acute PE", "PROBLEM", 319, 327], ["Pulmonary", "ANATOMY", 25, 34], ["Embolism", "OBSERVATION", 35, 43], ["largest", "OBSERVATION_MODIFIER", 81, 88], ["PE", "OBSERVATION", 163, 165], ["acute", "OBSERVATION_MODIFIER", 319, 324], ["PE", "OBSERVATION", 325, 327]]], ["7 Although many of these recommendations apply to patients with PE and COVID-19, some unique factors associated with the pandemic necessitate addressing these patients separately.IntroductionThe current COVID-19 pandemic has illustrated the importance of aggressive evaluation and management, when considering exposure to an highly communicable viral disease that has multisystem effects and a high mortality rate.", [["PE", "DISEASE", 64, 66], ["viral disease", "DISEASE", 345, 358], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 159, 167], ["PE", "PROBLEM", 64, 66], ["COVID", "TREATMENT", 71, 76], ["aggressive evaluation", "TEST", 255, 276], ["management", "TREATMENT", 281, 291], ["an highly communicable viral disease", "PROBLEM", 322, 358], ["multisystem effects", "PROBLEM", 368, 387], ["a high mortality rate", "PROBLEM", 392, 413], ["PE", "OBSERVATION", 64, 66], ["viral disease", "OBSERVATION", 345, 358]]], ["Those who become infected are potentially vectors of viral transmittance in our homes, our community and throughout the world.", [["infected", "OBSERVATION", 17, 25], ["viral transmittance", "OBSERVATION", 53, 72]]], ["Every exposure can further exacerbate the pandemic.", [["the pandemic", "PROBLEM", 38, 50], ["pandemic", "OBSERVATION_MODIFIER", 42, 50]]], ["Thus, the goal must be to deliver optimal care without compromise to our patients, while mitigating direct or indirect exposure and spread of the virus.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["the virus", "PROBLEM", 142, 151]]], ["There is emerging evidence that COVID-19 infected patients are prone to thrombosis and pulmonary embolism (PE).", [["pulmonary", "ANATOMY", 87, 96], ["thrombosis", "DISEASE", 72, 82], ["pulmonary embolism", "DISEASE", 87, 105], ["PE", "DISEASE", 107, 109], ["COVID-19", "ORGANISM", 32, 40], ["patients", "ORGANISM", 50, 58], ["pulmonary", "ORGAN", 87, 96], ["patients", "SPECIES", 50, 58], ["COVID", "TEST", 32, 37], ["thrombosis", "PROBLEM", 72, 82], ["pulmonary embolism", "PROBLEM", 87, 105], ["PE", "PROBLEM", 107, 109], ["infected", "OBSERVATION_MODIFIER", 41, 49], ["thrombosis", "OBSERVATION", 72, 82], ["pulmonary", "ANATOMY", 87, 96], ["embolism", "OBSERVATION", 97, 105], ["PE", "OBSERVATION", 107, 109]]], ["8 Table 1) , and offers a safe and efficient way to diagnose and treat PE without compromising patient care.", [["PE", "DISEASE", 71, 73], ["patient", "ORGANISM", 95, 102], ["patient", "SPECIES", 95, 102], ["PE", "PROBLEM", 71, 73], ["PE", "OBSERVATION", 71, 73]]], ["Please refer to the www.cdc.gov website for the most up to date information specific to COVID-19. \u2022 What testing should be performed during follow up?PERT:Pulmonary embolism response teams bring together a multi-disciplinary group of specialists to treat patients with severe PE.", [["Pulmonary", "ANATOMY", 155, 164], ["Pulmonary embolism", "DISEASE", 155, 173], ["PE", "DISEASE", 276, 278], ["patients", "ORGANISM", 255, 263], ["COVID-19", "DNA", 88, 96], ["patients", "SPECIES", 255, 263], ["What testing", "TEST", 100, 112], ["Pulmonary embolism", "PROBLEM", 155, 173], ["severe PE", "PROBLEM", 269, 278], ["Pulmonary", "ANATOMY", 155, 164], ["embolism", "OBSERVATION", 165, 173], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["PE", "OBSERVATION", 276, 278]]], ["13 The goal is to coordinate and expedite the diagnosis and treatment of PE with a team of physicians from different specialties.", [["PE", "DISEASE", 73, 75], ["treatment", "TREATMENT", 60, 69], ["PE", "PROBLEM", 73, 75], ["PE", "OBSERVATION", 73, 75]]], ["There is no defined or optimal structure of PERT, and the make up varies by institution.", [["no defined", "UNCERTAINTY", 9, 19], ["optimal", "OBSERVATION_MODIFIER", 23, 30], ["structure", "OBSERVATION", 31, 40]]], ["13 A team may include all or a combination of cardiac surgery, critical care, emergency medicine, hematology, interventional and noninterventional cardiology, interventional radiology pulmonary medicine, vascular medicine, vascular surgery, and pharmacy.", [["cardiac", "ANATOMY", 46, 53], ["pulmonary", "ANATOMY", 184, 193], ["vascular", "ANATOMY", 204, 212], ["vascular", "ANATOMY", 223, 231], ["cardiac", "ORGAN", 46, 53], ["pulmonary", "ORGAN", 184, 193], ["vascular", "MULTI-TISSUE_STRUCTURE", 204, 212], ["vascular", "MULTI-TISSUE_STRUCTURE", 223, 231], ["cardiac surgery", "TREATMENT", 46, 61], ["cardiac", "ANATOMY", 46, 53], ["surgery", "OBSERVATION", 54, 61], ["pulmonary", "ANATOMY", 184, 193], ["vascular", "ANATOMY", 204, 212], ["vascular", "ANATOMY", 223, 231]]], ["14 One of the main advantages of PERT is that this multi-disciplinary approach occurs in real time and allows for the rapid evaluation of risks, J o u r n a l P r e -p r o o f formulation of a treatment plan that suits each patient, and mobilization of appropriate resources to provide the highest quality of care to patients with PE.", [["PE", "DISEASE", 331, 333], ["patient", "ORGANISM", 224, 231], ["patients", "ORGANISM", 317, 325], ["patient", "SPECIES", 224, 231], ["patients", "SPECIES", 317, 325], ["this multi-disciplinary approach", "TREATMENT", 46, 78], ["the rapid evaluation", "TEST", 114, 134], ["formulation", "TREATMENT", 176, 187], ["a treatment plan", "TREATMENT", 191, 207], ["PE", "PROBLEM", 331, 333], ["main", "OBSERVATION_MODIFIER", 14, 18], ["PE", "OBSERVATION", 331, 333]]], ["15 This approach, now more than ever, seems essential in the COVID-19 era.PERT:Although the exact incidence of VTE associated with COVID-19 is currently unknown, reports range from as low as 1% in the general wards to as high as 31% in intensive care units.", [["VTE", "DISEASE", 111, 114], ["the COVID", "TEST", 57, 66], ["VTE", "PROBLEM", 111, 114], ["COVID", "TEST", 131, 136], ["VTE", "OBSERVATION", 111, 114]]], ["19 However, this study also found that elevations in D-dimer >2500 ng/mL at initial presentation were also predictive of bleeding complications during hospitalization.", [["bleeding", "DISEASE", 121, 129], ["D-dimer", "GENE_OR_GENE_PRODUCT", 53, 60], ["this study", "TEST", 12, 22], ["elevations in D-dimer", "PROBLEM", 39, 60], ["bleeding complications", "PROBLEM", 121, 143], ["elevations", "OBSERVATION_MODIFIER", 39, 49], ["bleeding", "OBSERVATION", 121, 129]]], ["In the same way, data from China indicated that patients at the highest risk of developing a PE were the same patients at the highest risk of bleeding.", [["PE", "DISEASE", 93, 95], ["bleeding", "DISEASE", 142, 150], ["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 110, 118], ["a PE", "PROBLEM", 91, 95], ["bleeding", "PROBLEM", 142, 150], ["PE", "OBSERVATION", 93, 95], ["bleeding", "OBSERVATION", 142, 150]]], ["24 At this point and in line with the recently published CHEST guidelines, there is insufficient evidence to recommend using an elevated D-dimer or any other laboratory data to guide clinical practice for VTE diagnosis.", [["VTE", "DISEASE", 205, 208], ["D-dimer", "GENE_OR_GENE_PRODUCT", 137, 144], ["D-dimer", "PROTEIN", 137, 144], ["an elevated D-dimer", "PROBLEM", 125, 144], ["VTE diagnosis", "TEST", 205, 218], ["CHEST", "ANATOMY", 57, 62]]], ["25 Thus, we recommend that biomarkers should not be used in the diagnostic evaluation for suspected DVT or PE.PERT:Given the limited data to support the use of biomarkers to diagnosis PE in COVID-19PERT:patients, standard diagnostic testing should be considered ( Figure 1 ).", [["DVT", "DISEASE", 100, 103], ["PE", "DISEASE", 107, 109], ["PE", "DISEASE", 184, 186], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["biomarkers", "TEST", 27, 37], ["the diagnostic evaluation", "TEST", 60, 85], ["DVT", "PROBLEM", 100, 103], ["PE", "PROBLEM", 107, 109], ["PE", "PROBLEM", 184, 186], ["standard diagnostic testing", "TEST", 213, 240], ["DVT", "OBSERVATION", 100, 103], ["PE", "OBSERVATION", 107, 109], ["PE", "OBSERVATION", 184, 186]]], ["Interventions Decisions about procedural intervention should be grounded in a discussion of risk-benefit ratio with a multi-disciplinary PERT consultation.", [["Interventions", "TREATMENT", 0, 13], ["procedural intervention", "TREATMENT", 30, 53]]], ["During this pandemic, the relative risks and benefits have shifted, due to the risk of viral transmission with transportation of COVID-19 positive patients to invasive laboratories or opertating rooms.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["COVID", "TEST", 129, 134]]], ["Furthermore, patient circumstances (e.g. proning) may make interventional procedures unsafe or impossible.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["interventional procedures", "TREATMENT", 59, 84]]], ["The evidence base regarding optimal treatment for higher risk PE is evolving and remains unclear as to which patients might benefit from interventional therapies.", [["PE", "DISEASE", 62, 64], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["optimal treatment", "TREATMENT", 28, 45], ["higher risk PE", "PROBLEM", 50, 64], ["interventional therapies", "TREATMENT", 137, 161], ["base", "OBSERVATION_MODIFIER", 13, 17], ["PE", "OBSERVATION", 62, 64]]], ["38 Given the absence of a well-defined benefit for invasive therapy and the potential for viral transmission, a conservative approach leaning towards medical therapy (e.g.PERT:anticoagulation or IV peripheral fibrinolysis) should be considered in patients with COVID- 19 .", [["COVID- 19", "CHEMICAL", 261, 270], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["invasive therapy", "TREATMENT", 51, 67], ["viral transmission", "PROBLEM", 90, 108], ["a conservative approach", "TREATMENT", 110, 133], ["medical therapy", "TREATMENT", 150, 165], ["anticoagulation", "TREATMENT", 176, 191], ["IV peripheral fibrinolysis)", "TREATMENT", 195, 222], ["COVID", "TEST", 261, 266]]], ["In general, procedural means of treating PE should be applied to only severe cases in which medical therapy is unlikely to be successful or contraindicated.", [["PE", "DISEASE", 41, 43], ["treating PE", "PROBLEM", 32, 43], ["severe cases", "PROBLEM", 70, 82], ["medical therapy", "TREATMENT", 92, 107], ["PE", "OBSERVATION", 41, 43]]], ["Presently, there is no data to support one intervention over another and it is a strength of a PERT, using a multidisciplinary discussion platform, to arrive at these decisions based on each patients unique clinical scenario ( Figure 1 ).PERT:Hemodynamically stable patients should be medically managed with anticoagulation alone.PERT:Careful monitoring is prudent in order to identify patients who become unstable and require emergency intervention.", [["patients", "ORGANISM", 191, 199], ["patients", "ORGANISM", 266, 274], ["patients", "ORGANISM", 386, 394], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 266, 274], ["patients", "SPECIES", 386, 394], ["anticoagulation", "TREATMENT", 308, 323], ["Careful monitoring", "TEST", 335, 353], ["unstable", "PROBLEM", 406, 414], ["emergency intervention", "TREATMENT", 427, 449], ["no", "UNCERTAINTY", 20, 22], ["Hemodynamically", "OBSERVATION_MODIFIER", 243, 258], ["stable", "OBSERVATION", 259, 265]]], ["Urgent and emergent cases can be identified as those that, acutely or sub-acutely, develop hemodynamic instability characterized by increasing It is important to note that autopsies have identified microvascular thrombi in COVID -19PERT:infected patients.", [["microvascular thrombi", "ANATOMY", 198, 219], ["hemodynamic instability", "DISEASE", 91, 114], ["microvascular thrombi", "DISEASE", 198, 219], ["COVID -19PERT", "CHEMICAL", 223, 236], ["microvascular thrombi", "PATHOLOGICAL_FORMATION", 198, 219], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 246, 254], ["hemodynamic instability", "PROBLEM", 91, 114], ["microvascular thrombi", "PROBLEM", 198, 219], ["hemodynamic instability", "OBSERVATION", 91, 114], ["increasing", "OBSERVATION_MODIFIER", 132, 142], ["microvascular", "ANATOMY", 198, 211], ["thrombi", "OBSERVATION", 212, 219], ["infected", "OBSERVATION", 237, 245]]], ["41, 42 Unlike most DVT and PE events, the clinical onset of these microthrombi is unknown and lacks specific physical findings or imaging signatures.", [["DVT", "DISEASE", 19, 22], ["microthrombi", "DISEASE", 66, 78], ["microthrombi", "CANCER", 66, 78], ["most DVT", "PROBLEM", 14, 22], ["PE events", "PROBLEM", 27, 36], ["these microthrombi", "PROBLEM", 60, 78], ["imaging signatures", "TEST", 130, 148], ["most", "OBSERVATION_MODIFIER", 14, 18], ["DVT", "OBSERVATION", 19, 22], ["PE", "OBSERVATION", 27, 29], ["microthrombi", "OBSERVATION", 66, 78]]], ["Position Statement:PERT:\u2022 Indications and contraindications for thrombolysis remain unchanged.\u2022 The risk-benefit ratio of medical and interventional therapy may require adjustment in patients with concurrent COVID-19 and PE.\u2022Transfer of CareGiven the potential of exposure to other patients and staff, interhospital transfer of COVID-19 patients should only occur when the receiving hospital offers treatment that is imminently needed and beyond the capabilities of the sending hospital.", [["PE", "DISEASE", 221, 223], ["COVID-19", "CHEMICAL", 208, 216], ["patients", "ORGANISM", 183, 191], ["patients", "ORGANISM", 282, 290], ["patients", "ORGANISM", 337, 345], ["patients", "SPECIES", 183, 191], ["patients", "SPECIES", 282, 290], ["patients", "SPECIES", 337, 345], ["thrombolysis", "TREATMENT", 64, 76], ["medical and interventional therapy", "TREATMENT", 122, 156], ["concurrent COVID", "TEST", 197, 213], ["PE", "PROBLEM", 221, 223], ["treatment", "TREATMENT", 399, 408], ["unchanged", "OBSERVATION_MODIFIER", 84, 93], ["PE", "OBSERVATION", 221, 223]]], ["Whenever possible, COVID-19 status should be identified prior to transfer.J o u r n a l P r e -p r o o fPhysician-to-physician communication should occur regarding the necessity of transfer, as well as the logistics and potential liabilities.", [["COVID", "PROTEIN", 19, 24], ["COVID", "TEST", 19, 24], ["fPhysician", "TEST", 103, 113]]], ["Existing hospital transfer policies for PE patients, regardless of COVID-19 status, should incorporate the following: There must be a well-defined clinical benefit or resources or services that are not available at the sending hospital, such as intensive care unit care, endovascular intervention or surgical services, ECMO, and neurosurgical services.", [["PE", "DISEASE", 40, 42], ["patients", "ORGANISM", 43, 51], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 271, 283], ["patients", "SPECIES", 43, 51], ["PE", "PROBLEM", 40, 42], ["COVID", "TEST", 67, 72], ["intensive care unit care", "TREATMENT", 245, 269], ["endovascular intervention", "TREATMENT", 271, 296], ["surgical services", "TREATMENT", 300, 317], ["ECMO", "TREATMENT", 319, 323], ["PE", "OBSERVATION", 40, 42]]], ["PERTs can be instrumental not only to help make the decision as to whether or not to transfer a patient, but also to mobilize the resources and carry out the treatment plans that are deemed necessary once the transfer occurs.J o u r n a l P r e -p r o o fAll hospital, state and federal guidelines for avoiding viral transmission, including those found on www.cdc.gov HYPERLINK \"http://www.cdc.gov/\", should be followed in any case of patient transfer.Position Statement: \u2022 Transfer of care for a COVID-19 patient with PE should be requested when needed services are not available at originating institution and are necessaryfor best care of the patient.Follow upAdequate follow up for all PE patients is essential for recovery and for optimal prevention of subsequent thromboembolic events.", [["viral transmission", "DISEASE", 311, 329], ["PE", "DISEASE", 519, 521], ["PE", "DISEASE", 690, 692], ["thromboembolic", "DISEASE", 769, 783], ["PERTs", "SIMPLE_CHEMICAL", 0, 5], ["patient", "ORGANISM", 96, 103], ["patient", "ORGANISM", 435, 442], ["patient", "ORGANISM", 506, 513], ["patient", "ORGANISM", 646, 653], ["patients", "ORGANISM", 693, 701], ["patient", "SPECIES", 96, 103], ["patient", "SPECIES", 435, 442], ["patient", "SPECIES", 506, 513], ["patient", "SPECIES", 646, 653], ["patients", "SPECIES", 693, 701], ["the treatment plans", "TREATMENT", 154, 173], ["PE", "PROBLEM", 519, 521], ["subsequent thromboembolic events", "PROBLEM", 758, 790], ["PE", "OBSERVATION", 519, 521], ["PE", "OBSERVATION", 690, 692], ["thromboembolic", "OBSERVATION", 769, 783]]], ["Such followup is even more critically important in the successful recovery of patients with concomitant COVID-19Follow upand PE.", [["PE", "DISEASE", 125, 127], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["concomitant COVID", "TREATMENT", 92, 109], ["PE", "PROBLEM", 125, 127], ["PE", "OBSERVATION", 125, 127]]], ["If PERT follow up clinics are not available, dedicated hematology, pulmonary or vascular medicine clinics, for example, may provide similar continuity.Follow upPrior to discharge, providers must assure appropriate hand off to the next level ofJ o u r n a l P r e -p r o o fWhen an intervention is necessary for a PE patients with COVID-19, invasive laboratory and operating room (OR) personnel should be kept to the minimum that is required for safe conduct of the procedure, and should don and doff specified and approved personal protective equipment (PPE).", [["pulmonary", "ANATOMY", 67, 76], ["vascular", "ANATOMY", 80, 88], ["PE", "DISEASE", 313, 315], ["pulmonary", "MULTI-TISSUE_STRUCTURE", 67, 76], ["vascular", "MULTI-TISSUE_STRUCTURE", 80, 88], ["patients", "ORGANISM", 316, 324], ["patients", "SPECIES", 316, 324], ["an intervention", "TREATMENT", 278, 293], ["COVID", "TEST", 330, 335], ["the procedure", "TREATMENT", 461, 474], ["pulmonary", "ANATOMY", 67, 76], ["vascular", "ANATOMY", 80, 88], ["PE", "OBSERVATION", 313, 315]]], ["Careful planning should be exercised and when possible, the team should anticipate and lay out the resources (medications, instruments, devices) that will potentially be needed so as to expedite the procedure and minimize supply runs.", [["medications", "TREATMENT", 110, 121], ["instruments, devices", "TREATMENT", 123, 143], ["the procedure", "TREATMENT", 195, 208]]], ["Every precaution should be taken to prevent aerosolization of patient respiratory secretions throughout the procedure.", [["respiratory secretions", "ANATOMY", 70, 92], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["Every precaution", "TREATMENT", 0, 16], ["patient respiratory secretions", "PROBLEM", 62, 92], ["the procedure", "TREATMENT", 104, 117], ["aerosolization", "OBSERVATION", 44, 58], ["respiratory", "ANATOMY", 70, 81], ["secretions", "OBSERVATION", 82, 92]]], ["After the procedure, the room should be terminally cleaned, in accordance with hospital policy regarding COVID-19 infection prevention.J o u r n a l P r e -p r o o fPosition Statement:\u2022 \u2022 \u2022 \u2022 Careful and thoughtful advanced planning for interventional or operativeprocedures, particularly with regards to required personnel and equipment, will expedite procedures and minimize staff exposure.Conclusion:The current COVID-19 era has complicated the diagnosis, risk startification and treatment of patients with PE.", [["infection", "DISEASE", 114, 123], ["PE", "DISEASE", 510, 512], ["patients", "ORGANISM", 496, 504], ["patients", "SPECIES", 496, 504], ["the procedure", "TREATMENT", 6, 19], ["COVID-19 infection prevention", "TREATMENT", 105, 134], ["interventional or operativeprocedures", "TREATMENT", 237, 274], ["expedite procedures", "TREATMENT", 344, 363], ["risk startification", "TREATMENT", 459, 478], ["treatment", "TREATMENT", 483, 492], ["PE", "PROBLEM", 510, 512], ["infection", "OBSERVATION", 114, 123], ["PE", "OBSERVATION", 510, 512]]], ["The PERT approach can significantly aid in the care of these vulnerable and complicated patients.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["The PERT approach", "TREATMENT", 0, 17]]], ["Through a multi-disciplinary clinical discussion, PERTevaluations assess the hemodynamic status, provide cardiopulmonary evaluation, weigh the impact of co-morbid conditions, and define the best anticoagulation or interventional management.", [["cardiopulmonary evaluation", "TEST", 105, 131], ["co-morbid conditions", "TREATMENT", 153, 173], ["the best anticoagulation", "TREATMENT", 186, 210], ["interventional management", "TREATMENT", 214, 239]]], ["Vigilance and special measures are also required for management of such patients, in order to optimize outcome while protecting others in the environment.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["special measures", "TREATMENT", 14, 30], ["management", "TREATMENT", 53, 63]]], ["Modifications of previously defined algorithm for the diagnosis and management of PE must be considered.", [["PE", "DISEASE", 82, 84], ["management", "TREATMENT", 68, 78], ["PE", "PROBLEM", 82, 84], ["PE", "OBSERVATION", 82, 84]]], ["As more is learned about COVID-19, ongoing refinements will be necessary to address this vulnerable population.Conclusion:The PERT consortium COVID-19 and PE registry will be a reservoir for such information.PERTinent PearlsVisit the PERT website, www.pertconsortium.org for archived and upcoming webinars,", [["COVID", "TEST", 25, 30], ["this vulnerable population", "PROBLEM", 84, 110], ["The PERT consortium COVID", "TEST", 122, 147], ["PE registry", "TREATMENT", 155, 166], ["a reservoir", "TREATMENT", 175, 186], ["PE", "OBSERVATION", 155, 157]]]], "98e910dd909a432e0e0684625f5a7f4178cea8b4": [["Trend-Vector statistical methodINTRODUCTIONNowadays the creation of a new medicine costs more than one billion dollars and the price of this process is growing steadily day by day [1] .", [["a new medicine costs", "TREATMENT", 68, 88]]], ["During recent decades different theoretical approaches have been used to facilitate and accelerate the process of new drugs creation that is not only very expensive, but also is a multistep and long-term activity [2] .", [["new drugs creation", "TREATMENT", 114, 132]]], ["Different quantitative structure-activity relationship (QSAR) approaches are used in this case.", [["quantitative", "OBSERVATION_MODIFIER", 10, 22], ["structure", "OBSERVATION_MODIFIER", 23, 32], ["activity", "OBSERVATION_MODIFIER", 33, 41]]], ["For many years, QSAR has been used successfully for the analysis of huge variety of endpoints, e.g., antiviral and anticancer activity, toxicity [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] .", [["anticancer", "ANATOMY", 115, 125], ["toxicity", "DISEASE", 136, 144], ["[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13]", "CHEMICAL", 145, 192], ["anticancer", "CANCER", 115, 125], ["[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 145, 197], ["QSAR", "TREATMENT", 16, 20], ["antiviral and anticancer activity", "TREATMENT", 101, 134]]], ["Many different QSAR methods [16] [17] [18] [19] [20] have been developed since the second half of the last century and new techniques and improvements are still being created [21] .", [["[16] [17] [18] [19] [20]", "SIMPLE_CHEMICAL", 28, 52]]], ["These approaches differ mainly by the principles and levels of representation and description of molecular structure.", [["molecular structure", "OBSERVATION", 97, 116]]], ["The degree of adequacy of molecular structure models varies from 1D to 4D level:INTRODUCTION\u2022 1D models consider only the gross formula of a molecule (for example, glycine -C 2 H 4 NO 2 ).", [["glycine", "CHEMICAL", 164, 171], ["NO", "CHEMICAL", 181, 183], ["glycine -C 2 H 4 NO 2", "CHEMICAL", 164, 185], ["INTRODUCTION\u2022 1D models", "TREATMENT", 80, 103], ["glycine -C 2 H", "TREATMENT", 164, 178], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["adequacy", "OBSERVATION_MODIFIER", 14, 22], ["molecular structure", "OBSERVATION", 26, 45]]], ["These models are very popular [3, 23] .", [["very", "OBSERVATION_MODIFIER", 17, 21], ["popular", "OBSERVATION", 22, 29]]], ["The capacity of such approaches is due to the fact that the topological models of molecular structure, in an implicit form, contain information about possible conformations of the compound.", [["capacity", "OBSERVATION_MODIFIER", 4, 12], ["molecular structure", "OBSERVATION", 82, 101]]], ["Our operational experience shows that 2D level of representation of the molecular structure is enough for the solution of more than 90% of existing QSAR/QSPR tasks. \u2022 3D-QSAR models [16, 17, 19, 20] give full structural information taking into account composition, topology, and spatial shape of molecule for one conformer only.", [["existing QSAR", "TEST", 139, 152], ["QSPR tasks", "TEST", 153, 163], ["QSAR models", "TEST", 170, 181]]], ["These models are widespread.", [["widespread", "OBSERVATION_MODIFIER", 17, 27]]], ["These models are similar to 3D models, but compared to them the structural information is considered for a set of conformers (conditionally the fourth dimension), instead of one fixed conformation (also see Chapter 3).INTRODUCTIONThe description of compounds from 1D to 4D models reflects the hierarchy of molecular structure representation.", [["molecular structure", "OBSERVATION", 306, 325]]], ["However, it's only one of the principles of HiT QSAR.", [["HiT QSAR", "PROBLEM", 44, 52]]], ["Innovative aspect and main advantages of HiT QSAR involve \u2022 Simplex representation of molecular structure that provides universality, diversity, and flexibility of the description of compounds related to different structural types. \u2022 HiT QSAR that, depending on the concrete aims of research, allows for the construction of the optimal strategy for QSAR model generation, avoiding at the same time superfluous complications that do not result in an increase in the adequacy of the model. \u2022 HiT QSAR does not have the restrictions of such well-known and widely used approaches as CoMFA, CoMSIA, and HASL.", [["HiT", "SIMPLE_CHEMICAL", 41, 44], ["HiT QSAR", "TREATMENT", 41, 49], ["HiT QSAR", "PROBLEM", 234, 242], ["QSAR model generation", "TREATMENT", 349, 370], ["superfluous complications", "PROBLEM", 398, 423], ["increase", "OBSERVATION_MODIFIER", 449, 457]]], ["Usage of such methods is limited by the requirement for a structurally homogeneous set of molecules and the use of only one conformer.INTRODUCTION\u2022 HiT QSAR does not have the HQSAR restrictions that are related to the ambiguity of descriptor system formation. \u2022 At every stage of HiT QSAR use, we can determine the molecular structural features that are important for the studied activity and exclude the rest.", [["such methods", "TREATMENT", 9, 21], ["a structurally homogeneous set of molecules", "PROBLEM", 56, 99]]], ["It shows unambiguously the limits of QSAR models' complication and ensures that resources are not wasted on needless calculations.INTRODUCTIONThe efficiency of the HiT QSAR has been demonstrated through the example of various QSAR tasks, e.g., given in [3, 10-12, 22, 25-37] .HiT QSAR ConceptIn this chapter, the hierarchic QSAR technology (HiT QSAR) [31, 32, 36, 37] based on the simplex representation of molecular structure (SiRMS) has been considered.", [["QSAR models' complication", "PROBLEM", 37, 62], ["needless calculations", "TEST", 108, 129], ["the HiT QSAR", "PROBLEM", 160, 172], ["various QSAR tasks", "TEST", 218, 236], ["HiT QSAR", "TEST", 341, 349], ["efficiency", "OBSERVATION_MODIFIER", 146, 156], ["HiT QSAR", "OBSERVATION", 164, 172]]], ["This method has proved efficient in numerous studies for solving different \"structure-activity/property\" problems [3, 10-12, 22, 25-37] .", [["solving different \"structure", "PROBLEM", 57, 85]]], ["The essence of the strategy presented is based on the solution of QSAR problems via the sequence of the permanently improved molecular structure models (from 1D to 4D) ( Figure 5-1) .", [["QSAR problems", "PROBLEM", 66, 79]]], ["Thus, at each stage of the hierarchical system, the QSAR task is not solved ab ovo, but with the use of the information received from a previous stage.", [["hierarchical system", "ANATOMY", 27, 46]]], ["It leads to more effective interpretation of the obtained QSAR models because the approach reveals molecular fragments/models for which the detailed development of structure is important.", [["molecular fragments/models", "PROBLEM", 99, 125], ["molecular fragments", "OBSERVATION", 99, 118]]], ["The main feature of the strategy presented consists of the multiple-aspect hierarchy (Figure 5-1), related to \u2022 models describing molecular structure (1D \u2192 2D \u2192 3D \u2192 4D); \u2022 scales of activity estimation (binomial \u2192 nominal \u2192 ordinal \u2192 continual); \u2022 mathematical methods used to establish structure-activity relationships [pattern recognition \u2192 rank correlation \u2192 multivariate regression \u2192 partial least squares (PLS)]; \u2022 final aims of the solution of the QSAR task (prediction \u2192 interpretation \u2192 structure optimization \u2192 molecular design).HiT QSAR ConceptThe set of different QSAR models that supplement each other results from the HiT QSAR application.", [["activity estimation", "TEST", 183, 202], ["mathematical methods", "TREATMENT", 249, 269], ["different QSAR models", "TREATMENT", 566, 587], ["the HiT QSAR application", "TREATMENT", 628, 652], ["main", "OBSERVATION_MODIFIER", 4, 8], ["multiple", "OBSERVATION_MODIFIER", 59, 67], ["molecular structure", "OBSERVATION", 130, 149]]], ["These models altogether, in combination, solve the problems of virtual screening, evaluation of the influence of structural factors on activity, modification of known molecular structures, and the design of new high-potency potential antiviral agents or other compounds with desired properties.HiT QSAR ConceptThe scheme for HiT QSAR is shown in Figure 5 -1.", [["structural factors", "PROTEIN", 113, 131], ["virtual screening", "TEST", 63, 80], ["evaluation", "TEST", 82, 92], ["structural factors", "PROBLEM", 113, 131], ["known molecular structures", "PROBLEM", 161, 187], ["antiviral agents", "TREATMENT", 234, 250], ["HiT QSAR", "TEST", 325, 333]]], ["It is necessary to note that after the 2D modeling, the QSAR task is solved at the 4D level, because there is no a priori information available about a \"productive\" conformation (the conformer that interacts with a biological target most effectively) for 3D-QSAR models.", [["the QSAR task", "TEST", 52, 65]]], ["This information comes only after the development of 4D-QSAR models and activity calculation for all conformers considered.", [["4D-QSAR models", "TEST", 53, 67], ["activity calculation", "TEST", 72, 92]]], ["This is the main difference between HiT QSAR and ordinary 3D-QSAR approaches, where the investigated conformers have been chosen through a less vigorous process.", [["HiT", "SIMPLE_CHEMICAL", 36, 39], ["HiT QSAR", "TEST", 36, 44], ["main", "OBSERVATION_MODIFIER", 12, 16], ["difference", "OBSERVATION_MODIFIER", 17, 27]]], ["In all cases (1D-4D), different statistical methods can be used to obtain the QSAR models (the \"Statistic block\" in Figure 5 -1).HiT QSAR ConceptThe principal feature of the HiT QSAR is its multi-hierarchy, i.e., not only the hierarchy of different models but also that the hierarchy of the aims has been taken into account (Figure 5-1, unit -\"Final Aims\").", [["different statistical methods", "TREATMENT", 22, 51], ["the QSAR models", "TEST", 74, 89], ["the HiT QSAR", "PROBLEM", 170, 182], ["HiT QSAR", "OBSERVATION", 174, 182]]], ["These models altogether, in combination, solve the problem of the creation of the new compounds and issue relating to the desired set of properties.", [["new", "OBSERVATION_MODIFIER", 82, 85]]], ["It's also necessary to note that these resulting QSAR models have been chosen in accordance with the QECD principles for the validation of (Q)SARs [38] , i.e., they have a defined endpoint, an unambiguous algorithm, a defined domain of applicability (DA), mechanistic interpretation, have good statistical fit, and are robust and predictive.", [["these resulting QSAR models", "PROBLEM", 33, 60], ["the QECD principles", "TREATMENT", 97, 116], ["an unambiguous algorithm", "TEST", 190, 214], ["mechanistic interpretation", "TEST", 256, 282]]], ["Thus, we assume that the proposed strategy provides a solution to solve all problems dealing with virtual screening, modeling of functional (biological) targets, advancement of hypotheses regarding mechanisms of action, and, finally, the design of the new compounds with desired properties.5.2.2.Hierarchy of Molecular ModelsSimplex Representation of Molecular Structure (SiRMS)In the framework of SiRMS, any molecule can be represented as a system of different simplexes (tetratomic fragments of fixed composition, structure, chirality, and symmetry) [29, 31, 32, 39] ( Figure 5 -2).", [["SiRMS", "PROTEIN", 398, 403], ["a solution", "TREATMENT", 52, 62], ["virtual screening", "TEST", 98, 115], ["any molecule", "PROBLEM", 405, 417], ["different simplexes (tetratomic fragments of fixed composition", "TREATMENT", 452, 514], ["Molecular ModelsSimplex", "OBSERVATION", 309, 332], ["Molecular Structure", "OBSERVATION", 351, 370]]], ["At the 1D level, a simplex is a combination of four atoms contained in the molecule ( Figure 5 -2).", [["simplex", "DISEASE", 19, 26], ["a simplex", "PROBLEM", 17, 26], ["simplex", "OBSERVATION", 19, 26], ["molecule", "ANATOMY", 75, 83]]], ["The simplex descriptor (SD) at this level is the number of quadruples of atoms of the definite composition.", [["The simplex descriptor (SD) at this level", "PROBLEM", 0, 41], ["simplex", "OBSERVATION_MODIFIER", 4, 11], ["definite", "UNCERTAINTY", 86, 94], ["composition", "OBSERVATION_MODIFIER", 95, 106]]], ["For the compoundSimplex Representation of Molecular Structure (SiRMS)The values of f(j), f(l), f(m) have been calculated analogically.", [["Molecular Structure", "OBSERVATION", 42, 61]]], ["It is possible to define the number of smaller fragments (\"pairs,\" \"triples\") by the same scheme.", [["fragments", "ANATOMY", 47, 56], ["smaller fragments (\"pairs", "PROBLEM", 39, 64], ["number", "OBSERVATION_MODIFIER", 29, 35], ["smaller", "OBSERVATION_MODIFIER", 39, 46], ["fragments", "OBSERVATION", 47, 56]]], ["In this case some of i, j, l, m parameters are equal to zero.Simplex Representation of Molecular Structure (SiRMS)2D models.", [["Molecular Structure", "OBSERVATION", 87, 106]]], ["At the 2D level, the connectivity of atoms in simplex, atom type, and bond nature (single, double, triple, aromatic) has been considered.", [["atoms", "ANATOMY_MODIFIER", 37, 42]]], ["Atoms in simplex can be differentiated on the basis of different characteristics, especially \u2022 atom individuality (nature or more detailed type of atom); \u2022 partial atom charge [40] (see Figure 5 -2) (reflects electrostatic properties); \u2022 lipophilicity of atom [41] (reflects hydrophobic properties); \u2022 atomic refraction [42] (partially reflects the ability of the atom to dispersion interactions); For atomic characteristics, which have real values (charge, lipophilicity, refraction, etc.) the division of values range into definite discrete groups is carried out at the preliminary stage.", [["simplex", "ORGANISM", 9, 16], ["atom [41]", "SIMPLE_CHEMICAL", 255, 264], ["Atoms in simplex", "PROBLEM", 0, 16], ["partial atom charge", "PROBLEM", 156, 175]]], ["The number of groups (G) is a tuning parameter and can be varied (as a rule G = 3-7).Simplex Representation of Molecular Structure (SiRMS)The usage of sundry variants of simplex vertexes (atoms) differentiation represents an important part of SiRMS.", [["simplex", "ORGANISM", 170, 177], ["SiRMS", "PROTEIN", 243, 248], ["a rule G", "TEST", 69, 77], ["simplex vertexes (atoms)", "TREATMENT", 170, 194], ["Molecular Structure", "OBSERVATION", 111, 130], ["simplex vertexes", "OBSERVATION", 170, 186]]], ["We consider that specification of atoms only by their nature (actually reflects atom identity, for example, C, N, O) realized in many QSAR methods limits the possibilities of pharmacophore fragment selection.", [["C", "CHEMICAL", 108, 109], ["N", "CHEMICAL", 111, 112], ["O", "CHEMICAL", 114, 115], ["pharmacophore fragment selection", "PROBLEM", 175, 207], ["pharmacophore fragment", "OBSERVATION", 175, 197]]], ["For example, if the -NH-group has been selected as the fragment (pharmacophore) determining activity and the ability of H-bond formation is a factor determining its activity, H-bonds donors, for example, the OH-group will be missed.", [["H", "CHEMICAL", 120, 121], ["OH", "CHEMICAL", 208, 210], ["NH", "CHEMICAL", 21, 23], ["H", "CHEMICAL", 120, 121], ["H", "CHEMICAL", 175, 176], ["OH", "CHEMICAL", 208, 210], ["H-bond", "SIMPLE_CHEMICAL", 120, 126], ["OH", "SIMPLE_CHEMICAL", 208, 210]]], ["The use of atom differentiation using H-bond marks mentioned above avoids this situation.", [["H", "CHEMICAL", 38, 39]]], ["One can make analogous examples for other atomic properties (lipophilicity, partial charge, refraction, etc.).Simplex Representation of Molecular Structure (SiRMS)Thus, the SD at the 2D level is a number of simplexes of fixed composition and topology.", [["the SD", "PROBLEM", 169, 175], ["Molecular Structure", "OBSERVATION", 136, 155]]], ["It is necessary to note that, in addition to the simplex descriptors, other structural parameters, corresponding to molecular fragments of different size, can be used for 1D and 2D-QSAR analysis.", [["the simplex descriptors", "PROBLEM", 45, 68], ["molecular fragments of different size", "PROBLEM", 116, 153], ["1D and 2D-QSAR analysis", "TEST", 171, 194], ["fragments", "OBSERVATION_MODIFIER", 126, 135], ["different", "OBSERVATION_MODIFIER", 139, 148], ["size", "OBSERVATION_MODIFIER", 149, 153]]], ["The use of 1-4 atomic fragments is preferable because further extension of the fragment length could increase the probability of the model overfitting and decrease its predictivity and DA.Simplex Representation of Molecular Structure (SiRMS)2.5D models.", [["DA", "CHEMICAL", 185, 187], ["DA", "SIMPLE_CHEMICAL", 185, 187], ["1-4 atomic fragments", "DNA", 11, 31], ["1-4 atomic fragments", "TREATMENT", 11, 31], ["the fragment length", "PROBLEM", 75, 94], ["the model overfitting", "PROBLEM", 129, 150], ["fragments", "OBSERVATION", 22, 31], ["fragment", "OBSERVATION_MODIFIER", 79, 87], ["length", "OBSERVATION_MODIFIER", 88, 94], ["overfitting", "OBSERVATION", 139, 150], ["Molecular Structure", "OBSERVATION", 214, 233]]], ["Although the most adequate description of stereochemistry of compounds is possible only on 3D and 4D levels of molecular structure modeling, 2D models of molecules can also provide stereochemical information.", [["molecular structure", "OBSERVATION", 111, 130]]], ["In the case when a compound contains a chiral center on the atom X (X = C, Si, P, etc.), the special marks X A , X R , X S (A -achiral X atom, R -\"right\" surrounding of X atom, S -\"left\" surrounding of X atom) can be used to reflect the stereochemistry information of such a center.", [["C", "CHEMICAL", 72, 73], ["Si", "CHEMICAL", 75, 77], ["P", "CHEMICAL", 79, 80], ["X = C", "SIMPLE_CHEMICAL", 68, 73], ["X A", "SIMPLE_CHEMICAL", 107, 110], ["X R", "SIMPLE_CHEMICAL", 113, 116], ["A -achiral X atom", "SIMPLE_CHEMICAL", 124, 141], ["X S", "TEST", 119, 122], ["A -achiral X atom", "TEST", 124, 141], ["right", "ANATOMY_MODIFIER", 147, 152], ["left", "ANATOMY_MODIFIER", 181, 185]]], ["For example, in the situation where atom X has been differentiated to three different types depending on its stereochemical surroundings, i.e., X A , X R , X S , the different types are analyzed in the molecular model as separate atoms.", [["atom X", "PROTEIN", 36, 42], ["three different types", "OBSERVATION_MODIFIER", 70, 91], ["different types", "OBSERVATION_MODIFIER", 166, 181]]], ["If simplex vertexes (X atoms) have been differentiated by some physicalchemical properties (e.g., partial charges, lipophilicity) then the differences between atoms X A , X R , X S will be leveled as in normal 2D models.", [["X atoms", "SIMPLE_CHEMICAL", 21, 28], ["X R", "GENE_OR_GENE_PRODUCT", 171, 174], ["simplex vertexes (X atoms", "PROBLEM", 3, 28], ["X R , X S", "TEST", 171, 180], ["physicalchemical properties", "OBSERVATION_MODIFIER", 63, 90]]], ["For subsequent QSAR analysis, the simplexes differentiated by atom individuality have been used separately and in combination with those differentiated by physical-chemical properties.Simplex Representation of Molecular Structure (SiRMS)3D models.", [["subsequent QSAR analysis", "TEST", 4, 28], ["Molecular Structure", "OBSERVATION", 210, 229]]], ["It is possible to differentiate all the simplexes as right (R), left (L), symmetrical (S), and plane (P) achiral.", [["right", "ANATOMY_MODIFIER", 53, 58], ["left", "ANATOMY_MODIFIER", 64, 68], ["L", "ANATOMY_MODIFIER", 70, 71]]], ["For example:Simplex Representation of Molecular Structure (SiRMS)The stereochemical configuration of simplexes is defined by modified Kahn-Ingold-Prelog rules [39] .", [["Simplex", "OBSERVATION_MODIFIER", 12, 19], ["Molecular Structure", "OBSERVATION", 38, 57], ["stereochemical configuration", "OBSERVATION", 69, 97]]], ["A SD at this level is a number of simplexes of fixed composition, topology, chirality, and symmetry.Simplex Representation of Molecular Structure (SiRMS)4D models.", [["SD", "DISEASE", 2, 4], ["A SD at this level", "PROBLEM", 0, 18], ["SD", "OBSERVATION", 2, 4], ["Molecular Structure", "OBSERVATION", 126, 145]]], ["(5-2) (P k ). where N is a number of conformers being considered.Simplex Representation of Molecular Structure (SiRMS)As is well known [44] , the probability of conformation P k is defined by its energy equation :Simplex Representation of Molecular Structure (SiRMS)where E i and E k are the energies of conformations i and k, respectively.", [["P k", "DNA", 174, 177], ["Molecular Structure", "PROTEIN", 239, 258], ["SiRMS", "PROTEIN", 260, 265], ["Molecular Structure", "OBSERVATION", 91, 110], ["Molecular Structure", "OBSERVATION", 239, 258]]], ["The conformers are analyzed within an energy band of 5-7 kcal/mol.", [["an energy band", "TEST", 35, 49]]], ["Thus, the molecular SD at the 4D level takes into account the probability of the realization of the 3D-level SD in the set of conformers.", [["the molecular SD", "PROBLEM", 6, 22]]], ["At the 4D level the other 3D whole-molecule parameters, which are efficient for the description of spatial forms of the conformer (e.g., characteristics of inertia ellipsoid, dipole moment), can be used along with SD.", [["SD", "DISEASE", 214, 216], ["inertia ellipsoid, dipole moment", "TREATMENT", 156, 188]]], ["An example of the representation of a molecule as sets of simplexes with different levels of structure detailed (1D-4D) is depicted in Figure 5 -2.Simplex Representation of Molecular Structure (SiRMS)Double nD models.", [["a molecule", "PROBLEM", 36, 46], ["Molecular Structure", "OBSERVATION", 173, 192]]], ["It is also applicable for mixtures of compounds with synergetic or anti-synergetic action [45] .", [["mixtures of compounds", "TREATMENT", 26, 47], ["synergetic or anti-synergetic action", "TREATMENT", 53, 89]]], ["Because of these issues, the SiRMS approach has been developed and improved in order to make this method suitable for the execution of QSAR analysis for molecular mixtures and ensembles.", [["the SiRMS approach", "TREATMENT", 25, 43], ["QSAR analysis", "TEST", 135, 148], ["molecular mixtures", "TREATMENT", 153, 171], ["improved", "OBSERVATION_MODIFIER", 67, 75]]], ["With this purpose it's necessary to indicate whether the parts of unbound simplexes belong to the same molecule or to a different one.", [["simplexes", "SIMPLE_CHEMICAL", 74, 83], ["unbound simplexes", "PROBLEM", 66, 83]]], ["In the latter case, such unbound simplex will reflect the structure not of a single molecule, but will characterize a pair of different molecules.", [["such unbound simplex", "PROBLEM", 20, 40]]], ["Their usage allows for the analysis of synergism, anti-synergism, or competition in the mixture's interaction with the biological target.", [["the analysis", "TEST", 23, 35], ["synergism", "PROBLEM", 39, 48], ["anti-synergism", "TREATMENT", 50, 64]]], ["Obviously, such an approach is suitable for different nD-QSAR models, where n = 1-4 1 .", [["QSAR models", "TEST", 57, 68]]], ["If in the same task both mixtures and single compounds have been considered, it's necessary to represent individual compounds as the mixture of two similar molecules for the correct description of such systems [46] .", [["individual compounds", "PROBLEM", 105, 125]]], ["For molecular ensembles (associates), it is necessary to use one more simplex type -simplexes with intermolecular bonds.", [["intermolecular bonds", "OBSERVATION", 99, 119]]], ["In this chapter, the application of the \"double nD-QSAR\" approach is demonstrated with the example of chiral AChE inhibitors [46] (see Section 5.4.4).Lattice ModelThe lattice model (LM) approach has been developed by the authors [19] using similar principles as CoMFA and CoMSIA (see Chapter 4) , which utilize a more elaborated description of the molecules and consider parameters reflecting peculiarities of the intermolecular interaction of the compounds analyzed and their spatial structure.", [["AChE", "SIMPLE_CHEMICAL", 109, 113], ["the \"double nD-QSAR\" approach", "TREATMENT", 36, 65], ["chiral AChE inhibitors", "TREATMENT", 102, 124], ["Lattice ModelThe lattice model (LM) approach", "TREATMENT", 150, 194]]], ["In the first, the spatial structure of the analyzed molecules is obtained from experimental data (i.e., X-ray analysis) or from quantum mechanical calculations.", [["experimental data", "TEST", 79, 96], ["X-ray analysis", "TEST", 104, 118], ["quantum mechanical calculations", "TREATMENT", 128, 159]]], ["In the case of flexible molecules, it is necessary to select one of the stable conformations.", [["flexible molecules", "OBSERVATION", 15, 33], ["stable", "OBSERVATION", 72, 78]]], ["The conformation of each molecule is placed into a lattice of cubic cells.", [["cells", "ANATOMY", 68, 73], ["cells", "CELL", 68, 73], ["cubic cells", "CELL_TYPE", 62, 73], ["a lattice of cubic cells", "TREATMENT", 49, 73], ["cubic cells", "OBSERVATION", 62, 73]]], ["The size of a cell can be varied, by default it equals 2 \u00c5, that corresponds approximately to the average van der Waals radius of an organogenic atom.", [["cell", "ANATOMY", 14, 18], ["cell", "CELL", 14, 18], ["size", "OBSERVATION_MODIFIER", 4, 8], ["cell", "OBSERVATION", 14, 18], ["varied", "OBSERVATION_MODIFIER", 26, 32]]], ["The invariant disposition of the molecule in the lattice is achieved by the superposition of the center of mass of the molecules with the origin of the coordinates.", [["invariant", "OBSERVATION_MODIFIER", 4, 13], ["disposition", "OBSERVATION_MODIFIER", 14, 25], ["center", "OBSERVATION_MODIFIER", 97, 103], ["mass", "OBSERVATION", 107, 111], ["molecules", "OBSERVATION_MODIFIER", 119, 128], ["origin", "ANATOMY_MODIFIER", 138, 144]]], ["In addition, the principal axes of inertia of the molecule are also superimposed with the coordinate axes of the lattice.", [["principal", "OBSERVATION_MODIFIER", 17, 26], ["axes", "OBSERVATION_MODIFIER", 27, 31], ["inertia", "OBSERVATION_MODIFIER", 35, 42], ["molecule", "OBSERVATION", 50, 58], ["lattice", "OBSERVATION_MODIFIER", 113, 120]]], ["If the analyzed structures contain a large common structural fragment, their alignment is carried out mainly according to this fragment.Lattice ModelAll structural parameters in the LM can be classified as follows:Lattice Model\u2022 Integral parameters describing properties of the whole molecular structure; \u2022 Local parameters describing the separate fragments of the molecule; \u2022 Field parameters describing the influence of the molecule on the enclosing space.Lattice ModelIntegral parameters are characteristics of inertia ellipsoid, dipole moment, molecular refraction, lipophilicity, parachor, and average polarizability.", [["fragment", "CELLULAR_COMPONENT", 127, 135], ["a large common structural fragment", "PROBLEM", 35, 69], ["Lattice ModelAll structural parameters", "TEST", 136, 174], ["Lattice Model\u2022 Integral parameters", "TREATMENT", 214, 248], ["Field parameters", "TEST", 377, 393], ["Lattice ModelIntegral parameters", "TEST", 458, 490], ["inertia ellipsoid", "PROBLEM", 514, 531], ["lipophilicity", "TEST", 570, 583], ["parachor", "TEST", 585, 593], ["large", "OBSERVATION_MODIFIER", 37, 42], ["common", "OBSERVATION_MODIFIER", 43, 49], ["structural fragment", "OBSERVATION", 50, 69], ["alignment", "OBSERVATION_MODIFIER", 77, 86], ["fragment", "OBSERVATION", 127, 135], ["LM", "ANATOMY", 182, 184], ["molecule", "ANATOMY", 365, 373], ["inertia ellipsoid", "OBSERVATION", 514, 531], ["molecular refraction", "OBSERVATION", 548, 568], ["average polarizability", "OBSERVATION", 599, 621]]], ["If available, some information about the environment and mutual disposition of the pharmacophores can be also included into the analysis [48] .Lattice ModelLocal parameters were used to describe the properties of cells occupied by atoms.", [["cells", "ANATOMY", 213, 218], ["cells", "CELL", 213, 218], ["the analysis", "TEST", 124, 136], ["Lattice ModelLocal parameters", "TREATMENT", 143, 172]]], ["They include parameters corresponding to the presence or absence of some atoms in the cell (i.e., the presence of C or O), average lipophilicity, refraction, polarizability, electrostatic charge, and electronegativity of fragments and atoms.", [["cell", "ANATOMY", 86, 90], ["C", "CHEMICAL", 114, 115], ["O", "CHEMICAL", 119, 120], ["cell", "CELL", 86, 90], ["some atoms in the cell", "PROBLEM", 68, 90], ["electrostatic charge", "PROBLEM", 174, 194], ["electronegativity of fragments and atoms", "PROBLEM", 200, 240], ["electrostatic charge", "OBSERVATION", 174, 194]]], ["All charge characteristics were calculated using the Jolly-Perry [40, 49] method of smoothing of electronegativity. where i is the number of the cell, j is the number of the atom, q j is the charge of the atom j [40, 49] , and r ij is the distance between the atom j and the cell i; (2) A lipophilicity potential [50] in the vacant cell [Eq.", [["cell", "ANATOMY", 145, 149], ["cell", "ANATOMY", 275, 279], ["cell", "ANATOMY", 332, 336], ["cell", "CELL", 145, 149], ["cell", "CELL", 275, 279], ["cell", "CELL", 332, 336], ["smoothing of electronegativity", "PROBLEM", 84, 114], ["ij", "ANATOMY", 229, 231], ["atom j", "OBSERVATION", 260, 266], ["cell", "ANATOMY", 275, 279], ["vacant cell", "OBSERVATION", 325, 336]]], ["(5-5)]:Lattice Modelwhere i is the number of the cell, j is the number of the atom, f j is the lipophilicity of the atom (group), and r ij is the distance between the atom j and the cell i; (3) A probability of an occupancy of a vacant cell by different atoms i, k (\"probeatoms\") or probability of it to be empty [Eq.", [["cell", "ANATOMY", 49, 53], ["cell", "ANATOMY", 182, 186], ["cell", "ANATOMY", 236, 240], ["cell", "CELL", 49, 53], ["cell", "CELL", 182, 186], ["cell", "CELL", 236, 240], ["lipophilicity", "OBSERVATION", 95, 108], ["atom", "ANATOMY_MODIFIER", 116, 120], ["r", "ANATOMY_MODIFIER", 134, 135], ["ij", "ANATOMY", 136, 138], ["atom j", "OBSERVATION", 167, 173], ["cell", "ANATOMY", 182, 186], ["occupancy", "OBSERVATION", 214, 223], ["vacant cell", "OBSERVATION", 229, 240], ["empty", "OBSERVATION", 307, 312]]], ["(5-6)]:Lattice Modelwhere E i or E k is the energy of interaction between the molecule and the corresponding probe-atom i or k in the analyzed cell.", [["cell", "ANATOMY", 143, 147], ["cell", "CELL", 143, 147]]], ["A set of atoms C sp 3 , N sp 3 , O sp 3 , C sp 2 , N sp 2 , O sp 2 Cl, H and the absence of any atom (\"vacuum\") were used as probes.", [["C", "CHEMICAL", 15, 16], ["N", "CHEMICAL", 24, 25], ["O", "CHEMICAL", 33, 34], ["C", "CHEMICAL", 42, 43], ["N", "CHEMICAL", 51, 52], ["O", "CHEMICAL", 60, 61], ["Cl", "CHEMICAL", 67, 69], ["H", "CHEMICAL", 71, 72], ["N sp 3", "SIMPLE_CHEMICAL", 24, 30], ["O sp 3", "SIMPLE_CHEMICAL", 33, 39], ["C sp 2 , N sp 2 , O sp 2 Cl, H", "SIMPLE_CHEMICAL", 42, 72], ["A set of atoms C sp", "TEST", 0, 19], ["sp", "TEST", 44, 46], ["sp", "TEST", 62, 64], ["any atom", "TEST", 92, 100]]], ["If CoMFA [16] uses energy attributes to characterize the analyzed cells, in LM the probabilities of the occupancy of a cell represents a different approach for the description of interactions between the molecule and the biological target.", [["cells", "ANATOMY", 66, 71], ["cell", "ANATOMY", 119, 123], ["cells", "CELL", 66, 71], ["cell", "CELL", 119, 123], ["the analyzed cells", "PROBLEM", 53, 71]]], ["It might be argued that a probability-based scheme offers improvements over an energy-based method.", [["an energy-based method", "TREATMENT", 76, 98]]], ["(4) A possibility of the presence of hydrogen bond donor or acceptors in the cell.Lattice ModelIt is assumed that such a hydrogen bond can be formed between this donor or this acceptor and the analyzed molecule.Lattice ModelAll structural parameters, i.e., integral, local, and field parameters contain an exhaustive description of the molecular structure.", [["cell", "ANATOMY", 77, 81], ["hydrogen", "CHEMICAL", 37, 45], ["hydrogen", "CHEMICAL", 121, 129], ["cell", "CELL", 77, 81], ["hydrogen bond donor", "TREATMENT", 37, 56], ["a hydrogen bond", "PROBLEM", 119, 134], ["this acceptor", "TREATMENT", 171, 184], ["Lattice ModelAll structural parameters", "TEST", 211, 249], ["local, and field parameters", "TEST", 267, 294], ["hydrogen bond", "OBSERVATION", 37, 50], ["molecular structure", "OBSERVATION", 336, 355]]], ["This reduces the probability of missing the most significant parameters required to correlate activity of the analyzed molecules with their structure.Lattice ModelThe efficiency of the LM approach has been demonstrated on different tasks, e.g., [19, 48, 51, 52] .Whole-Molecule Descriptors and Fourier Transform of Local ParametersSDs at all levels of differentiation (1D-4D) are the fragmentary parameters which describe not a molecule as a whole, but its different parts.", [["the LM approach", "TREATMENT", 181, 196], ["different tasks", "TEST", 222, 237], ["Local ParametersSDs", "TREATMENT", 315, 334], ["efficiency", "OBSERVATION_MODIFIER", 167, 177], ["LM", "ANATOMY", 185, 187]]], ["As a result of the Fourier transformation, the high-frequency harmonics characterize small fragments while the low-frequency harmonics correspond to the global molecule properties.", [["the Fourier transformation", "PROBLEM", 15, 41], ["small fragments", "PROBLEM", 85, 100], ["high", "OBSERVATION_MODIFIER", 47, 51], ["small", "OBSERVATION_MODIFIER", 85, 90], ["fragments", "OBSERVATION", 91, 100], ["low-frequency harmonics", "OBSERVATION_MODIFIER", 111, 134]]], ["(5-7):Whole-Molecule Descriptors and Fourier Transform of Local ParametersThe amplitudes and phase angle in Eq.", [["Whole-Molecule Descriptors", "TREATMENT", 6, 32], ["Local Parameters", "TEST", 58, 74]]], ["5-9 are defined as follows:Whole-Molecule Descriptors and Fourier Transform of Local Parameterswhere k is the number of harmonics, N is the total number of simplex descriptors, M = int(N-1)/2 is the total number of harmonics, a k and b k are the coefficients of expansion procedure, q n/2 = 0 for even N.Whole-Molecule Descriptors and Fourier Transform of Local ParametersValues of amplitudes (a k , b k , q k ) can be used as the parameters for the solution of QSAR tasks [19, 54] .", [["a k", "TEST", 226, 229], ["expansion procedure", "TREATMENT", 262, 281], ["Local ParametersValues", "TEST", 356, 378], ["amplitudes", "TEST", 382, 392], ["a k", "TEST", 394, 397], [", b k , q k )", "TREATMENT", 398, 411], ["QSAR tasks", "TEST", 462, 472]]], ["PLS equations containing amplitudes a k and b k can be mechanistically interpreted, because they can be represented as a linear combination of source structural parameters (5-7).", [["PLS equations", "TEST", 0, 13], ["a k and b k", "TEST", 36, 47]]], ["Amplitudes q k have poor mechanistic interpretation because of the more complex dependence from the source structural parameters (5) (6) (7) (8) (9) .", [["Amplitudes", "TEST", 0, 10], ["more complex", "OBSERVATION_MODIFIER", 67, 79], ["dependence", "OBSERVATION", 80, 90]]], ["However, all the amplitudes (a k , b k , q k ) separately or together allow for wellfitted, robust, and predictive models to be obtained; hence, they can be used as an additional (completely different) tool for the virtual screening.Whole-Molecule Descriptors and Fourier Transform of Local ParametersSuch whole-molecule parameters, such as characteristics of inertia ellipsoid (moments of inertia I X , I Y , I Z and its ratio I X /I Y , I Y /I Z , I X /I Z ), dipole moment, molecular refraction, lipophilicity, also can be used for different levels of representation of the molecular structure.Whole-Molecule Descriptors and Fourier Transform of Local ParametersAll mentioned integral parameters can be united with SD which usually leads to the most adequate model that unites the advantages of molecular descriptors of every mentioned type.Hierarchy of Statistical MethodsAs was mentioned above, different statistical methods have been used in HiT QSAR to establish the structure-activity relationship depending on the scale of the investigated property (binomial \u2192 nominal \u2192 ordinal \u2192 continual).Classification TreesThe classification tree (CT) approach is a non-parametric statistical method of analysis [55] .", [["I X", "PROTEIN", 398, 401], ["I Y", "PROTEIN", 404, 407], ["I Z", "PROTEIN", 410, 413], ["I X", "PROTEIN", 428, 431], ["I Y", "PROTEIN", 433, 436], ["I Y", "PROTEIN", 439, 442], ["I Z", "PROTEIN", 444, 447], ["I X", "PROTEIN", 450, 453], ["I Z", "PROTEIN", 455, 458], ["the amplitudes", "TEST", 13, 27], ["a k", "TEST", 29, 32], ["predictive models", "TEST", 104, 121], ["the virtual screening", "TEST", 211, 232], ["Whole-Molecule Descriptors", "TREATMENT", 233, 259], ["Local Parameters", "TEST", 285, 301], ["inertia ellipsoid", "TEST", 360, 377], ["Local Parameters", "TEST", 649, 665], ["HiT QSAR", "TEST", 948, 956], ["molecular refraction", "OBSERVATION", 477, 497], ["molecular structure", "OBSERVATION", 577, 596]]], ["It allows for the analysis of data sets regardless of the number of investigated compounds and the number of their characteristics (descriptors).", [["the analysis", "TEST", 14, 26]]], ["In the CT approach, the models obtained represent the hierarchical sets of rules based on descriptors selected for the description of the investigated property.", [["the CT approach", "TEST", 3, 18]]], ["For example, a simple rule can be \"IF lipophilicity > 3 THEN compound is active.\"", [["lipophilicity", "PROBLEM", 38, 51], ["active", "OBSERVATION_MODIFIER", 73, 79]]], ["In fact, such model is presented by a set of consecutive nodes, and each of them contains certain sets of compounds which correspond to this node rule.", [["node", "ANATOMY", 141, 145], ["consecutive nodes", "PROBLEM", 45, 62], ["this node rule", "TEST", 136, 150], ["nodes", "OBSERVATION", 57, 62], ["node", "OBSERVATION", 141, 145]]], ["The CT method has several advantages: obtaining of intuitively understandable models using natural language, quick learning and predicting processes, non-linearity of obtained models, and the ability to develop models using ranked values of the activity (it allows for the analysis of sets of compounds with heterogeneous experimental activity values).", [["The CT method", "TEST", 0, 13], ["the analysis", "TEST", 269, 281]]], ["The usage of CT methods for QSAR analysis is limited due to the poor mechanistic interpretation of the models.", [["CT methods", "TEST", 13, 23], ["QSAR analysis", "TEST", 28, 41]]], ["It is difficult to make quantitative estimation of the influence of descriptors used in the model and to determine structural fragments interfering or promoting activity.Classification TreesA new approach for the interpretation of CT models, based on a trend-vector procedure (see Section 5.2.3.3), has been proposed to solve this problem.", [["structural fragments", "PROBLEM", 115, 135], ["CT models", "TEST", 231, 240], ["a trend-vector procedure", "TREATMENT", 251, 275], ["fragments", "OBSERVATION", 126, 135]]], ["(5-11)]:Classification Treeswhere T j is the relative influence of jth descriptor on investigated property, m is the number of compounds in the certain node, A i is the activity rank of ith compound, and A mean is the mean value of activity rank for the whole set of compounds.", [["node", "ANATOMY", 152, 156], ["node", "MULTI-TISSUE_STRUCTURE", 152, 156], ["compounds", "OBSERVATION_MODIFIER", 127, 136], ["node", "OBSERVATION", 152, 156]]], ["The relative influence (T j ) of each descriptor used in the CT model are calculated by applying Eq.", [["The relative influence (T j ) of each descriptor", "TREATMENT", 0, 48], ["the CT model", "TEST", 57, 69]]], ["(5) (6) (7) (8) (9) (10) (11) to each node of the model (excepting the root node).", [["node", "ANATOMY", 38, 42], ["root node", "ANATOMY", 71, 80], ["root node", "MULTI-TISSUE_STRUCTURE", 71, 80], ["(5) (6) (7) (8) (9) (10) (11) to each node of the model", "PROBLEM", 0, 55], ["node", "OBSERVATION", 38, 42], ["root", "ANATOMY", 71, 75], ["node", "OBSERVATION", 76, 80]]], ["Furthermore, each calculated influence has a corresponding range of descriptor values (D) according to node rule, within which this influence has been implemented.", [["node rule", "TEST", 103, 112], ["node", "OBSERVATION", 103, 107]]], ["As a result of such analyses, ranges of descriptor values and corresponding relative influences can be determined.", [["such analyses", "TEST", 15, 28]]], ["It can be considered as a restriction of the method.", [["the method", "TREATMENT", 41, 51]]], ["However, estimation of activity level is an appropriate result in many cases relating to the investigation of biological activity.", [["estimation of activity level", "PROBLEM", 9, 37]]], ["In the case of the usage of simplex (fragmentary) descriptors for the representation of molecular structure, T j values obtained in this manner are the cumulative influences of all simplexes of a certain type in the molecule.", [["T j", "GENE_OR_GENE_PRODUCT", 109, 112], ["simplex (fragmentary) descriptors", "PROBLEM", 28, 61], ["T j values", "TEST", 109, 119], ["molecular structure", "OBSERVATION", 88, 107]]], ["(5) (6) (7) (8) (9) (10) (11) (12) .Classification Treeswhere T a is the relative influence of each atom included in the jth simplex of certain molecule, T j is the relative influence of the jth simplex, 4N j is the number of jth simplexes (value of jth descriptor) in certain molecules multiplied by four (number of atoms in a simplex).", [["simplex", "DISEASE", 328, 335], ["6) (7) (8) (9) (10)", "SIMPLE_CHEMICAL", 5, 24], ["T j", "GENE_OR_GENE_PRODUCT", 154, 157], ["T j", "PROTEIN", 154, 157]]], ["Calculated relative atom influences can be visualized on the investigated compounds.", [["Calculated relative atom influences", "PROBLEM", 0, 35], ["atom influences", "OBSERVATION", 20, 35]]], ["They allow for the determination of the relative influences of separate molecular fragments by summarizing the influences of individual atoms included in certain fragments.Trend-VectorThe trend-vector (TV) procedure [19, 56, 57] does not depend on the form of corresponding dependence and can use many structural parameters.", [["fragments", "ANATOMY", 162, 171], ["separate molecular fragments", "PROBLEM", 63, 91], ["individual atoms", "PROBLEM", 125, 141], ["The trend-vector (TV) procedure", "TREATMENT", 184, 215], ["corresponding dependence", "PROBLEM", 260, 284], ["molecular fragments", "OBSERVATION", 72, 91], ["certain fragments", "OBSERVATION", 154, 171]]], ["This method can predict the properties of analyzed molecules only in a rank scale and can be used if biological data are represented in an ordinal scale (see Figure 5 -1).", [["This method", "TREATMENT", 0, 11], ["a rank scale", "TEST", 69, 81], ["biological data", "TEST", 101, 116], ["an ordinal scale", "TEST", 136, 152]]], ["Similar to a dipole moment vector, TV characterizes a division of \"conventional charges\" (corresponding to active and inactive classes) in the multi-dimensional space of structural parameters S ij (i = 1,n -number of molecules, j = 1,m -number of structural parameters).", [["a dipole moment vector", "TREATMENT", 11, 33], ["active", "OBSERVATION_MODIFIER", 107, 113], ["ij", "ANATOMY", 194, 196]]], ["Each component of a TV is determined by Eq.", [["a TV", "TEST", 18, 22]]], ["(5-13)Trend-Vectorand reflects a degree and direction of influence of the jth structural parameter on the magnitude of a property A. The prediction of activity is obtained using the following relation:Trend-VectorIt is important to note that each component of the TV is calculated independently from the others and its contribution to a model is not adjusted.", [["the TV", "TEST", 260, 266]]], ["The quality of the structureproperty relationship can be estimated by the Spearman rank correlation coefficient calculated between ranks of the experimental and calculated activities A i .Trend-VectorThe search for models using the TV method in HiT QSAR is achieved by the methods of exhaustive or partial search after the removal of mutual correlations.", [["Trend-Vector", "TREATMENT", 188, 200], ["the TV method", "TREATMENT", 228, 241], ["HiT QSAR", "TEST", 245, 253], ["the removal", "TREATMENT", 319, 330]]], ["Noise elimination can be one of the probable explanations of the success of the TV procedure.Multiple Linear RegressionThe greatest number of QSAR/QSPR investigations has been made using linear statistic methods [58] .", [["the TV procedure", "TREATMENT", 76, 92], ["Multiple Linear Regression", "PROBLEM", 93, 119], ["QSAR/QSPR investigations", "TEST", 142, 166], ["Linear", "OBSERVATION_MODIFIER", 102, 108], ["Regression", "OBSERVATION", 109, 119], ["greatest", "OBSERVATION_MODIFIER", 123, 131], ["number", "OBSERVATION_MODIFIER", 132, 138]]], ["(5-15)]:Multiple Linear Regressionwhere y is the calculated values of investigated property (y), x i is the structural descriptors (independent variables), a i is the regression coefficients determined during the analysis by the least squares method, n is the number of variables in the regression equation.Multiple Linear RegressionThe use of linear approaches is very convenient for investigations because the theory of selection of the most important attributes and obtaining of the final equations is well developed for such methods.", [["the analysis", "TEST", 209, 221], ["Multiple Linear Regression", "PROBLEM", 307, 333], ["investigations", "TEST", 385, 399], ["Multiple", "OBSERVATION_MODIFIER", 8, 16], ["Linear", "OBSERVATION_MODIFIER", 17, 23], ["Regressionwhere", "OBSERVATION", 24, 39], ["Linear", "OBSERVATION_MODIFIER", 316, 322], ["Regression", "OBSERVATION", 323, 333]]], ["The R 2 value is explained by regression measure of the part of common scatter relative to average y.", [["R 2", "GENE_OR_GENE_PRODUCT", 4, 7], ["The R 2 value", "TEST", 0, 13]]], ["(5-16)] [58] :Multiple Linear Regressionwhere m is the number of molecules in the training set and F xp (n-1, m-n, 1-\u03b1) is the percent points of the F-distribution for given level of significance 1-\u03b1.", [["Multiple Linear Regressionwhere m", "PROBLEM", 14, 47], ["m-n", "TEST", 110, 113], ["Multiple", "OBSERVATION_MODIFIER", 14, 22], ["Linear", "OBSERVATION_MODIFIER", 23, 29], ["Regressionwhere", "OBSERVATION", 30, 45]]], ["The relative simplicity of regression approaches is also their shortcoming; they show poor results during the extrapolation of complicated structure-activity relationships.", [["simplicity", "OBSERVATION_MODIFIER", 13, 23]]], ["Their usage is further hampered in the case of large numbers of descriptors, since the total number of descriptors in a MLR equation must be at least ten times fewer than the number of training set compounds [59] .Partial Least Squares or Projection to Latent Structures (PLS)A great number of simplex descriptors have been generated in HiT QSAR.", [["a MLR equation", "TREATMENT", 118, 132], ["Partial Least Squares", "TREATMENT", 214, 235], ["simplex descriptors", "PROBLEM", 294, 313], ["large", "OBSERVATION_MODIFIER", 47, 52], ["numbers", "OBSERVATION_MODIFIER", 53, 60]]], ["The PLS regression model may be written as Eq.", [["The PLS regression model", "TREATMENT", 0, 24]]], ["This is not apparently different from MLR (see Section 5.2.3.3), except that the values of the coefficients b are calculated using PLS.", [["PLS", "TEST", 131, 134], ["not apparently", "UNCERTAINTY", 8, 22], ["different", "OBSERVATION_MODIFIER", 23, 32]]], ["However, the assumptions underlying PLS are radically different from those of MLR.", [["the assumptions underlying PLS", "PROBLEM", 9, 39]]], ["In PLS one assumes the x-variables to be collinear and PLS estimates the covariance structure in terms of a limited number of weights and loadings.", [["PLS", "DNA", 55, 58]]], ["In this way, PLS can analyze any number of x-variables (K) relating to the number of objects (N) [62] .Data Cleaning and MiningThe removal of highly correlated and constant descriptors, the use of genetic algorithms (GA) [63] , trend-vector methods [56, 57] , and automatic variable selection (AVS) strategies that are similar to interactive variable selection (IVS) [61] and evolutionary variable selection (EVS) [60] have been used for selection of descriptors in PLS.", [["Data Cleaning", "TREATMENT", 103, 116], ["The removal", "TREATMENT", 127, 138], ["genetic algorithms", "TEST", 197, 215], ["automatic variable selection (AVS) strategies", "PROBLEM", 264, 309], ["descriptors in PLS", "TEST", 451, 469]]], ["The removal of highly correlated descriptors is not necessary for PLS analysis, since descriptors are reduced to series of uncorrelated latent variables.", [["The removal", "TREATMENT", 0, 11], ["PLS analysis", "TEST", 66, 78]]], ["However, this procedure frequently helps to obtain more adequate models and reduce a number of used variables up to five times.", [["this procedure", "TREATMENT", 9, 23]]], ["During this procedure one descriptor from each pair having a pair correlation coefficient r satisfying |r| > 0.90 has been eliminated.Automatic Variable Selection (AVS) Strategy in PLSThe AVS strategy in PLS is used to obtain highly adequate models by removing the \"noise\" data, i.e., systematic variations in X (descriptors space) that are orthogonal to Y (investigated property).", [["this procedure", "TREATMENT", 7, 21], ["Automatic Variable Selection (AVS)", "TREATMENT", 134, 168], ["PLSThe AVS strategy", "TREATMENT", 181, 200], ["Variable", "OBSERVATION_MODIFIER", 144, 152], ["Selection", "OBSERVATION", 153, 162]]], ["This strategy is similar to IVS [61] , EVS [60] , OSC [64] , and O-PLS [65] and has the same objective but uses different means.", [["O-PLS", "SIMPLE_CHEMICAL", 65, 70], ["IVS", "TEST", 28, 31], ["EVS", "TEST", 39, 42], ["OSC", "TEST", 50, 53], ["PLS", "TEST", 67, 70]]], ["The essence of AVS consists of the following: at the first step of the AVS the model containing all descriptors is obtained.", [["AVS", "OBSERVATION", 15, 18]]], ["Then variables with the smallest normalized regression coefficients (b i , Eq.", [["the smallest normalized regression coefficients", "PROBLEM", 20, 67]]], ["This procedure has been repeated stepwise until the amount of variables equals 1.", [["This procedure", "TREATMENT", 0, 14]]], ["The AVS strategy can be used either for all structural parameters or after different variable selection procedures (e.g., removal of highly correlated descriptors, TV procedure, GA).", [["The AVS strategy", "TREATMENT", 0, 16], ["different variable selection procedures", "TREATMENT", 75, 114], ["removal", "TREATMENT", 122, 129], ["TV procedure", "TREATMENT", 164, 176]]], ["An application of the AVS procedure resulted in the decreasing of the model complexity (number of descriptors and latent variables) and an increase in model predictivity and robustness.Genetic AlgorithmsGA imitates such properties of living nature as natural selection, adaptability, heredity.", [["the AVS procedure", "TREATMENT", 18, 35], ["an increase in model predictivity", "PROBLEM", 136, 169], ["decreasing", "OBSERVATION_MODIFIER", 52, 62], ["model", "OBSERVATION_MODIFIER", 70, 75], ["complexity", "OBSERVATION_MODIFIER", 76, 86], ["increase", "OBSERVATION_MODIFIER", 139, 147], ["model predictivity", "OBSERVATION", 151, 169]]], ["The use of the heuristic organized operations of \"reproduction,\" \"crossing,\" and \"mutation\" from casual or user-selected starting \"populations\" generates the new \"chromosomes\" -or models.", [["chromosomes", "ANATOMY", 163, 174], ["chromosomes", "CELLULAR_COMPONENT", 163, 174], ["chromosomes", "DNA", 163, 174]]], ["The utility of the GA is its flexibility.", [["GA", "CHEMICAL", 19, 21]]], ["With adjustment of the small set of algorithm parameters (number of generations, crossover and mutation type, crossover and mutation probability, and type of selection), it is possible to find a balance between the time for search and the quality of decision.", [["algorithm parameters", "TEST", 36, 56], ["mutation probability", "PROBLEM", 124, 144], ["small", "OBSERVATION_MODIFIER", 23, 28]]], ["In the HiT QSAR, GA is used as a tool for the selection of adequate PLS, MLR, and TV models.", [["GA", "CHEMICAL", 17, 19], ["GA", "SIMPLE_CHEMICAL", 17, 19], ["MLR", "TEST", 73, 76]]], ["Descriptors from the best model obtained by the preliminary AVS procedure have usually been used as the starting \"population.\"", [["the preliminary AVS procedure", "TREATMENT", 44, 73]]], ["GA is not a tool for the elucidation of the global maximum or minimum, and very often a subsequent AVS procedure and different enumerative techniques allow one to increase the quality of the obtained PLS models.Enumerative TechniquesAs mentioned above, the usage of the methods of exhaustive or partial searching (depending on the number of selected descriptors) after AVS or GA very often allow one to increase the quality of the obtained models (PLS, MLR, and TV).", [["GA", "CHEMICAL", 0, 2], ["a subsequent AVS procedure", "TREATMENT", 86, 112], ["different enumerative techniques", "TREATMENT", 117, 149], ["AVS", "TREATMENT", 369, 372], ["PLS", "TEST", 448, 451]]], ["After the statistical processing model or models with the best combinations of statistic characteristics (R 2 , Q 2 ) have been selected from the obtained resulting list, and they may be submitted for subsequent validation using an external test set.", [["an external test set", "TEST", 229, 249]]], ["This procedure can be repeated several times using as input an initial set of SD of different levels of molecular structure representation (usually 2D-4D) and/or with various kinds of atom differentiation (see above) with the purpose to develop several resulting \"predictive\" QSAR models for consensus modeling.", [["This procedure", "TREATMENT", 0, 14], ["molecular structure representation", "PROBLEM", 104, 138], ["molecular structure", "OBSERVATION", 104, 123]]], ["This approach is believed to yield more accurate predictions.Validation of QSAR ModelsTo have any practical utility, up-to-date QSAR investigations must be used to make predictions [66] .", [["QSAR investigations", "TEST", 128, 147]]], ["Cross-validation is the statistical practice of partitioning a sample of data into subsets such that the analysis is initially performed on a single subset, while the other subset(s) are retained for subsequent use to confirm and validate the initial analysis.", [["the analysis", "TEST", 101, 113], ["the initial analysis", "TEST", 239, 259]]], ["In QSAR analysis, only two types of cross-validation are used:Validation of QSAR Models(1) K-fold cross-validation.", [["QSAR analysis", "TEST", 3, 16], ["QSAR Models", "TEST", 76, 87], ["K-fold cross-validation", "TEST", 91, 114]]], ["In K-fold cross-validation, the original sample is partitioned into K subsamples.", [["K", "CHEMICAL", 3, 4], ["the original sample", "TEST", 28, 47]]], ["Of the K subsamples, a single subsample is retained as the validation data for testing the model and the remaining K -1 subsamples are used as training data.", [["the validation data", "TEST", 55, 74], ["testing the model", "TEST", 79, 96], ["the remaining K", "TEST", 101, 116], ["training data", "TEST", 143, 156]]], ["The cross-validation process is then repeated K times (the folds), with each of the K subsamples used exactly once as the validation data.Validation of QSAR Models(2) Leave-one-out cross-validation.", [["the K subsamples", "TREATMENT", 80, 96], ["the validation data", "TEST", 118, 137]]], ["As the name suggests, leave-one-out crossvalidation (LOOCV) involves using a single observation from the original sample as the validation datum and the remaining observations as the training data.", [["the validation datum", "TEST", 124, 144], ["the training data", "TEST", 179, 196]]], ["This is repeated such that each observation in the sample is used once as the validation data.", [["the validation data", "TEST", 74, 93]]], ["This is the same as a K-fold cross-validation with K being equal to the number of observations in the original sample.Validation of QSAR ModelsThe determination coefficient (Q 2 ) calculated in cross-validation terms is the main characteristic of model robustness.", [["a K-fold cross-validation", "TREATMENT", 20, 45], ["K", "TEST", 51, 52], ["The determination coefficient", "TEST", 143, 172], ["main", "OBSERVATION_MODIFIER", 224, 228], ["model robustness", "OBSERVATION", 247, 263]]], ["The shortfalls of cross-validation are the following:Validation of QSAR Models(1) The training task must be solved N times leading to substantial calculative expenses in time and resources.", [["The training task", "TREATMENT", 82, 99]]], ["(2) The estimation of cross-validation assumes that the training algorithm is alreadyValidation of QSAR Modelsgiven.", [["the training algorithm", "TREATMENT", 52, 74]]], ["It has no idea how to obtain \"good\" algorithms and which properties must be inherent to them.", [["no", "UNCERTAINTY", 7, 9]]], ["(3) An attempt to use cross-validation for training as an optimizable criterion leads to loss of its unbiasedness property and there is a risk of overfitting.Validation of QSAR ModelsAt the same time statistical fit should not be confused with the ability of a model to make predictions.", [["cross-validation", "TEST", 22, 38], ["training", "TREATMENT", 43, 51], ["overfitting", "PROBLEM", 146, 157], ["overfitting", "OBSERVATION", 146, 157]]], ["The only method to obtain a meaningful assessment of statistical fit is to utilize the so-called \"test set\".", [["a meaningful assessment", "TEST", 26, 49]]], ["During this procedure a certain proportion of the data set molecules (10-85%) are removed to form the test set before the modeling process begins (remaining molecules form the training set).", [["this procedure", "TREATMENT", 7, 21], ["the test", "TEST", 98, 106]]], ["Once a model has been developed, predictions can be made for the test set.", [["the test set", "TEST", 61, 73]]], ["This is the only method by which the validity of a QSAR can be more or less truly assessed.", [["a QSAR", "TREATMENT", 49, 55]]], ["It is important that both training and test sets cover the structural space of the complete data set as much as possible.Validation of QSAR ModelsIn the HiT QSAR, the following procedure has been used for the formation of the test set: a dissimilarity matrix for all initial training set molecules has been developed on the basis of relevant structural descriptors.", [["test sets", "TEST", 39, 48], ["the following procedure", "TREATMENT", 163, 186], ["a dissimilarity matrix", "TREATMENT", 236, 258], ["all initial training set molecules", "TREATMENT", 263, 297]]], ["Such a descriptor set can be obtained using different procedures for descriptor selection (for example, see Chapter 4) or directly from the model generated for all investigated compounds.", [["different procedures", "TREATMENT", 44, 64], ["descriptor selection", "TEST", 69, 89]]], ["In our opinion the use of the whole set of descriptors generated at the very beginning is not completely correct, because during QSAR research we are interested not in structural similarity by itself, but from the point of view of the investigated activity and the descriptor selection will help the avoidance of some distortions caused by the insignificance of structural parameters from the initial set for this task.Validation of QSAR ModelsA dissimilarity matrix is based on the estimation of structural dissimilarity between all investigated molecules.", [["some distortions", "PROBLEM", 313, 329], ["this task", "TEST", 409, 418], ["structural dissimilarity", "PROBLEM", 497, 521]]], ["(5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) ]:Validation of QSAR Modelswhere n is the a number of molecules in data set.", [["6) (7) (8) (9) (10) (11) (12) (13", "SIMPLE_CHEMICAL", 5, 38]]], ["Thus, total structural dissimilarity toward the rest of initial training set compounds could be calculated for every molecule from a sum of the corresponding Euclidean distances.", [["total structural dissimilarity", "PROBLEM", 6, 36]]], ["Most likely, the use of several (three is the enough minimum) test sets constructed by different principles and subsequent comparison and averaging of the obtained results is more preferable than the use of only one set for the model validation.", [["test sets", "TEST", 62, 71], ["the model validation", "TEST", 224, 244]]], ["In that way, the first test set has been constructed to maximize its diversity from the training set, i.e., the compounds with maximal dissimilarity were chosen.", [["the first test set", "TEST", 13, 31]]], ["This is the most rigorous estimation, sometimes it can lead to the elimination of all of the dissimilar compounds from the training set, i.e., such splitting of the training set when the test set structures would not be predicted correctly by the developed model and would be situated outside of DA.", [["DA", "CHEMICAL", 296, 298], ["DA", "SIMPLE_CHEMICAL", 296, 298], ["the training", "TREATMENT", 161, 173], ["the test set structures", "TEST", 183, 206]]], ["The second test set is created in order to minimize its diversity from the training set, i.e., less dissimilar compounds from each group were removed.", [["The second test set", "TEST", 0, 19], ["less", "OBSERVATION_MODIFIER", 95, 99], ["dissimilar", "OBSERVATION_MODIFIER", 100, 110], ["compounds", "OBSERVATION_MODIFIER", 111, 120]]], ["The last test set has been chosen in random manner taking into account activity variation only.Hierarchy of Aims of QSAR InvestigationHiT QSAR provides not only hierarchy of molecular models, systems of descriptors, and statistical models, but also the hierarchy of the aims of QSAR investigation ( Figure 5-1 ).", [["The last test set", "TEST", 0, 17], ["QSAR Investigation", "TEST", 116, 134], ["HiT QSAR", "TEST", 134, 142], ["QSAR investigation", "TEST", 278, 296]]], ["Targets of the first level are activity prediction or virtual screening.", [["virtual screening", "TEST", 54, 71]]], ["Any descriptors could be used here, even those that are only poorly interpretable or noninterpretable, e.g., different topological indices, informational-topological indices, eigenvalues of various structural matrices.", [["topological indices", "TEST", 154, 173], ["various structural matrices", "OBSERVATION", 190, 217]]], ["In other words, at this level descriptors which are not expected to be used for subsequent analysis of structural factors promoting or interfering with activity can be used.", [["structural factors", "PROTEIN", 103, 121], ["structural factors", "PROBLEM", 103, 121]]], ["Only descriptors which have clear physico-chemical meaning, e.g., reflecting such parameters of the molecule such as dipole moment, lipophilicity, polarizability, van der Waals volume, can be used at this level.", [["lipophilicity, polarizability, van der Waals volume", "TREATMENT", 132, 183]]], ["Analysis of QSAR models corresponding to this level allows one to reveal structural factors promoting or interfering with the investigated property.", [["QSAR models", "TEST", 12, 23], ["structural factors", "PROBLEM", 73, 91]]], ["Such information can be useful for the generation of hypotheses about mechanisms of biological action and assumptions about the structure of biological target.", [["biological action", "TREATMENT", 84, 101]]], ["Finally, the presence of information useful for molecular design is expected from QSAR models corresponding to the third level of purposes.", [["molecular design", "PROBLEM", 48, 64], ["QSAR models", "TEST", 82, 93]]], ["As a rule, fragmentary descriptors have been used in such models.", [["fragmentary descriptors", "PROBLEM", 11, 34]]], ["In this case, the analysis of the degree and direction of influence of such descriptors on activity can give immediate information for the optimization of known structures and design of novel substances with desired properties.5.2.6.1.Virtual Screening (Including Consensus Modeling and DA)5.2.6.1.As mentioned above, QSAR investigations must be used to make predictions for compounds with unknown activity values (so-called \"virtual screening\").", [["DA", "CHEMICAL", 287, 289], ["the analysis", "TEST", 14, 26], ["known structures", "PROBLEM", 155, 171], ["Virtual Screening", "TEST", 235, 252], ["DA", "TEST", 287, 289], ["QSAR investigations", "TEST", 318, 337]]], ["It also represents one of the crucial concepts of HiT QSAR [31, 36] and can be briefly described by the statement \"More models that are good and different.\"", [["HiT QSAR", "TEST", 50, 58]]], ["The efficiency of this technique can be easily explained by the fact that nearly the same predictions obtained by different and independent methods (either statistical or descriptors generation) are more reliable than single prediction made by even the best fitted and predictable model.", [["this technique", "TREATMENT", 18, 32]]], ["From another aspect, in order to analyze the predictivity of PLS models and according to the OECD QSAR principles [38] , different DA procedures have been included in the HiT QSAR.", [["DA", "CHEMICAL", 131, 133], ["PLS models", "TEST", 61, 71], ["different DA procedures", "TREATMENT", 121, 144]]], ["The first procedure is an integral DA called \"ellipsoid\" developed by the authors [11] .", [["DA", "CHEMICAL", 35, 37], ["The first procedure", "TREATMENT", 0, 19]]], ["It represents a line at the 1D level; an ellipse at the 2D level; an ellipsoid at the 3D level; and multidimensional ellipsoids in more complicated n-dimensional spaces.", [["a line", "TREATMENT", 14, 20], ["an ellipse at the 2D level", "TEST", 38, 64], ["multidimensional ellipsoids in more complicated n-dimensional spaces", "PROBLEM", 100, 168], ["line", "OBSERVATION", 16, 20], ["ellipse", "OBSERVATION_MODIFIER", 41, 48], ["ellipsoid", "OBSERVATION_MODIFIER", 69, 78], ["multidimensional", "OBSERVATION_MODIFIER", 100, 116], ["ellipsoids", "OBSERVATION_MODIFIER", 117, 127], ["more complicated", "OBSERVATION_MODIFIER", 131, 147], ["n-dimensional spaces", "OBSERVATION", 148, 168]]], ["For each coordinate axis (T 1 and T 2 in our case) the root-mean-square deviations S T1 and S T2 have been determined.", [["root", "ANATOMY", 55, 59], ["square deviations S T1 and S T2", "PROBLEM", 65, 96], ["root", "ANATOMY", 55, 59]]], ["DA represents an ellipsoid that is built from the molecules of the training set distribution center (T 1 = 0; T 2 = 0) with the semi-axes length 3S T1 and 3S T2 , respectively [11] ( Figure 5-5) .", [["DA", "CHEMICAL", 0, 2], ["DA", "SIMPLE_CHEMICAL", 0, 2], ["an ellipsoid", "PROBLEM", 14, 26], ["the semi-axes length", "TEST", 124, 144], ["ellipsoid", "OBSERVATION", 17, 26]]], ["If a work set molecule does not correspond to the DA criteria, it is termed \"influential,\" i.e., it has unique (for given training set) structural features that distinguish it from the other compounds.", [["DA", "CHEMICAL", 50, 52], ["structural features", "PROBLEM", 136, 155]]], ["If a new molecule from the prediction set is situated out of the DA (region outside ellipsoid), its prognosis from the corresponding QSAR model is less reliable (model extrapolation).", [["DA", "CHEMICAL", 65, 67], ["a new molecule", "PROBLEM", 3, 17], ["the corresponding QSAR model", "TEST", 115, 143], ["new", "OBSERVATION_MODIFIER", 5, 8], ["molecule", "OBSERVATION_MODIFIER", 9, 17], ["DA", "ANATOMY", 65, 67]]], ["And, naturally, the prognoses for molecules nearest to the center of the DA are most reliable.5.2.6.1.The second approach -the integral DA rectangle has been also developed by the authors [11] .", [["DA", "CHEMICAL", 73, 75], ["DA", "CHEMICAL", 136, 138], ["DA", "SIMPLE_CHEMICAL", 73, 75], ["The second approach", "TREATMENT", 102, 121], ["the integral DA rectangle", "TREATMENT", 123, 148]]], ["Two extreme points (so-called virtual activity and inactivity etalons) are determined in a space of structural features.", [["extreme", "OBSERVATION_MODIFIER", 4, 11]]], ["The first one has maximal values of descriptors (training set data) promoting activity and minimal interfering.", [["minimal", "OBSERVATION_MODIFIER", 91, 98], ["interfering", "OBSERVATION", 99, 110]]], ["This point corresponds to a hypothetic molecule -the peculiar activity etalon.", [["hypothetic molecule", "PROTEIN", 28, 47], ["hypothetic molecule", "OBSERVATION", 28, 47], ["peculiar", "OBSERVATION_MODIFIER", 53, 61], ["activity etalon", "OBSERVATION", 62, 77]]], ["The second point, analogically, is an inactivity etalon, i.e. contains maximal values of descriptors interfering activity and minimal promoting.", [["an inactivity etalon", "TREATMENT", 35, 55], ["inactivity etalon", "OBSERVATION", 38, 55], ["minimal", "OBSERVATION_MODIFIER", 126, 133], ["promoting", "OBSERVATION_MODIFIER", 134, 143]]], ["Vectors that unite these points (directed from inactive to active) depict the tendency of activity change in the variable space.", [["Vectors", "TREATMENT", 0, 7], ["activity change in the variable space", "PROBLEM", 90, 127], ["activity change", "OBSERVATION", 90, 105], ["variable", "OBSERVATION_MODIFIER", 113, 121], ["space", "OBSERVATION_MODIFIER", 122, 127]]], ["This vector is a diagonal for the rectangle that determines DA [11] (Figure 5-5 ).", [["DA", "CHEMICAL", 60, 62], ["DA", "TEST", 60, 62]]], ["All the mentioned trends concern the \"influential\" points from the training set and model extrapolation for new molecules from the prediction set remain and for the DA rectangle approach.5.2.6.1.The third method is based on the estimation of leverage value h i [68] .", [["DA", "CHEMICAL", 165, 167], ["model extrapolation", "TREATMENT", 84, 103], ["new molecules", "PROBLEM", 108, 121], ["the DA rectangle approach", "TREATMENT", 161, 186]]], ["It has been visualized as a Williams plot [69] and is described in detail in [70] .", [["a Williams plot", "TEST", 26, 41]]], ["For leverage, a value of 3 is commonly used as a cut-off value for accepting predictions, because points that lie \u00b13 standard deviations from the mean cover 99% of the normally distributed data.", [["a value", "TEST", 14, 21]]], ["For training set molecules high leverage values do not always indicate outliers from the model, i.e., points that are outside the model domain.", [["training set molecules", "TEST", 4, 26]]], ["If high leverage points (h i > h cr , separated by vertical bold line) fit the model well (i.e., have small residuals), they are called \"good high leverage points\" or good influence points.", [["cr", "TEST", 33, 35], ["small residuals", "PROBLEM", 102, 117], ["small", "OBSERVATION_MODIFIER", 102, 107], ["residuals", "OBSERVATION", 108, 117]]], ["High leverage points, which do not fit the model (i.e., have large residuals) are called \"bad high leverage points\" or bad influence points.", [["High leverage points", "PROBLEM", 0, 20], ["large residuals", "PROBLEM", 61, 76], ["large", "OBSERVATION_MODIFIER", 61, 66], ["residuals", "OBSERVATION", 67, 76]]], ["A new molecule is situated out of the DA (model extrapolation) if it has h i > h cr = 3(A+1)/M, where A -number of the PLS latent variables and M -number of molecules in a work set.5.2.6.1.Recently, a local (Tree) approach for DA estimation has been developed by authors in order to avoid the inclusion of hollow space into the DA that is the lack of integral DA methods.", [["DA", "CHEMICAL", 38, 40], ["DA", "CHEMICAL", 227, 229], ["DA", "CHEMICAL", 328, 330], ["DA", "CHEMICAL", 360, 362], ["DA", "SIMPLE_CHEMICAL", 38, 40], ["DA", "SIMPLE_CHEMICAL", 227, 229], ["DA", "SIMPLE_CHEMICAL", 328, 330], ["DA", "SIMPLE_CHEMICAL", 360, 362], ["A new molecule", "PROBLEM", 0, 14], ["cr", "TEST", 81, 83], ["a local (Tree) approach", "TREATMENT", 199, 222], ["DA estimation", "TEST", 227, 240], ["new", "OBSERVATION_MODIFIER", 2, 5], ["molecule", "OBSERVATION", 6, 14], ["DA", "ANATOMY", 38, 40]]], ["The following are required for its realization:5.2.6.1.(1) Obtaining of a distance matrix between the training set molecules in the structural space of descriptors of the QSAR model.", [["a distance matrix", "TREATMENT", 72, 89], ["the training set molecules", "TREATMENT", 98, 124]]], ["The molecules in the given approach have been analyzed in the coordinates of the latent variables of the PLS model considered.5.2.6.1.(2) Detection of the shortest distances between molecules using the abovementioned matrix.", [["matrix", "CELLULAR_COMPONENT", 217, 223], ["the PLS model", "TEST", 101, 114], ["the abovementioned matrix", "TREATMENT", 198, 223], ["molecules", "OBSERVATION_MODIFIER", 4, 13]]], ["Building of an extreme short distance tree for all training set molecules.", [["an extreme short distance tree", "TREATMENT", 12, 42], ["all training set molecules", "TREATMENT", 47, 73], ["extreme", "OBSERVATION_MODIFIER", 15, 22], ["short", "OBSERVATION_MODIFIER", 23, 28]]], ["(3) Finding of average distance (d av ) and its root-mean-square deviation (\u03c3 ) for inclusion in the tree average values.", [["average distance (d av ) and its root", "PROBLEM", 15, 52], ["av", "ANATOMY", 35, 37], ["root", "ANATOMY", 48, 52], ["square deviation", "OBSERVATION", 58, 74], ["tree", "ANATOMY_MODIFIER", 101, 105]]], ["Such a distance is the characteristic of average density of molecules distribution in the structural space.5.2.6.1.Following this procedure, all the points corresponding to test set molecules have been taken into account in the structural space.", [["this procedure", "TREATMENT", 125, 139], ["test set molecules", "TEST", 173, 191], ["average", "OBSERVATION_MODIFIER", 41, 48], ["density", "OBSERVATION", 49, 56], ["molecules", "OBSERVATION_MODIFIER", 60, 69], ["distribution", "OBSERVATION_MODIFIER", 70, 82], ["structural space", "OBSERVATION", 90, 106]]], ["If any of test set molecules have been situated on the distance bigger than d av +3\u03c3 from the nearest training set point, it means that this test set molecule is situated outside DA.", [["DA", "CHEMICAL", 179, 181], ["DA", "SIMPLE_CHEMICAL", 179, 181], ["test set molecules", "TEST", 10, 28]]], ["Respectively, molecules belonging to the DA are situated on the distance less than d av +3\u03c3 from the training set points.", [["DA", "CHEMICAL", 41, 43], ["DA", "SIMPLE_CHEMICAL", 41, 43]]], ["The scheme of DA estimation has been depicted in Figure 5 -5.5.2.6.1.Such an approach for DA estimation is similar, to some extent, to methods described in [70] .", [["DA", "CHEMICAL", 14, 16], ["DA", "CHEMICAL", 90, 92], ["DA estimation", "TEST", 14, 27], ["DA estimation", "TEST", 90, 103]]], ["As opposed to integral approaches, e.g. [11] , where the convex region (polyhedron, ellipsoid) which could contain vast cavities has been determined in the structural space, the approach presented here is local.", [["vast cavities", "PROBLEM", 115, 128], ["convex", "ANATOMY_MODIFIER", 57, 63], ["vast cavities", "OBSERVATION", 115, 128]]], ["The presence of cavities in the structural space which correspond to DA is undesirable and it has been eliminated in the given approach.5.2.6.1.Summarizing, it's necessary to note that if a new structure is lying inside the DA, it is not a final argument for a correct prediction; rather, it is an indication of the reduced uncertainty of a prediction.", [["DA", "CHEMICAL", 69, 71], ["DA", "CHEMICAL", 224, 226], ["DA", "SIMPLE_CHEMICAL", 69, 71], ["DA", "SIMPLE_CHEMICAL", 224, 226], ["cavities in the structural space", "PROBLEM", 16, 48], ["DA", "PROBLEM", 69, 71], ["cavities", "OBSERVATION", 16, 24], ["structural space", "OBSERVATION", 32, 48], ["DA", "OBSERVATION", 69, 71], ["undesirable", "OBSERVATION_MODIFIER", 75, 86], ["reduced", "OBSERVATION_MODIFIER", 316, 323]]], ["In exactly the same way, the situation of the compound outside the DA does not lead to the rejection of the prediction; it is just an indication of the increased uncertainty of the subsequent virtual screening prediction.", [["DA", "CHEMICAL", 67, 69], ["DA", "SIMPLE_CHEMICAL", 67, 69], ["virtual screening prediction", "TEST", 192, 220], ["rejection", "OBSERVATION", 91, 100], ["increased", "OBSERVATION_MODIFIER", 152, 161]]], ["Unfortunately, there is currently no unbiased estimation of prognosis reliability, and the relative character of any DA procedure was reflected in [11, 70] .", [["DA", "CHEMICAL", 117, 119], ["DA", "SIMPLE_CHEMICAL", 117, 119], ["any DA procedure", "TREATMENT", 113, 129]]], ["Thus, it should be remembered that the DA is not a guide to action but only a probable recommendation.5.2.6.1.All of the mentioned DA procedures together, or separately, are applied to selected single models before being averaged in consensus model.", [["DA", "CHEMICAL", 39, 41], ["DA", "CHEMICAL", 131, 133], ["DA", "SIMPLE_CHEMICAL", 39, 41], ["DA procedures", "TREATMENT", 131, 144]]], ["The accuracy of the DA consensus model has been compared with the adequacy of consensus models without DA consideration.", [["DA", "CHEMICAL", 20, 22], ["DA", "CHEMICAL", 103, 105]]], ["The authors recommend the use of consensus DA models for subsequent virtual screening excepting the case of substantial loss of coverage of training and prediction sets with only a limited benefit in predictivity.Inverse Task Solution and Interpretation of QSAR ModelsUsing Eq.Inverse Task Solution and Interpretation of QSAR ModelsAccording to this formula, the atom contribution depends on the number of simplexes which include this atom.", [["DA", "CHEMICAL", 43, 45], ["subsequent virtual screening", "TEST", 57, 85], ["coverage of training", "TREATMENT", 128, 148], ["Inverse Task Solution", "TREATMENT", 213, 234], ["QSAR ModelsUsing Eq.Inverse Task Solution", "TREATMENT", 257, 298], ["QSAR ModelsAccording", "TREATMENT", 321, 341]]], ["This value (number of simplexes) is not constant; it varies in different molecules and depends on other constituents (surroundings), and hence, this contribution is non-additive.", [["This value", "TEST", 0, 10], ["not", "UNCERTAINTY", 36, 39], ["constant", "OBSERVATION_MODIFIER", 40, 48]]], ["Atoms that have a positive or negative influence on the studied biological activity of compounds can be colored.", [["a positive or negative influence", "PROBLEM", 16, 48]]], ["Atoms and structural fragments reducing antiviral activity are colored in red (dark gray in printed version) and that enhance antiviral Atoms and structural fragments reducing antiviral activity are colored in dark gray and that enhancing antiviral activity in light gray and white activity in green (light gray and white in printed version).", [["Atoms and structural fragments", "PROBLEM", 0, 30], ["antiviral activity", "PROBLEM", 40, 58], ["red (dark gray", "PROBLEM", 74, 88], ["enhance antiviral Atoms", "PROBLEM", 118, 141], ["structural fragments", "PROBLEM", 146, 166], ["colored in dark gray", "PROBLEM", 199, 219], ["light gray", "TEST", 261, 271], ["white activity in green (light gray", "PROBLEM", 276, 311], ["structural", "OBSERVATION_MODIFIER", 10, 20], ["fragments", "OBSERVATION_MODIFIER", 21, 30], ["reducing", "OBSERVATION_MODIFIER", 31, 39], ["antiviral activity", "OBSERVATION", 40, 58], ["antiviral Atoms", "OBSERVATION", 126, 141], ["fragments", "OBSERVATION_MODIFIER", 157, 166], ["antiviral activity", "OBSERVATION", 176, 194], ["dark gray", "OBSERVATION_MODIFIER", 210, 219], ["enhancing", "OBSERVATION_MODIFIER", 229, 238], ["antiviral activity", "OBSERVATION", 239, 257], ["white activity", "OBSERVATION_MODIFIER", 276, 290]]], ["Atoms and fragments with no effect are colored in gray.Inverse Task Solution and Interpretation of QSAR ModelsThe automatic search procedure for pre-defined fragments from the data set and their relative effect on activity has been realized in HiT QSAR.", [["fragments", "ANATOMY", 10, 19], ["Atoms and fragments", "PROBLEM", 0, 19], ["Inverse Task Solution", "TREATMENT", 55, 76], ["The automatic search procedure", "TREATMENT", 110, 140], ["pre-defined fragments", "PROBLEM", 145, 166], ["the data", "TEST", 172, 180], ["fragments", "OBSERVATION", 10, 19], ["no", "UNCERTAINTY", 25, 27], ["effect", "OBSERVATION_MODIFIER", 28, 34], ["colored", "OBSERVATION", 39, 46], ["fragments", "OBSERVATION", 157, 166]]], ["The procedure of the fragment searching in molecule is based on a fast algorithm for solving the maximum clique problem [71] .", [["The procedure", "TREATMENT", 0, 13], ["the fragment", "PROBLEM", 17, 29], ["a fast algorithm", "TEST", 64, 80], ["solving the maximum clique problem", "TREATMENT", 85, 119], ["fragment", "OBSERVATION", 21, 29]]], ["Some molecular fragments promoting and interfering anti-influenza activity [12, 29, 34] are represented in Table 5 -1 as well as their average relative influence on it.Molecular DesignIt is possible to design compounds with a desired activity level from the SiRMS via the generation of allowed combinations of simplexes determining the investigated property.", [["SiRMS", "SIMPLE_CHEMICAL", 258, 263], ["simplexes", "SIMPLE_CHEMICAL", 310, 319], ["Some molecular fragments", "PROBLEM", 0, 24], ["design compounds", "PROBLEM", 202, 218], ["simplexes", "TREATMENT", 310, 319], ["molecular", "OBSERVATION_MODIFIER", 5, 14], ["fragments", "OBSERVATION", 15, 24], ["interfering", "OBSERVATION_MODIFIER", 39, 50], ["anti-influenza activity", "OBSERVATION", 51, 74]]], ["The simplest way is soft drug design [72] that consists of replacing of undesired substituents by more active ones, or by the insertion of fragments, promoting the activity instead of non-active parts of molecule or hydrogen atoms.", [["hydrogen", "CHEMICAL", 216, 224], ["hydrogen", "CHEMICAL", 216, 224], ["hydrogen atoms", "SIMPLE_CHEMICAL", 216, 230], ["undesired substituents", "PROBLEM", 72, 94], ["the insertion of fragments", "TREATMENT", 122, 148], ["soft drug", "OBSERVATION_MODIFIER", 20, 29], ["undesired substituents", "OBSERVATION", 72, 94], ["active", "OBSERVATION_MODIFIER", 103, 109], ["fragments", "OBSERVATION", 139, 148], ["activity", "OBSERVATION_MODIFIER", 164, 172]]], ["The use of this technique allows one to retain newly designed compounds in the same region of structural space as the training set compounds.", [["this technique", "TREATMENT", 11, 25], ["structural space", "OBSERVATION", 94, 110]]], ["The accuracy of prognosis can be estimated using the DA techniques (see below).", [["DA", "CHEMICAL", 53, 55], ["the DA techniques", "TREATMENT", 49, 66]]], ["However, the use of soft drug design keeps within the limits of the initial chemical class of training set compounds.", [["soft drug design", "TREATMENT", 20, 36]]], ["More drastic drug design is, certainly, more risky, but it allows for much more dramatic results.", [["drastic", "OBSERVATION_MODIFIER", 5, 12], ["drug", "OBSERVATION", 13, 17]]], ["Almost certainly, new structures would lie outside the DA region.", [["DA", "CHEMICAL", 55, 57], ["new structures", "PROBLEM", 18, 32], ["new", "OBSERVATION_MODIFIER", 18, 21], ["DA", "OBSERVATION", 55, 57]]], ["That, however, does not mean uncertainty of prediction, but extrapolation of the model predictivity and a certain lack of any DA procedure.", [["DA", "CHEMICAL", 126, 128], ["any DA procedure", "TREATMENT", 122, 138]]], ["It was demonstrated in [12, 28, 29] , where, in searching for a new antiviral and anticancer agents, we started our investigations from macrocyclic pyridinophanes and through several convolutions of QSAR analyses came out with nitrogen analogues of crown ethers in the first and acyclic aromatic structures with the azomethine fragment in the second case.HiT QSAR SoftwareThe HiT QSAR software for Windows has been designed and developed as an instrument for high-value QSAR investigations including the solution of the following tasks: As was mentioned above, the proposed technology operates on a set of different models.", [["anticancer", "ANATOMY", 82, 92], ["pyridinophanes", "CHEMICAL", 148, 162], ["nitrogen", "CHEMICAL", 227, 235], ["crown ethers", "CHEMICAL", 249, 261], ["azomethine", "CHEMICAL", 316, 326], ["pyridinophanes", "CHEMICAL", 148, 162], ["nitrogen", "CHEMICAL", 227, 235], ["crown ethers", "CHEMICAL", 249, 261], ["azomethine", "CHEMICAL", 316, 326], ["anticancer", "CANCER", 82, 92], ["macrocyclic pyridinophanes", "SIMPLE_CHEMICAL", 136, 162], ["crown ethers", "SIMPLE_CHEMICAL", 249, 261], ["azomethine", "SIMPLE_CHEMICAL", 316, 326], ["a new antiviral and anticancer agents", "TREATMENT", 62, 99], ["our investigations", "TEST", 112, 130], ["macrocyclic pyridinophanes", "TREATMENT", 136, 162], ["QSAR analyses", "TEST", 199, 212], ["nitrogen analogues of crown ethers", "TREATMENT", 227, 261], ["the azomethine fragment", "TREATMENT", 312, 335], ["The HiT QSAR software", "TEST", 372, 393], ["an instrument", "TEST", 441, 454], ["QSAR investigations", "TEST", 470, 489], ["new", "OBSERVATION_MODIFIER", 64, 67], ["antiviral", "OBSERVATION", 68, 77], ["crown ethers", "OBSERVATION", 249, 261], ["azomethine fragment", "OBSERVATION", 316, 335]]], ["At the preliminary stage \"Model 0\" (Figure 5-7) is generated for the initial division of investigated molecules into training and test sets.", [["test sets", "TEST", 130, 139]]], ["In all cases, such statistical characteristics as R 2 , Q 2 , R 2 test have been taken into account as well as the model DA.COMPARATIVE ANALYSIS OF HiT QSAR EFFICIENCYThe HiT QSAR based on SiRMS has proved efficient in numerous studies to solve different \"structure-activity/property\" problems [3, 10-12, 25-30, 33, 35] and it has been interesting to compare it with the other successful QSAR approaches and software.", [["DA", "CHEMICAL", 121, 123], ["SiRMS", "CHEMICAL", 189, 194], ["Q 2 , R 2 test", "TEST", 56, 70], ["HiT QSAR", "TEST", 148, 156], ["HiT QSAR", "TEST", 171, 179], ["SiRMS", "TREATMENT", 189, 194]]], ["The results of a comparative analysis are shown in Table 5 -2.", [["a comparative analysis", "TEST", 15, 37]]], ["Obviously, HiT QSAR does not have the problem of the optimal alignment of the set of molecules considered that is inherent to CoMFA and its analogues [16] [17] [18] [19] .", [["CoMFA", "SIMPLE_CHEMICAL", 126, 131], ["[16] [17] [18] [19]", "SIMPLE_CHEMICAL", 150, 169], ["HiT QSAR", "TEST", 11, 19]]], ["The SiRMS approach is similar to HQSAR [20] in certain ways, but has none of its restrictions (only topological representation of molecular structure an ambiguity of descriptor formation during the molecular hologram hashing).", [["The SiRMS approach", "TREATMENT", 0, 18], ["the molecular hologram hashing", "TREATMENT", 194, 224]]], ["In addition, contrary to HQSAR, different physical and chemical properties of atoms (charge, lipophilicity, etc.) can be taken into account in SiRMS (Table 5 -2).", [["HQSAR", "TREATMENT", 25, 30]]], ["Thus, main advantages of the HiT QSAR are the following:COMPARATIVE ANALYSIS OF HiT QSAR EFFICIENCY\u2022 The use of different (1D-4D) levels of molecular modeling; \u2022 The absence of the \"molecular alignment\" problem;COMPARATIVE ANALYSIS OF HiT QSAR EFFICIENCY\u2022 Explicit consideration of stereochemical features of molecules; \u2022 Consideration of different physical and chemical properties of atoms;COMPARATIVE ANALYSIS OF HiT QSAR EFFICIENCY\u2022 Clear methods (rules) for molecular design.Angiotensin Converting Enzyme (ACE) InhibitorsAfter such a theoretical comparative analysis, it was logical to test the efficiency of the proposed HiT QSAR on real representative sets of compounds.", [["Angiotensin", "CHEMICAL", 479, 490], ["Angiotensin Converting Enzyme", "GENE_OR_GENE_PRODUCT", 479, 508], ["ACE", "GENE_OR_GENE_PRODUCT", 510, 513], ["the HiT QSAR", "TEST", 25, 37], ["different (1D-4D)", "TREATMENT", 112, 129], ["the \"molecular alignment\" problem", "PROBLEM", 177, 210], ["stereochemical features of molecules", "PROBLEM", 282, 318], ["Angiotensin Converting Enzyme (ACE) Inhibitors", "TREATMENT", 479, 525], ["a theoretical comparative analysis", "TEST", 536, 570], ["the proposed HiT QSAR", "PROBLEM", 613, 634]]], ["All such sets only contain structurally similar compounds to avoid the \"molecular alignment\" problem and, therefore, to facilitate the usage of the \"lattice\" approaches (CoMFA and CoMSIA).", [["the \"molecular alignment\" problem", "PROBLEM", 67, 100], ["the \"lattice\" approaches", "TREATMENT", 144, 168], ["structurally", "OBSERVATION_MODIFIER", 27, 39], ["similar compounds", "OBSERVATION", 40, 57]]], ["One hundred and fourteen angiotensin converting enzyme (ACE) inhibitors [73] represent the first set.", [["angiotensin", "CHEMICAL", 25, 36], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 25, 54], ["ACE", "GENE_OR_GENE_PRODUCT", 56, 59], ["angiotensin converting enzyme", "PROTEIN", 25, 54], ["ACE", "PROTEIN", 56, 59], ["fourteen angiotensin converting enzyme (ACE) inhibitors", "TREATMENT", 16, 71]]], ["Different statistic models obtained byAngiotensin Converting Enzyme (ACE) InhibitorsHiT QSAR have been compared with those published in [73] .", [["byAngiotensin Converting Enzyme", "GENE_OR_GENE_PRODUCT", 36, 67], ["Different statistic models", "PROBLEM", 0, 26], ["byAngiotensin Converting Enzyme (ACE) Inhibitors", "TREATMENT", 36, 84], ["HiT QSAR", "TEST", 84, 92]]], ["The structure of enalaprat -a representative compound from the ACE data set is displayed below:Angiotensin Converting Enzyme (ACE) InhibitorsThe ability of ACE inhibition (pIC 50 ) has been investigated.", [["enalaprat", "CHEMICAL", 17, 26], ["Angiotensin", "CHEMICAL", 95, 106], ["enalaprat", "CHEMICAL", 17, 26], ["enalaprat", "SIMPLE_CHEMICAL", 17, 26], ["ACE", "GENE_OR_GENE_PRODUCT", 63, 66], ["Angiotensin Converting Enzyme", "GENE_OR_GENE_PRODUCT", 95, 124], ["ACE", "GENE_OR_GENE_PRODUCT", 126, 129], ["ACE", "GENE_OR_GENE_PRODUCT", 156, 159], ["the ACE data", "TEST", 59, 71], ["Angiotensin Converting Enzyme (ACE) Inhibitors", "TREATMENT", 95, 141], ["ACE inhibition (pIC", "TREATMENT", 156, 175]]], ["The training set consists of 76 compounds and 38 structures were used in a test set [73] .", [["a test set", "TEST", 73, 83]]], ["In the given work, we have compared the resulting PLS-models built with the use of descriptors generated from the following QSAR approaches:Angiotensin Converting Enzyme (ACE) Inhibitors(a) CoMFA -comparative molecular fields analysis [16] ; (b) CoMSIA -comparative molecular similarity indexes analysis [18] ; (c) EVA -eigenvalue analysis [74] ; (d) HQSAR -hologram QSAR [20] ; (e) the Cerius 2 program (Accelrys, Inc., San Diego, CA) -method of traditional integral (whole-molecule) 2D and 2.5D 2 descriptors generation; (f) HiT QSAR based on SiRMS [3, 11, 32] .Angiotensin Converting Enzyme (ACE) InhibitorsBecause all the mentioned approaches compare parameters generated at 2D or 3D levels of molecular structure representation, the corresponding SD, the Fourier parameters, and united models with mixed (simplex + Fourier) parameters were taken for comparison.", [["Angiotensin", "CHEMICAL", 140, 151], ["Angiotensin", "CHEMICAL", 564, 575], ["Angiotensin Converting Enzyme", "GENE_OR_GENE_PRODUCT", 140, 169], ["ACE", "SIMPLE_CHEMICAL", 171, 174], ["Angiotensin Converting Enzyme", "GENE_OR_GENE_PRODUCT", 564, 593], ["ACE", "GENE_OR_GENE_PRODUCT", 595, 598], ["Angiotensin Converting Enzyme (ACE) Inhibitors", "TREATMENT", 140, 186], ["CoMFA", "TEST", 190, 195], ["comparative molecular fields analysis", "TEST", 197, 234], ["CoMSIA", "TEST", 246, 252], ["eigenvalue analysis", "TEST", 320, 339], ["traditional integral (whole-molecule) 2D", "TREATMENT", 447, 487], ["HiT QSAR", "TEST", 527, 535], ["Angiotensin Converting Enzyme (ACE) Inhibitors", "TREATMENT", 564, 610], ["the Fourier parameters", "TEST", 756, 778], ["mixed (simplex + Fourier) parameters", "TREATMENT", 803, 839]]], ["The advantage of HiT QSAR over other methods is revealed by the comparison of such statistical descriptions of the QSAR models, as the determination coefficient for training (R 2 ) and test (R 2 test ) sets; the determination coefficient calculated in the cross-validation terms (Q 2 ) as well as the standard errors of prediction for both sets (see Table 5 -3).", [["HiT", "SIMPLE_CHEMICAL", 17, 20], ["HiT QSAR", "TEST", 17, 25], ["other methods", "TEST", 31, 44], ["test (R 2 test ) sets", "TEST", 185, 206], ["the determination coefficient", "TEST", 208, 237]]], ["For example, for SiRMS Q 2 = 0.81-0.87, for the Fourier models Q 2 = 0.73-0.80, and for the other methods Q 2 = 0.65-0.72.", [["SiRMS", "TEST", 17, 22], ["the Fourier models", "TEST", 44, 62], ["the other methods", "TEST", 88, 105]]], ["It is necessary to note that the transition to 3D level allows for the improvement of the quality of the QSAR models obtained.", [["the QSAR models", "TEST", 101, 116]]], ["At the same time, the usage of the Fourier parameters does not lead to good predictive models (R 2 test = 0.37-0.51) for this task.", [["the Fourier parameters", "TEST", 31, 53], ["this task", "TEST", 121, 130]]], ["United models (simplex + Fourier) have the same predictive power as the simplex ones, but, because of the presence of integral parameters, they are sufficiently different to provide another aspect of the property.Acetylcholinesterase (AChE) InhibitorsThe second set used for comparative analysis consisted of 111 acetylcholinesterase (AChE) inhibitors.", [["Acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 213, 233], ["AChE", "GENE_OR_GENE_PRODUCT", 235, 239], ["acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 313, 333], ["AChE", "GENE_OR_GENE_PRODUCT", 335, 339], ["Acetylcholinesterase", "PROTEIN", 213, 233], ["AChE", "PROTEIN", 235, 239], ["AChE", "PROTEIN", 335, 339], ["Acetylcholinesterase (AChE) Inhibitors", "TREATMENT", 213, 251], ["comparative analysis", "TEST", 275, 295], ["111 acetylcholinesterase (AChE) inhibitors", "TREATMENT", 309, 351]]], ["The structure of E2020 -a representative compound from the AChE data set is displayed below:Acetylcholinesterase (AChE) InhibitorsThe ability to model AChE inhibition (pIC 50 ) has been investigated.", [["E2020", "CHEMICAL", 17, 22], ["E2020", "CHEMICAL", 17, 22], ["E2020", "SIMPLE_CHEMICAL", 17, 22], ["AChE", "GENE_OR_GENE_PRODUCT", 59, 63], ["Acetylcholinesterase", "GENE_OR_GENE_PRODUCT", 92, 112], ["AChE", "GENE_OR_GENE_PRODUCT", 114, 118], ["AChE", "GENE_OR_GENE_PRODUCT", 151, 155], ["AChE", "PROTEIN", 59, 63], ["Acetylcholinesterase", "PROTEIN", 92, 112], ["AChE", "PROTEIN", 114, 118], ["AChE", "PROTEIN", 151, 155], ["the AChE data", "TEST", 55, 68], ["Acetylcholinesterase (AChE) Inhibitors", "TREATMENT", 92, 130], ["model AChE inhibition (pIC", "TREATMENT", 145, 171]]], ["The training set consists of 74 compounds and 37 structures were used as a test set [73] .", [["a test set", "TEST", 73, 83]]], ["The main trends revealed for the ACE set were also the same for the AChE inhibitors.", [["ACE", "GENE_OR_GENE_PRODUCT", 33, 36], ["AChE", "GENE_OR_GENE_PRODUCT", 68, 72], ["the ACE set", "TREATMENT", 29, 40], ["the AChE inhibitors", "TREATMENT", 64, 83], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The advantage of HiT QSAR over other methods have been observed with all statistical parameters (Table 5 -3), but especially on predictivity of the models: for SiRMS R 2 test = 0.74-0.82, for the Fourier models R 2 test = 0.59-0.61, and for the other methods R 2 test = 0.16-0.47.", [["HiT", "SIMPLE_CHEMICAL", 17, 20], ["HiT QSAR", "TEST", 17, 25], ["other methods", "TREATMENT", 31, 44], ["SiRMS R 2 test", "TEST", 160, 174], ["the Fourier models", "TEST", 192, 210], ["the other methods", "TEST", 241, 258]]], ["As in the previous case, consideration of the spatial structure of investigated compounds improved the quality of the models obtained. where R 2 -correlation coefficient Q 2 -cross-validation correlation coefficient (10-fold, see Chapter 5) R 2 test -correlation coefficient for test set S ws -standard error of a prediction for training set S test -standard error of a prediction for test set A -number of PLS latent variables * Statistic characteristics from [73] were shown * * Mix = Simplex + Fourier descriptors Summarizing, it is necessary to note that we understand that the advantage of simplex descriptors generated in HiT QSAR may be partially a result of some of the differences in the statistical approaches applied (e.g., in addition to GA, TV and AVS procedures have been used).", [["test", "TEST", 279, 283], ["training set S test", "TEST", 329, 348], ["a prediction", "TEST", 368, 380], ["test", "TEST", 385, 389], ["simplex descriptors", "PROBLEM", 595, 614], ["HiT QSAR", "TEST", 628, 636], ["GA", "TEST", 750, 752], ["TV", "TEST", 754, 756], ["AVS procedures", "TREATMENT", 761, 775]]], ["However, these mathematical differences are not responsible for all the improvements in the investigated approaches.", [["not responsible", "UNCERTAINTY", 44, 59]]], ["Thus, it is obvious from the results obtained that HiT QSAR simplex models are well-fitted, robust and, in the main, they are much more predictive than QSAR models developed by other approaches.HiT QSAR APPLICATIONSThe application of HiT QSAR for the solution of different QSAR/QSPR tasks on different levels of representation of molecular structure is highlighted briefly below.", [["HiT", "SIMPLE_CHEMICAL", 234, 237], ["HiT QSAR simplex models", "PROBLEM", 51, 74], ["HiT QSAR", "TREATMENT", 234, 242], ["the solution of different QSAR", "TREATMENT", 247, 277], ["QSPR tasks", "TEST", 278, 288], ["main", "OBSERVATION_MODIFIER", 111, 115], ["molecular structure", "OBSERVATION", 330, 349]]], ["The PLS method has been used for the development of QSAR models in all the cases described below.Antiviral ActivityBecause a lot of different viral serotypes and strains exist, vaccine development for prevention of a wide variety of viral infections is considered to be impracticable.", [["viral infections", "DISEASE", 233, 249], ["The PLS method", "TEST", 0, 14], ["Antiviral", "TREATMENT", 97, 106], ["different viral serotypes", "TREATMENT", 132, 157], ["strains exist", "TREATMENT", 162, 175], ["vaccine", "TREATMENT", 177, 184], ["viral infections", "PROBLEM", 233, 249], ["viral serotypes", "OBSERVATION", 142, 157], ["viral infections", "OBSERVATION", 233, 249]]], ["The present treatment options for such infections are unsatisfactory [75] [76] [77] .", [["infections", "DISEASE", 39, 49], ["such infections", "PROBLEM", 34, 49]]], ["However, there are ongoing attempts to develop antiviral drugs [78] [79] [80] [81] [82] [83] [84] .", [["[78] [79] [80] [81] [82] [83]", "CHEMICAL", 63, 92], ["[78] [79] [80] [81] [82] [83] [84]", "SIMPLE_CHEMICAL", 63, 97], ["antiviral drugs", "TREATMENT", 47, 62]]], ["That is why computational approaches, which can distinguish highly active inhibitors from less useful compounds and predict more potent substances, have been used for the analysis of antiviral activity for many years [4, 6, 7, 12, 13, 29] .Antiherpetic Activity of N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine Derivatives 3 (2D)HiT QSAR was applied to evaluate the influence of the structure of 48 N,N -(bis-5-nitropyrimidyl)dispirotripiperazines (see structures below) on their antiherpetic activity, selectivity, and cytotoxicity with the purpose to understand the chemicobiological interactions governing their activities, and to design new compounds with strong antiviral activity [3] .Antiherpetic Activity of N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine Derivatives 3 (2D)The common logarithms of 50% cytotoxic concentration (CC 50 ) in GMK cells, 50% inhibitory concentration (IC 50 ) against HSV-1, and the selectivity index (SI = CC 50 /IC 50 ) were used to develop 2D-QSAR models.", [["GMK cells", "ANATOMY", 851, 860], ["N,N -(bis-5-nitropyrimidyl", "CHEMICAL", 265, 291], ["Dispirotripiperazine", "CHEMICAL", 293, 313], ["N -(bis-5-nitropyrimidyl)dispirotripiperazines", "CHEMICAL", 404, 450], ["N,N -(bis-5-nitropyrimidyl", "CHEMICAL", 719, 745], ["Dispirotripiperazine", "CHEMICAL", 747, 767], ["CC", "CHEMICAL", 840, 842], ["N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine", "CHEMICAL", 265, 313], ["N,N -(bis-5-nitropyrimidyl)dispirotripiperazines", "CHEMICAL", 402, 450], ["N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine", "CHEMICAL", 719, 767], ["N -(bis-5-nitropyrimidyl) Dispirotripiperazine Derivatives 3", "SIMPLE_CHEMICAL", 267, 327], ["48 N,N -(bis-5-nitropyrimidyl)dispirotripiperazines", "SIMPLE_CHEMICAL", 399, 450], ["N -(bis-5-nitropyrimidyl) Dispirotripiperazine", "SIMPLE_CHEMICAL", 721, 767], ["GMK cells", "CELL", 851, 860], ["HSV-1", "ORGANISM", 908, 913], ["GMK cells", "CELL_LINE", 851, 860], ["HSV-1", "SPECIES", 908, 913], ["antiviral activity", "TREATMENT", 183, 201], ["Antiherpetic Activity of N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine Derivatives", "TREATMENT", 240, 325], ["HiT QSAR", "TEST", 332, 340], ["bis", "TEST", 408, 411], ["nitropyrimidyl)dispirotripiperazines", "TREATMENT", 414, 450], ["Antiherpetic Activity of N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine Derivatives", "TREATMENT", 694, 779], ["50% cytotoxic concentration (CC", "TREATMENT", 811, 842], ["HSV", "TEST", 908, 911], ["the selectivity index", "TEST", 919, 940]]], ["Spirobromine -a medicine with a nitrogen-containing dispiro structure possessing anti-HSV-1 activity was included in the training set.", [["Spirobromine", "CHEMICAL", 0, 12], ["nitrogen", "CHEMICAL", 32, 40], ["Spirobromine", "CHEMICAL", 0, 12], ["nitrogen", "CHEMICAL", 32, 40], ["Spirobromine", "SIMPLE_CHEMICAL", 0, 12], ["nitrogen", "SIMPLE_CHEMICAL", 32, 40], ["dispiro", "SIMPLE_CHEMICAL", 52, 59], ["anti-HSV-1", "GENE_OR_GENE_PRODUCT", 81, 91], ["anti-HSV", "PROTEIN", 81, 89], ["Spirobromine -a medicine", "TREATMENT", 0, 24], ["a nitrogen-containing dispiro structure possessing anti-HSV", "TREATMENT", 30, 89]]], ["The statistic characteristics of QSAR models obtained are quite high (R 2 = 0.84-0.91; Q 2 = 0.61-0.68; R 2 test = 0.68-0.71) and allow for the prediction of antiherpetic activity, cytotoxicity, and selectivity of new compounds.", [["QSAR models", "TEST", 33, 44], ["R 2 test", "TEST", 104, 112], ["antiherpetic activity", "PROBLEM", 158, 179], ["cytotoxicity", "PROBLEM", 181, 193], ["antiherpetic activity", "OBSERVATION", 158, 179], ["new", "OBSERVATION_MODIFIER", 214, 217], ["compounds", "OBSERVATION", 218, 227]]], ["Electrostatic factors (38%) and hydrophobicity (25%) were the most important determinants of antiherpetic activity (Figure 5-8) .", [["Electrostatic factors", "TEST", 0, 21], ["hydrophobicity", "TEST", 32, 46], ["antiherpetic activity", "OBSERVATION", 93, 114]]], ["The results of the QSAR analysis demonstrate a high impact of individual structural fragments for antiviral activity.", [["the QSAR analysis", "TEST", 15, 32], ["individual structural fragments", "PROBLEM", 62, 93], ["antiviral activity", "TREATMENT", 98, 116], ["high", "OBSERVATION_MODIFIER", 47, 51], ["structural fragments", "OBSERVATION", 73, 93], ["antiviral activity", "OBSERVATION", 98, 116]]], ["Molecular fragments that promote and interfere with antiviral activity were defined on the basis of the models obtained.", [["Molecular fragments", "PROBLEM", 0, 19], ["antiviral activity", "TREATMENT", 52, 70], ["fragments", "OBSERVATION", 10, 19]]], ["Thus, for example, the insertion of non-cationic linkers such as N-(2-aminoethyl)ethane-1,2-diamine, ethylenediamine, or piperazine instead of dispirotripiperazine leads to a complete loss of activity while the presence of methyloxirane leads to a strong increase.", [["N-(2-aminoethyl)ethane-1,2-diamine", "CHEMICAL", 65, 99], ["ethylenediamine", "CHEMICAL", 101, 116], ["piperazine", "CHEMICAL", 121, 131], ["dispirotripiperazine", "CHEMICAL", 143, 163], ["methyloxirane", "CHEMICAL", 223, 236], ["N-(2-aminoethyl)ethane-1,2-diamine", "CHEMICAL", 65, 99], ["ethylenediamine", "CHEMICAL", 101, 116], ["piperazine", "CHEMICAL", 121, 131], ["dispirotripiperazine", "CHEMICAL", 143, 163], ["methyloxirane", "CHEMICAL", 223, 236], ["N-(2-aminoethyl)ethane-1,2-diamine", "SIMPLE_CHEMICAL", 65, 99], ["ethylenediamine", "SIMPLE_CHEMICAL", 101, 116], ["piperazine", "SIMPLE_CHEMICAL", 121, 131], ["dispirotripiperazine", "SIMPLE_CHEMICAL", 143, 163], ["methyloxirane", "SIMPLE_CHEMICAL", 223, 236], ["the insertion of non-cationic linkers", "TREATMENT", 19, 56], ["N-(2-aminoethyl)ethane", "TREATMENT", 65, 87], ["diamine", "TREATMENT", 92, 99], ["ethylenediamine", "TREATMENT", 101, 116], ["piperazine", "TREATMENT", 121, 131], ["dispirotripiperazine", "TREATMENT", 143, 163], ["methyloxirane leads", "TREATMENT", 223, 242]]], ["Using the established results and observations, several new dispirotripiperazine derivatives -potential antiviral agents -were computationally designed.", [["dispirotripiperazine", "CHEMICAL", 60, 80], ["dispirotripiperazine", "CHEMICAL", 60, 80], ["dispirotripiperazine derivatives", "SIMPLE_CHEMICAL", 60, 92], ["several new dispirotripiperazine derivatives", "TREATMENT", 48, 92], ["antiviral agents", "TREATMENT", 104, 120]]], ["Two of these new compounds (1 and 2, Table 5 -4) were synthesized.", [["5 -4", "SIMPLE_CHEMICAL", 43, 47], ["new", "OBSERVATION_MODIFIER", 13, 16], ["compounds", "OBSERVATION_MODIFIER", 17, 26]]], ["The results of biological tests confirm the predicted high values of antiviral activity and selectivity (they are about two logarithmic units more active and one order more selective than spirobromine) as well as low toxicity of these compounds.", [["spirobromine", "CHEMICAL", 188, 200], ["toxicity", "DISEASE", 217, 225], ["spirobromine", "CHEMICAL", 188, 200], ["spirobromine", "SIMPLE_CHEMICAL", 188, 200], ["biological tests", "TEST", 15, 31], ["spirobromine", "TREATMENT", 188, 200], ["low toxicity of these compounds", "PROBLEM", 213, 244], ["antiviral activity", "OBSERVATION", 69, 87], ["low toxicity", "OBSERVATION_MODIFIER", 213, 225]]], ["The antiherpetic data set was similar to that for the anti-influenza study and was also characterized by essential structural variety: different macrocyclic pyridinophanes and their acyclic analogues plus well-known antiviral agents including acyclovir as a reference compound: The antiherpetic activity against HSV-1 strain US was expressed as a percentage of the inhibition of HSV reproduction in treated cell cultures (Hep-2) in comparison with untreated ones.", [["cell cultures", "ANATOMY", 407, 420], ["Hep-2", "ANATOMY", 422, 427], ["pyridinophanes", "CHEMICAL", 157, 171], ["acyclovir", "CHEMICAL", 243, 252], ["pyridinophanes", "CHEMICAL", 157, 171], ["acyclovir", "CHEMICAL", 243, 252], ["pyridinophanes", "SIMPLE_CHEMICAL", 157, 171], ["acyclovir", "SIMPLE_CHEMICAL", 243, 252], ["HSV-1 strain", "ORGANISM", 312, 324], ["US", "ORGANISM", 325, 327], ["HSV", "ORGANISM", 379, 382], ["cell cultures", "CELL", 407, 420], ["Hep-2", "CELL", 422, 427], ["treated cell cultures", "CELL_LINE", 399, 420], ["Hep-2", "CELL_LINE", 422, 427], ["HSV-1", "SPECIES", 312, 317], ["HSV-1", "SPECIES", 312, 317], ["HSV", "SPECIES", 379, 382], ["The antiherpetic data", "TEST", 0, 21], ["the anti-influenza study", "TEST", 50, 74], ["different macrocyclic pyridinophanes", "TREATMENT", 135, 171], ["their acyclic analogues", "TREATMENT", 176, 199], ["antiviral agents", "TREATMENT", 216, 232], ["acyclovir", "TREATMENT", 243, 252], ["HSV", "PROBLEM", 312, 315], ["HSV reproduction", "PROBLEM", 379, 395], ["cell cultures", "TEST", 407, 420], ["Hep", "TEST", 422, 425], ["antiherpetic activity", "OBSERVATION", 282, 303]]], ["As in previous cases, the antiherpetic study has a multistep cyclic character: synthesis -biological tests -QSAR analysis -virtual screening and computer-assisted drug design -synthesis -, etc. [25, 28, 29, 34] .", [["the antiherpetic study", "TEST", 22, 44], ["biological tests", "TEST", 90, 106], ["QSAR analysis", "TEST", 108, 121], ["virtual screening", "TEST", 123, 140]]], ["Initially, 14 compounds (mostly macrocyclic pyridinophanes and their acyclic analogues) have been investigated for antiherpetic activity [29] .", [["pyridinophanes", "CHEMICAL", 44, 58], ["pyridinophanes", "CHEMICAL", 44, 58], ["macrocyclic pyridinophanes", "SIMPLE_CHEMICAL", 32, 58], ["mostly macrocyclic pyridinophanes", "TREATMENT", 25, 58], ["their acyclic analogues", "TREATMENT", 63, 86], ["antiherpetic activity", "PROBLEM", 115, 136]]], ["At the present stage [25] , after the several QSAR convolutions, 37 compounds were divided between training and test sets (26 and 11 compounds respectively) and the set of QSAR models with different adequacy levels (2D, 4D, and 3D) has been obtained as a result of the investigations.", [["test sets", "TEST", 112, 121], ["the investigations", "TEST", 265, 283]]], ["All the obtained QSAR models were well fitted, robust, predictive (R 2 = 0.82-0.90, Q 2 = 0.60-0.65, R 2 test = 0.70-0.78), and have a defined DA and clear mechanistic interpretation.", [["DA", "CHEMICAL", 143, 145], ["QSAR models", "TEST", 17, 28], ["predictive", "TEST", 55, 65], ["R 2 test", "TEST", 101, 109]]], ["For the 3D-QSAR investigations the set of \"productive\" conformers has been used.", [["QSAR investigations", "TEST", 11, 30], ["\"productive\" conformers", "PROBLEM", 42, 65]]], ["They were determined as the most active from the results of 4D-QSAR modeling.Antiherpetic Activity of N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine Derivatives 3 (2D)All the models developed (2D-4D) indicate the impact of hydrophobic (~50%) and electrostatic (~20%) factors on the variation of antiherpetic activity.", [["N,N -(bis-5-nitropyrimidyl", "CHEMICAL", 102, 128], ["N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine", "CHEMICAL", 102, 150], ["N -(bis-5-nitropyrimidyl) Dispirotripiperazine", "SIMPLE_CHEMICAL", 104, 150], ["4D-QSAR modeling", "TEST", 60, 76], ["Antiherpetic Activity of N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine Derivatives", "TREATMENT", 77, 162], ["antiherpetic activity", "TREATMENT", 297, 318], ["antiherpetic activity", "OBSERVATION", 297, 318]]], ["The strong promotion of antiherpetic activity by aminoethylene fragments was revealed.", [["aminoethylene", "CHEMICAL", 49, 62], ["aminoethylene", "CHEMICAL", 49, 62], ["aminoethylene", "SIMPLE_CHEMICAL", 49, 62], ["antiherpetic activity", "PROBLEM", 24, 45], ["aminoethylene fragments", "PROBLEM", 49, 72], ["strong", "OBSERVATION_MODIFIER", 4, 10], ["antiherpetic activity", "OBSERVATION", 24, 45]]], ["It was also discovered that an important factor for the HSV inhibition is the presence of an amino group connected to aliphatic fragment.", [["amino", "CHEMICAL", 93, 98], ["HSV", "ORGANISM", 56, 59], ["aliphatic fragment", "PROTEIN", 118, 136], ["HSV", "SPECIES", 56, 59], ["the HSV inhibition", "PROBLEM", 52, 70], ["an amino group", "TREATMENT", 90, 104], ["aliphatic fragment", "PROBLEM", 118, 136], ["aliphatic fragment", "OBSERVATION", 118, 136]]], ["A tendency of antiviral activity increasing with the strengthening of acceptor properties of compound's aromatic rings was revealed.", [["aromatic rings", "SIMPLE_CHEMICAL", 104, 118], ["A tendency of antiviral activity", "PROBLEM", 0, 32], ["tendency", "OBSERVATION_MODIFIER", 2, 10], ["antiviral activity", "OBSERVATION", 14, 32], ["aromatic rings", "OBSERVATION", 104, 118]]], ["This information was used for the design of potent antiherpetic agent 1 (Table 5 -4).", [["potent antiherpetic agent", "TREATMENT", 44, 69]]], ["The use of SiRMS allows to progress in searching for new antiherpetic agents starting from macrocyclic pyridinophanes [29] and finishing in symmetric piperazine containing macroheterocycle 1,4,7,10,13, 16 was developed using HiT QSAR based on SiRMS to reveal chemico-biological interactions governing their activities as well as their probable mode of action, and to design new compounds with a strong antiviral activity [11] .", [["SiRMS", "CHEMICAL", 11, 16], ["macrocyclic pyridinophanes [29]", "CHEMICAL", 91, 122], ["piperazine", "CHEMICAL", 150, 160], ["macroheterocycle 1,4,7,10,13, 16", "CHEMICAL", 172, 204], ["pyridinophanes", "CHEMICAL", 103, 117], ["piperazine", "CHEMICAL", 150, 160], ["antiherpetic agents", "SIMPLE_CHEMICAL", 57, 76], ["pyridinophanes [29]", "SIMPLE_CHEMICAL", 103, 122], ["symmetric piperazine", "SIMPLE_CHEMICAL", 140, 160], ["macroheterocycle 1,4,7,10,13, 16", "SIMPLE_CHEMICAL", 172, 204], ["HiT", "SIMPLE_CHEMICAL", 225, 228], ["SiRMS", "SIMPLE_CHEMICAL", 243, 248], ["SiRMS", "TREATMENT", 11, 16], ["new antiherpetic agents", "TREATMENT", 53, 76], ["macrocyclic pyridinophanes", "TREATMENT", 91, 117], ["symmetric piperazine containing macroheterocycle", "TREATMENT", 140, 188], ["HiT QSAR", "TEST", 225, 233], ["SiRMS", "TEST", 243, 248]]], ["The common logarithms of 50% cytotoxic concentration (CC 50 ) in HeLa cells, the 50% inhibitory concentration (IC 50 ) against human rhinovirus 2 (HRV-2), and the selectivity index (SI = CC 50 /IC 50 ) of [(biphenyloxy)propyl]isoxazole derivatives were used as cytotoxicity, antiviral activity, and selectivity assessments, respectively.", [["HeLa cells", "ANATOMY", 65, 75], ["CC", "CHEMICAL", 54, 56], ["[(biphenyloxy)propyl]isoxazole", "CHEMICAL", 205, 235], ["[(biphenyloxy)propyl]isoxazole", "CHEMICAL", 205, 235], ["HeLa cells", "CELL", 65, 75], ["human", "ORGANISM", 127, 132], ["rhinovirus 2", "ORGANISM", 133, 145], ["[(biphenyloxy)propyl]isoxazole derivatives", "SIMPLE_CHEMICAL", 205, 247], ["HeLa cells", "CELL_LINE", 65, 75], ["human", "SPECIES", 127, 132], ["rhinovirus", "SPECIES", 133, 143], ["human rhinovirus", "SPECIES", 127, 143], ["The common logarithms", "TEST", 0, 21], ["cytotoxic concentration", "TEST", 29, 52], ["CC", "TEST", 54, 56], ["HeLa cells", "TEST", 65, 75], ["IC", "TEST", 111, 113], ["human rhinovirus", "TEST", 127, 143], ["HRV", "TEST", 147, 150], ["the selectivity index", "TEST", 159, 180], ["CC", "TEST", 187, 189], ["[(biphenyloxy)propyl]isoxazole derivatives", "TREATMENT", 205, 247], ["cytotoxicity", "TREATMENT", 261, 273], ["antiviral activity", "TREATMENT", 275, 293], ["selectivity assessments", "TEST", 299, 322]]], ["The set of molecules consists of 18 compounds including pleconaril as a reference compound.", [["pleconaril", "CHEMICAL", 56, 66], ["pleconaril", "CHEMICAL", 56, 66], ["pleconaril", "SIMPLE_CHEMICAL", 56, 66]]], ["They have not been divided into training and test sets because of the low number of compounds (i.e., the structural information contained in each molecule in this case is unique and useful).", [["test sets", "TEST", 45, 54], ["low number", "OBSERVATION_MODIFIER", 70, 80]]], ["The statistic characteristics of the resulting 2D-QSAR models are quite satisfactory (R 2 = 0.84-0.92; Q 2 = 0.70-0.87) for the prediction of CC 50 , IC 50 , and SI values and permit the virtual screening and molecular design of new compounds with high anti-HRV-2 activity.", [["CC", "CHEMICAL", 142, 144], ["anti-HRV-2", "GENE_OR_GENE_PRODUCT", 253, 263], ["anti-HRV", "PROTEIN", 253, 261], ["QSAR models", "TEST", 50, 61], ["CC", "TEST", 142, 144], ["IC", "TEST", 150, 152], ["the virtual screening", "TEST", 183, 204], ["new compounds", "PROBLEM", 229, 242], ["high anti-HRV", "TREATMENT", 248, 261], ["new", "OBSERVATION_MODIFIER", 229, 232]]], ["The results indicate the high influence of atom s individuality on all the investigated properties (~40%), electrostatic factors on selectivity (~50%), where these factors along with atom individuality play the determining role, and hydrophobic interactions on the antiviral activity (~40%).", [["electrostatic factors", "PROTEIN", 107, 128], ["electrostatic factors", "PROBLEM", 107, 128], ["selectivity", "TEST", 132, 143], ["the antiviral activity", "TEST", 261, 283]]], ["The presence of terminal 5-trifluoromethyl-1,2,4-oxadiazole and p-fluorophenyl fragments in a molecule leads to strong enhancement of its useful properties, i.e., increase of activity toward HRV-2 as well as selectivity and decrease of cytotoxicity.", [["5-trifluoromethyl-1,2,4-oxadiazole", "CHEMICAL", 25, 59], ["p-fluorophenyl", "CHEMICAL", 64, 78], ["5-trifluoromethyl-1,2,4-oxadiazole", "CHEMICAL", 25, 59], ["p-fluorophenyl", "CHEMICAL", 64, 78], ["5-trifluoromethyl-1,2,4-oxadiazole", "SIMPLE_CHEMICAL", 25, 59], ["p-fluorophenyl fragments", "SIMPLE_CHEMICAL", 64, 88], ["HRV-2", "GENE_OR_GENE_PRODUCT", 191, 196], ["terminal 5-trifluoromethyl", "TREATMENT", 16, 42], ["oxadiazole and p-fluorophenyl fragments", "TREATMENT", 49, 88], ["HRV", "TEST", 191, 194], ["cytotoxicity", "PROBLEM", 236, 248], ["terminal", "OBSERVATION_MODIFIER", 16, 24], ["strong", "OBSERVATION_MODIFIER", 112, 118], ["enhancement", "OBSERVATION_MODIFIER", 119, 130], ["increase", "OBSERVATION_MODIFIER", 163, 171], ["cytotoxicity", "OBSERVATION", 236, 248]]], ["An additional terminal aromatic ring -naphthalene or phenyl -strongly reduces activity toward HRV-2 and, to a lesser degree, SI.", [["naphthalene", "CHEMICAL", 38, 49], ["phenyl", "CHEMICAL", 53, 59], ["naphthalene", "CHEMICAL", 38, 49], ["phenyl", "CHEMICAL", 53, 59], ["aromatic ring -naphthalene", "SIMPLE_CHEMICAL", 23, 49], ["phenyl", "SIMPLE_CHEMICAL", 53, 59], ["An additional terminal aromatic ring -naphthalene", "TREATMENT", 0, 49], ["phenyl", "TREATMENT", 53, 59], ["HRV", "TEST", 94, 97], ["terminal", "OBSERVATION_MODIFIER", 14, 22], ["aromatic ring", "OBSERVATION", 23, 36], ["lesser degree", "OBSERVATION_MODIFIER", 110, 123]]], ["The virtual screening and molecular design of new well-tolerated compounds with strong anti-HRV-2 activity has been performed on the basis of QSAR results.", [["anti-HRV-2", "GENE_OR_GENE_PRODUCT", 87, 97], ["anti-HRV", "PROTEIN", 87, 95], ["The virtual screening", "TEST", 0, 21], ["strong anti-HRV-2 activity", "TREATMENT", 80, 106]]], ["Three different DA approaches (DA rectangle and ellipsoid as well as leverage) give nearly the same results for each QSAR model and additionally allow for the estimation of the quality of the prediction for all designed compounds.", [["DA", "CHEMICAL", 16, 18], ["DA", "CHEMICAL", 31, 33], ["Three different DA approaches (DA rectangle and ellipsoid", "TREATMENT", 0, 57], ["each QSAR model", "TEST", 112, 127]]], ["A hypothesis to the effect that external benzene substituent must have negative electrostatic potential and definite length L (approximately 5.5-5.6 A) to possess strong antiviral activity has been suggested.", [["benzene", "CHEMICAL", 41, 48], ["benzene", "CHEMICAL", 41, 48], ["benzene", "SIMPLE_CHEMICAL", 41, 48], ["A hypothesis", "PROBLEM", 0, 12], ["external benzene substituent", "PROBLEM", 32, 60], ["strong antiviral activity", "PROBLEM", 163, 188], ["length", "OBSERVATION_MODIFIER", 117, 123], ["antiviral activity", "OBSERVATION", 170, 188]]], ["Most probably, the fluorine atom in the para-position of terminal aromatic ring (compounds 2-4, Table 5 -4) is quite complementary (L = 5.59 A) to the receptor cavity for such an interaction.", [["fluorine", "CHEMICAL", 19, 27], ["para-position of terminal aromatic", "CHEMICAL", 40, 74], ["compounds 2-4, Table 5 -4", "CHEMICAL", 81, 106], ["fluorine", "CHEMICAL", 19, 27], ["fluorine atom", "SIMPLE_CHEMICAL", 19, 32], ["the fluorine atom", "PROBLEM", 15, 32], ["terminal aromatic ring (compounds", "TREATMENT", 57, 90], ["fluorine atom", "OBSERVATION", 19, 32], ["terminal", "ANATOMY_MODIFIER", 57, 65], ["aromatic ring", "OBSERVATION", 66, 79]]], ["It is necessary to note that pleconaril (L = 5.54 A) completely satisfies the indicated criteria.", [["pleconaril", "CHEMICAL", 29, 39], ["pleconaril", "CHEMICAL", 29, 39], ["pleconaril", "SIMPLE_CHEMICAL", 29, 39], ["pleconaril", "TEST", 29, 39]]], ["In the case of nitroaromatics, the accumulation of nitro groups in the region of receptor cavity will lead to strengthening of electrostatic interactions with the biological target and, therefore, to an increase in activity.Antiherpetic Activity of N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine Derivatives 3 (2D)Several new compounds have been designed computationally and predicted as having high activity and selectivity.", [["nitro", "CHEMICAL", 51, 56], ["N,N -(bis-5-nitropyrimidyl", "CHEMICAL", 249, 275], ["nitroaromatics", "CHEMICAL", 15, 29], ["nitro", "CHEMICAL", 51, 56], ["N,N -(bis-5-nitropyrimidyl) Dispirotripiperazine", "CHEMICAL", 249, 297], ["nitroaromatics", "SIMPLE_CHEMICAL", 15, 29], ["N -(bis-5-nitropyrimidyl) Dispirotripiperazine Derivatives 3", "SIMPLE_CHEMICAL", 251, 311], ["nitroaromatics", "TREATMENT", 15, 29], ["nitro groups", "TREATMENT", 51, 63], ["receptor cavity", "PROBLEM", 81, 96], ["electrostatic interactions", "PROBLEM", 127, 153], ["Antiherpetic Activity of N,N -(bis", "TREATMENT", 224, 258], ["nitropyrimidyl) Dispirotripiperazine Derivatives", "TREATMENT", 261, 309], ["nitro groups", "OBSERVATION", 51, 63], ["receptor cavity", "OBSERVATION", 81, 96], ["electrostatic interactions", "OBSERVATION", 127, 153], ["increase", "OBSERVATION_MODIFIER", 203, 211]]], ["Subsequent experimental testing revealed a strong coincidence between experimental and predicted anti-HRV-2 activity and SI.", [["anti-HRV-2", "GENE_OR_GENE_PRODUCT", 97, 107], ["anti-HRV", "PROTEIN", 97, 105], ["Subsequent experimental testing", "TEST", 0, 31]]], ["Compounds 2-4 are similar in their cytotoxicity level to plecanoril, but they are more active and selective.Anti-influenza Activity of Macrocyclic Pyridinophanes 4 (2D-4D)All the advantages of HiT QSAR were demonstrated during the investigation of anti-influenza activity on the data set possessing structural variety: different macrocyclic pyridinophanes, their acyclic analogues, and well-known antiviral agents (deiteforin, remantadine, ribavirin, ambenum, and others) [12, 29] :Anti-influenza Activity of Macrocyclic Pyridinophanes 4 (2D-4D)Anti-influenza activity (virus A/Hong Kong/1/68 (H3N2)) was expressed in lgTID 50 and reflected the suppression of viral replication in \"experimental\" samples in comparison with \"controls.\"", [["samples", "ANATOMY", 696, 703], ["Compounds 2-4", "CHEMICAL", 0, 13], ["plecanoril", "CHEMICAL", 57, 67], ["pyridinophanes", "CHEMICAL", 341, 355], ["deiteforin", "CHEMICAL", 415, 425], ["remantadine", "CHEMICAL", 427, 438], ["ribavirin", "CHEMICAL", 440, 449], ["ambenum", "CHEMICAL", 451, 458], ["Macrocyclic Pyridinophanes 4 (2D-4D", "CHEMICAL", 509, 544], ["plecanoril", "CHEMICAL", 57, 67], ["Macrocyclic Pyridinophanes", "CHEMICAL", 135, 161], ["pyridinophanes", "CHEMICAL", 341, 355], ["deiteforin", "CHEMICAL", 415, 425], ["remantadine", "CHEMICAL", 427, 438], ["ribavirin", "CHEMICAL", 440, 449], ["ambenum", "CHEMICAL", 451, 458], ["Macrocyclic Pyridinophanes", "CHEMICAL", 509, 535], ["2-4", "SIMPLE_CHEMICAL", 10, 13], ["plecanoril", "SIMPLE_CHEMICAL", 57, 67], ["Macrocyclic Pyridinophanes 4", "SIMPLE_CHEMICAL", 135, 163], ["HiT", "SIMPLE_CHEMICAL", 193, 196], ["pyridinophanes", "SIMPLE_CHEMICAL", 341, 355], ["deiteforin", "SIMPLE_CHEMICAL", 415, 425], ["remantadine", "SIMPLE_CHEMICAL", 427, 438], ["ribavirin", "SIMPLE_CHEMICAL", 440, 449], ["ambenum", "SIMPLE_CHEMICAL", 451, 458], ["Macrocyclic Pyridinophanes 4", "SIMPLE_CHEMICAL", 509, 537], ["2D-4D", "SIMPLE_CHEMICAL", 539, 544], ["Hong Kong/1/68 (H3N2)", "ORGANISM", 578, 599], ["lgTID 50", "CELL", 618, 626], ["lgTID 50", "PROTEIN", 618, 626], ["Hong Kong/1/68 (H3N2)", "SPECIES", 578, 599], ["Anti-influenza Activity of Macrocyclic Pyridinophanes", "TREATMENT", 108, 161], ["HiT QSAR", "TREATMENT", 193, 201], ["anti-influenza activity", "TREATMENT", 248, 271], ["different macrocyclic pyridinophanes", "TREATMENT", 319, 355], ["their acyclic analogues", "TREATMENT", 357, 380], ["antiviral agents", "TREATMENT", 397, 413], ["deiteforin", "TREATMENT", 415, 425], ["remantadine", "TREATMENT", 427, 438], ["ribavirin", "TREATMENT", 440, 449], ["ambenum", "TREATMENT", 451, 458], ["Anti-influenza Activity of Macrocyclic Pyridinophanes", "TREATMENT", 482, 535], ["Anti-influenza activity", "PROBLEM", 545, 568], ["viral replication", "PROBLEM", 660, 677], ["viral replication", "OBSERVATION", 660, 677]]], ["The structures investigated were divided between training and test sets (25 and 6 compounds, respectively).Anti-influenza Activity of Macrocyclic Pyridinophanes 4 (2D-4D)In accordance with the hierarchical principles of the approach offered, the QSAR analysis was solved sequentially on the 2D, 4D, and 3D levels.", [["Macrocyclic Pyridinophanes", "CHEMICAL", 134, 160], ["test sets", "TEST", 62, 71], ["Anti-influenza Activity of Macrocyclic Pyridinophanes", "TREATMENT", 107, 160], ["the QSAR analysis", "TEST", 242, 259]]], ["6 The set of QSAR models with different adequacy levels (2D, 4D, and 3D) was obtained as a result of the investigations.", [["QSAR models", "TEST", 13, 24], ["different adequacy levels", "TEST", 30, 55], ["the investigations", "TEST", 101, 119]]], ["All the obtained QSAR models were well fitted, robust, predictive (R 2 = 0.94-0.98, Q 2 = 0.85-0.95, and R 2 test = 0.98-0.99) 7 , and have defined DA and clear mechanistic interpretation.", [["DA", "CHEMICAL", 148, 150], ["QSAR models", "TEST", 17, 28], ["predictive", "TEST", 55, 65]]], ["For 3D-QSAR investigations the set of \"productive\" conformers has been used.", [["3D-QSAR investigations", "TEST", 4, 26]]], ["They were determined as the most active from the results of 4D-QSAR modeling.", [["4D-QSAR modeling", "TEST", 60, 76]]], ["The results indicate the great impact of atom individuality on the variation of anti-influenza activity (37-50%).", [["anti-influenza activity", "TREATMENT", 80, 103], ["great", "OBSERVATION_MODIFIER", 25, 30], ["atom individuality", "OBSERVATION", 41, 59], ["anti-influenza activity", "OBSERVATION", 80, 103]]], ["Hydrophobic/hydrophilic and electrostatic interactions also played an important role (15-22%).", [["Hydrophobic/hydrophilic and electrostatic interactions", "PROBLEM", 0, 54], ["hydrophilic", "OBSERVATION_MODIFIER", 12, 23], ["electrostatic interactions", "OBSERVATION", 28, 54]]], ["The shape of molecules (4D and 3D models) also effects anti-influenza activity but has the smallest influence (11 and 16%, respectively).", [["anti-influenza activity", "PROBLEM", 55, 78], ["shape", "OBSERVATION_MODIFIER", 4, 9], ["molecules", "OBSERVATION", 13, 22], ["anti-influenza activity", "OBSERVATION", 55, 78], ["smallest", "OBSERVATION_MODIFIER", 91, 99]]], ["The cylindrical form of molecules (I X /I Y \u2192 1) with small diameters (I Y \u2192 min) promotes antiinfluenza activity.", [["antiinfluenza", "CANCER", 91, 104], ["I X", "PROTEIN", 35, 38], ["I Y \u2192 1", "PROTEIN", 40, 47], ["cylindrical", "OBSERVATION_MODIFIER", 4, 15], ["molecules", "OBSERVATION", 24, 33], ["small", "OBSERVATION_MODIFIER", 54, 59], ["diameters", "OBSERVATION_MODIFIER", 60, 69], ["antiinfluenza activity", "OBSERVATION", 91, 113]]], ["The molecular fragments governing the change of anti-influenza activity and their average relative influence (Table 5 -1) were determined.", [["The molecular fragments", "PROBLEM", 0, 23], ["anti-influenza activity", "TREATMENT", 48, 71], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["fragments", "OBSERVATION", 14, 23], ["change", "OBSERVATION_MODIFIER", 38, 44], ["anti-influenza activity", "OBSERVATION", 48, 71]]], ["For example, the presence of oxyethylene or 2-iminomethylphenol fragments promotes antiviral activity and aminoethylene fragments decreases it.Anti-influenza Activity of Macrocyclic Pyridinophanes 4 (2D-4D)The purposeful design of new molecules 5-7 (Table 5 -4) with adjusted activity level was developed by obtained results.", [["oxyethylene", "CHEMICAL", 29, 40], ["2-iminomethylphenol", "CHEMICAL", 44, 63], ["aminoethylene", "CHEMICAL", 106, 119], ["Macrocyclic Pyridinophanes", "CHEMICAL", 170, 196], ["oxyethylene", "CHEMICAL", 29, 40], ["2-iminomethylphenol", "CHEMICAL", 44, 63], ["aminoethylene", "CHEMICAL", 106, 119], ["Macrocyclic Pyridinophanes", "CHEMICAL", 170, 196], ["oxyethylene", "SIMPLE_CHEMICAL", 29, 40], ["2-iminomethylphenol", "SIMPLE_CHEMICAL", 44, 63], ["aminoethylene fragments", "SIMPLE_CHEMICAL", 106, 129], ["oxyethylene", "TREATMENT", 29, 40], ["2-iminomethylphenol fragments", "TREATMENT", 44, 73], ["antiviral activity", "TREATMENT", 83, 101], ["aminoethylene fragments", "TREATMENT", 106, 129], ["Anti-influenza Activity of Macrocyclic Pyridinophanes", "TREATMENT", 143, 196], ["new molecules", "TEST", 231, 244], ["antiviral activity", "OBSERVATION", 83, 101], ["aminoethylene fragments", "OBSERVATION", 106, 129], ["decreases", "OBSERVATION_MODIFIER", 130, 139]]], ["The high level of all predicted (all the resulting 2D-4D models show the strong coincidence of predictions) values of anti-influenza activity was confirmed experimentally.", [["anti-influenza activity", "PROBLEM", 118, 141], ["high", "OBSERVATION_MODIFIER", 4, 8], ["anti-influenza activity", "OBSERVATION", 118, 141]]], ["Thus, during the QSAR investigations [12, 29] the search for active compounds began from macrocyclic pyridinophanes and finally results in benzene derivatives containing the 2-iminomethyl-phenol fragment (5-7, Table 5 -4).Anticancer Activity of MacroCyclic Schiff Bases 8 (2D and 4D)The investigation of influence of the molecular structure of macrocyclic Schiff bases (see structures below) on their anticancer activity has been carried out byAnticancer Activity of MacroCyclic Schiff Bases 8 (2D and 4D)means of the 4D-QSAR SiRMS approach [10] .", [["anticancer", "ANATOMY", 401, 411], ["pyridinophanes", "CHEMICAL", 101, 115], ["benzene", "CHEMICAL", 139, 146], ["2-iminomethyl-phenol", "CHEMICAL", 174, 194], ["pyridinophanes", "CHEMICAL", 101, 115], ["benzene", "CHEMICAL", 139, 146], ["2-iminomethyl-phenol", "CHEMICAL", 174, 194], ["MacroCyclic Schiff Bases 8", "CHEMICAL", 245, 271], ["Schiff bases", "CHEMICAL", 356, 368], ["macrocyclic pyridinophanes", "SIMPLE_CHEMICAL", 89, 115], ["benzene derivatives", "SIMPLE_CHEMICAL", 139, 158], ["2-iminomethyl-phenol fragment", "SIMPLE_CHEMICAL", 174, 203], ["macrocyclic Schiff bases", "SIMPLE_CHEMICAL", 344, 368], ["anticancer", "CANCER", 401, 411], ["the QSAR investigations", "TEST", 13, 36], ["active compounds", "PROBLEM", 61, 77], ["macrocyclic pyridinophanes", "TREATMENT", 89, 115], ["benzene derivatives", "TREATMENT", 139, 158], ["the 2-iminomethyl-phenol fragment", "TREATMENT", 170, 203], ["MacroCyclic Schiff Bases", "TREATMENT", 245, 269], ["macrocyclic Schiff bases", "PROBLEM", 344, 368], ["MacroCyclic Schiff Bases", "TREATMENT", 467, 491], ["the 4D-QSAR SiRMS approach", "TREATMENT", 514, 540], ["benzene derivatives", "OBSERVATION", 139, 158], ["phenol fragment", "OBSERVATION", 188, 203], ["MacroCyclic Schiff", "OBSERVATION", 245, 263], ["macrocyclic Schiff", "OBSERVATION", 344, 362]]], ["The panel of investigated human malignant tumors includes 60 lines of the following nine cell cultures: leukemia, CNS cancer, prostate cancer, breast cancer, melanoma, non-small cell lung cancer, colon cancer, ovarian cancer, and renal cancer.", [["malignant tumors", "ANATOMY", 32, 48], ["cell cultures", "ANATOMY", 89, 102], ["leukemia", "ANATOMY", 104, 112], ["CNS cancer", "ANATOMY", 114, 124], ["prostate cancer", "ANATOMY", 126, 141], ["breast cancer", "ANATOMY", 143, 156], ["melanoma", "ANATOMY", 158, 166], ["non-small cell lung cancer", "ANATOMY", 168, 194], ["colon cancer", "ANATOMY", 196, 208], ["ovarian cancer", "ANATOMY", 210, 224], ["renal cancer", "ANATOMY", 230, 242], ["malignant tumors", "DISEASE", 32, 48], ["leukemia", "DISEASE", 104, 112], ["CNS cancer", "DISEASE", 114, 124], ["prostate cancer", "DISEASE", 126, 141], ["breast cancer", "DISEASE", 143, 156], ["melanoma", "DISEASE", 158, 166], ["non-small cell lung cancer", "DISEASE", 168, 194], ["colon cancer", "DISEASE", 196, 208], ["ovarian cancer", "DISEASE", 210, 224], ["renal cancer", "DISEASE", 230, 242], ["human", "ORGANISM", 26, 31], ["malignant tumors", "CANCER", 32, 48], ["cell cultures", "CELL", 89, 102], ["leukemia", "CANCER", 104, 112], ["CNS cancer", "CANCER", 114, 124], ["prostate cancer", "CANCER", 126, 141], ["breast cancer", "CANCER", 143, 156], ["melanoma", "CANCER", 158, 166], ["non-small cell lung cancer", "CANCER", 168, 194], ["colon cancer", "CANCER", 196, 208], ["ovarian cancer", "CANCER", 210, 224], ["renal cancer", "CANCER", 230, 242], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["The panel", "TEST", 0, 9], ["investigated human malignant tumors", "PROBLEM", 13, 48], ["60 lines", "TREATMENT", 58, 66], ["nine cell cultures", "TEST", 84, 102], ["leukemia", "PROBLEM", 104, 112], ["CNS cancer", "PROBLEM", 114, 124], ["prostate cancer", "PROBLEM", 126, 141], ["breast cancer", "PROBLEM", 143, 156], ["melanoma", "PROBLEM", 158, 166], ["non-small cell lung cancer", "PROBLEM", 168, 194], ["colon cancer", "PROBLEM", 196, 208], ["ovarian cancer", "PROBLEM", 210, 224], ["renal cancer", "PROBLEM", 230, 242], ["malignant", "OBSERVATION_MODIFIER", 32, 41], ["tumors", "OBSERVATION", 42, 48], ["60 lines", "OBSERVATION_MODIFIER", 58, 66], ["leukemia", "OBSERVATION", 104, 112], ["CNS", "ANATOMY", 114, 117], ["cancer", "OBSERVATION", 118, 124], ["prostate", "ANATOMY", 126, 134], ["cancer", "OBSERVATION", 135, 141], ["breast", "ANATOMY", 143, 149], ["cancer", "OBSERVATION", 150, 156], ["melanoma", "OBSERVATION", 158, 166], ["non-small cell", "OBSERVATION", 168, 182], ["lung", "ANATOMY", 183, 187], ["cancer", "OBSERVATION", 188, 194], ["colon", "ANATOMY", 196, 201], ["cancer", "OBSERVATION", 202, 208], ["ovarian", "ANATOMY", 210, 217], ["cancer", "OBSERVATION", 218, 224], ["renal", "ANATOMY", 230, 235], ["cancer", "OBSERVATION", 236, 242]]], ["Anticancer activity was expressed as the percent of the corresponding cell growth.", [["cell", "ANATOMY", 70, 74], ["Anticancer", "CANCER", 0, 10], ["cell", "CELL", 70, 74], ["Anticancer activity", "TREATMENT", 0, 19], ["cell growth", "OBSERVATION", 70, 81]]], ["The training set is very structurally dissimilar and consists of 30 macrocyclic pyridinophanes, their analogues, and some other compounds.", [["pyridinophanes", "CHEMICAL", 80, 94], ["pyridinophanes", "CHEMICAL", 80, 94], ["pyridinophanes", "SIMPLE_CHEMICAL", 80, 94], ["very structurally dissimilar", "PROBLEM", 20, 48], ["30 macrocyclic pyridinophanes", "TREATMENT", 65, 94]]], ["The use of simple topological models generated by EMMA [85] allows the description of the anticancer activity of macrocyclic pyridinophanes (MCP) for only five cell cultures [86] .", [["anticancer", "ANATOMY", 90, 100], ["cell cultures", "ANATOMY", 160, 173], ["EMMA", "CHEMICAL", 50, 54], ["macrocyclic pyridinophanes", "CHEMICAL", 113, 139], ["macrocyclic pyridinophanes", "CHEMICAL", 113, 139], ["anticancer", "CANCER", 90, 100], ["macrocyclic pyridinophanes", "SIMPLE_CHEMICAL", 113, 139], ["MCP", "SIMPLE_CHEMICAL", 141, 144], ["cell cultures", "CELL", 160, 173], ["MCP", "PROTEIN", 141, 144], ["macrocyclic pyridinophanes (MCP)", "TREATMENT", 113, 145], ["five cell cultures", "TEST", 155, 173]]], ["These studies show that even within the simple topological model it is possible to detect some patterns of the relationship between the structure of MCP and their activity.", [["MCP", "GENE_OR_GENE_PRODUCT", 149, 152], ["MCP", "PROTEIN", 149, 152], ["These studies", "TEST", 0, 13], ["MCP", "OBSERVATION_MODIFIER", 149, 152], ["activity", "OBSERVATION_MODIFIER", 163, 171]]], ["The consideration of spatial structure improves the situation, but only at the 4D level reliable QSAR models (R 2 = 0.74-0.98; Q 2 = 0.54-0.84) were obtained for all of the investigated cells (except leukemia, where Q 2 < 0.5; however, even in this case the designed compound was predicted correctly) and averaged activity (most of lines and cells are highly correlated) that indicate the importance of not the most active or favorable single conformer but the set of interacting conformers within the limits of energy gap of 3 kcal/mol.", [["cells", "ANATOMY", 186, 191], ["leukemia", "ANATOMY", 200, 208], ["cells", "ANATOMY", 342, 347], ["leukemia", "DISEASE", 200, 208], ["cells", "CELL", 186, 191], ["leukemia", "CANCER", 200, 208], ["cells", "CELL", 342, 347], ["the investigated cells", "PROBLEM", 169, 191], ["leukemia", "PROBLEM", 200, 208], ["spatial structure", "OBSERVATION", 21, 38], ["leukemia", "OBSERVATION", 200, 208]]], ["It was discovered that the presence of the N 1 ,N 3 -dimethylenepropane-1,3-diamine fragment strongly promotes anticancer activity.", [["anticancer", "ANATOMY", 111, 121], ["N 1 ,N 3 -dimethylenepropane-1,3-diamine", "CHEMICAL", 43, 83], ["N 1 ,N 3 -dimethylenepropane-1,3-diamine", "CHEMICAL", 43, 83], ["N 1 ,N 3 -dimethylenepropane-1,3-diamine fragment", "SIMPLE_CHEMICAL", 43, 92], ["anticancer", "CANCER", 111, 121], ["N", "TEST", 48, 49], ["dimethylenepropane", "TREATMENT", 53, 71], ["diamine fragment", "PROBLEM", 76, 92], ["anticancer activity", "OBSERVATION", 111, 130]]], ["This fragment was used as a linker between two naphthalen-2-oles that leads to the creation of universal anticancer agent active against all mentioned tumors except prostate cancer.", [["anticancer", "ANATOMY", 105, 115], ["tumors", "ANATOMY", 151, 157], ["prostate cancer", "ANATOMY", 165, 180], ["naphthalen-2-oles", "CHEMICAL", 47, 64], ["tumors", "DISEASE", 151, 157], ["prostate cancer", "DISEASE", 165, 180], ["naphthalen-2-oles", "CHEMICAL", 47, 64], ["fragment", "CELLULAR_COMPONENT", 5, 13], ["naphthalen-2-oles", "SIMPLE_CHEMICAL", 47, 64], ["anticancer", "CANCER", 105, 115], ["tumors", "CANCER", 151, 157], ["prostate cancer", "CANCER", 165, 180], ["This fragment", "PROBLEM", 0, 13], ["a linker between two naphthalen", "TREATMENT", 26, 57], ["universal anticancer agent", "TREATMENT", 95, 121], ["all mentioned tumors", "PROBLEM", 137, 157], ["prostate cancer", "PROBLEM", 165, 180], ["fragment", "OBSERVATION", 5, 13], ["tumors", "OBSERVATION", 151, 157], ["prostate", "ANATOMY", 165, 173], ["cancer", "OBSERVATION", 174, 180]]], ["It is necessary to note that the use of SiRMS allow one starting from 12 macrocyclic pyridinophanes [86] in the search for anticancer agents to finally result in symmetric open-chained aromatic compounds connected by above-mentioned linker [10] .Toxicity to Rats 8 (1D-2D)HiT QSAR based on 1D and 2D simplex models and some other approaches for the description of molecular structure have been applied for (i) evaluation of the influence of the characteristics (constitutional and structural) on the toxicity of 28 nitroaromatic compounds (some of them belonging to a widely known class of explosives, see structures below); (ii) prediction of the toxicity of new nitroaromatic derivatives; (iii) analysis of the effects of substitution in nitroaromatic compounds on in vivo toxicity The 50% lethal dose to rats (LD 50 ) has been used to develop the QSAR models based on simplex representation of molecular structure.", [["anticancer", "ANATOMY", 123, 133], ["SiRMS", "CHEMICAL", 40, 45], ["pyridinophanes", "CHEMICAL", 85, 99], ["Toxicity", "DISEASE", 246, 254], ["toxicity", "DISEASE", 500, 508], ["toxicity", "DISEASE", 648, 656], ["toxicity", "DISEASE", 775, 783], ["pyridinophanes", "CHEMICAL", 85, 99], ["SiRMS", "SIMPLE_CHEMICAL", 40, 45], ["anticancer", "CANCER", 123, 133], ["open-chained aromatic compounds", "SIMPLE_CHEMICAL", 172, 203], ["nitroaromatic derivatives", "SIMPLE_CHEMICAL", 664, 689], ["nitroaromatic compounds", "SIMPLE_CHEMICAL", 740, 763], ["rats", "ORGANISM", 807, 811], ["Rats", "SPECIES", 258, 262], ["rats", "SPECIES", 807, 811], ["SiRMS", "TREATMENT", 40, 45], ["anticancer agents", "TREATMENT", 123, 140], ["Rats", "TEST", 258, 262], ["HiT QSAR", "TEST", 272, 280], ["1D and 2D simplex models", "TREATMENT", 290, 314], ["evaluation", "TEST", 410, 420], ["the toxicity of 28 nitroaromatic compounds", "PROBLEM", 496, 538], ["the toxicity", "PROBLEM", 644, 656], ["new nitroaromatic derivatives", "TREATMENT", 660, 689], ["substitution in nitroaromatic compounds", "PROBLEM", 724, 763], ["vivo toxicity", "TREATMENT", 770, 783], ["the QSAR models", "TEST", 846, 861], ["symmetric", "OBSERVATION_MODIFIER", 162, 171], ["open", "OBSERVATION", 172, 176], ["aromatic compounds", "OBSERVATION", 185, 203], ["nitroaromatic derivatives", "OBSERVATION", 664, 689], ["nitroaromatic compounds", "OBSERVATION", 740, 763], ["molecular structure", "OBSERVATION", 897, 916]]], ["The preliminary 1D-QSAR results show that even the information on the composition of molecules reveals the main characteristics for the variations in toxicity [87] .Toxicity to Rats 8 (1D-2D)A novel 1D-QSAR approach that allows for the analysis of the non-additive effects of molecular fragments on toxicity has been proposed [87] .", [["toxicity", "DISEASE", 150, 158], ["Toxicity", "DISEASE", 165, 173], ["toxicity", "DISEASE", 299, 307], ["Rats", "SPECIES", 177, 181], ["the variations in toxicity", "PROBLEM", 132, 158], ["A novel 1D-QSAR approach", "TREATMENT", 191, 215], ["the analysis", "TEST", 232, 244], ["molecular fragments", "PROBLEM", 276, 295], ["main", "OBSERVATION_MODIFIER", 107, 111], ["molecular fragments", "OBSERVATION", 276, 295]]], ["The necessity of the consideration of substituents' impact for the development of adequate QSAR models of nitroaromatics' toxicity was demonstrated.Toxicity to Rats 8 (1D-2D)The statistic characteristics for all the 1D-QSAR models developed, with the exception of the additive models, were quite satisfactory (R 2 = 0.81-0.92; Q 2 = 0.64-0.83; R 2 test = 0.84-0.87).", [["nitroaromatics", "CHEMICAL", 106, 120], ["toxicity", "DISEASE", 122, 130], ["Toxicity", "DISEASE", 148, 156], ["nitroaromatics", "SIMPLE_CHEMICAL", 106, 120], ["Rats", "SPECIES", 160, 164], ["substituents' impact", "TREATMENT", 38, 58], ["nitroaromatics' toxicity", "PROBLEM", 106, 130], ["QSAR models", "TEST", 219, 230], ["Q", "TEST", 327, 328], ["R 2 test", "TEST", 344, 352]]], ["Successful performance of such models is due to their non-additivity, i.e., the possibility of taking into account the mutual influence of substituents in a benzene ring which governs variations in toxicity and could be mediated through the different C-H fragments of the ring.Toxicity to Rats 8 (1D-2D)The passage to 2D level, i.e., consideration of topology, allows for the improvement of the quality of the obtained QSAR models (R 2 = 0.96-0.98; Q 2 = 0.91-0.93; R 2 test = 0.89-0.92) to predict the activity for 41 novel compounds designed by the application of new combinations of substituents represented in the training set [37] .", [["benzene", "CHEMICAL", 157, 164], ["toxicity", "DISEASE", 198, 206], ["C-H", "CHEMICAL", 251, 254], ["Toxicity", "DISEASE", 277, 285], ["benzene", "CHEMICAL", 157, 164], ["C-H", "CHEMICAL", 251, 254], ["benzene", "SIMPLE_CHEMICAL", 157, 164], ["C-H fragments", "PROTEIN", 251, 264], ["Rats", "SPECIES", 289, 293], ["a benzene ring", "TREATMENT", 155, 169], ["QSAR models", "TEST", 419, 430], ["R 2 test", "TEST", 466, 474], ["new combinations of substituents", "TREATMENT", 566, 598], ["benzene ring", "OBSERVATION", 157, 169], ["ring", "ANATOMY_MODIFIER", 272, 276]]], ["The comprehensive analysis of variations in toxicity as a function of the position and nature of the substituent was performed.", [["toxicity", "DISEASE", 44, 52], ["The comprehensive analysis", "TEST", 0, 26], ["variations in toxicity", "PROBLEM", 30, 52]]], ["Molecular fragments that promote and interfere with toxicity were defined on the basis of models obtained.", [["fragments", "ANATOMY", 10, 19], ["toxicity", "DISEASE", 52, 60], ["Molecular fragments", "PROBLEM", 0, 19], ["toxicity", "PROBLEM", 52, 60], ["fragments", "OBSERVATION", 10, 19]]], ["In particular, it was found that in most cases, insertion of fluorine and hydroxyl groups into nitroaromatics increases toxicity, whereas insertion of a methyl group has the opposite effect.", [["fluorine", "CHEMICAL", 61, 69], ["hydroxyl", "CHEMICAL", 74, 82], ["nitroaromatics", "CHEMICAL", 95, 109], ["toxicity", "DISEASE", 120, 128], ["methyl", "CHEMICAL", 153, 159], ["fluorine", "CHEMICAL", 61, 69], ["hydroxyl", "CHEMICAL", 74, 82], ["nitroaromatics", "CHEMICAL", 95, 109], ["methyl", "CHEMICAL", 153, 159], ["fluorine", "SIMPLE_CHEMICAL", 61, 69], ["hydroxyl", "SIMPLE_CHEMICAL", 74, 82], ["nitroaromatics", "SIMPLE_CHEMICAL", 95, 109], ["methyl", "SIMPLE_CHEMICAL", 153, 159], ["insertion of fluorine and hydroxyl groups", "TREATMENT", 48, 89], ["nitroaromatics increases toxicity", "PROBLEM", 95, 128], ["a methyl group", "TREATMENT", 151, 165]]], ["The influence of chlorine on toxicity is ambiguous.", [["chlorine", "CHEMICAL", 17, 25], ["toxicity", "DISEASE", 29, 37], ["chlorine", "CHEMICAL", 17, 25], ["chlorine", "SIMPLE_CHEMICAL", 17, 25], ["chlorine on toxicity", "TREATMENT", 17, 37], ["chlorine", "OBSERVATION", 17, 25]]], ["Insertion of chlorine at the ortho-position to the nitro group leads to substantial increase in toxicity, whereas the second chlorine atom (at the para-position to the first) results in a considerable decrease in toxicity.", [["chlorine", "CHEMICAL", 13, 21], ["nitro", "CHEMICAL", 51, 56], ["toxicity", "DISEASE", 96, 104], ["chlorine", "CHEMICAL", 125, 133], ["toxicity", "DISEASE", 213, 221], ["chlorine", "CHEMICAL", 13, 21], ["nitro", "CHEMICAL", 51, 56], ["chlorine", "CHEMICAL", 125, 133], ["chlorine", "SIMPLE_CHEMICAL", 13, 21], ["chlorine atom", "SIMPLE_CHEMICAL", 125, 138], ["chlorine", "TREATMENT", 13, 21], ["the ortho-position", "TREATMENT", 25, 43], ["the nitro group", "TREATMENT", 47, 62], ["substantial increase in toxicity", "PROBLEM", 72, 104], ["the second chlorine atom", "PROBLEM", 114, 138], ["a considerable decrease in toxicity", "PROBLEM", 186, 221], ["chlorine", "OBSERVATION", 13, 21], ["substantial", "OBSERVATION_MODIFIER", 72, 83], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["toxicity", "OBSERVATION", 96, 104], ["considerable", "OBSERVATION_MODIFIER", 188, 200], ["decrease", "OBSERVATION_MODIFIER", 201, 209]]], ["The mutual influence of substituents in the benzene ring is substantially non-additive and plays a crucial role regarding toxicity.", [["benzene", "CHEMICAL", 44, 51], ["toxicity", "DISEASE", 122, 130], ["benzene", "CHEMICAL", 44, 51], ["benzene", "SIMPLE_CHEMICAL", 44, 51], ["substituents in the benzene ring", "TREATMENT", 24, 56]]], ["The influence of different substituents on toxicity can be mediated via different C-H fragments of the aromatic ring.Toxicity to Rats 8 (1D-2D)The correspondence between observed and predicted toxicity obtained by the 1D and 2D models was good.", [["toxicity", "DISEASE", 43, 51], ["C-H", "CHEMICAL", 82, 85], ["Toxicity", "DISEASE", 117, 125], ["toxicity", "DISEASE", 193, 201], ["C-H", "CHEMICAL", 82, 85], ["C-H fragments", "PROTEIN", 82, 95], ["Rats", "SPECIES", 129, 133], ["different substituents on toxicity", "TREATMENT", 17, 51], ["different C-H fragments of the aromatic ring", "TREATMENT", 72, 116], ["predicted toxicity", "PROBLEM", 183, 201], ["aromatic ring", "OBSERVATION", 103, 116]]], ["The single models obtained were summarized in the most adequate consensus model that allows for an improved accuracy of toxicity prediction and demonstrate its ability to be used as a virtual screening tool.5.4.3.2.Toxicity to Tetrahymena Pyriformis 9 (2D)5.4.3.2.The present study applies HiT QSAR to evaluate the influence of the structure of 95 various nitroaromatic compounds (including some widely known explosives, see structures below) to the toxicity to the ciliate T. pyriformis (QSTR -quantitative structure-toxicity relationship); for the virtual screening of toxicity of new nitroaromatic derivatives; analysis of the characteristics of the substituents in nitroaromatic compounds as to their influence on toxicity.", [["toxicity", "DISEASE", 120, 128], ["Toxicity", "DISEASE", 215, 223], ["toxicity", "DISEASE", 450, 458], ["toxicity", "DISEASE", 518, 526], ["toxicity", "DISEASE", 571, 579], ["toxicity", "DISEASE", 718, 726], ["T. pyriformis", "ORGANISM", 474, 487], ["nitroaromatic derivatives", "SIMPLE_CHEMICAL", 587, 612], ["T. pyriformis", "SPECIES", 474, 487], ["T. pyriformis", "SPECIES", 474, 487], ["toxicity prediction", "PROBLEM", 120, 139], ["a virtual screening tool", "TEST", 182, 206], ["Tetrahymena Pyriformis", "TEST", 227, 249], ["The present study", "TEST", 264, 281], ["HiT QSAR", "TEST", 290, 298], ["various nitroaromatic compounds", "PROBLEM", 348, 379], ["some widely known explosives", "PROBLEM", 391, 419], ["the toxicity", "PROBLEM", 446, 458], ["the ciliate T. pyriformis", "PROBLEM", 462, 487], ["the virtual screening", "TEST", 546, 567], ["new nitroaromatic derivatives", "TREATMENT", 583, 612], ["the substituents in nitroaromatic compounds", "PROBLEM", 649, 692], ["nitroaromatic derivatives", "OBSERVATION", 587, 612], ["nitroaromatic compounds", "OBSERVATION", 669, 692]]], ["The negative logarithm of the 50% inhibition growth concentration (IGC 50 ) was used to develop 2D simplex QSTR models.5.4.3.2.During the first part of the work the whole initial set of compounds was divided into three overlapping sets depending on the possible mechanism of action [88] .", [["IGC", "TEST", 67, 70]]], ["The 2D-QSTR PLS models obtained were quite satisfactory (R 2 = 0.84-0.95; Q 2 = 0.68-0.86).", [["The 2D-QSTR PLS models", "TEST", 0, 22]]], ["The predictive ability of the QSTR models was confirmed through the use of three different test sets (maximal similarity with training set, also minimal one and random choice, taking into account toxicity range only) for any obtained model (R 2 test = 0.57-0.85).5.4.3.2.The initial division into different sets was confirmed by the QSTR analysis, i.e., the models developed for structures with one mechanism (e.g., redox cyclers) cannot satisfactorily predict the others (e.g., those participating in nucleophilic attack).", [["toxicity", "DISEASE", 196, 204], ["QSTR", "DNA", 333, 337], ["the QSTR models", "TEST", 26, 41], ["the QSTR analysis", "TEST", 329, 346]]], ["However, the reliable predictive model can be obtained for all the compounds, regardless of mechanism, when structures of different modes of action are sufficiently represented in the training set.5.4.3.2.In addition, the classification and regression trees (CRT) algorithm has been used to obtain models that can predict possible mechanism of action.", [["CRT) algorithm", "TREATMENT", 259, 273]]], ["The quality of the CRT models obtained is also quite good.", [["the CRT models", "TEST", 15, 29]]], ["The final models had only 15-20% misclassification errors.", [["15-", "OBSERVATION_MODIFIER", 26, 29]]], ["The obtained models have correctly predicted mechanism of action for compounds of the test set (76-81%).5.4.3.2.The comparative analysis of similarity/difference of all nine selected QSAR models has been carried out using the correlation coefficient and Euclidean distance between the sets of toxicity predicted values.", [["toxicity", "DISEASE", 293, 301], ["the test set", "TEST", 82, 94], ["The comparative analysis", "TEST", 112, 136]]], ["Hence, T. pyriformis toxicity by nitroaromatic compounds is complicated and multifactorial process where, most probably, factors determining penetration and delivery of toxicant to biological target play the most important role.", [["toxicity", "DISEASE", 21, 29], ["T. pyriformis", "ORGANISM", 7, 20], ["nitroaromatic compounds", "SIMPLE_CHEMICAL", 33, 56], ["T. pyriformis", "SPECIES", 7, 20], ["T. pyriformis", "SPECIES", 7, 20], ["T. pyriformis toxicity", "PROBLEM", 7, 29], ["nitroaromatic compounds", "PROBLEM", 33, 56], ["multifactorial process", "PROBLEM", 76, 98], ["pyriformis toxicity", "OBSERVATION", 10, 29], ["nitroaromatic compounds", "OBSERVATION", 33, 56], ["most probably", "UNCERTAINTY", 106, 119]]], ["Reactivity of nitroaromatics, seemingly, only has an auxiliary role.", [["nitroaromatics", "CHEMICAL", 14, 28], ["nitroaromatics", "CHEMICAL", 14, 28], ["nitroaromatics", "SIMPLE_CHEMICAL", 14, 28]]], ["This was confirmed by the absence of any correlation between toxicity and Hammett constants of substituents.", [["toxicity", "DISEASE", 61, 69], ["toxicity", "PROBLEM", 61, 69], ["Hammett constants of substituents", "PROBLEM", 74, 107]]], ["In this regard, the difference in the mechanisms of toxicant interaction with biomolecules (reactions of nucleophylic substitution or radical reduction of nitro group) is important but do not determine for the value of its toxicity.5.4.3.2.Molecular fragments that promote and interfere with toxicity were defined using the interpretation of the PLS models obtained.", [["nitro", "CHEMICAL", 155, 160], ["toxicity", "DISEASE", 223, 231], ["toxicity", "DISEASE", 292, 300], ["nitro", "CHEMICAL", 155, 160], ["nitro", "SIMPLE_CHEMICAL", 155, 160], ["toxicant interaction", "PROBLEM", 52, 72], ["nucleophylic substitution", "TREATMENT", 105, 130], ["radical reduction of nitro group", "TREATMENT", 134, 166], ["its toxicity", "PROBLEM", 219, 231], ["Molecular fragments", "PROBLEM", 240, 259], ["toxicity", "PROBLEM", 292, 300], ["the PLS models", "TEST", 342, 356], ["fragments", "OBSERVATION", 250, 259]]], ["For example, oxibutane and aminophenyl substituents promote the toxicity of nitroaromatics to T. pyriformis but carboxyl groups interfere with toxicity.", [["oxibutane", "CHEMICAL", 13, 22], ["aminophenyl", "CHEMICAL", 27, 38], ["toxicity", "DISEASE", 64, 72], ["toxicity", "DISEASE", 143, 151], ["oxibutane", "CHEMICAL", 13, 22], ["aminophenyl", "CHEMICAL", 27, 38], ["carboxyl", "CHEMICAL", 112, 120], ["oxibutane", "SIMPLE_CHEMICAL", 13, 22], ["aminophenyl substituents", "SIMPLE_CHEMICAL", 27, 51], ["nitroaromatics", "SIMPLE_CHEMICAL", 76, 90], ["T. pyriformis", "ORGANISM", 94, 107], ["T. pyriformis", "SPECIES", 94, 107], ["T. pyriformis", "SPECIES", 94, 107], ["oxibutane", "TREATMENT", 13, 22], ["aminophenyl substituents", "TREATMENT", 27, 51], ["nitroaromatics", "TREATMENT", 76, 90], ["T. pyriformis", "TREATMENT", 94, 107], ["carboxyl groups", "TREATMENT", 112, 127], ["toxicity", "PROBLEM", 143, 151]]], ["It was also shown that substituent interference in the benzene ring plays the determining role for toxicity.", [["benzene", "CHEMICAL", 55, 62], ["toxicity", "DISEASE", 99, 107], ["benzene", "CHEMICAL", 55, 62], ["benzene", "SIMPLE_CHEMICAL", 55, 62], ["substituent interference", "PROBLEM", 23, 47], ["the benzene ring", "TREATMENT", 51, 67], ["toxicity", "PROBLEM", 99, 107], ["substituent interference", "OBSERVATION", 23, 47], ["benzene ring", "OBSERVATION", 55, 67]]], ["Contributions of the substituents to toxicity are substantially non-additive.", [["toxicity", "DISEASE", 37, 45], ["the substituents to toxicity", "PROBLEM", 17, 45], ["substantially non-additive", "PROBLEM", 50, 76], ["substituents", "OBSERVATION_MODIFIER", 21, 33], ["non-additive", "OBSERVATION_MODIFIER", 64, 76]]], ["Substituents interference effects the activation of aromatic C-H fragments with regard to toxicity.5.4.3.2.The structural factors of nitroaromatics which characterize their hydrophobicity and ability to form electrostatic interactions are the most important for the toxic action of the compounds investigated; local structural characteristics (presence of one or other fragments) are more important than integral (whole-molecule) ones.5.4.3.2.All the nine selected models were used for consensus predictions of toxicity of an external test set which consists of 63 nitroaromatics.", [["aromatic C-H", "CHEMICAL", 52, 64], ["toxicity", "DISEASE", 90, 98], ["toxicity", "DISEASE", 511, 519], ["C-H", "CHEMICAL", 61, 64], ["nitroaromatics", "CHEMICAL", 565, 579], ["aromatic C-H", "SIMPLE_CHEMICAL", 52, 64], ["nitroaromatics", "SIMPLE_CHEMICAL", 133, 147], ["aromatic C-H fragments", "PROTEIN", 52, 74], ["Substituents interference", "PROBLEM", 0, 25], ["aromatic C-H fragments", "PROBLEM", 52, 74], ["toxicity", "PROBLEM", 90, 98], ["nitroaromatics", "TREATMENT", 133, 147], ["their hydrophobicity", "PROBLEM", 167, 187], ["electrostatic interactions", "PROBLEM", 208, 234], ["the compounds", "PROBLEM", 282, 295], ["other fragments)", "PROBLEM", 363, 379], ["an external test set", "TEST", 523, 543], ["aromatic C-H fragments", "OBSERVATION_MODIFIER", 52, 74], ["fragments", "OBSERVATION", 369, 378]]], ["PLS models based on compounds from one mechanism of action were used for consensus predictions only in the case when the CRT model was able to predict such a mechanism.", [["PLS models", "TEST", 0, 10], ["the CRT model", "TEST", 117, 130]]], ["Thus, the predictivity of the consensus model on the external test set was quite satisfactory (R 2 test = 0.64).", [["the external test set", "TEST", 49, 70]]], ["Atom individuality (including stereochemistry of the chiral surroundings of the asymmetric phosphorus atom) plays the determining role in the variation of activity and is followed by the dispersion and electrostatic characteristics of the OPs.", [["phosphorus", "CHEMICAL", 91, 101], ["phosphorus", "CHEMICAL", 91, 101], ["Atom individuality", "TEST", 0, 18], ["the asymmetric phosphorus atom", "TREATMENT", 76, 106]]], ["The molecular fragments promoting or interfering with the activities investigated were determined.", [["fragments", "ANATOMY", 14, 23], ["The molecular fragments", "PROBLEM", 0, 23], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["fragments", "OBSERVATION", 14, 23], ["interfering", "OBSERVATION_MODIFIER", 37, 48]]], ["Identical fragments in the achiral compounds have smaller contributions to activity in comparison with their role in chiral molecules.", [["Identical fragments in the achiral compounds", "PROBLEM", 0, 44], ["fragments", "OBSERVATION", 10, 19], ["achiral", "ANATOMY_MODIFIER", 27, 34], ["smaller", "OBSERVATION_MODIFIER", 50, 57], ["activity", "OBSERVATION_MODIFIER", 75, 83]]], ["The influence of phosphorus on the AChE inhibition has a wide range of variation and is very dependent on its surroundings.", [["phosphorus", "CHEMICAL", 17, 27], ["phosphorus", "CHEMICAL", 17, 27], ["phosphorus", "SIMPLE_CHEMICAL", 17, 27], ["AChE", "GENE_OR_GENE_PRODUCT", 35, 39], ["AChE", "PROTEIN", 35, 39], ["phosphorus", "TREATMENT", 17, 27], ["the AChE inhibition", "TREATMENT", 31, 50], ["very dependent", "PROBLEM", 88, 102], ["wide range", "OBSERVATION_MODIFIER", 57, 67], ["very", "OBSERVATION_MODIFIER", 88, 92], ["dependent", "OBSERVATION_MODIFIER", 93, 102]]], ["The substitution of oxygen in \u2265 P = O by sulfur leads to decreasing AChE inhibition.", [["oxygen", "CHEMICAL", 20, 26], ["sulfur", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 20, 26], ["P = O", "CHEMICAL", 32, 37], ["sulfur", "CHEMICAL", 41, 47], ["oxygen", "SIMPLE_CHEMICAL", 20, 26], ["\u2265 P = O", "SIMPLE_CHEMICAL", 30, 37], ["sulfur", "SIMPLE_CHEMICAL", 41, 47], ["AChE", "GENE_OR_GENE_PRODUCT", 68, 72], ["AChE", "PROTEIN", 68, 72], ["The substitution of oxygen", "TREATMENT", 0, 26], ["decreasing AChE inhibition", "PROBLEM", 57, 83], ["oxygen", "OBSERVATION_MODIFIER", 20, 26]]], ["The presence of the 2-sulphanylpropane fragment facilitates a decrease in activity.", [["2-sulphanylpropane", "CHEMICAL", 20, 38], ["2-sulphanylpropane", "CHEMICAL", 20, 38], ["2-sulphanylpropane", "SIMPLE_CHEMICAL", 20, 38], ["2-sulphanylpropane fragment", "DNA", 20, 47], ["the 2-sulphanylpropane fragment", "TREATMENT", 16, 47], ["a decrease in activity", "PROBLEM", 60, 82], ["decrease", "OBSERVATION_MODIFIER", 62, 70], ["activity", "OBSERVATION_MODIFIER", 74, 82]]], ["Oxyme-containing fragments are actively promoting with activity.", [["Oxyme", "CHEMICAL", 0, 5], ["Oxyme", "SIMPLE_CHEMICAL", 0, 5], ["Oxyme", "PROTEIN", 0, 5], ["Oxyme-containing fragments", "TREATMENT", 0, 26], ["fragments", "OBSERVATION", 17, 26]]], ["The most active predicted compound (2-[(E)-({[cyano(cyclopentyloxy)phosphoryl]oxy}imino)methyl]-1-methylpyridinium) contains oxyme and cyclopentyl parts and is more toxic than oxyme-containing OPs from the training set.AChE InhibitionIt was also shown in the given work that the topological models of molecular structure (2.5D and double 2.5D) with the identification of stereochemical center of investigated compounds allow for the description of the OPs' ability to inhibit AChE.5.4.5.5-HT 1A Affinity (1D-4D) 11 This work was devoted to the analysis of the influence of the structure of N-alkyl-N -arylpiperazine derivatives (see structures below) on their affinity for the 5-HT 1A receptors (5-HT 1A R).", [["2-[(E)-({[cyano(cyclopentyloxy)phosphoryl]oxy}imino)methyl]-1-methylpyridinium", "CHEMICAL", 36, 114], ["oxyme", "CHEMICAL", 125, 130], ["cyclopentyl", "CHEMICAL", 135, 146], ["HT", "DISEASE", 489, 491], ["N-alkyl-N -arylpiperazine", "CHEMICAL", 590, 615], ["5-HT", "CHEMICAL", 677, 681], ["5-HT", "CHEMICAL", 696, 700], ["2-[(E)-({[cyano(cyclopentyloxy)phosphoryl]oxy}imino)methyl]-1-methylpyridinium", "CHEMICAL", 36, 114], ["oxyme", "CHEMICAL", 125, 130], ["cyclopentyl", "CHEMICAL", 135, 146], ["oxyme", "CHEMICAL", 176, 181], ["N-alkyl-N -arylpiperazine", "CHEMICAL", 590, 615], ["5-HT", "CHEMICAL", 677, 681], ["5-HT", "CHEMICAL", 696, 700], ["2-[(E)-({[cyano(cyclopentyloxy)phosphoryl]oxy}imino)methyl]-1-methylpyridinium", "SIMPLE_CHEMICAL", 36, 114], ["oxyme", "SIMPLE_CHEMICAL", 125, 130], ["cyclopentyl parts", "SIMPLE_CHEMICAL", 135, 152], ["oxyme-containing OPs", "SIMPLE_CHEMICAL", 176, 196], ["AChE", "GENE_OR_GENE_PRODUCT", 219, 223], ["N-alkyl-N -arylpiperazine derivatives", "SIMPLE_CHEMICAL", 590, 627], ["5-HT 1A receptors", "GENE_OR_GENE_PRODUCT", 677, 694], ["5-HT 1A R", "GENE_OR_GENE_PRODUCT", 696, 705], ["AChE", "PROTEIN", 219, 223], ["AChE", "PROTEIN", 476, 480], ["5-HT 1A receptors", "PROTEIN", 677, 694], ["(E)-({[cyano(cyclopentyloxy)phosphoryl]oxy}imino", "TREATMENT", 39, 87], ["methyl]-1-methylpyridinium)", "TREATMENT", 88, 115], ["oxyme and cyclopentyl parts", "TREATMENT", 125, 152], ["AChE Inhibition", "TREATMENT", 219, 234], ["AChE", "TEST", 476, 480], ["Affinity", "TEST", 495, 503], ["the analysis", "TEST", 540, 552], ["N-alkyl", "TREATMENT", 590, 597], ["N -arylpiperazine derivatives", "TREATMENT", 598, 627], ["toxic", "OBSERVATION_MODIFIER", 165, 170]]], ["Several PLS and MLR models have been obtained for the training set containing 42 ligands of 5-HT 1A R represented on the 1D-4D levels by SiRMS [32] .", [["5-HT", "CHEMICAL", 92, 96], ["5-HT", "CHEMICAL", 92, 96], ["5-HT 1A R", "GENE_OR_GENE_PRODUCT", 92, 101], ["Several PLS and MLR models", "TEST", 0, 26], ["ligands", "TEST", 81, 88]]], ["There is improvement in the models from 1D \u2192 2D \u2192 4D \u2192 3D.", [["1D \u2192 2D \u2192 4D \u2192 3D", "CELL_LINE", 40, 57], ["improvement", "OBSERVATION_MODIFIER", 9, 20]]], ["Molecular fragments which have an influence on the affinity for 5-HT 1A R have been identified.", [["5-HT", "CHEMICAL", 64, 68], ["5-HT", "CHEMICAL", 64, 68], ["5-HT 1A R", "GENE_OR_GENE_PRODUCT", 64, 73], ["Molecular fragments", "PROBLEM", 0, 19], ["the affinity", "TEST", 47, 59], ["fragments", "OBSERVATION", 10, 19]]], ["Analysis of the spatial structure of \"productive\" conformers determined according to 4D-QSAR model shows considerable similarity to the existing pharmacophore models [89] [90] [91] and has allowed for improvement.5.4.5.The 2D-QSAR classification task has been solved using the PLS and CRT methods for the set of 364 ligands of 5-HT 1A R (284 in the training set and 62 in the test set) [92] .", [["5-HT", "CHEMICAL", 327, 331], ["5-HT", "CHEMICAL", 327, 331], ["5-HT 1A R", "GENE_OR_GENE_PRODUCT", 327, 336], ["4D-QSAR model", "TEST", 85, 98], ["pharmacophore models", "TEST", 145, 165], ["the PLS", "TEST", 273, 280], ["CRT methods", "TEST", 285, 296]]], ["The PLS model showed a 65% accuracy for the prediction of test set compounds and the CRT model -74%.", [["The PLS model", "TEST", 0, 13], ["the CRT model", "TEST", 81, 94]]], ["It has been shown that, in general, a polymethylene chain comprising three or fewer CH 2 groups has a negative influence on affinity for 5-HT 1A R and a chain comprising four or more CH 2 groups has a positive influence.", [["polymethylene", "CHEMICAL", 38, 51], ["5-HT", "CHEMICAL", 137, 141], ["polymethylene", "CHEMICAL", 38, 51], ["CH", "CHEMICAL", 84, 86], ["5-HT", "CHEMICAL", 137, 141], ["CH", "CHEMICAL", 183, 185], ["5-HT 1A R", "GENE_OR_GENE_PRODUCT", 137, 146], ["a polymethylene chain", "TREATMENT", 36, 57], ["a positive influence", "PROBLEM", 199, 219], ["positive", "OBSERVATION", 201, 209]]], ["Electron-donating substituents (o-OCH 3 , o-OH, o-Cl) at the ortho-position of phenyl ring strongly promoted affinity.", [["o-OCH 3 , o-OH, o-Cl", "CHEMICAL", 32, 52], ["phenyl", "CHEMICAL", 79, 85], ["o-OCH", "CHEMICAL", 32, 37], ["o-OH", "CHEMICAL", 42, 46], ["Cl", "CHEMICAL", 50, 52], ["phenyl", "CHEMICAL", 79, 85], ["Electron-donating substituents", "SIMPLE_CHEMICAL", 0, 30], ["o-OCH 3 , o-OH, o-Cl", "SIMPLE_CHEMICAL", 32, 52], ["ortho-position of phenyl ring", "SIMPLE_CHEMICAL", 61, 90], ["the ortho-position of phenyl ring", "TREATMENT", 57, 90]]], ["A 2,3-dihydrobenzodioxin-5-yl residue has a similar influence on affinity.", [["2,3-dihydrobenzodioxin-5-yl", "CHEMICAL", 2, 29], ["2,3-dihydrobenzodioxin-5-yl", "CHEMICAL", 2, 29], ["2,3-dihydrobenzodioxin-5-yl", "SIMPLE_CHEMICAL", 2, 29], ["dihydrobenzodioxin", "TREATMENT", 6, 24]]], ["Electron-accepting substituents (m-CF 3 ) in phenyl have high affinity.", [["phenyl", "CHEMICAL", 45, 51], ["phenyl", "CHEMICAL", 45, 51], ["m-CF 3", "SIMPLE_CHEMICAL", 33, 39], ["phenyl", "SIMPLE_CHEMICAL", 45, 51], ["Electron", "TEST", 0, 8], ["substituents (m-CF", "TREATMENT", 19, 37], ["high affinity", "PROBLEM", 57, 70], ["high affinity", "OBSERVATION", 57, 70]]], ["Electron-accepting substituents at the para-position of the phenyl ring (p-NO 2 , p-F) have a stronger negative influence on affinity to 5-HT 1A R than electron-donating ones (p-OCH 3 ).", [["p-NO 2 , p-F", "CHEMICAL", 73, 85], ["5-HT", "CHEMICAL", 137, 141], ["phenyl", "CHEMICAL", 60, 66], ["p-NO 2 , p-F", "CHEMICAL", 73, 85], ["5-HT", "CHEMICAL", 137, 141], ["p-OCH 3", "CHEMICAL", 176, 183], ["phenyl ring", "SIMPLE_CHEMICAL", 60, 71], ["p-NO 2 , p-F", "SIMPLE_CHEMICAL", 73, 85], ["5-HT 1A R", "SIMPLE_CHEMICAL", 137, 146], ["electron-donating ones", "SIMPLE_CHEMICAL", 152, 174], ["substituents", "TREATMENT", 19, 31], ["the phenyl ring", "TREATMENT", 56, 71], ["affinity", "TEST", 125, 133], ["phenyl ring", "OBSERVATION", 60, 71]]], ["The following conclusions have been made about the influence of the terminal fragments (substituents of N-alkyl group) on affinity.", [["N-alkyl", "CHEMICAL", 104, 111], ["N-alkyl", "CHEMICAL", 104, 111], ["the terminal fragments (substituents of N-alkyl group)", "TREATMENT", 64, 118], ["terminal", "OBSERVATION_MODIFIER", 68, 76], ["fragments", "OBSERVATION", 77, 86]]], ["Saturated polycyclic fragments and small aromatic residues demonstrated positive influence on affinity and larger aromatic fragments show a negative effect.", [["Saturated polycyclic fragments", "PROBLEM", 0, 30], ["small aromatic residues", "PROBLEM", 35, 58], ["positive influence on affinity", "PROBLEM", 72, 102], ["larger aromatic fragments", "PROBLEM", 107, 132], ["polycyclic fragments", "OBSERVATION", 10, 30], ["small", "OBSERVATION_MODIFIER", 35, 40], ["aromatic residues", "OBSERVATION", 41, 58], ["larger", "OBSERVATION_MODIFIER", 107, 113], ["aromatic fragments", "OBSERVATION", 114, 132], ["negative effect", "OBSERVATION", 140, 155]]], ["According to the following analysis, the optimal van der Waals volume for the terminal moiety must be approximately 500 \u00c5 3 or less.5.4.5.Molecular design and virtual screening of new potential ligands of 5-HT 1A R has been developed on the basis of the obtained results.", [["5-HT", "CHEMICAL", 205, 209], ["5-HT", "CHEMICAL", 205, 209], ["5-HT 1A R", "GENE_OR_GENE_PRODUCT", 205, 214], ["the optimal van der Waals volume for the terminal moiety", "TREATMENT", 37, 93], ["virtual screening", "TEST", 159, 176], ["new potential ligands", "TEST", 180, 201]]], ["Several most promising compounds have been chosen for subsequent investigations, two of them are represented in Table 5 -4 (8 and 9).Pharmacokinetic Properties of Substituted Benzodiazepines (2D)The influence of the structure of substituted benzodiazepines (27 compounds, see below) 12 on the variation of their pharmacokinetic properties including bioavailability, semi-elimination period, clearance, and volume of distribution in the organism of man has been studied [94] .", [["Benzodiazepines", "CHEMICAL", 175, 190], ["benzodiazepines", "CHEMICAL", 241, 256], ["Benzodiazepines", "CHEMICAL", 175, 190], ["benzodiazepines", "CHEMICAL", 241, 256], ["benzodiazepines", "SIMPLE_CHEMICAL", 241, 256], ["man", "ORGANISM", 448, 451], ["man", "SPECIES", 448, 451], ["subsequent investigations", "TEST", 54, 79], ["Substituted Benzodiazepines", "TREATMENT", 163, 190], ["substituted benzodiazepines", "TREATMENT", 229, 256], ["clearance", "TEST", 391, 400], ["Substituted Benzodiazepines", "OBSERVATION", 163, 190]]], ["Simplex descriptors in addition to some integral parameters generated by the Dragon software [93] were used for the development of statistic models.Pharmacokinetic Properties of Substituted Benzodiazepines (2D)Reasonably adequate quantitative \"structure-pharmacokinetic properties\" relationships were obtained using the PLS and MLR statistical approaches (R 2 = 0.91-0.95, Q 2 = 0.81-0.94) [94] .", [["Benzodiazepines", "CHEMICAL", 190, 205], ["Benzodiazepines", "CHEMICAL", 190, 205], ["Simplex descriptors", "PROBLEM", 0, 19], ["Substituted Benzodiazepines", "TREATMENT", 178, 205], ["the PLS", "TEST", 316, 323]]], ["Structural factors affecting the change of pharmacokinetic properties of substituted benzodiazepines were revealed on the basis of the obtained models.Pharmacokinetic Properties of Substituted Benzodiazepines (2D)Bioavailability.", [["benzodiazepines", "CHEMICAL", 85, 100], ["Benzodiazepines", "CHEMICAL", 193, 208], ["benzodiazepines", "CHEMICAL", 85, 100], ["Benzodiazepines", "CHEMICAL", 193, 208], ["benzodiazepines", "SIMPLE_CHEMICAL", 85, 100], ["Structural factors", "PROBLEM", 0, 18], ["substituted benzodiazepines", "TREATMENT", 73, 100], ["Substituted Benzodiazepines", "TREATMENT", 181, 208]]], ["Although there is no correlation between absolute bioavailability (F) and lipophilicity (R\u22480), the trend of increasing of molecular fragments' contribution to common bioavailability alongside with increasing of its lipophilicity is observed quite clearly.", [["lipophilicity", "TEST", 74, 87], ["molecular fragments", "PROBLEM", 122, 141], ["common bioavailability", "PROBLEM", 159, 181], ["no", "UNCERTAINTY", 18, 20], ["increasing", "OBSERVATION_MODIFIER", 108, 118], ["molecular fragments", "OBSERVATION", 122, 141], ["increasing", "OBSERVATION_MODIFIER", 197, 207], ["lipophilicity", "OBSERVATION", 215, 228]]], ["This trend is the most evident in case of aromatic fragments.", [["aromatic fragments", "PROBLEM", 42, 60], ["most evident", "OBSERVATION_MODIFIER", 18, 30], ["aromatic fragments", "OBSERVATION", 42, 60]]], ["Pentamerous aromatic heterocycles have the greatest influence on bioavailability.Pharmacokinetic Properties of Substituted Benzodiazepines (2D)Thus, the presence of benzene rings in a molecule increases its bioavailability in a series of substituted benzodiazepines and substitution on the aromatic rings leads to a decrease in bioavailability.", [["Pentamerous aromatic heterocycles", "CHEMICAL", 0, 33], ["Benzodiazepines", "CHEMICAL", 123, 138], ["benzene", "CHEMICAL", 165, 172], ["benzodiazepines", "CHEMICAL", 250, 265], ["Pentamerous aromatic heterocycles", "CHEMICAL", 0, 33], ["Benzodiazepines", "CHEMICAL", 123, 138], ["benzene", "CHEMICAL", 165, 172], ["benzodiazepines", "CHEMICAL", 250, 265], ["Pentamerous aromatic heterocycles", "SIMPLE_CHEMICAL", 0, 33], ["benzene rings", "SIMPLE_CHEMICAL", 165, 178], ["benzodiazepines", "SIMPLE_CHEMICAL", 250, 265], ["Pentamerous aromatic heterocycles", "TREATMENT", 0, 33], ["Substituted Benzodiazepines", "TREATMENT", 111, 138], ["benzene rings", "PROBLEM", 165, 178], ["a molecule", "PROBLEM", 182, 192], ["substituted benzodiazepines", "TREATMENT", 238, 265], ["substitution", "TREATMENT", 270, 282], ["the aromatic rings", "TREATMENT", 286, 304], ["a decrease in bioavailability", "PROBLEM", 314, 343], ["aromatic heterocycles", "OBSERVATION", 12, 33], ["greatest", "OBSERVATION_MODIFIER", 43, 51], ["Substituted Benzodiazepines", "OBSERVATION", 111, 138], ["benzene rings", "OBSERVATION", 165, 178], ["aromatic rings", "OBSERVATION", 290, 304], ["decrease", "OBSERVATION_MODIFIER", 316, 324]]], ["Also one can note that the more oxygen atoms in a molecule, the lower the bioavailability.", [["oxygen", "CHEMICAL", 32, 38], ["oxygen", "CHEMICAL", 32, 38], ["oxygen atoms", "SIMPLE_CHEMICAL", 32, 44]]], ["It has been determined that the oxygen atoms are hydrogen bond acceptors.", [["oxygen", "CHEMICAL", 32, 38], ["oxygen", "CHEMICAL", 32, 38], ["hydrogen", "CHEMICAL", 49, 57], ["oxygen atoms", "SIMPLE_CHEMICAL", 32, 44], ["hydrogen bond acceptors", "SIMPLE_CHEMICAL", 49, 72], ["the oxygen atoms", "PROBLEM", 28, 44], ["hydrogen bond acceptors", "TREATMENT", 49, 72]]], ["This is in agreement with Lipinski's \"rule of five\" [24] , whereby good bioavailability is observed when the drug corresponds to the following physico-chemical characteristics: molecular weight < 500; log P \u2264 5; number of groups -proton donors \u2264 5; number of groups -proton acceptors \u2264 10.Pharmacokinetic Properties of Substituted Benzodiazepines (2D)Clearance.", [["Benzodiazepines", "CHEMICAL", 331, 346], ["Benzodiazepines", "CHEMICAL", 331, 346], ["molecular weight", "TEST", 177, 193], ["proton donors \u2264", "TREATMENT", 230, 245], ["proton acceptors", "TREATMENT", 267, 283], ["Substituted Benzodiazepines", "TREATMENT", 319, 346]]], ["For clearance (Cl) of the investigated series, the trend is opposite to that for bioavailability.", [["Cl", "CHEMICAL", 15, 17]]], ["Thus, the presence of H-donors in a molecule, substitution in aromatic rings as well as an increase of molecule saturation leads to an increase in clearance.Pharmacokinetic Properties of Substituted Benzodiazepines (2D)Time of semi-elimination.", [["H", "CHEMICAL", 22, 23], ["Benzodiazepines", "CHEMICAL", 199, 214], ["H", "CHEMICAL", 22, 23], ["Benzodiazepines", "CHEMICAL", 199, 214], ["a molecule", "PROBLEM", 34, 44], ["substitution in aromatic rings", "TREATMENT", 46, 76], ["an increase of molecule saturation", "PROBLEM", 88, 122], ["Substituted Benzodiazepines", "TREATMENT", 187, 214], ["aromatic rings", "OBSERVATION", 62, 76], ["increase", "OBSERVATION_MODIFIER", 91, 99], ["molecule saturation", "OBSERVATION", 103, 122], ["increase", "OBSERVATION_MODIFIER", 135, 143]]], ["The influence of structural fragments on the variation of the time of semi-elimination is similar to that described for bioavailability.", [["structural fragments", "PROBLEM", 17, 37], ["structural", "OBSERVATION_MODIFIER", 17, 27], ["fragments", "OBSERVATION", 28, 37]]], ["Thus, all lipophilic aromatic fragments have high values for increasing semi-elimination time.Pharmacokinetic Properties of Substituted Benzodiazepines (2D)Volume of distribution.", [["Benzodiazepines", "CHEMICAL", 136, 151], ["Benzodiazepines", "CHEMICAL", 136, 151], ["all lipophilic aromatic fragments", "PROBLEM", 6, 39], ["Substituted Benzodiazepines (2D)Volume of distribution", "TREATMENT", 124, 178], ["lipophilic", "OBSERVATION_MODIFIER", 10, 20], ["aromatic fragments", "OBSERVATION", 21, 39], ["high values", "OBSERVATION_MODIFIER", 45, 56], ["Substituted Benzodiazepines", "OBSERVATION", 124, 151]]], ["During the analysis of the influence of structure of benzodiazepines on their volume of distribution, the same trends as for clearance were revealed.", [["benzodiazepines", "CHEMICAL", 53, 68], ["benzodiazepines", "CHEMICAL", 53, 68], ["benzodiazepines", "SIMPLE_CHEMICAL", 53, 68], ["the analysis", "TEST", 7, 19], ["benzodiazepines", "TREATMENT", 53, 68], ["clearance", "TEST", 125, 134]]], ["Thus, refraction (electronic polarizability) increases the volume of distribution and high aromaticity and hydrophilicity decrease it.Pharmacokinetic Properties of Substituted Benzodiazepines (2D)The resulting PLS models have been used for the development of virtual screening of pharmacokinetic properties of novel compounds belonging to bezdiazepines family [94] .5.4.7.Catalytic Activity of Crown Ethers 13 (3D)5.4.7.HiT QSAR was applied to develop the QSPR analysis of the phase-transfer catalytic properties of crown ethers in the reaction of benzyl alcohol oxidation by potassium chlorochromate: The objects of the investigation were 66 structurally dissimilar crown ethers, their acyclic analogues and related compounds.", [["Benzodiazepines", "CHEMICAL", 176, 191], ["bezdiazepines", "CHEMICAL", 339, 352], ["crown ethers", "CHEMICAL", 516, 528], ["benzyl alcohol", "CHEMICAL", 548, 562], ["potassium chlorochromate", "CHEMICAL", 576, 600], ["crown ethers", "CHEMICAL", 667, 679], ["Benzodiazepines", "CHEMICAL", 176, 191], ["bezdiazepines", "CHEMICAL", 339, 352], ["crown ethers", "CHEMICAL", 516, 528], ["benzyl alcohol", "CHEMICAL", 548, 562], ["potassium chlorochromate", "CHEMICAL", 576, 600], ["crown ethers", "CHEMICAL", 667, 679], ["bezdiazepines", "SIMPLE_CHEMICAL", 339, 352], ["[94] .5.4.7", "SIMPLE_CHEMICAL", 360, 371], ["crown ethers", "SIMPLE_CHEMICAL", 516, 528], ["benzyl alcohol", "SIMPLE_CHEMICAL", 548, 562], ["potassium chlorochromate", "SIMPLE_CHEMICAL", 576, 600], ["crown ethers", "SIMPLE_CHEMICAL", 667, 679], ["acyclic analogues", "SIMPLE_CHEMICAL", 687, 704], ["refraction (electronic polarizability", "TREATMENT", 6, 43], ["high aromaticity", "PROBLEM", 86, 102], ["hydrophilicity", "PROBLEM", 107, 121], ["Substituted Benzodiazepines", "TREATMENT", 164, 191], ["The resulting PLS models", "TREATMENT", 196, 220], ["virtual screening", "TEST", 259, 276], ["HiT QSAR", "TEST", 420, 428], ["the QSPR analysis", "TEST", 452, 469], ["the investigation", "TEST", 617, 634], ["structurally dissimilar crown ethers", "PROBLEM", 643, 679], ["their acyclic analogues", "PROBLEM", 681, 704], ["volume", "OBSERVATION_MODIFIER", 59, 65], ["high aromaticity", "OBSERVATION", 86, 102], ["hydrophilicity decrease", "OBSERVATION", 107, 130], ["crown ethers", "OBSERVATION", 667, 679], ["acyclic analogues", "OBSERVATION", 687, 704]]], ["The compounds were not divided into training and test sets.", [["test sets", "TEST", 49, 58]]], ["Catalytic activity was expressed as the percentage of conversion acceleration.5.4.7.The distinctive feature of this study is the absence of any reliable relationship between topololgical (2D) structure of crown ethers and their catalytic properties.", [["crown ethers", "CHEMICAL", 205, 217], ["crown ethers", "CHEMICAL", 205, 217], ["crown ethers", "SIMPLE_CHEMICAL", 205, 217], ["this study", "TEST", 111, 121], ["crown ethers", "OBSERVATION", 205, 217]]], ["At the 4D level a not very robust (Q 2 = 0.46) relationship was obtained and, only at the 3D level, after the selection of the conformations with the most acceptable formation of complexes with potassium, was a reliable model formed (R 2 = 0.87; Q 2 = 0.66).", [["potassium", "CHEMICAL", 194, 203], ["potassium", "CHEMICAL", 194, 203], ["potassium", "SIMPLE_CHEMICAL", 194, 203], ["potassium", "TREATMENT", 194, 203]]], ["Alongside the positive effect of biphenyl and diphenyloxide fragments on catalytic activity of the investigated compounds, the slight preference of \"transoid\" on cis-conformations of crown ethers containing mentioned fragments was shown.", [["fragments", "ANATOMY", 217, 226], ["biphenyl", "CHEMICAL", 33, 41], ["diphenyloxide", "CHEMICAL", 46, 59], ["crown ethers", "CHEMICAL", 183, 195], ["biphenyl", "CHEMICAL", 33, 41], ["diphenyloxide", "CHEMICAL", 46, 59], ["crown ethers", "CHEMICAL", 183, 195], ["biphenyl", "SIMPLE_CHEMICAL", 33, 41], ["diphenyloxide", "SIMPLE_CHEMICAL", 46, 59], ["crown ethers", "SIMPLE_CHEMICAL", 183, 195], ["biphenyl and diphenyloxide fragments", "TREATMENT", 33, 69], ["crown ethers", "TREATMENT", 183, 195], ["mentioned fragments", "PROBLEM", 207, 226], ["positive effect", "OBSERVATION_MODIFIER", 14, 29], ["slight", "OBSERVATION_MODIFIER", 127, 133], ["fragments", "OBSERVATION", 217, 226]]], ["The undesirability of the cyclohexyl fragment was determined as well as the certain limits of crown ether dentacy (4) (5) (6) (7) (8) .", [["cyclohexyl", "CHEMICAL", 26, 36], ["cyclohexyl", "CHEMICAL", 26, 36], ["crown ether dentacy (4) (5) (6) (7)", "CHEMICAL", 94, 129], ["4) (5) (6) (7)", "SIMPLE_CHEMICAL", 115, 129], ["the cyclohexyl fragment", "PROBLEM", 22, 45], ["cyclohexyl fragment", "OBSERVATION", 26, 45]]], ["These findings, as well as the predominant role of electrostatic factors in investigated process (~50%), correspond to the known mechanisms of catalytic action of the crown ethers.", [["crown ethers", "CHEMICAL", 167, 179], ["crown ethers", "CHEMICAL", 167, 179], ["crown ethers", "SIMPLE_CHEMICAL", 167, 179], ["electrostatic factors", "PROTEIN", 51, 72], ["electrostatic factors", "PROBLEM", 51, 72], ["electrostatic factors", "OBSERVATION", 51, 72], ["crown ethers", "OBSERVATION", 167, 179]]], ["Two potent catalysts 10 and 11 (Table 5 -4) were designed and introduced as a result of the QSPR analysis.Aqueous Solubility 14 (2D)This work was devoted to the development of new QSPR equations which will accurately predict S w for compounds of interest to the US Army (explosives and their metabolites) using the SiRMS approach with subsequent validation of the obtained results using a broad spectrum of available experimentally determined data.", [["Two potent catalysts", "TREATMENT", 0, 20], ["the QSPR analysis", "TEST", 88, 105], ["new QSPR equations", "PROBLEM", 176, 194], ["the SiRMS approach", "TREATMENT", 311, 329], ["potent", "OBSERVATION_MODIFIER", 4, 10]]], ["The series of the different QSPR models that supplement each other excludes the application of additive schemes and provides a solution to the problems of virtual screening, the evaluation of influence of the structural factors on solubility, etc., have been developed and used with the consensus part of hierarchical QSAR technology.Aqueous Solubility 14 (2D)The training set consists of 135 compounds and the test set includes 156 compounds.", [["structural factors", "PROTEIN", 209, 227], ["the different QSPR models", "TREATMENT", 14, 39], ["additive schemes", "TREATMENT", 95, 111], ["a solution", "TREATMENT", 125, 135], ["virtual screening", "TEST", 155, 172], ["the evaluation", "TEST", 174, 188], ["Aqueous Solubility", "TREATMENT", 334, 352], ["the test set", "TEST", 407, 419]]], ["Two-dimensional simplex and derived from them Fourier integral descriptors have been used to obtain the set of well-fitted, robust, and predictive (internally and externally) QSPR models (R 2 = 0.90-0.95; Q 2 = 0.85-0.91; R 2 test = 0.78-0.87).", [["QSPR models", "TEST", 175, 186], ["Q", "TEST", 205, 206], ["R 2 test", "TEST", 222, 230]]], ["External validation using four different test sets also reflects a high level of predictivity (R 2 test1 = 0.7-0.87; R 2 test2 = 0.82-0.88; R 2 test3 = 0.66-0.76; R 2 test4 = 0.86-0.91).", [["External validation", "TEST", 0, 19], ["four different test sets", "TEST", 26, 50], ["predictivity", "TEST", 81, 93], ["test1", "TEST", 99, 104], ["test2", "TEST", 121, 126], ["R", "TEST", 140, 141], ["test3", "TEST", 144, 149], ["test4", "TEST", 167, 172]]], ["Here test 1 -mixed set of 27 compounds from different chemical classes; test 2 -set of 100 pesticides; test 3 -McFarland set of 18 drugs and pesticides; and test 4 -Arthursson set of 11 drugs.", [["Here test", "TEST", 0, 9], ["test", "TEST", 72, 76], ["test", "TEST", 103, 107], ["pesticides", "TEST", 141, 151], ["test", "TEST", 157, 161]]], ["The application of DA estimated by the two different approaches (Ellipsoid DA and Williams Plot) leads to a loss of coverage but does not improve the quality of the prediction (R 2 testU = 0.87).Aqueous Solubility 14 (2D)Special attention was paid to the accurate prediction of the solubility of polynitro military compounds, e.g., HMX, RDX, CL-20.", [["DA", "CHEMICAL", 19, 21], ["DA", "CHEMICAL", 75, 77], ["HMX", "CHEMICAL", 332, 335], ["RDX", "CHEMICAL", 337, 340], ["CL-20", "CHEMICAL", 342, 347], ["polynitro", "CHEMICAL", 296, 305], ["DA", "SIMPLE_CHEMICAL", 19, 21], ["polynitro military compounds", "SIMPLE_CHEMICAL", 296, 324], ["HMX", "SIMPLE_CHEMICAL", 332, 335], ["RDX", "SIMPLE_CHEMICAL", 337, 340], ["CL-20", "SIMPLE_CHEMICAL", 342, 347], ["DA", "TREATMENT", 19, 21], ["a loss of coverage", "TREATMENT", 106, 124], ["the prediction", "TEST", 161, 175], ["Aqueous Solubility", "TREATMENT", 195, 213], ["CL", "TEST", 342, 344]]], ["Comparison of the solubility values for such compounds predicted by our QSPR results and EPI SuiteTM and SPARC techniques indicates that both DoD and Environmental Protection Agency will have considerable advantage using the SiRMS models developed here.CONCLUSIONSIn summary, it can be concluded that the QSAR technology considered is a universal instrument for the development of effective QSAR models which provide reliable enough virtual screening and targeted molecular design of various compounds with desired properties.", [["SPARC", "PROTEIN", 105, 110], ["the solubility values", "TEST", 14, 35], ["such compounds", "PROBLEM", 40, 54], ["our QSPR", "TEST", 68, 76], ["EPI SuiteTM", "TREATMENT", 89, 100], ["SPARC techniques", "TEST", 105, 121], ["the SiRMS models", "TREATMENT", 221, 237], ["a universal instrument", "TREATMENT", 335, 357], ["effective QSAR models", "PROBLEM", 381, 402], ["virtual screening", "TEST", 433, 450]]], ["This is a result of its hierarchical structure and wide descriptor system.", [["hierarchical structure", "OBSERVATION", 24, 46], ["wide", "OBSERVATION_MODIFIER", 51, 55]]], ["The comparative analysis of HiT QSAR with the most popular modern QSAR approaches reflects its advantage, especially in predictivity.", [["The comparative analysis", "TEST", 0, 24], ["HiT QSAR", "TEST", 28, 36]]], ["The efficiency of HiT QSAR was demonstrated on various QSAR/QSPR tasks at different (1D-4D) levels of molecular modeling.", [["HiT", "SIMPLE_CHEMICAL", 18, 21], ["HiT QSAR", "TEST", 18, 26], ["various QSAR", "TEST", 47, 59], ["QSPR tasks", "TEST", 60, 70], ["molecular modeling", "PROBLEM", 102, 120], ["efficiency", "OBSERVATION_MODIFIER", 4, 14], ["HiT QSAR", "OBSERVATION", 18, 26], ["molecular modeling", "OBSERVATION", 102, 120]]], ["HiT QSAR is under permanent development and improvement.", [["HiT QSAR", "TEST", 0, 8], ["improvement", "OBSERVATION_MODIFIER", 44, 55]]], ["Currently the system of descriptors devoted to adequate description of structure of nanomaterials on the basis of carbon polyhedrons (fullerenes, nanotubes, etc.), algorithms of consensus modeling, and procedures for QSAR analysis of complex mixtures are under development.", [["carbon", "CHEMICAL", 114, 120], ["fullerenes", "CHEMICAL", 134, 144], ["carbon polyhedrons", "SIMPLE_CHEMICAL", 114, 132], ["fullerenes", "SIMPLE_CHEMICAL", 134, 144], ["carbon polyhedrons (fullerenes, nanotubes", "TREATMENT", 114, 155], ["consensus modeling", "TEST", 178, 196], ["QSAR analysis", "TEST", 217, 230], ["complex mixtures", "PROBLEM", 234, 250]]]], "PMC7455168": [], "PMC7105012": [["IntroductionRecent advances in medicine and science have led to the homo-hundred era, in which excess environmental and industrial advancements have exposed people to viral infections, such as Middle East respiratory syndrome, and harmful environments, such as fine dust.", [["viral infections", "DISEASE", 167, 183], ["Middle East respiratory syndrome", "DISEASE", 193, 225], ["people", "ORGANISM", 157, 163], ["people", "SPECIES", 157, 163], ["viral infections", "PROBLEM", 167, 183], ["Middle East respiratory syndrome", "PROBLEM", 193, 225], ["respiratory syndrome", "OBSERVATION", 205, 225]]], ["Therefore, there is growing interest in the development of drugs, drinks, and functional foods using natural substances with few side effects (Eliott, 1996).", [["growing", "OBSERVATION_MODIFIER", 20, 27], ["interest", "OBSERVATION_MODIFIER", 28, 36]]], ["As an essential element in the healthy lifestyle of modern individuals, the importance of immunity has been recognized; accordingly, there has been a recent increase in the consumption of health functional foods that assist in enhancing immunity.Introduction", [["essential", "OBSERVATION_MODIFIER", 6, 15], ["element", "OBSERVATION_MODIFIER", 16, 23], ["increase", "OBSERVATION_MODIFIER", 157, 165]]]], "37d73ae86b2011d4c1812a62661fb217eff81b2c": [["Dear Editor,As of April 4, the Italian Health Ministry reports more than 120,000 total cases and 15,000 deaths from coronavirus disease 2019 (COVID-19) nationwide [1] .", [["deaths", "DISEASE", 104, 110], ["coronavirus disease", "DISEASE", 116, 135], ["coronavirus disease", "PROBLEM", 116, 135], ["COVID", "TEST", 142, 147]]], ["Because of the striking and often unforeseeable rapidity of respiratory deterioration, about 10-25% of hospitalized patients require invasive ventilation [2] .", [["respiratory", "ANATOMY", 60, 71], ["respiratory deterioration", "DISEASE", 60, 85], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["respiratory deterioration", "PROBLEM", 60, 85], ["invasive ventilation", "TREATMENT", 133, 153], ["respiratory deterioration", "OBSERVATION", 60, 85]]], ["This has led to an unprecedented challenge for healthcare providers, especially in northern Italy, the nation's center of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) outbreak.", [["acute respiratory syndrome-coronavirus", "DISEASE", 129, 167], ["severe acute respiratory syndrome-coronavirus 2", "ORGANISM", 122, 169], ["SARS-CoV-2", "ORGANISM", 171, 181], ["-coronavirus", "SPECIES", 155, 167], ["severe acute respiratory syndrome-coronavirus", "SPECIES", 122, 167], ["SARS-CoV-2", "SPECIES", 171, 181], ["severe acute respiratory syndrome", "PROBLEM", 122, 155], ["coronavirus", "PROBLEM", 156, 167], ["SARS", "TEST", 171, 175], ["outbreak", "PROBLEM", 183, 191], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["respiratory syndrome", "OBSERVATION", 135, 155]]], ["Although Italy's national health system has 3.2 hospital beds per 1,000 people (as compared with 2.8 in the USA), the ability to test, contain people with suspected infection, and meet the needs of critically ill patients simultaneously has been outpaced.Dear Editor,After a time-lag of few weeks, in other countries -including the USA -hospitals are now overflowing with COVID-19 patients.", [["infection", "DISEASE", 165, 174], ["critically ill", "DISEASE", 198, 212], ["people", "ORGANISM", 72, 78], ["people", "ORGANISM", 143, 149], ["patients", "ORGANISM", 213, 221], ["patients", "ORGANISM", 381, 389], ["people", "SPECIES", 72, 78], ["people", "SPECIES", 143, 149], ["patients", "SPECIES", 213, 221], ["patients", "SPECIES", 381, 389], ["suspected infection", "PROBLEM", 155, 174], ["infection", "OBSERVATION", 165, 174]]], ["With the aim of reducing unnecessary patient traffic in the hospitals, protecting the safety of healthcare professionals, and allocating potentially scarce resources for the care of COVID-19 patients, the American College of Surgeons has recommended that hospital leaderships review and curtail all elective procedures until the predicted inflection point of the SARS-CoV-2 exposure graph is reached [3] .", [["SARS", "DISEASE", 363, 367], ["patient", "ORGANISM", 37, 44], ["patients", "ORGANISM", 191, 199], ["patient", "SPECIES", 37, 44], ["patients", "SPECIES", 191, 199], ["all elective procedures", "TREATMENT", 295, 318], ["the SARS", "TEST", 359, 367], ["CoV", "TEST", 368, 371]]], ["However, most surgical cases in tertiary care hospitals are scheduled for malignancies, which will continue to progress at variable, disease-specific rates.Dear Editor,Among solid tumors, pancreatic ductal adenocarcinoma portends a postoperative survival rate of only 30-35 months when a multimodal treatment strategy, including chemotherapy or chemoradiation is applied [4, 5] .", [["malignancies", "ANATOMY", 74, 86], ["solid tumors", "ANATOMY", 174, 186], ["pancreatic ductal adenocarcinoma", "ANATOMY", 188, 220], ["malignancies", "DISEASE", 74, 86], ["tumors", "DISEASE", 180, 186], ["pancreatic ductal adenocarcinoma", "DISEASE", 188, 220], ["malignancies", "CANCER", 74, 86], ["solid tumors", "CANCER", 174, 186], ["pancreatic ductal adenocarcinoma", "CANCER", 188, 220], ["malignancies", "PROBLEM", 74, 86], ["Among solid tumors", "PROBLEM", 168, 186], ["pancreatic ductal adenocarcinoma", "PROBLEM", 188, 220], ["a multimodal treatment strategy", "TREATMENT", 286, 317], ["chemotherapy", "TREATMENT", 329, 341], ["chemoradiation", "TREATMENT", 345, 359], ["tumors", "OBSERVATION", 180, 186], ["pancreatic", "ANATOMY", 188, 198], ["ductal", "ANATOMY_MODIFIER", 199, 205], ["adenocarcinoma", "OBSERVATION", 206, 220]]], ["Furthermore, the risk of PDAC progression with care delay is very high [6] .", [["PDAC", "ANATOMY", 25, 29], ["PDAC", "DISEASE", 25, 29], ["PDAC", "CANCER", 25, 29], ["PDAC progression with care delay", "PROBLEM", 25, 57], ["PDAC", "OBSERVATION", 25, 29]]], ["We herein describe the dynamics associated with SARS-CoV-2 outbreak at the Verona Pancreas Institute, a national referral center located in northern Italy and performing about 500 pancreatic resections annually.", [["pancreatic", "ANATOMY", 180, 190], ["pancreatic", "ORGAN", 180, 190], ["SARS-CoV", "SPECIES", 48, 56], ["SARS", "PROBLEM", 48, 52], ["500 pancreatic resections", "TREATMENT", 176, 201], ["Pancreas", "ANATOMY", 82, 90], ["pancreatic", "ANATOMY", 180, 190], ["resections", "OBSERVATION", 191, 201]]], ["Furthermore, we discuss practical hints for patient triaging in pancreatic cancer surgery.Dear Editor,The number of COVID-19 cases skyrocketed in Veneto region and Verona area in mid-March.", [["pancreatic cancer", "ANATOMY", 64, 81], ["pancreatic cancer", "DISEASE", 64, 81], ["patient", "ORGANISM", 44, 51], ["pancreatic cancer", "CANCER", 64, 81], ["patient", "SPECIES", 44, 51], ["pancreatic cancer surgery", "TREATMENT", 64, 89], ["COVID", "TEST", 116, 121], ["Verona area in mid-March", "TREATMENT", 164, 188], ["pancreatic", "ANATOMY", 64, 74], ["cancer", "OBSERVATION", 75, 81], ["mid-March", "ANATOMY", 179, 188]]], ["Because of a very rapid shortage of ventilators, nonemergent surgical procedures were initially halved and then canceled as of March 16, when the operating theaters were reshaped into makeshift ICU.", [["nonemergent surgical procedures", "TREATMENT", 49, 80], ["very", "OBSERVATION_MODIFIER", 13, 17], ["rapid", "OBSERVATION_MODIFIER", 18, 23]]], ["After 2 weeks, thanks to the opening of additional ICU spots, pancreatic procedures were resumed at 25% of the usual volume.Dear Editor,The shortage of operative slots calls for a framework to guide the patient selection process.", [["pancreatic", "ANATOMY", 62, 72], ["pancreatic", "ORGAN", 62, 72], ["patient", "ORGANISM", 203, 210], ["patient", "SPECIES", 203, 210], ["pancreatic procedures", "TREATMENT", 62, 83], ["pancreatic", "ANATOMY", 62, 72]]], ["More than 70% of patients operated at our institution are from outside Veneto and live a considerable distance away.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["Although traveling is against the principle of limiting people circulation, a selection process based primarily on geographical criteria would contrast the patient's right of choosing his/her care Marchegiani providers, an important aspect in pancreatic surgery, whereby the volume-outcome correlation is well established.", [["pancreatic", "ANATOMY", 243, 253], ["people", "ORGANISM", 56, 62], ["patient", "ORGANISM", 156, 163], ["pancreatic", "ORGAN", 243, 253], ["people", "SPECIES", 56, 62], ["patient", "SPECIES", 156, 163], ["a selection process", "PROBLEM", 76, 95], ["his/her care Marchegiani providers", "TREATMENT", 184, 218], ["pancreatic surgery", "TREATMENT", 243, 261], ["pancreatic", "ANATOMY", 243, 253], ["surgery", "OBSERVATION", 254, 261]]], ["Nonetheless, the sharp reduction of domestic flights and high-speed train frequencies has led some patients from southern Italy to withdraw from our waiting list and seek immediate care at their local institutions.Dear Editor,The 2nd and most important question is which type of pancreatic malignancies prioritizes for surgery.", [["pancreatic malignancies", "ANATOMY", 279, 302], ["pancreatic malignancies", "DISEASE", 279, 302], ["patients", "ORGANISM", 99, 107], ["pancreatic malignancies", "CANCER", 279, 302], ["patients", "SPECIES", 99, 107], ["domestic flights", "TREATMENT", 36, 52], ["high-speed train frequencies", "TREATMENT", 57, 85], ["pancreatic malignancies", "PROBLEM", 279, 302], ["surgery", "TREATMENT", 319, 326], ["sharp", "OBSERVATION_MODIFIER", 17, 22], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["pancreatic", "ANATOMY", 279, 289], ["malignancies", "OBSERVATION", 290, 302]]], ["During the highest peak of SARS-CoV-2 outbreak, in a \"damagecontrol perspective,\" there may be no room for pancreatic surgery because of the associated postoperative complications (with a 20% rate of ICU admission), the elevated costs, and the relatively poor oncologic outcomes as compared to other cancers.", [["pancreatic", "ANATOMY", 107, 117], ["cancers", "ANATOMY", 300, 307], ["SARS", "DISEASE", 27, 31], ["cancers", "DISEASE", 300, 307], ["pancreatic", "ORGAN", 107, 117], ["cancers", "CANCER", 300, 307], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 27, 31], ["pancreatic surgery", "TREATMENT", 107, 125], ["the associated postoperative complications", "PROBLEM", 137, 179], ["the elevated costs", "PROBLEM", 216, 234], ["the relatively poor oncologic outcomes", "PROBLEM", 240, 278], ["other cancers", "PROBLEM", 294, 307], ["pancreatic", "ANATOMY", 107, 117], ["surgery", "OBSERVATION", 118, 125], ["postoperative", "OBSERVATION_MODIFIER", 152, 165], ["complications", "OBSERVATION", 166, 179], ["elevated", "OBSERVATION_MODIFIER", 220, 228], ["costs", "OBSERVATION", 229, 234], ["cancers", "OBSERVATION", 300, 307]]], ["Yet, the plateau phase Italy has entered -the duration of which could be in the range of several weeks to months -will likely prolong the operative slots constraints and the surgical waiting list.", [["plateau", "OBSERVATION_MODIFIER", 9, 16], ["phase", "OBSERVATION_MODIFIER", 17, 22]]], ["Recommendations based on our approach to pancreatic surgery in a COVID hub with reduced resources for elective cancer cases are as follows:Dear Editor,Upfront pancreatectomy for PDAC should be discouraged.", [["pancreatic", "ANATOMY", 41, 51], ["cancer", "ANATOMY", 111, 117], ["PDAC", "ANATOMY", 178, 182], ["cancer", "DISEASE", 111, 117], ["PDAC", "DISEASE", 178, 182], ["pancreatic", "ORGAN", 41, 51], ["cancer", "CANCER", 111, 117], ["PDAC", "CANCER", 178, 182], ["pancreatic surgery", "TREATMENT", 41, 59], ["elective cancer cases", "PROBLEM", 102, 123], ["Upfront pancreatectomy", "TREATMENT", 151, 173], ["PDAC", "PROBLEM", 178, 182], ["pancreatic", "ANATOMY", 41, 51], ["surgery", "OBSERVATION", 52, 59], ["cancer", "OBSERVATION", 111, 117], ["pancreatectomy", "OBSERVATION", 159, 173]]], ["The Oncological Review Committees should always consider neoadjuvant therapy, which acts as a biology equalizer at every stage of localized PDAC.", [["PDAC", "ANATOMY", 140, 144], ["PDAC", "DISEASE", 140, 144], ["PDAC", "CANCER", 140, 144], ["neoadjuvant therapy", "TREATMENT", 57, 76], ["localized PDAC", "TREATMENT", 130, 144], ["PDAC", "OBSERVATION", 140, 144]]], ["Nonetheless, the authors are aware that in certain circumstances, concern may arise as to whether chemotherapy-induced im-munosuppression could increase the risk of becoming seriously ill from COVID-19.Dear Editor,Patients eligible for surgical exploration following neoadjuvant/induction chemotherapy or chemoradiation should be prioritized.", [["munosuppression", "DISEASE", 122, 137], ["COVID-19", "CHEMICAL", 193, 201], ["Patients", "ORGANISM", 214, 222], ["Patients", "SPECIES", 214, 222], ["chemotherapy-induced im-munosuppression", "TREATMENT", 98, 137], ["COVID", "TEST", 193, 198], ["surgical exploration", "TREATMENT", 236, 256], ["neoadjuvant/induction chemotherapy", "TREATMENT", 267, 301], ["chemoradiation", "TREATMENT", 305, 319]]], ["It has been indeed shown that the rate of post-pancreatectomy morbidity following neoadjuvant therapy is reduced, despite the clinical burden of complications could be remarkable [7] .", [["post-pancreatectomy morbidity", "TREATMENT", 42, 71], ["neoadjuvant therapy", "TREATMENT", 82, 101], ["complications", "PROBLEM", 145, 158]]], ["However, there is a wide spectrum of surgical candidates following primary chemotherapy, ranging from resectable patients to patients exhibiting major solid tumor contacts with peripancreatic vasculature, in whom vascular resection is anticipated.", [["solid tumor contacts", "ANATOMY", 151, 171], ["peripancreatic vasculature", "ANATOMY", 177, 203], ["vascular", "ANATOMY", 213, 221], ["tumor", "DISEASE", 157, 162], ["patients", "ORGANISM", 113, 121], ["patients", "ORGANISM", 125, 133], ["solid tumor", "CANCER", 151, 162], ["peripancreatic vasculature", "MULTI-TISSUE_STRUCTURE", 177, 203], ["vascular", "MULTI-TISSUE_STRUCTURE", 213, 221], ["patients", "SPECIES", 113, 121], ["patients", "SPECIES", 125, 133], ["surgical candidates", "TREATMENT", 37, 56], ["primary chemotherapy", "TREATMENT", 67, 87], ["major solid tumor", "PROBLEM", 145, 162], ["peripancreatic vasculature", "PROBLEM", 177, 203], ["vascular resection", "TREATMENT", 213, 231], ["wide", "OBSERVATION_MODIFIER", 20, 24], ["major", "OBSERVATION_MODIFIER", 145, 150], ["solid", "OBSERVATION_MODIFIER", 151, 156], ["tumor", "OBSERVATION", 157, 162], ["peripancreatic", "ANATOMY_MODIFIER", 177, 191], ["vasculature", "ANATOMY", 192, 203], ["vascular", "ANATOMY", 213, 221], ["resection", "OBSERVATION", 222, 231]]], ["For these latter cases with a high likelihood of prolonged operative time, blood loss, and postoperative ICU utilization, the risk of surgical delay to the individual patient must be carefully balanced against the imminent availability of these resources for patients with COVID-19.Dear Editor,Although PDAC is by far the most common malignancy, attention should be paid to other cancer types, including ampullary and duodenal adenocarcinoma, which are associated with a better prognosis relative to PDAC.", [["blood", "ANATOMY", 75, 80], ["PDAC", "ANATOMY", 303, 307], ["cancer", "ANATOMY", 380, 386], ["ampullary", "ANATOMY", 404, 413], ["duodenal adenocarcinoma", "ANATOMY", 418, 441], ["PDAC", "ANATOMY", 500, 504], ["blood loss", "DISEASE", 75, 85], ["PDAC", "DISEASE", 303, 307], ["malignancy", "DISEASE", 334, 344], ["cancer", "DISEASE", 380, 386], ["ampullary and duodenal adenocarcinoma", "DISEASE", 404, 441], ["PDAC", "DISEASE", 500, 504], ["COVID-19", "CHEMICAL", 273, 281], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["patient", "ORGANISM", 167, 174], ["patients", "ORGANISM", 259, 267], ["PDAC", "CANCER", 303, 307], ["malignancy", "CANCER", 334, 344], ["cancer", "CANCER", 380, 386], ["ampullary", "CANCER", 404, 413], ["duodenal adenocarcinoma", "CANCER", 418, 441], ["PDAC", "CANCER", 500, 504], ["patient", "SPECIES", 167, 174], ["patients", "SPECIES", 259, 267], ["blood loss", "PROBLEM", 75, 85], ["postoperative ICU utilization", "TREATMENT", 91, 120], ["surgical delay", "PROBLEM", 134, 148], ["COVID", "TEST", 273, 278], ["PDAC", "PROBLEM", 303, 307], ["other cancer types", "PROBLEM", 374, 392], ["ampullary and duodenal adenocarcinoma", "PROBLEM", 404, 441], ["PDAC", "ANATOMY", 303, 307], ["most common", "OBSERVATION_MODIFIER", 322, 333], ["malignancy", "OBSERVATION", 334, 344], ["cancer", "OBSERVATION", 380, 386], ["ampullary", "ANATOMY", 404, 413], ["duodenal", "ANATOMY", 418, 426], ["adenocarcinoma", "OBSERVATION", 427, 441]]], ["Remarkably, no neoadjuvant strategies have been established for these cancer types.Dear Editor,All patients scheduled for pancreatectomy should be tested for SARS-CoV-2 prior to hospital admission.", [["cancer", "ANATOMY", 70, 76], ["cancer", "DISEASE", 70, 76], ["SARS", "DISEASE", 158, 162], ["cancer", "CANCER", 70, 76], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["neoadjuvant strategies", "TREATMENT", 15, 37], ["these cancer types", "PROBLEM", 64, 82], ["pancreatectomy", "TREATMENT", 122, 136], ["SARS", "PROBLEM", 158, 162], ["CoV", "TEST", 163, 166], ["cancer", "OBSERVATION", 70, 76], ["pancreatectomy", "OBSERVATION", 122, 136]]], ["Positive testing imposes surgical delay and re-testing following a 14-day quarantine period.Dear Editor,COVID-19 is a competing risk for patients requiring surgical care.", [["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["surgical delay", "PROBLEM", 25, 39], ["surgical care", "TREATMENT", 156, 169], ["surgical delay", "OBSERVATION", 25, 39]]], ["Age and comorbidities should be carefully weighed against the expected oncological outcomes and the risk of severe symptoms and mortality in the circumstances of COVID-19 during the postoperative period or recovery phase.Dear Editor,Pancreatectomies for low-grade or benign neoplasms should be delayed.Dear Editor,These hints can be coupled with general principles provided from surgical associations around the world as we triage pancreatic cancer patients during the pandemic: \u2212 Prioritize the protection of all healthcare providers (#SavetheHospital). \u2212 Convert to virtual practices (electronic messaging, telephone, and vide ocalls) for patient visits and multidisciplinary boards. \u2212 Allocate psychological-support resources to help patients, families, and providers dealing with disruption of normal services. \u2212 Stay in touch with patients whose surgery has been delayed, in order to monitor their clinical conditions and improve the quality of life during this difficult period.", [["low-grade", "ANATOMY", 254, 263], ["benign neoplasms", "ANATOMY", 267, 283], ["pancreatic cancer", "ANATOMY", 431, 448], ["neoplasms", "DISEASE", 274, 283], ["pancreatic cancer", "DISEASE", 431, 448], ["low-grade", "CANCER", 254, 263], ["benign neoplasms", "CANCER", 267, 283], ["pancreatic cancer", "CANCER", 431, 448], ["patients", "ORGANISM", 449, 457], ["patient", "ORGANISM", 641, 648], ["patients", "ORGANISM", 737, 745], ["patients", "ORGANISM", 836, 844], ["patients", "SPECIES", 449, 457], ["patient", "SPECIES", 641, 648], ["patients", "SPECIES", 737, 745], ["patients", "SPECIES", 836, 844], ["Age and comorbidities", "PROBLEM", 0, 21], ["severe symptoms", "PROBLEM", 108, 123], ["COVID", "TEST", 162, 167], ["Pancreatectomies", "TREATMENT", 233, 249], ["low-grade or benign neoplasms", "PROBLEM", 254, 283], ["pancreatic cancer", "PROBLEM", 431, 448], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["Pancreatectomies", "OBSERVATION", 233, 249], ["low-grade", "OBSERVATION_MODIFIER", 254, 263], ["benign", "OBSERVATION_MODIFIER", 267, 273], ["neoplasms", "OBSERVATION", 274, 283], ["pancreatic", "ANATOMY", 431, 441], ["cancer", "OBSERVATION", 442, 448]]], ["This may prevent any feelings of abandonment that patients may experience. \u2212 Interrupt research programs on technical innovation in surgery (e.g., minimally invasive surgery and robotic surgery programs) if funded by public institutions, given the possible upcoming severe economic recession.Dear Editor,The authors are aware that these recommendations are not evidence based.", [["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["surgery", "TREATMENT", 132, 139], ["minimally invasive surgery", "TREATMENT", 147, 173], ["robotic surgery programs", "TREATMENT", 178, 202], ["upcoming severe economic recession", "PROBLEM", 257, 291], ["severe", "OBSERVATION_MODIFIER", 266, 272], ["economic", "OBSERVATION_MODIFIER", 273, 281], ["recession", "OBSERVATION", 282, 291]]], ["Shared recommendations by Oncological Review Committees can help optimizing the resource allocation process and mitigate the enormous emotional burden to which we are individually exposed in an unprecedented crisis.", [["the enormous emotional burden", "PROBLEM", 121, 150]]], ["Because of its aggressive biology, PDAC would virtually require immediate care.", [["PDAC", "ANATOMY", 35, 39], ["PDAC", "DISEASE", 35, 39], ["PDAC", "CANCER", 35, 39], ["PDAC", "TREATMENT", 35, 39], ["immediate care", "TREATMENT", 64, 78], ["aggressive", "OBSERVATION_MODIFIER", 15, 25]]], ["Many pancreatic cancer patients in Italy will receive suboptimal care or even no treatment as referral hospitals are carrying the catastrophic brunt of thousands of COVID-19 cases.", [["pancreatic cancer", "ANATOMY", 5, 22], ["pancreatic cancer", "DISEASE", 5, 22], ["pancreatic cancer", "CANCER", 5, 22], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["Many pancreatic cancer", "PROBLEM", 0, 22], ["suboptimal care", "TREATMENT", 54, 69], ["treatment", "TREATMENT", 81, 90], ["COVID", "TEST", 165, 170], ["pancreatic", "ANATOMY", 5, 15], ["cancer", "OBSERVATION", 16, 22]]], ["These \"indirect\" deaths that will inevitably occur, although hard to track, should be added to the overall lethality of SARS-CoV-2 as the outbreak has finally faded away.", [["deaths", "DISEASE", 17, 23], ["SARS", "DISEASE", 120, 124], ["SARS-CoV-2", "ORGANISM", 120, 130], ["SARS-CoV", "SPECIES", 120, 128], ["SARS", "PROBLEM", 120, 124]]], ["In these difficult times, our love (pancreatic surgery) in the time of cholera (COVID-19) is tremendously struggling.", [["pancreatic", "ANATOMY", 36, 46], ["cholera", "DISEASE", 71, 78], ["pancreatic", "ORGAN", 36, 46], ["our love (pancreatic surgery", "TREATMENT", 26, 54], ["cholera (COVID", "TREATMENT", 71, 85], ["pancreatic", "ANATOMY", 36, 46]]]], "66e28b5f2c84536bd0f3695c3a0dc3f88dd354ee": [["On 7 January, the coronavirus disease (COVID-2019) which was named as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by International Committee on Taxonomy of Viruses on 11 February, 2020, was identified as the causative virus by Chinese authorities [17] , and has become a pandemic especially by travelers [16] .", [["coronavirus disease", "DISEASE", 18, 37], ["acute respiratory syndrome coronavirus", "DISEASE", 79, 117], ["coronavirus", "ORGANISM", 18, 29], ["severe acute respiratory syndrome coronavirus", "SPECIES", 72, 117], ["SARS-CoV", "SPECIES", 121, 129], ["the coronavirus disease", "PROBLEM", 14, 37], ["COVID", "TEST", 39, 44], ["a severe acute respiratory syndrome coronavirus", "PROBLEM", 70, 117], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["the causative virus", "PROBLEM", 223, 242], ["coronavirus disease", "OBSERVATION", 18, 37], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["respiratory syndrome", "OBSERVATION", 85, 105]]], ["This forced the World Health Organization (WHO) to consider the dramatic spread of the infection in March 2020 as a public health emergency of international concern.", [["infection", "DISEASE", 87, 96], ["the infection", "PROBLEM", 83, 96], ["infection", "OBSERVATION", 87, 96]]], ["This epidemic is characterized by its rapid spread and its symptoms do not appear quickly.", [["its rapid spread", "PROBLEM", 34, 50], ["its symptoms", "PROBLEM", 55, 67], ["rapid", "OBSERVATION_MODIFIER", 38, 43], ["spread", "OBSERVATION_MODIFIER", 44, 50]]], ["In addition, there is no anti-viral treatment or vaccination officially approved for the management or prevention of this epidemic.", [["anti-viral treatment", "TREATMENT", 25, 45], ["vaccination", "TREATMENT", 49, 60], ["the management", "TREATMENT", 85, 99], ["this epidemic", "PROBLEM", 117, 130], ["no", "UNCERTAINTY", 22, 24], ["anti-viral treatment", "OBSERVATION", 25, 45]]], ["In order to fight this outbreak, the public health decision and policy makers should decide and follow strategic and health-care management.", [["health-care management", "TREATMENT", 117, 139]]], ["Since the declaration of the first case of COVID-19 in Tunisia in early March 2020, thousands of screenings have been carried out in Tunisia.", [["screenings", "TEST", 97, 107]]], ["Following the first recommendations of the WHO Tunisia, as France, Italy or Spain, first opted for rare and targeted screenings on suspicious people, their entourage and certain sources of contamination; in particular for people arriving from abroad.", [["people", "ORGANISM", 142, 148], ["people", "ORGANISM", 222, 228], ["people", "SPECIES", 142, 148], ["people", "SPECIES", 222, 228], ["contamination", "PROBLEM", 189, 202]]], ["Next, If a person is positive, the authorities try to trace all the people with whom he has been in contact and they are called to place themselves in self-containment without necessarily being tested.", [["people", "ORGANISM", 68, 74], ["person", "SPECIES", 11, 17], ["people", "SPECIES", 68, 74]]], ["They can only be tested if they themselves have symptoms of COVID-19.IntroductionIt is clear that the low number of screenings, mainly on \"suspect\" cases or those presenting significant symptoms, does not give a precise idea of the number of people who could potentially be infected without knowing them.", [["COVID-19", "CHEMICAL", 60, 68], ["people", "ORGANISM", 242, 248], ["people", "SPECIES", 242, 248], ["symptoms", "PROBLEM", 48, 56], ["COVID", "TEST", 60, 65], ["significant symptoms", "PROBLEM", 174, 194], ["clear", "OBSERVATION", 87, 92], ["low number", "OBSERVATION_MODIFIER", 102, 112], ["infected", "OBSERVATION", 274, 282]]], ["This gap between the day of infection and the day of diagnosis can have serious consequences on the spread of the epidemic.", [["infection", "DISEASE", 28, 37], ["infection", "PROBLEM", 28, 37], ["infection", "OBSERVATION", 28, 37]]], ["All this shows the complexity of the situation since the unknown things related to the epidemic are more important than the things we already know.IntroductionThese are the daily question that must be answered: how many people exactly recover from COVID-19?", [["COVID-19", "CHEMICAL", 248, 256], ["people", "ORGANISM", 220, 226], ["people", "SPECIES", 220, 226], ["COVID", "TEST", 248, 253], ["complexity", "OBSERVATION_MODIFIER", 19, 29]]], ["How many people are infected from COVID-19?", [["COVID-19", "CHEMICAL", 34, 42], ["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["COVID", "TEST", 34, 39], ["infected", "OBSERVATION", 20, 28]]], ["How many people died from COVID-19?IntroductionRecently, several mathematical models have been published in order to be able to study the dynamics and the evolution of this pandemic.", [["COVID-19", "CHEMICAL", 26, 34], ["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["COVID", "TEST", 26, 31], ["this pandemic", "PROBLEM", 168, 181]]], ["It appears from clinical experiences and recent articles that knowing the data of infected people in the population would be very useful to have better models of when disease will peak and decline, and also when we can begin to let people go back to work.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["people", "SPECIES", 232, 238], ["disease", "PROBLEM", 167, 174]]], ["Also, knowing the real number of recovered people also could indicate how easily people can build immunity against the virus.", [["people", "ORGANISM", 43, 49], ["people", "ORGANISM", 81, 87], ["people", "SPECIES", 43, 49], ["people", "SPECIES", 81, 87], ["the virus", "PROBLEM", 115, 124]]], ["Motivated by the above discussion our method comprises seven phenotypes; the susceptible humans, exposed humans, infectious humans, the recovered humans, the quarantine population, the recovered-exposed and the dead population in order to improve and adapt the susceptible-infected-recovered (SIR) model.", [["humans", "ORGANISM", 89, 95], ["humans", "ORGANISM", 105, 111], ["humans", "ORGANISM", 124, 130], ["humans", "ORGANISM", 146, 152], ["humans", "SPECIES", 89, 95], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 124, 130], ["humans", "SPECIES", 146, 152], ["humans", "SPECIES", 89, 95], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 124, 130], ["humans", "SPECIES", 146, 152], ["the quarantine population", "TREATMENT", 154, 179], ["the dead population", "TREATMENT", 207, 226], ["infectious", "OBSERVATION", 113, 123]]], ["In fact, we noticed that people previously infected and recovered from COVID-19 are generally excluded as susceptible individuals in the modeling, which would have an impact on predicting the number of cases that will occur in the near future.", [["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31], ["COVID", "TEST", 71, 76], ["infected", "OBSERVATION", 43, 51]]], ["In addition, at the individual level, if people can find out if they have been or slightly infected and cured, and if they show civility and respect the distancing, they can safely return to work once the general quarantine is off.IntroductionOur main contributions in this paper are: -We gave a model of dynamical behavior of COVID-19 in Tunisia.Introduction-We studied the qualitative properties of our model.", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["slightly infected", "PROBLEM", 82, 99], ["the general quarantine", "TREATMENT", 201, 223], ["COVID", "TREATMENT", 327, 332], ["slightly", "OBSERVATION_MODIFIER", 82, 90], ["infected", "OBSERVATION", 91, 99]]], ["Section 3 is devoted to the mathematical analysis: Boundness, positivity, and the equilibrium point. the dynamics of exposed and infected population are also studied in this section.", [["the mathematical analysis", "TEST", 24, 49], ["infected population", "PROBLEM", 129, 148], ["infected", "OBSERVATION_MODIFIER", 129, 137]]], ["Section 5 concludes the paper with some recommendations.Mathematical modelThe classical susceptible-infected-recovered (SIR) model in epidemiology [5] allows the determination of critical condition of disease development in the population irrespective of the total population size over a short period of time.", [["disease development", "PROBLEM", 201, 220], ["susceptible", "OBSERVATION_MODIFIER", 88, 99], ["infected", "OBSERVATION_MODIFIER", 100, 108], ["disease", "OBSERVATION", 201, 208], ["total", "OBSERVATION_MODIFIER", 259, 264], ["population", "OBSERVATION_MODIFIER", 265, 275], ["size", "OBSERVATION_MODIFIER", 276, 280]]], ["The SIR is considered from the following simplest ODE system:Mathematical modelFor the sizes of the susceptible sub-population S, infected I, and recovered R. The term \u03bb N IS describes the disease transmission rate due to the contacts between susceptible and infected individuals, \u03b2I characterizes the rate of recovery of infected people.", [["\u03b2I", "GENE_OR_GENE_PRODUCT", 281, 283], ["people", "ORGANISM", 331, 337], ["\u03b2I", "PROTEIN", 281, 283], ["people", "SPECIES", 331, 337], ["the disease transmission rate", "PROBLEM", 185, 214], ["the contacts between susceptible and infected individuals", "PROBLEM", 222, 279], ["sizes", "OBSERVATION_MODIFIER", 87, 92], ["susceptible", "OBSERVATION_MODIFIER", 100, 111], ["sub", "OBSERVATION_MODIFIER", 112, 115], ["-population", "OBSERVATION_MODIFIER", 115, 126], ["infected", "OBSERVATION", 130, 138], ["infected", "OBSERVATION", 322, 330]]], ["It is assumed here that the recovered individuals do not return to susceptible class, that is, recovered individuals have immunity against the disease; they cannot become infected again and cannot infect susceptible either.Mathematical modelDay by day, we see that the specifics of this virus require more complex models.", [["the disease", "PROBLEM", 139, 150], ["this virus", "PROBLEM", 282, 292], ["infected", "OBSERVATION", 171, 179]]], ["Roughly speaking, it is necessary to question the duration of the incubation, or the presence of people who do not have symptoms after their infection, but who nevertheless participate in the spread of the virus and consider compartments for these different cases.", [["infection", "DISEASE", 141, 150], ["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103], ["symptoms", "PROBLEM", 120, 128], ["their infection", "PROBLEM", 135, 150], ["the virus", "PROBLEM", 202, 211], ["infection", "OBSERVATION", 141, 150]]], ["In our work, we have used a 7-Phenotype model which takes into account people who are infected, exposed, recovered, those susceptible, the deceased, Quarantine but also recovered-exposed people who are not counted by the government.Mathematical modelThe interaction between the above sub-populations can be described by the compartmental diagram in FigureBasic Properties of the ModelObviously, the system (2.2) can be written as followsBasic Properties of the ModelwhereBasic Properties of the Modelwith the initial conditions satisfying the following inequalities Given the non-negative initial conditions (3.2), then the solutions S(t), E(t), I(t), E r (t), R(t), D(t) and Q(t) are non-negative for all t \u2265 0 and bounded.Basic Properties of the ModelProof.Basic Properties of the ModelFirst, let us prove that the solution of the system (3.1) is positive.Basic Properties of the ModelThen, we haveBasic Properties of the ModelFrom the second case; S and E are not both negative as the same time.Basic Properties of the Model3 rd case: Suppose that \u2203t 1 > 0 such thatBasic Properties of the Model4 th case: Suppose that \u2203t 1 > 0 such thatBasic Properties of the Model 7We can write E as the following formBasic Properties of the Model 7witch is impossible.Basic Properties of the Model 7We can write E as the following formBasic Properties of the Model 7which is impossible.", [["people", "ORGANISM", 71, 77], ["people", "ORGANISM", 187, 193], ["people", "SPECIES", 71, 77], ["people", "SPECIES", 187, 193], ["a 7-Phenotype model", "TREATMENT", 26, 45], ["the compartmental diagram", "TEST", 320, 345], ["the solutions S", "TEST", 620, 635], ["all t \u2265", "TEST", 702, 709], ["infected", "OBSERVATION", 86, 94], ["positive", "OBSERVATION", 849, 857]]], ["Therefore, we get E r , R, D and Q as increasing functions.", [["D", "SIMPLE_CHEMICAL", 27, 28]]], ["Thus, we have E r , R, D and Q as positive functions.", [["D", "SIMPLE_CHEMICAL", 23, 24]]], ["Now, we prove that the solution is bounded.", [["the solution", "TREATMENT", 19, 31]]], ["From the positivity of the solution, we have the following inequalityBasic Properties of the Model 7Then, by integratingBasic Properties of the Model 7We can deduce that S(t) \u2264 S(0) and E(t) \u2264 S(0) + E(0), for all positive real t.Basic Properties of the Model 7By the same way, we get E(t) + S(t) + I(t) \u2264 (S(0) + E(0) + I(0))e \u2212m 2 t ; where m 2 = min{\u03bb 3 , \u03b1 2 , \u03b2 2 + \u03b2 2 }.Basic Properties of the Model 7Then, I(t) \u2264 S(0) + E(0) + I(0) for t \u2265 0.Basic Properties of the Model 73.2 Disease free equilibrium, Reproduction number R 0 and extinction of infected population 8Basic Properties of the Model 7For E r ,R, D and Q, using the recent inequalities, we haveBasic Properties of the Model 7From integratingBasic Properties of the Model 7Thus, the proof is given.", [["S", "TEST", 177, 178], ["S", "TEST", 193, 194], ["e", "TEST", 326, 327], ["\u2212m", "TEST", 328, 330], ["m", "TEST", 343, 344], ["min{\u03bb", "TEST", 349, 354], ["\u03b1", "TEST", 359, 360], ["\u03b2", "TEST", 365, 366], ["Basic Properties", "TEST", 377, 393], ["Model", "TEST", 401, 406], ["S", "TEST", 421, 422], ["Disease free equilibrium", "PROBLEM", 485, 509], ["the Model", "TEST", 594, 603], ["infected", "OBSERVATION", 553, 561]]], ["Firstly, the function X \u2208 R 7 \u2192 AX + f (X) is continuous.Existence and uniqueness of the solutionPose X = (S, E, I, E r , R, Q, D) and Y = (S , E , I , E r , R , Q , D ).", [["AX", "CHEMICAL", 32, 34], ["X \u2208 R 7", "DNA", 22, 29], ["AX + f (X)", "DNA", 32, 42], ["the function", "TEST", 9, 21], ["R", "TEST", 26, 27]]], ["From the bounded solution, we getExistence and uniqueness of the solutionThen, the Cauchy-Lipschitz is satisfied, and consquently, the model (3.1) possesses a unique solution [2] .Disease free equilibrium, Reproduction number R 0 and extinction of infected populationAt the disease-free state, there is no disease in the human population which implies E = I = R = D = Q = E r = 0.", [["human", "ORGANISM", 321, 326], ["human", "SPECIES", 321, 326], ["human", "SPECIES", 321, 326], ["a unique solution", "TREATMENT", 157, 174], ["Disease free equilibrium", "PROBLEM", 180, 204], ["infected population", "PROBLEM", 248, 267], ["disease in the human population", "PROBLEM", 306, 337], ["E", "TEST", 352, 353], ["infected", "OBSERVATION", 248, 256], ["disease", "OBSERVATION", 274, 281], ["free", "OBSERVATION_MODIFIER", 282, 286], ["no", "UNCERTAINTY", 303, 305], ["disease", "OBSERVATION", 306, 313]]], ["Thus, the disease-free equilibrium of the model (3.1) is given by N, 0, 0, 0, 0, 0, 0) .Disease free equilibrium, Reproduction number R 0 and extinction of infected population 9We can also verify whether or not the state-point is stable.", [["the disease", "PROBLEM", 6, 17], ["Disease free equilibrium", "PROBLEM", 88, 112], ["disease", "OBSERVATION", 10, 17], ["free", "OBSERVATION_MODIFIER", 18, 22], ["infected", "OBSERVATION", 156, 164], ["stable", "OBSERVATION_MODIFIER", 230, 236]]], ["In our case, according the positivity of our model, we have from the first equation of system (2.2)Disease free equilibrium, Reproduction number R 0 and extinction of infected population 9As a result, the state-point is unstable.", [["Disease free equilibrium", "PROBLEM", 99, 123], ["infected population", "PROBLEM", 167, 186], ["infected", "OBSERVATION_MODIFIER", 167, 175], ["unstable", "OBSERVATION", 220, 228]]], ["Now, let us calculate the basic reproduction number R 0 which is the average number of secondary infections caused by an infectious individual during his or her entire period of infectiousness (Diekmann et al) [3] .", [["infections", "DISEASE", 97, 107], ["secondary infections", "PROBLEM", 87, 107], ["infectiousness", "PROBLEM", 178, 192], ["secondary", "OBSERVATION_MODIFIER", 87, 96], ["infections", "OBSERVATION", 97, 107], ["infectious", "OBSERVATION", 121, 131]]], ["The basic reproduction number is an important non-dimensional quantity in epidemiology as it sets the threshold in the study of a disease both for predicting its outbreak and for evaluating its control strategies.", [["the study", "TEST", 115, 124], ["a disease", "PROBLEM", 128, 137], ["disease", "OBSERVATION", 130, 137]]], ["Using the next generation operator approach by van den Driessche and Watmough [15] , we haveDisease free equilibrium, Reproduction number R 0 and extinction of infected population 9And we have the corresponding effective control reproduction number defined as in [3] R 0 (t) =Disease free equilibrium, Reproduction number R 0 and extinction of infected population 9This quantity provides us with a clear index to evaluate the control strategy for any time t.Disease free equilibrium, Reproduction number R 0 and extinction of infected population 9Theorem 3.3.", [["the next generation operator approach", "TREATMENT", 6, 43], ["infected population", "PROBLEM", 160, 179], ["Disease free equilibrium", "PROBLEM", 276, 300], ["infected population", "PROBLEM", 344, 363], ["the control strategy", "TREATMENT", 422, 442], ["any time t.Disease free equilibrium", "PROBLEM", 447, 482], ["infected population 9Theorem", "TEST", 526, 554], ["infected", "OBSERVATION", 344, 352], ["infected", "OBSERVATION_MODIFIER", 526, 534]]], ["If R 0 < 1 , then exposed and infected population will extinct.Disease free equilibrium, Reproduction number R 0 and extinction of infected population 9Proof.", [["Disease free equilibrium", "PROBLEM", 63, 87], ["infected", "OBSERVATION_MODIFIER", 30, 38], ["population", "OBSERVATION", 39, 49], ["infected", "OBSERVATION", 131, 139]]], ["Let us define the Lyapunov functionalDisease free equilibrium, Reproduction number R 0 and extinction of infected population 9The derivative of V is given byDisease free equilibrium, Reproduction number R 0 and extinction of infected population 9Thus,Disease free equilibrium, Reproduction number R 0 and extinction of infected population 9where V (0) = \u03bb 2 I(0) + (\u03b2 1 + \u03b2 2 )E(0).", [["Lyapunov", "DNA", 18, 26], ["Disease free equilibrium", "PROBLEM", 37, 61], ["infected population", "PROBLEM", 105, 124], ["byDisease free equilibrium", "PROBLEM", 155, 181], ["infected population", "PROBLEM", 225, 244], ["Disease free equilibrium", "PROBLEM", 251, 275], ["infected population", "TEST", 319, 338], ["V", "TEST", 346, 347], ["\u03b2", "TEST", 366, 367], ["infected", "OBSERVATION", 105, 113], ["infected", "OBSERVATION_MODIFIER", 225, 233], ["infected", "OBSERVATION", 319, 327]]], ["Therefore, for R 0 < 1 we haveDisease free equilibrium, Reproduction number R 0 and extinction of infected population 9This shows that the disease will be extinct if R 0 < 1.3.3The effect of quarantine strategies 10The effect of quarantine strategiesAs most countries of the world, Tunisia fights vigorously against the spread of the COVID-19 epidemic with some disabilities such as the lack of medical equipment.", [["Disease free equilibrium", "PROBLEM", 30, 54], ["infected population", "PROBLEM", 98, 117], ["the disease", "PROBLEM", 135, 146], ["quarantine strategies", "TREATMENT", 191, 212], ["quarantine strategies", "TREATMENT", 229, 250], ["the COVID", "TEST", 330, 339], ["medical equipment", "TREATMENT", 395, 412], ["infected", "OBSERVATION", 98, 106], ["disease", "OBSERVATION", 139, 146]]], ["In addition, since the number of beds in intensive care in the hospital is reduced and insufficient, the infected population is not fully hospitalized except in cases with fairly severe symptoms.", [["the infected population", "PROBLEM", 101, 124], ["fairly severe symptoms", "PROBLEM", 172, 194], ["reduced", "OBSERVATION_MODIFIER", 75, 82], ["insufficient", "OBSERVATION_MODIFIER", 87, 99], ["infected", "OBSERVATION_MODIFIER", 105, 113], ["population", "OBSERVATION", 114, 124], ["severe", "OBSERVATION_MODIFIER", 179, 185], ["symptoms", "OBSERVATION", 186, 194]]], ["Besides, the rest of the population should respect total isolation.", [["total isolation", "TREATMENT", 51, 66]]], ["The natural question here is: What is the impact of this decision in other words this quarantine strategy?The effect of quarantine strategiesBy equation one in the system (2.2), the susceptible population can be evaluate from the following expressionThe effect of quarantine strategiesIt is clear that the parameter \u03bb 3 reduces the number of people exposed to infection with the disease.", [["infection", "DISEASE", 360, 369], ["people", "ORGANISM", 342, 348], ["people", "SPECIES", 342, 348], ["quarantine strategiesBy equation", "TREATMENT", 120, 152], ["the susceptible population", "PROBLEM", 178, 204], ["quarantine strategies", "TREATMENT", 264, 285], ["infection", "PROBLEM", 360, 369], ["the disease", "PROBLEM", 375, 386], ["clear", "OBSERVATION", 291, 296], ["infection", "OBSERVATION", 360, 369], ["disease", "OBSERVATION", 379, 386]]], ["From the evolution of exponential function, we can deduce that when the rate \u03bb 3 is getting bigger, the susceptible population is getting smaller.The effect of quarantine strategiesWhen the \u03bb 3 = 0, we have this diagram and the corresponding non-linear differential equationsThe effect of quarantine strategieswhere the parameters were defined in the Table 1 .The effect of quarantine strategiesClearly, by the first equation, one has which implies that the disease almost infected every susceptible person.The effect of quarantine strategiesThis theoretical result which justifies the quarantine strategy will be consolidated by a numerical study in the following paragraph.Numerical StimulationsUsing data of Tunisia from March 14 th to April 8 th 2020, we can estimate the parameters'values.", [["person", "SPECIES", 500, 506], ["the susceptible population", "PROBLEM", 100, 126], ["quarantine strategies", "TREATMENT", 160, 181], ["this diagram", "TEST", 207, 219], ["quarantine strategieswhere", "TREATMENT", 289, 315], ["quarantine strategies", "TREATMENT", 374, 395], ["the disease", "PROBLEM", 454, 465], ["quarantine strategies", "TREATMENT", 521, 542], ["the quarantine strategy", "TREATMENT", 582, 605], ["a numerical study", "TEST", 630, 647], ["exponential function", "OBSERVATION", 22, 42], ["susceptible", "OBSERVATION_MODIFIER", 104, 115], ["population", "OBSERVATION", 116, 126], ["smaller", "OBSERVATION_MODIFIER", 138, 145], ["infected", "OBSERVATION", 473, 481]]], ["The results can be summarized as follows:Numerical Stimulationsparameters values And for stimulation, we chose the following initial condition: S(0) = N-E(0)-I(0), E(0) =200, I(0) =18, E r (0) = R(0) = D(0) = 0.", [["D", "TEST", 202, 203]]], ["In addition to the population plots in Figures 4.1 and 4 .2, we collected some meaningful quantitative information about the model parameters (Table 2 ) and the peak values for infected and exposed populations ( Table 3) .", [["the population plots", "TEST", 15, 35], ["Figures", "TEST", 39, 46], ["the peak values", "TEST", 157, 172], ["infected", "PROBLEM", 177, 185]]], ["The results can be summarized as follows :Numerical StimulationsPeak infected Table 3 : Infected and exposed peak values in Tunisia region.Numerical StimulationsAnd we have R 0 < 1, therefore the disease will disappear.Numerical StimulationsThe human body needs around 10 days to get rid of the organism.", [["body", "ANATOMY", 251, 255], ["human", "ORGANISM", 245, 250], ["body", "ORGANISM_SUBDIVISION", 251, 255], ["human", "SPECIES", 245, 250], ["human", "SPECIES", 245, 250], ["Infected", "PROBLEM", 88, 96], ["Numerical Stimulations", "TEST", 139, 161], ["the disease", "PROBLEM", 192, 203], ["Numerical Stimulations", "TREATMENT", 219, 241], ["the organism", "PROBLEM", 291, 303], ["Infected", "OBSERVATION", 88, 96], ["peak values", "OBSERVATION", 109, 120], ["disease", "OBSERVATION", 196, 203]]], ["However, cases where the body needed 21 days to get rid of symptoms are detected.", [["body", "ANATOMY", 25, 29], ["body", "ORGANISM_SUBDIVISION", 25, 29], ["symptoms", "PROBLEM", 59, 67]]], ["So after the peak, it is logical that the rate of recovered population increases.", [["recovered", "OBSERVATION_MODIFIER", 50, 59], ["population", "OBSERVATION_MODIFIER", 60, 70], ["increases", "OBSERVATION_MODIFIER", 71, 80]]], ["Then, we can get the following Figures To make a better illustration of quarantine strategy, we tested different home quarantine rates (\u03bb 3 ) in Figures (4.7.a-h) .", [["quarantine strategy", "TREATMENT", 72, 91]]], ["The change in the \u03bb 3 parameter generates a consequent variation in the rate of the infected population and the deceased persons (Figures 4.8.a-b) .Numerical StimulationsThe most spectacular is the case \u03bb 3 = 0 which corresponds to Q = 0; or in other words, in the absence of a quarantine strategy.", [["persons", "SPECIES", 121, 128], ["a consequent variation", "PROBLEM", 42, 64], ["Figures", "TEST", 130, 137], ["Numerical Stimulations", "TEST", 148, 170], ["a quarantine strategy", "TREATMENT", 276, 297], ["change", "OBSERVATION_MODIFIER", 4, 10], ["infected", "OBSERVATION", 84, 92], ["most", "OBSERVATION_MODIFIER", 174, 178], ["spectacular", "OBSERVATION_MODIFIER", 179, 190]]], ["We can see that on the 20th day of the epidemic we get 3, 75x10 5 infected people (Figure 4.9 .a).", [["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81]]], ["This number is far above the capacity of health structures in Tunisia.", [["capacity", "OBSERVATION_MODIFIER", 29, 37]]], ["Consequently, the choice of containment strategy has significantly reduced the number of deceased and infected persons.DiscussionBased on the COVID-19 cases data collected from March 14 th to April 8 th , we estimated the basic reproduction numberR 0 and the prediction of the epidemic's evolution.DiscussionAccording to the comparison between the official epidemic data based on our model (Figure 4 .1) one can see that the simulation curve model of the number of confirmed Infections I(t) and the number of dead people D(t) match the official data curve very well during the period of 30 days.DiscussionOn the one side, the case of this epidemic in Tunisia is not critical: the peak of infected cases less than 700 which was very comfortable than many Arabian countries (Emirate, Qatar, Morocco, Algeria, ...) and also Western countries (Portugal, France, Spania...).DiscussionOn the other side, the number of infected and dead due to this disease remains relatively low in Tunisia compared to what is happening elsewhere in the world.", [["deceased and infected", "DISEASE", 89, 110], ["Infections", "DISEASE", 475, 485], ["infected", "DISEASE", 912, 920], ["persons", "ORGANISM", 111, 118], ["persons", "SPECIES", 111, 118], ["people", "SPECIES", 514, 520], ["containment strategy", "TREATMENT", 28, 48], ["the COVID", "TEST", 138, 147], ["the simulation curve", "TEST", 421, 441], ["this disease", "PROBLEM", 937, 949], ["infected", "OBSERVATION", 102, 110], ["Infections", "OBSERVATION", 475, 485], ["infected", "OBSERVATION", 688, 696], ["infected", "OBSERVATION", 912, 920]]], ["Health policies are probably there for something but is it enough to have a plausible theory?DiscussionBased on the data at the start of the disease in March, we can deduce from the theoretical study and the numerical simulations that the modification of the parameter \u03bb 3 generates a consequent variation in the rate of the infected population and deceased persons (Figures 4.8.a-b) .", [["persons", "SPECIES", 358, 365], ["the theoretical study", "TEST", 178, 199], ["a consequent variation", "PROBLEM", 283, 305], ["Figures", "TEST", 367, 374], ["infected", "OBSERVATION", 325, 333]]], ["In other words, in the absence of a quarantine strategy, we can see that on the 20th day of the epidemic, we get 3,75x10 5 infected people (Figure 4.9 .a).", [["people", "ORGANISM", 132, 138], ["people", "SPECIES", 132, 138]]], ["This number is much higher than the current capacity of health structures in Tunisia.", [["much", "OBSERVATION_MODIFIER", 15, 19], ["higher", "OBSERVATION_MODIFIER", 20, 26]]], ["Consequently, the choice of the containment strategy considerably reduced the number of dead and infected people.DiscussionWith the absence of drug and vaccination, we found that home quarantine can really limit the spread of the epidemic.", [["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["the containment strategy", "TREATMENT", 28, 52], ["vaccination", "TREATMENT", 152, 163], ["home quarantine", "TREATMENT", 179, 194]]], ["The indicator of infected cases is not the problem.", [["infected cases", "PROBLEM", 17, 31], ["infected", "OBSERVATION", 17, 25]]], ["And after 50 days in Figure 4 .2, the indicator of infected cases shows less infected people.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["infected cases", "PROBLEM", 51, 65], ["infected", "OBSERVATION", 51, 59], ["less", "OBSERVATION_MODIFIER", 72, 76], ["infected", "OBSERVATION", 77, 85]]], ["Accordingly, the government is considering the relaxation of the quarantine strategy.DiscussionThe proposed model is flexible and we believe it could be easily adapted to monitor various infected are as with different restriction policies.ConclusionIn this article, we presented a new model based on nonlinear differential equations allowing to model this COVID-19 in Tunisia.", [["the quarantine strategy", "TREATMENT", 61, 84], ["different restriction policies", "TREATMENT", 208, 238], ["nonlinear differential equations", "PROBLEM", 300, 332], ["this COVID", "TEST", 351, 361]]], ["The aim of our work, at first, is to provide initial ideas and guidelines for a quantitative and qualitative study of our considered model.", [["qualitative study", "TEST", 97, 114]]], ["In particular, the positivity, boundness and the existence of a solution are established.", [["boundness", "PROBLEM", 31, 40], ["a solution", "TREATMENT", 62, 72]]], ["The impact of the quarantine strategy is also investigated and discussed by two methods.", [["the quarantine strategy", "TREATMENT", 14, 37]]], ["It thus appears that in addition to a rigorous application of quarantine, accurately nearcasting the epidemic trend and projecting the peak time require real-time data and the knowledge about the implementation resources in order to construct the adequate policy and effective decisions of major public health interventions.", [["quarantine", "TREATMENT", 62, 72], ["major public health interventions", "TREATMENT", 290, 323]]]], "880d3a65e93a987c730cc71af94918ca1eb6393d": [["Objective: Only 10 cases of intussusception after Roux-en-Y gastric bypass (RYGB) surgery and 11 cases of intussusception complicating pregnancy have been reported in the literature with one previous case common to both groups.", [["gastric", "ANATOMY", 60, 67], ["intussusception", "DISEASE", 28, 43], ["intussusception", "DISEASE", 106, 121], ["gastric", "MULTI-TISSUE_STRUCTURE", 60, 67], ["intussusception", "PROBLEM", 28, 43], ["Roux-en-Y gastric bypass", "TREATMENT", 50, 74], ["RYGB) surgery", "TREATMENT", 76, 89], ["intussusception complicating pregnancy", "PROBLEM", 106, 144], ["gastric", "ANATOMY", 60, 67], ["bypass", "OBSERVATION", 68, 74]]], ["We present an unusual case of intussusception complicating pregnancy following open RYGB.", [["intussusception", "DISEASE", 30, 45], ["intussusception complicating pregnancy", "PROBLEM", 30, 68], ["open RYGB", "TREATMENT", 79, 88], ["intussusception", "OBSERVATION", 30, 45], ["RYGB", "OBSERVATION", 84, 88]]], ["Methods: 34-year-old female had a normal vaginal delivery at full term and on post-partum day one, she developed sudden onset of mid abdominal pain.", [["vaginal", "ANATOMY", 41, 48], ["abdominal", "ANATOMY", 133, 142], ["abdominal pain", "DISEASE", 133, 147], ["female", "ORGANISM", 21, 27], ["vaginal", "ORGANISM_SUBDIVISION", 41, 48], ["abdominal", "ORGANISM_SUBDIVISION", 133, 142], ["mid abdominal pain", "PROBLEM", 129, 147], ["vaginal", "ANATOMY", 41, 48], ["mid", "ANATOMY_MODIFIER", 129, 132], ["abdominal", "ANATOMY", 133, 142], ["pain", "OBSERVATION", 143, 147]]], ["On evaluation she had significant periumbilical tenderness but no peritoneal signs and an elevated white count.", [["peritoneal", "ANATOMY", 66, 76], ["tenderness", "DISEASE", 48, 58], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 66, 76], ["evaluation", "TEST", 3, 13], ["significant periumbilical tenderness", "PROBLEM", 22, 58], ["peritoneal signs", "PROBLEM", 66, 82], ["an elevated white count", "PROBLEM", 87, 110], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["periumbilical", "ANATOMY", 34, 47], ["tenderness", "OBSERVATION", 48, 58], ["no", "UNCERTAINTY", 63, 65], ["peritoneal", "ANATOMY", 66, 76], ["signs", "OBSERVATION", 77, 82], ["elevated", "OBSERVATION_MODIFIER", 90, 98], ["white count", "OBSERVATION", 99, 110]]], ["CT scan showed a large intussusception measuring 15 \u00b7 10 \u00b7 10 cm.", [["intussusception", "DISEASE", 23, 38], ["CT scan", "TEST", 0, 7], ["a large intussusception", "PROBLEM", 15, 38], ["large", "OBSERVATION_MODIFIER", 17, 22], ["intussusception", "OBSERVATION", 23, 38], ["15 \u00b7 10 \u00b7 10 cm", "OBSERVATION_MODIFIER", 49, 64]]], ["Past surgical history significant for open RYGB five years earlier with subsequent 140-lb weight loss and normal previous pregnancies after gastric bypass.", [["gastric", "ANATOMY", 140, 147], ["weight loss", "DISEASE", 90, 101], ["gastric", "ORGAN", 140, 147], ["open RYGB", "TREATMENT", 38, 47], ["weight loss", "PROBLEM", 90, 101], ["normal previous pregnancies", "PROBLEM", 106, 133], ["gastric bypass", "TREATMENT", 140, 154], ["140-lb", "OBSERVATION_MODIFIER", 83, 89], ["normal", "OBSERVATION", 106, 112], ["gastric", "ANATOMY", 140, 147], ["bypass", "OBSERVATION", 148, 154]]], ["Results: The patient underwent exploratory laparotomy, lysis of adhesions, reduction of intussusception and resection of 180 cm of small bowel with end-to-side jejunojejunal anastomosis.", [["adhesions", "ANATOMY", 64, 73], ["bowel", "ANATOMY", 137, 142], ["jejunojejunal", "ANATOMY", 160, 173], ["adhesions", "DISEASE", 64, 73], ["intussusception", "DISEASE", 88, 103], ["patient", "ORGANISM", 13, 20], ["bowel", "ORGAN", 137, 142], ["patient", "SPECIES", 13, 20], ["exploratory laparotomy", "TEST", 31, 53], ["lysis", "TREATMENT", 55, 60], ["adhesions", "PROBLEM", 64, 73], ["reduction", "TREATMENT", 75, 84], ["intussusception", "PROBLEM", 88, 103], ["resection", "TREATMENT", 108, 117], ["end-to-side jejunojejunal anastomosis", "TREATMENT", 148, 185], ["laparotomy", "OBSERVATION", 43, 53], ["adhesions", "OBSERVATION", 64, 73], ["intussusception", "OBSERVATION", 88, 103], ["resection", "OBSERVATION", 108, 117], ["180 cm", "OBSERVATION_MODIFIER", 121, 127], ["small", "ANATOMY_MODIFIER", 131, 136], ["bowel", "ANATOMY", 137, 142], ["jejunojejunal", "ANATOMY", 160, 173], ["anastomosis", "OBSERVATION", 174, 185]]], ["Intraoperative findings included retrograde intussusception at the jejunojeunal anastomosis, with marked dilation of the Roux and biliopancreatic limb and a decompressed efferent limb.", [["jejunojeunal", "ANATOMY", 67, 79], ["biliopancreatic limb", "ANATOMY", 130, 150], ["efferent limb", "ANATOMY", 170, 183], ["intussusception", "DISEASE", 44, 59], ["biliopancreatic limb", "ORGANISM_SUBDIVISION", 130, 150], ["efferent limb", "ORGANISM_SUBDIVISION", 170, 183], ["Intraoperative findings", "TEST", 0, 23], ["retrograde intussusception", "PROBLEM", 33, 59], ["the jejunojeunal anastomosis", "TREATMENT", 63, 91], ["marked dilation of the Roux and biliopancreatic limb", "PROBLEM", 98, 150], ["a decompressed efferent limb", "TREATMENT", 155, 183], ["retrograde intussusception", "OBSERVATION", 33, 59], ["jejunojeunal anastomosis", "OBSERVATION", 67, 91], ["marked", "OBSERVATION_MODIFIER", 98, 104], ["dilation", "OBSERVATION", 105, 113], ["Roux", "ANATOMY_MODIFIER", 121, 125], ["biliopancreatic limb", "ANATOMY", 130, 150], ["decompressed", "OBSERVATION", 157, 169], ["efferent limb", "OBSERVATION", 170, 183]]], ["The incarcerated small intestine within the intussusception appeared to have ischemic injury.", [["small intestine", "ANATOMY", 17, 32], ["intussusception", "DISEASE", 44, 59], ["ischemic injury", "DISEASE", 77, 92], ["small intestine", "ORGAN", 17, 32], ["The incarcerated small intestine", "PROBLEM", 0, 32], ["the intussusception", "PROBLEM", 40, 59], ["ischemic injury", "PROBLEM", 77, 92], ["incarcerated", "OBSERVATION", 4, 16], ["small intestine", "ANATOMY", 17, 32], ["intussusception", "OBSERVATION", 44, 59], ["ischemic", "OBSERVATION_MODIFIER", 77, 85], ["injury", "OBSERVATION", 86, 92]]], ["Intraoperative pathology of small bowel showed recent hemorrhage, mucosal ulceration, transmural edema and exudate formation, consistent with ischemic-related changes.", [["bowel", "ANATOMY", 34, 39], ["mucosal", "ANATOMY", 66, 73], ["transmural edema", "ANATOMY", 86, 102], ["exudate", "ANATOMY", 107, 114], ["hemorrhage", "DISEASE", 54, 64], ["edema", "DISEASE", 97, 102], ["bowel", "ORGAN", 34, 39], ["mucosal ulceration", "PATHOLOGICAL_FORMATION", 66, 84], ["transmural edema", "PATHOLOGICAL_FORMATION", 86, 102], ["exudate", "TISSUE", 107, 114], ["Intraoperative pathology", "TEST", 0, 24], ["recent hemorrhage", "PROBLEM", 47, 64], ["mucosal ulceration", "PROBLEM", 66, 84], ["transmural edema", "PROBLEM", 86, 102], ["exudate formation", "PROBLEM", 107, 124], ["ischemic-related changes", "PROBLEM", 142, 166], ["small", "ANATOMY_MODIFIER", 28, 33], ["bowel", "ANATOMY", 34, 39], ["hemorrhage", "OBSERVATION", 54, 64], ["mucosal", "ANATOMY", 66, 73], ["ulceration", "OBSERVATION", 74, 84], ["transmural", "OBSERVATION_MODIFIER", 86, 96], ["edema", "OBSERVATION", 97, 102], ["exudate", "OBSERVATION", 107, 114], ["consistent with", "UNCERTAINTY", 126, 141], ["ischemic", "OBSERVATION", 142, 150]]], ["Postoperative course was uneventful and the patient went home on the fourth postoperative day.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51]]], ["Conclusion:Intussusception following RYGB and during pregnancy is a rare complication.", [["Intussusception", "DISEASE", 11, 26], ["Intussusception", "PROBLEM", 11, 26], ["RYGB", "TREATMENT", 37, 41], ["a rare complication", "PROBLEM", 66, 85], ["Intussusception", "OBSERVATION", 11, 26]]], ["Some studies have postulated abnormal motility to be a causative factor of retrograde intussusception in gastric bypass patients.", [["gastric", "ANATOMY", 105, 112], ["abnormal motility", "DISEASE", 29, 46], ["intussusception", "DISEASE", 86, 101], ["gastric", "ORGAN", 105, 112], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["Some studies", "TEST", 0, 12], ["abnormal motility", "PROBLEM", 29, 46], ["retrograde intussusception", "PROBLEM", 75, 101], ["gastric bypass patients", "TREATMENT", 105, 128], ["abnormal", "OBSERVATION_MODIFIER", 29, 37], ["motility", "OBSERVATION_MODIFIER", 38, 46], ["retrograde", "OBSERVATION_MODIFIER", 75, 85], ["intussusception", "OBSERVATION", 86, 101], ["gastric", "ANATOMY", 105, 112], ["bypass", "OBSERVATION", 113, 119]]], ["Pregnancy following RYGB is speculated to cause intussusception due to altered anatomic relationships secondary to a growing uterus.", [["uterus", "ANATOMY", 125, 131], ["intussusception", "DISEASE", 48, 63], ["uterus", "ORGAN", 125, 131], ["Pregnancy following RYGB", "PROBLEM", 0, 24], ["intussusception", "PROBLEM", 48, 63], ["altered anatomic relationships", "PROBLEM", 71, 101], ["a growing uterus", "PROBLEM", 115, 131], ["uterus", "ANATOMY", 125, 131]]], ["The effect of pregnancy itself on intussusception needs to be further investigated with hormonal changes possibly playing a role.", [["intussusception", "DISEASE", 34, 49], ["pregnancy itself", "PROBLEM", 14, 30], ["intussusception", "PROBLEM", 34, 49], ["hormonal changes", "PROBLEM", 88, 104]]], ["Operative revision and reversal represent treatment alternatives for patients who fail primary bariatric operations.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["Operative revision", "TREATMENT", 0, 18], ["reversal", "TREATMENT", 23, 31], ["treatment alternatives", "TREATMENT", 42, 64], ["primary bariatric operations", "TREATMENT", 87, 115], ["revision", "OBSERVATION", 10, 18]]], ["This review focuses on a small group of patients who had reversal rather than revision of their primary operation.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["reversal", "TREATMENT", 57, 65], ["revision", "TREATMENT", 78, 86], ["their primary operation", "TREATMENT", 90, 113]]], ["Methods: This study reviews 2532 primary and 238 revisional operations that were performed by one surgeon over a 27-year period.", [["revisional operations", "TREATMENT", 49, 70]]], ["Primary operations were performed by other surgeons in 75 of the revision patients.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Primary operations", "TREATMENT", 0, 18], ["the revision patients", "TREATMENT", 61, 82], ["revision", "OBSERVATION", 65, 73]]], ["The indications for revision were complications in 73 patients (31%) and weight loss failure in 165 patients (69%).", [["weight loss failure", "DISEASE", 73, 92], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 100, 108], ["revision", "TREATMENT", 20, 28], ["weight loss failure", "PROBLEM", 73, 92]]], ["Results: Ten patients had reversal rather than revision including 5 who requested reversal for severe outlet stenosis after banded restrictive procedures and 5 who were recommended to have reversal due to active abuse of prescription drugs (2) or tobacco (1) and 2 with severe metabolic complications related to malabsorption.", [["outlet stenosis", "DISEASE", 102, 117], ["metabolic complications", "DISEASE", 277, 300], ["malabsorption", "DISEASE", 312, 325], ["patients", "ORGANISM", 13, 21], ["tobacco", "ORGANISM", 247, 254], ["patients", "SPECIES", 13, 21], ["tobacco", "SPECIES", 247, 254], ["tobacco", "SPECIES", 247, 254], ["reversal", "TREATMENT", 26, 34], ["revision", "TREATMENT", 47, 55], ["severe outlet stenosis", "PROBLEM", 95, 117], ["banded restrictive procedures", "TREATMENT", 124, 153], ["reversal", "TREATMENT", 189, 197], ["prescription drugs", "TREATMENT", 221, 239], ["severe metabolic complications", "PROBLEM", 270, 300], ["malabsorption", "PROBLEM", 312, 325], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["outlet", "OBSERVATION_MODIFIER", 102, 108], ["stenosis", "OBSERVATION", 109, 117], ["restrictive", "OBSERVATION_MODIFIER", 131, 142], ["metabolic complications", "OBSERVATION", 277, 300]]], ["Weight regain occurred in all but one patient who was followed for > 12 months.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["Weight", "TEST", 0, 6]]], ["Two patients subsequently requested another bariatric operation after regaining weight, only one of which was performed with34% EWL post revision.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["another bariatric operation", "TREATMENT", 36, 63], ["revision", "TREATMENT", 137, 145], ["revision", "OBSERVATION", 137, 145]]], ["One of the 10 patients had a post operative wound infection.", [["wound", "ANATOMY", 44, 49], ["wound infection", "DISEASE", 44, 59], ["patients", "ORGANISM", 14, 22], ["wound", "PATHOLOGICAL_FORMATION", 44, 49], ["patients", "SPECIES", 14, 22], ["a post operative wound infection", "PROBLEM", 27, 59], ["post operative", "OBSERVATION_MODIFIER", 29, 43], ["wound", "ANATOMY", 44, 49], ["infection", "OBSERVATION", 50, 59]]], ["There were no other complications or deaths in this subgroup.", [["deaths", "DISEASE", 37, 43], ["other complications", "PROBLEM", 14, 33], ["deaths", "PROBLEM", 37, 43], ["no other", "UNCERTAINTY", 11, 19], ["complications", "OBSERVATION", 20, 33]]], ["Conclusions: Approximately 1.0% of patients who have bariatric surgery will require reversal for troublesome complications.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["bariatric surgery", "TREATMENT", 53, 70], ["reversal", "TREATMENT", 84, 92], ["troublesome complications", "PROBLEM", 97, 122]]], ["Active substance abuse and non-Compliance with physician\u00d5s recommendations contributed towards the decision to reverse rather than revise the primary operation.", [["substance abuse", "DISEASE", 7, 22], ["the primary operation", "TREATMENT", 138, 159], ["substance abuse", "OBSERVATION", 7, 22]]]], "PMC3187809": [["IntroductionIFN-\u03b1 and IFN-\u03b2 are structurally related cytokines of the type I interferon family which mediate an early innate immune response to viral infections.", [["viral infections", "DISEASE", 144, 160], ["IntroductionIFN-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 17], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 22, 27], ["type I interferon", "GENE_OR_GENE_PRODUCT", 70, 87], ["IntroductionIFN", "PROTEIN", 0, 15], ["-\u03b1", "PROTEIN", 15, 17], ["IFN", "PROTEIN", 22, 25], ["\u03b2", "PROTEIN", 26, 27], ["cytokines", "PROTEIN", 53, 62], ["type I interferon family", "PROTEIN", 70, 94], ["viral infections", "PROBLEM", 144, 160], ["viral infections", "OBSERVATION", 144, 160]]], ["There are 13 distinct IFN-\u03b1 genes present in the human genome, and a single gene encoding for IFN-\u03b2.", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 22, 27], ["human", "ORGANISM", 49, 54], ["IFN-\u03b1 genes", "DNA", 22, 33], ["human genome", "DNA", 49, 61], ["IFN", "PROTEIN", 94, 97], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["13 distinct", "OBSERVATION_MODIFIER", 10, 21], ["human genome", "ANATOMY", 49, 61]]], ["These genes are transcriptionally activated in cells sensing a virus infection through pattern recognition receptors such as the retinoic acid inducible gene I (RIG-I) helicase.", [["cells", "ANATOMY", 47, 52], ["infection", "DISEASE", 69, 78], ["retinoic acid", "CHEMICAL", 129, 142], ["retinoic acid", "CHEMICAL", 129, 142], ["cells", "CELL", 47, 52], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 87, 116], ["retinoic acid inducible gene I", "GENE_OR_GENE_PRODUCT", 129, 159], ["RIG-I", "GENE_OR_GENE_PRODUCT", 161, 166], ["pattern recognition receptors", "PROTEIN", 87, 116], ["retinoic acid inducible gene I (RIG-I) helicase", "PROTEIN", 129, 176], ["a virus infection", "PROBLEM", 61, 78], ["recognition receptors", "TREATMENT", 95, 116], ["the retinoic acid inducible gene I (RIG-I) helicase", "PROBLEM", 125, 176]]], ["Following secretion, IFN-\u03b1 and IFN-\u03b2 act similarly by binding to a common, ubiquitously expressed IFN-\u03b1/\u03b2 receptor resulting in the activation of the JAK/STAT signal transduction pathway and transcription of \u201cIFN-induced genes\u201d [1], [2].", [["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 21, 26], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 31, 36], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 98, 103], ["\u03b2 receptor", "GENE_OR_GENE_PRODUCT", 104, 114], ["JAK", "GENE_OR_GENE_PRODUCT", 150, 153], ["STAT", "GENE_OR_GENE_PRODUCT", 154, 158], ["IFN", "GENE_OR_GENE_PRODUCT", 209, 212], ["IFN", "PROTEIN", 21, 24], ["\u03b1", "PROTEIN", 25, 26], ["IFN", "PROTEIN", 31, 34], ["\u03b2", "PROTEIN", 35, 36], ["IFN", "PROTEIN", 98, 101], ["\u03b1", "PROTEIN", 102, 103], ["\u03b2 receptor", "PROTEIN", 104, 114], ["JAK", "PROTEIN", 150, 153], ["STAT", "PROTEIN", 154, 158], ["IFN", "PROTEIN", 209, 212], ["secretion", "TEST", 10, 19], ["IFN", "TEST", 21, 24], ["IFN", "TREATMENT", 31, 34], ["the JAK", "TREATMENT", 146, 153], ["STAT signal transduction pathway", "TREATMENT", 154, 186]]], ["Several of these genes encode for proteins with strong antiviral activity, i.e. Mx protein, protein kinase R, and 2\u2032-5\u2032oligo(A) synthetase [3].", [["Mx protein", "GENE_OR_GENE_PRODUCT", 80, 90], ["protein kinase R", "GENE_OR_GENE_PRODUCT", 92, 108], ["2\u2032-5\u2032oligo(A) synthetase", "GENE_OR_GENE_PRODUCT", 114, 138], ["Mx protein", "PROTEIN", 80, 90], ["protein kinase R", "PROTEIN", 92, 108], ["2\u2032", "PROTEIN", 114, 116], ["5\u2032oligo(A) synthetase", "PROTEIN", 117, 138], ["Mx protein", "TEST", 80, 90], ["protein kinase R", "TEST", 92, 108]]], ["Due to their autocrine action, type I IFN may attenuate virus replication in infected cells.", [["cells", "ANATOMY", 86, 91], ["type I IFN", "GENE_OR_GENE_PRODUCT", 31, 41], ["cells", "CELL", 86, 91], ["type I IFN", "PROTEIN", 31, 41], ["infected cells", "CELL_TYPE", 77, 91], ["type I IFN", "PROBLEM", 31, 41], ["attenuate virus replication in infected cells", "PROBLEM", 46, 91], ["infected cells", "OBSERVATION", 77, 91]]], ["Probably more important is the paracrine action of type I IFN, which induces an antiviral state in previously uninfected cells, thereby blocking virus dissemination in the organism.", [["cells", "ANATOMY", 121, 126], ["type I IFN", "GENE_OR_GENE_PRODUCT", 51, 61], ["cells", "CELL", 121, 126], ["type I IFN", "PROTEIN", 51, 61], ["uninfected cells", "CELL_TYPE", 110, 126], ["type I IFN", "PROBLEM", 51, 61], ["an antiviral state", "PROBLEM", 77, 95], ["previously uninfected cells", "PROBLEM", 99, 126], ["thereby blocking virus dissemination in the organism", "PROBLEM", 128, 180], ["antiviral state", "OBSERVATION", 80, 95], ["uninfected cells", "OBSERVATION", 110, 126]]], ["In addition to this \u201cclassical\u201d antiviral function, type I IFNs are known to affect cell proliferation and differentiation, to modulate the immune response, to inhibit angiogenesis, and to promote apoptosis [4], [5].", [["cell", "ANATOMY", 84, 88], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 52, 63], ["cell", "CELL", 84, 88], ["type I IFNs", "PROTEIN", 52, 63], ["this \u201cclassical\u201d antiviral function", "PROBLEM", 15, 50], ["type I IFNs", "PROBLEM", 52, 63], ["cell proliferation", "PROBLEM", 84, 102], ["antiviral function", "OBSERVATION", 32, 50], ["cell proliferation", "OBSERVATION", 84, 102]]], ["Genetically engineered type I IFNs are currently in clinical use for the treatment of multiple sclerosis [6], chronic hepatitis C virus infection [7], and certain types of cancer [8], [9].", [["cancer", "ANATOMY", 172, 178], ["multiple sclerosis", "DISEASE", 86, 104], ["chronic hepatitis C virus infection", "DISEASE", 110, 145], ["cancer", "DISEASE", 172, 178], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 23, 34], ["chronic hepatitis C virus", "ORGANISM", 110, 135], ["cancer", "CANCER", 172, 178], ["type I IFNs", "PROTEIN", 23, 34], ["hepatitis C virus", "SPECIES", 118, 135], ["hepatitis C virus", "SPECIES", 118, 135], ["multiple sclerosis", "PROBLEM", 86, 104], ["chronic hepatitis C virus infection", "PROBLEM", 110, 145], ["cancer", "PROBLEM", 172, 178], ["multiple", "OBSERVATION_MODIFIER", 86, 94], ["sclerosis", "OBSERVATION", 95, 104], ["chronic", "OBSERVATION_MODIFIER", 110, 117], ["hepatitis", "OBSERVATION", 118, 127], ["cancer", "OBSERVATION", 172, 178]]], ["An issue of increasing importance is the determination of neutralizing antibodies that are induced in some patients following recombinant IFN therapy [10].IntroductionApart from IFN-\u03b1/\u03b2, cytokines such as IFN-\u03b3 (type II IFN) and IFN-\u03bb (type III IFN) exhibit antiviral activities, although they bind to distinct receptors.", [["IFN", "CHEMICAL", 138, 141], ["patients", "ORGANISM", 107, 115], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 178, 183], ["\u03b2", "GENE_OR_GENE_PRODUCT", 184, 185], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 205, 210], ["type II IFN", "GENE_OR_GENE_PRODUCT", 212, 223], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 229, 234], ["type III IFN", "GENE_OR_GENE_PRODUCT", 236, 248], ["neutralizing antibodies", "PROTEIN", 58, 81], ["IFN", "PROTEIN", 138, 141], ["IFN", "PROTEIN", 178, 181], ["\u03b1", "PROTEIN", 182, 183], ["\u03b2", "PROTEIN", 184, 185], ["cytokines", "PROTEIN", 187, 196], ["IFN-\u03b3", "PROTEIN", 205, 210], ["type II IFN", "PROTEIN", 212, 223], ["IFN", "PROTEIN", 229, 232], ["\u03bb", "PROTEIN", 233, 234], ["type III IFN", "PROTEIN", 236, 248], ["patients", "SPECIES", 107, 115], ["neutralizing antibodies", "PROBLEM", 58, 81], ["recombinant IFN therapy", "TREATMENT", 126, 149], ["IntroductionApart", "TEST", 155, 172], ["IFN", "TEST", 178, 181], ["\u03b2", "PROBLEM", 184, 185], ["cytokines", "PROBLEM", 187, 196], ["IFN-\u03b3 (type II IFN)", "PROBLEM", 205, 224], ["IFN", "TEST", 229, 232], ["type III IFN)", "PROBLEM", 236, 249], ["antiviral activities", "PROBLEM", 258, 278], ["increasing", "OBSERVATION_MODIFIER", 12, 22], ["antiviral activities", "OBSERVATION", 258, 278]]], ["In particular, type III IFNs induce transcriptional activation of antiviral genes similar to those activated by type I IFN.", [["type III IFNs", "GENE_OR_GENE_PRODUCT", 15, 28], ["type I IFN", "GENE_OR_GENE_PRODUCT", 112, 122], ["type III IFNs", "PROTEIN", 15, 28], ["antiviral genes", "DNA", 66, 81], ["type I IFN", "PROTEIN", 112, 122], ["type III IFNs", "PROBLEM", 15, 28], ["antiviral genes", "PROBLEM", 66, 81], ["type III", "OBSERVATION_MODIFIER", 15, 23], ["transcriptional activation", "OBSERVATION", 36, 62], ["antiviral genes", "OBSERVATION", 66, 81]]], ["Type III IFNs act primarily on epithelial cells [11] and probably play an important role in the innate immune response of epithelial tissues to virus infections [12], [13].IntroductionThe accurate determination of antiviral IFN activity is a cumbersome issue.", [["epithelial cells", "ANATOMY", 31, 47], ["epithelial tissues", "ANATOMY", 122, 140], ["infections", "DISEASE", 150, 160], ["Type III IFNs", "GENE_OR_GENE_PRODUCT", 0, 13], ["epithelial cells", "CELL", 31, 47], ["epithelial tissues", "TISSUE", 122, 140], ["Type III IFNs", "PROTEIN", 0, 13], ["epithelial cells", "CELL_TYPE", 31, 47], ["IFN", "PROTEIN", 224, 227], ["Type III IFNs act", "PROBLEM", 0, 17], ["epithelial cells", "PROBLEM", 31, 47], ["epithelial tissues", "PROBLEM", 122, 140], ["virus infections", "PROBLEM", 144, 160], ["antiviral IFN activity", "TREATMENT", 214, 236], ["epithelial tissues", "OBSERVATION", 122, 140]]], ["In the \u201cclassical\u201d bioassay, serial dilutions of both a test sample with unknown IFN activity and a type I IFN standard are incubated with an appropriate cell line prior to infection with a cytolytic virus such as vesicular stomatitis virus (VSV), encephalomyocarditis virus, or Sendai virus [14], [15].", [["sample", "ANATOMY", 61, 67], ["cell line", "ANATOMY", 154, 163], ["infection", "DISEASE", 173, 182], ["vesicular stomatitis", "DISEASE", 214, 234], ["encephalomyocarditis virus", "DISEASE", 248, 274], ["cell line", "CELL", 154, 163], ["vesicular stomatitis virus", "ORGANISM", 214, 240], ["VSV", "ORGANISM", 242, 245], ["encephalomyocarditis virus", "ORGANISM", 248, 274], ["Sendai virus", "ORGANISM", 279, 291], ["IFN", "PROTEIN", 81, 84], ["vesicular stomatitis virus", "SPECIES", 214, 240], ["encephalomyocarditis virus", "SPECIES", 248, 274], ["Sendai virus", "SPECIES", 279, 291], ["vesicular stomatitis virus", "SPECIES", 214, 240], ["VSV", "SPECIES", 242, 245], ["encephalomyocarditis virus", "SPECIES", 248, 274], ["Sendai virus", "SPECIES", 279, 291], ["serial dilutions", "TREATMENT", 29, 45], ["a test sample", "TEST", 54, 67], ["unknown IFN activity", "PROBLEM", 73, 93], ["a type I IFN standard", "TREATMENT", 98, 119], ["an appropriate cell line", "TREATMENT", 139, 163], ["infection", "PROBLEM", 173, 182], ["a cytolytic virus", "PROBLEM", 188, 205], ["vesicular stomatitis virus (VSV)", "PROBLEM", 214, 246], ["encephalomyocarditis virus", "PROBLEM", 248, 274], ["Sendai virus", "PROBLEM", 279, 291], ["cell line", "OBSERVATION", 154, 163], ["infection", "OBSERVATION", 173, 182], ["vesicular stomatitis", "OBSERVATION", 214, 234]]], ["The reciprocal value of the highest type I IFN dilution mediating protection of 50% of the cells from virus-induced cytopathic effects (CPE) is defined as one unit of type I IFN per volume.", [["cells", "ANATOMY", 91, 96], ["type I IFN", "GENE_OR_GENE_PRODUCT", 36, 46], ["cells", "CELL", 91, 96], ["type I IFN", "GENE_OR_GENE_PRODUCT", 167, 177], ["IFN", "PROTEIN", 43, 46], ["IFN", "PROTEIN", 174, 177], ["The reciprocal value", "TEST", 0, 20], ["the highest type I IFN dilution mediating protection", "TREATMENT", 24, 76], ["virus", "PROBLEM", 102, 107], ["cytopathic effects", "PROBLEM", 116, 134], ["type I IFN per volume", "TREATMENT", 167, 188], ["cytopathic", "OBSERVATION_MODIFIER", 116, 126]]], ["This classical IFN bioassay is time-consuming because the CPE normally needs 24 hours or more to develop.", [["IFN", "PROTEIN", 15, 18], ["the CPE", "PROBLEM", 54, 61]]], ["A faster readout can be achieved with recombinant viruses expressing reporter proteins such as green fluorescent protein (GFP) or firefly luciferase [16], [17], [18], [19].", [["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 95, 120], ["GFP", "GENE_OR_GENE_PRODUCT", 122, 125], ["luciferase", "GENE_OR_GENE_PRODUCT", 138, 148], ["reporter proteins", "PROTEIN", 69, 86], ["green fluorescent protein", "PROTEIN", 95, 120], ["GFP", "PROTEIN", 122, 125], ["A faster readout", "TREATMENT", 0, 16], ["reporter proteins", "TEST", 69, 86], ["green fluorescent protein (GFP", "TEST", 95, 125], ["firefly luciferase", "TEST", 130, 148]]], ["For example, a recently published IFN bioassay can only be performed in biosafety level 3 (BSL-3) facilities, because the test makes use of a recombinant Rift Valley Fever virus [19].", [["Rift Valley Fever", "DISEASE", 154, 171], ["recombinant", "ORGANISM", 142, 153], ["Rift Valley Fever virus", "ORGANISM", 154, 177], ["IFN", "PROTEIN", 34, 37], ["Rift Valley Fever virus", "SPECIES", 154, 177], ["Rift Valley Fever virus", "SPECIES", 154, 177], ["a recently published IFN bioassay", "PROBLEM", 13, 46], ["a recombinant Rift Valley Fever virus", "PROBLEM", 140, 177]]], ["Viral replicon-based bioassays that take advantage of disabled propagation-incompetent viruses may provide an attractive alternative to live virus-based bioassays.", [["Viral replicon", "TREATMENT", 0, 14], ["disabled propagation", "PROBLEM", 54, 74], ["incompetent viruses", "PROBLEM", 75, 94], ["live virus", "TREATMENT", 136, 146]]], ["A human hepatoma cell line harbouring a selectable hepatitis C virus replicon has been successfully employed for the measurement of type I IFN from patients with chronic hepatitis C virus infection [20].", [["hepatoma cell line", "ANATOMY", 8, 26], ["hepatitis C", "DISEASE", 51, 62], ["chronic hepatitis C virus infection", "DISEASE", 162, 197], ["human", "ORGANISM", 2, 7], ["hepatoma cell line", "CELL", 8, 26], ["hepatitis C virus", "ORGANISM", 51, 68], ["type I IFN", "GENE_OR_GENE_PRODUCT", 132, 142], ["patients", "ORGANISM", 148, 156], ["chronic hepatitis C virus", "ORGANISM", 162, 187], ["human hepatoma cell line", "CELL_LINE", 2, 26], ["type I IFN", "PROTEIN", 132, 142], ["human", "SPECIES", 2, 7], ["hepatitis C virus", "SPECIES", 51, 68], ["patients", "SPECIES", 148, 156], ["hepatitis C virus", "SPECIES", 170, 187], ["human", "SPECIES", 2, 7], ["hepatitis C virus", "SPECIES", 51, 68], ["hepatitis C virus", "SPECIES", 170, 187], ["A human hepatoma cell line", "TREATMENT", 0, 26], ["a selectable hepatitis C virus replicon", "TREATMENT", 38, 77], ["type I IFN", "PROBLEM", 132, 142], ["chronic hepatitis C virus infection", "PROBLEM", 162, 197], ["hepatoma cell line", "OBSERVATION", 8, 26], ["selectable", "OBSERVATION_MODIFIER", 40, 50], ["hepatitis", "OBSERVATION", 51, 60], ["chronic", "OBSERVATION_MODIFIER", 162, 169], ["hepatitis", "OBSERVATION", 170, 179]]], ["However, as type I IFNs act in a species-dependent manner, this system may not be applicable to animal IFNs.", [["type I IFNs", "GENE_OR_GENE_PRODUCT", 12, 23], ["IFNs", "GENE_OR_GENE_PRODUCT", 103, 107], ["type I IFNs", "PROTEIN", 12, 23], ["IFNs", "PROTEIN", 103, 107]]], ["Transgenic cell lines expressing a reporter gene under control of an IFN-responsive promoter may also be used to determine IFN activity under biosafe conditions [21], [22].", [["cell lines", "ANATOMY", 11, 21], ["cell lines", "CELL", 11, 21], ["IFN", "GENE_OR_GENE_PRODUCT", 69, 72], ["IFN", "GENE_OR_GENE_PRODUCT", 123, 126], ["Transgenic cell lines", "CELL_LINE", 0, 21], ["reporter gene", "DNA", 35, 48], ["IFN-responsive promoter", "DNA", 69, 92], ["IFN", "PROTEIN", 123, 126], ["Transgenic cell lines", "TREATMENT", 0, 21], ["an IFN-responsive promoter", "TREATMENT", 66, 92], ["cell lines", "OBSERVATION", 11, 21]]], ["However, it is difficult to simply relate transcriptional reporter gene activation to antiviral activity.IntroductionIn this report, a novel type I IFN bioassay is presented, which is based on BSL-1-classified VSV replicon particles.", [["BSL-1", "GENE_OR_GENE_PRODUCT", 193, 198], ["VSV", "ORGANISM", 210, 213], ["transcriptional reporter gene", "DNA", 42, 71], ["antiviral activity", "TREATMENT", 86, 104], ["a novel type I IFN bioassay", "PROBLEM", 133, 160], ["BSL", "TEST", 193, 196], ["antiviral activity", "OBSERVATION", 86, 104], ["VSV replicon", "OBSERVATION", 210, 222]]], ["The assay is highly sensitive and quantifiable due to the expression of a firefly luciferase reporter gene.", [["luciferase", "GENE_OR_GENE_PRODUCT", 82, 92], ["firefly luciferase reporter gene", "DNA", 74, 106], ["The assay", "TEST", 0, 9]]], ["In addition, the assay can be rapidly performed within 6 to 7 hours and may be used to determine the antiviral activity of IFNs from humans as well as other species.", [["IFNs", "GENE_OR_GENE_PRODUCT", 123, 127], ["humans", "ORGANISM", 133, 139], ["IFNs", "PROTEIN", 123, 127], ["humans", "SPECIES", 133, 139], ["humans", "SPECIES", 133, 139], ["the assay", "TEST", 13, 22]]], ["Thus, this bioassay may be of general interest for all those who want to determine the antiviral activity of cytokines such as type I IFNs.Cells ::: Materials and MethodsBHK-21 cells were obtained from the German Cell Culture Collection (DSZM, Braunschweig, Germany) and grown in Earle's minimal essential medium (EMEM) supplemented with 5% fetal bovine serum (FBS).", [["Cells", "ANATOMY", 139, 144], ["MethodsBHK-21 cells", "ANATOMY", 163, 182], ["Cell", "ANATOMY", 213, 217], ["fetal bovine serum", "ANATOMY", 341, 359], ["FBS", "ANATOMY", 361, 364], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 127, 138], ["Cells", "CELL", 139, 144], ["MethodsBHK-21 cells", "CELL", 163, 182], ["bovine", "ORGANISM", 347, 353], ["serum", "ORGANISM_SUBSTANCE", 354, 359], ["FBS", "ORGANISM_SUBSTANCE", 361, 364], ["cytokines", "PROTEIN", 109, 118], ["type I IFNs", "PROTEIN", 127, 138], ["MethodsBHK-21 cells", "CELL_LINE", 163, 182], ["bovine", "SPECIES", 347, 353], ["bovine", "SPECIES", 347, 353], ["type I IFNs", "PROBLEM", 127, 138], ["Materials", "TEST", 149, 158], ["MethodsBHK", "TEST", 163, 173], ["the German Cell Culture Collection", "TEST", 202, 236], ["DSZM", "TEST", 238, 242], ["5% fetal bovine serum (FBS", "TREATMENT", 338, 364]]], ["BHK-G43, a transgenic BHK-21 cell clone expressing VSV G protein in a regulated manner, was maintained as described previously [23].", [["BHK-G43", "ANATOMY", 0, 7], ["BHK-21 cell clone", "ANATOMY", 22, 39], ["BHK-G43", "CELL", 0, 7], ["BHK-21 cell clone", "CELL", 22, 39], ["VSV G protein", "GENE_OR_GENE_PRODUCT", 51, 64], ["G43", "CELL_LINE", 4, 7], ["transgenic BHK-21 cell clone", "CELL_LINE", 11, 39], ["VSV G protein", "PROTEIN", 51, 64], ["VSV", "SPECIES", 51, 54], ["BHK", "TEST", 0, 3], ["a transgenic BHK", "TEST", 9, 25], ["cell clone", "TEST", 29, 39], ["VSV G protein", "TEST", 51, 64]]], ["The porcine kidney cell line PK-15 (ATCC, Manassas, VA) was propagated in Dulbecco's modified Eagle medium supplemented with nonessential amino acids, 1 mM Na-pyruvate and 5% horse serum.", [["kidney cell line PK-15", "ANATOMY", 12, 34], ["ATCC", "ANATOMY", 36, 40], ["Manassas", "ANATOMY", 42, 50], ["serum", "ANATOMY", 181, 186], ["amino acids", "CHEMICAL", 138, 149], ["Na-pyruvate", "CHEMICAL", 156, 167], ["amino acids", "CHEMICAL", 138, 149], ["Na-pyruvate", "CHEMICAL", 156, 167], ["porcine", "ORGANISM", 4, 11], ["kidney cell line PK-15", "CELL", 12, 34], ["ATCC", "CELL", 36, 40], ["VA", "CELL", 52, 54], ["amino acids", "AMINO_ACID", 138, 149], ["Na-pyruvate", "SIMPLE_CHEMICAL", 156, 167], ["horse", "ORGANISM", 175, 180], ["serum", "ORGANISM_SUBSTANCE", 181, 186], ["porcine kidney cell line", "CELL_LINE", 4, 28], ["PK-15", "CELL_LINE", 29, 34], ["porcine", "SPECIES", 4, 11], ["The porcine kidney cell line PK", "TEST", 0, 31], ["ATCC", "TEST", 36, 40], ["nonessential amino acids", "TEST", 125, 149], ["Na-pyruvate", "TEST", 156, 167], ["5% horse serum", "TEST", 172, 186], ["kidney", "ANATOMY", 12, 18], ["cell line", "OBSERVATION", 19, 28]]], ["D-17 canine osteosarcoma cells (ATCC), Calu-3 human lung adenocarcinoma cells (ATCC), and NHDF normal human dermal fibroblasts (Lonza, Cologne, Germany) were maintained in EMEM with 10% FBS.", [["D-17 canine osteosarcoma cells", "ANATOMY", 0, 30], ["ATCC", "ANATOMY", 32, 36], ["Calu-3", "ANATOMY", 39, 45], ["lung adenocarcinoma cells", "ANATOMY", 52, 77], ["ATCC", "ANATOMY", 79, 83], ["NHDF", "ANATOMY", 90, 94], ["dermal fibroblasts", "ANATOMY", 108, 126], ["FBS", "ANATOMY", 186, 189], ["osteosarcoma", "DISEASE", 12, 24], ["lung adenocarcinoma", "DISEASE", 52, 71], ["D-17 canine osteosarcoma cells", "CELL", 0, 30], ["ATCC", "CELL", 32, 36], ["Calu-3 human lung adenocarcinoma cells", "CELL", 39, 77], ["ATCC", "CELL", 79, 83], ["NHDF", "CELL", 90, 94], ["human", "ORGANISM", 102, 107], ["dermal fibroblasts", "CELL", 108, 126], ["Lonza", "CELL", 128, 133], ["FBS", "ORGANISM_SUBSTANCE", 186, 189], ["D-17 canine osteosarcoma cells", "CELL_LINE", 0, 30], ["ATCC", "CELL_LINE", 32, 36], ["Calu-3 human lung adenocarcinoma cells", "CELL_LINE", 39, 77], ["ATCC", "CELL_LINE", 79, 83], ["NHDF normal human dermal fibroblasts", "CELL_LINE", 90, 126], ["canine", "SPECIES", 5, 11], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 46, 51], ["ATCC", "SPECIES", 79, 83], ["human", "SPECIES", 102, 107], ["D-17 canine osteosarcoma cells", "PROBLEM", 0, 30], ["ATCC", "TEST", 32, 36], ["Calu", "TEST", 39, 43], ["human lung adenocarcinoma cells", "PROBLEM", 46, 77], ["ATCC", "TEST", 79, 83], ["NHDF", "PROBLEM", 90, 94], ["17 canine", "OBSERVATION_MODIFIER", 2, 11], ["osteosarcoma cells", "OBSERVATION", 12, 30], ["lung", "ANATOMY", 52, 56], ["adenocarcinoma cells", "OBSERVATION", 57, 77], ["human dermal fibroblasts", "OBSERVATION", 102, 126]]], ["The UMNSAH/DF-1 (DF-1) chicken fibroblast cell line (ATCC) was maintained in Dulbecco's Modified Eagle's Medium and 10% FBS.", [["UMNSAH/DF-1 (DF-1", "ANATOMY", 4, 21], ["fibroblast cell line", "ANATOMY", 31, 51], ["ATCC", "ANATOMY", 53, 57], ["FBS", "ANATOMY", 120, 123], ["UMNSAH/DF-1", "CELL", 4, 15], ["DF-1", "CELL", 17, 21], ["chicken", "ORGANISM", 23, 30], ["fibroblast cell line", "CELL", 31, 51], ["ATCC", "CELL", 53, 57], ["FBS", "ORGANISM_SUBSTANCE", 120, 123], ["UMNSAH/DF-1 (DF-1) chicken fibroblast cell line", "CELL_LINE", 4, 51], ["ATCC", "CELL_LINE", 53, 57], ["chicken", "SPECIES", 23, 30], ["chicken", "SPECIES", 23, 30], ["The UMNSAH/DF", "PROBLEM", 0, 13], ["chicken fibroblast cell line", "TREATMENT", 23, 51], ["fibroblast cell line", "OBSERVATION", 31, 51]]], ["All cell lines were cultured at 37\u00b0C in a humidified atmosphere containing 5% CO2, except DF-1 cells which were kept at 39\u00b0C. BALB 3T3 fibroblasts (subclone A31) were kindly provided by N. Pringle, University College, London, UK, and maintained in Dulbecco's Modified Eagle's Medium.Interferons ::: Materials and MethodsHuman and murine IFN-\u03b2 and human IFN-\u03bb (IL-29) were purchased from PBL InterferonSource (Piscataway, NJ).", [["cell lines", "ANATOMY", 4, 14], ["DF-1 cells", "ANATOMY", 90, 100], ["BALB 3T3 fibroblasts", "ANATOMY", 126, 146], ["subclone A31", "ANATOMY", 148, 160], ["CO2", "CHEMICAL", 78, 81], ["CO2", "CHEMICAL", 78, 81], ["cell lines", "CELL", 4, 14], ["C", "SIMPLE_CHEMICAL", 35, 36], ["CO2", "SIMPLE_CHEMICAL", 78, 81], ["DF-1 cells", "CELL", 90, 100], ["BALB 3T3 fibroblasts", "CELL", 126, 146], ["subclone A31", "CELL", 148, 160], ["murine", "ORGANISM", 330, 336], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 337, 342], ["human", "ORGANISM", 347, 352], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 353, 358], ["IL-29", "GENE_OR_GENE_PRODUCT", 360, 365], ["cell lines", "CELL_LINE", 4, 14], ["BALB 3T3 fibroblasts", "CELL_LINE", 126, 146], ["subclone A31", "CELL_LINE", 148, 160], ["Interferons", "PROTEIN", 283, 294], ["MethodsHuman and murine IFN-\u03b2", "PROTEIN", 313, 342], ["human IFN-\u03bb (IL-29", "PROTEIN", 347, 365], ["PBL", "CELL_TYPE", 387, 390], ["murine", "SPECIES", 330, 336], ["human", "SPECIES", 347, 352], ["human", "SPECIES", 347, 352], ["All cell lines", "TREATMENT", 0, 14], ["a humidified atmosphere", "TREATMENT", 40, 63], ["5% CO2", "TREATMENT", 75, 81], ["Materials", "TEST", 299, 308], ["MethodsHuman", "TREATMENT", 313, 325], ["murine IFN", "TEST", 330, 340], ["human IFN", "TEST", 347, 356], ["IL", "TEST", 360, 362], ["cell lines", "OBSERVATION", 4, 14]]], ["Recombinant porcine IFN-\u03b11 [24] was kindly provided by Nicolas Ruggli (IVI, Mittelh\u00e4usern, Switzerland).", [["porcine", "ORGANISM", 12, 19], ["IFN-\u03b11", "GENE_OR_GENE_PRODUCT", 20, 26], ["IFN", "PROTEIN", 20, 23], ["porcine", "SPECIES", 12, 19], ["Recombinant porcine IFN", "TREATMENT", 0, 23]]], ["Recombinant chicken IFN-\u03b1 [25] was kindly provided by Peter St\u00e4heli (University of Freiburg, Germany).", [["chicken", "ORGANISM", 12, 19], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 20, 25], ["IFN", "PROTEIN", 20, 23], ["chicken", "SPECIES", 12, 19], ["chicken", "SPECIES", 12, 19]]], ["Canine IFN-\u03b2 [26] was kindly provided by Philippe Plattet (Department of Clinical Research and Veterinary Public Health, University of Bern).Generation of VSV\u0394G(HA) containing 6 distinct transcription units (N-P-M-HA-eGFP-L) [28] was modified by replacing the influenza virus HA gene in the fourth position with eGFP taking advantage of MluI and BstEII endonuclease restriction sites upstream and downstream of the HA ORF, respectively.", [["Canine", "ORGANISM", 0, 6], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 7, 12], ["VSV\u0394G(HA)", "GENE_OR_GENE_PRODUCT", 155, 164], ["N-P-M-HA-eGFP-L) [28]", "GENE_OR_GENE_PRODUCT", 208, 229], ["eGFP", "GENE_OR_GENE_PRODUCT", 312, 316], ["MluI", "GENE_OR_GENE_PRODUCT", 337, 341], ["BstEII", "GENE_OR_GENE_PRODUCT", 346, 352], ["IFN", "PROTEIN", 7, 10], ["VSV\u0394G", "PROTEIN", 155, 160], ["HA", "PROTEIN", 161, 163], ["transcription units", "DNA", 187, 206], ["N-P-M-HA", "DNA", 208, 216], ["eGFP", "DNA", 217, 221], ["influenza virus HA gene", "DNA", 260, 283], ["eGFP", "DNA", 312, 316], ["MluI and BstEII endonuclease restriction sites", "DNA", 337, 383], ["HA ORF", "DNA", 415, 421], ["Canine", "SPECIES", 0, 6], ["influenza virus", "SPECIES", 260, 275], ["influenza virus", "SPECIES", 260, 275], ["VSV\u0394G(HA)", "TREATMENT", 155, 164], ["N-P-M-HA", "TEST", 208, 216], ["the influenza virus HA gene", "TREATMENT", 256, 283], ["MluI and BstEII endonuclease restriction", "TREATMENT", 337, 377], ["the HA ORF", "TREATMENT", 411, 421], ["influenza virus", "OBSERVATION", 260, 275]]], ["The firefly luciferase gene was amplified from the pBI-L plasmid (Clontech) by Pfu PCR and inserted into the fifth transcrition unit using XhoI and NheI endonuclease restriction sites.", [["luciferase", "GENE_OR_GENE_PRODUCT", 12, 22], ["Clontech", "GENE_OR_GENE_PRODUCT", 66, 74], ["XhoI", "GENE_OR_GENE_PRODUCT", 139, 143], ["NheI", "GENE_OR_GENE_PRODUCT", 148, 152], ["firefly luciferase gene", "DNA", 4, 27], ["pBI-L plasmid", "DNA", 51, 64], ["Clontech", "DNA", 66, 74], ["Pfu PCR", "DNA", 79, 86], ["fifth transcrition unit", "DNA", 109, 132], ["XhoI and NheI endonuclease restriction sites", "DNA", 139, 183], ["The firefly luciferase gene", "TEST", 0, 27], ["the pBI-L plasmid", "TREATMENT", 47, 64], ["XhoI", "TREATMENT", 139, 143], ["NheI endonuclease restriction sites", "TREATMENT", 148, 183]]], ["The resulting plasmid was designated pVSV\u0394G(Luc) replicon particles ::: Materials and MethodsFor generation of VSV\u0394G(Luc), 3 \u00b5g of pTM1-N, 5 \u00b5g of pTM1-P, and 2 \u00b5g of pTM1-L [28] using Lipofectamine\u2122 2000 transfection reagent (Invitrogen, Basel, Switzerland).", [["plasmid", "ANATOMY", 14, 21], ["pTM1-N", "CHEMICAL", 131, 137], ["pVSV\u0394G", "GENE_OR_GENE_PRODUCT", 37, 43], ["Luc", "ORGANISM", 44, 47], ["VSV\u0394G", "SIMPLE_CHEMICAL", 111, 116], ["Luc", "ORGANISM", 117, 120], ["pTM1-N", "SIMPLE_CHEMICAL", 131, 137], ["pTM1-P", "SIMPLE_CHEMICAL", 147, 153], ["pVSV\u0394G(Luc) replicon particles", "DNA", 37, 67], ["pTM1", "PROTEIN", 131, 135], ["pTM1", "PROTEIN", 147, 151], ["pTM1", "PROTEIN", 167, 171], ["The resulting plasmid", "TREATMENT", 0, 21], ["pTM1", "TEST", 131, 135], ["pTM1", "TEST", 147, 151], ["pTM1", "TEST", 167, 171], ["Lipofectamine\u2122 2000 transfection reagent", "TREATMENT", 185, 225]]], ["The cells were trypsinized 24 hours post transfection and seeded into T75 flasks along with an equal number of fresh BHK-G43 cells.", [["cells", "ANATOMY", 4, 9], ["BHK-G43 cells", "ANATOMY", 117, 130], ["cells", "CELL", 4, 9], ["BHK-G43 cells", "CELL", 117, 130], ["BHK-G43 cells", "CELL_LINE", 117, 130], ["transfection", "TREATMENT", 41, 53], ["G43 cells", "OBSERVATION", 121, 130]]], ["The cells were further incubated at 37\u00b0C for 24 hours in the presence of 10\u22129 M mifepristone.", [["cells", "ANATOMY", 4, 9], ["mifepristone", "CHEMICAL", 80, 92], ["mifepristone", "CHEMICAL", 80, 92], ["cells", "CELL", 4, 9], ["mifepristone", "SIMPLE_CHEMICAL", 80, 92], ["10\u22129 M mifepristone", "TREATMENT", 73, 92]]], ["The cell culture supernatant was clarified by low-speed centrifugation and passed through a 0.20-\u00b5m-pore size filter to deplete vaccinia virus.", [["cell culture supernatant", "ANATOMY", 4, 28], ["pore", "ANATOMY", 100, 104], ["cell", "CELL", 4, 8], ["vaccinia virus", "ORGANISM", 128, 142], ["vaccinia virus", "SPECIES", 128, 142], ["The cell culture", "TEST", 0, 16], ["low-speed centrifugation", "TREATMENT", 46, 70], ["a 0.20-\u00b5m-pore size filter", "TREATMENT", 90, 116], ["vaccinia virus", "PROBLEM", 128, 142], ["deplete vaccinia virus", "OBSERVATION", 120, 142]]], ["VSV\u0394G(Luc) replicon particles ::: Materials and MethodsMVA-T7 was titrated on DF-1 cells grown in 96-well microtiter plates.", [["DF-1 cells", "ANATOMY", 78, 88], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 0, 5], ["Luc", "GENE_OR_GENE_PRODUCT", 6, 9], ["DF-1 cells", "CELL", 78, 88], ["T7", "DNA", 59, 61], ["DF-1 cells", "CELL_LINE", 78, 88], ["Materials", "TEST", 34, 43], ["MethodsMVA-T7", "TREATMENT", 48, 61], ["DF", "TEST", 78, 80], ["T7", "ANATOMY", 59, 61]]], ["The cells were inoculated with tenfold serial virus dilutions for 90 min and overlayed with medium containing 0.9% methylcellulose.", [["cells", "ANATOMY", 4, 9], ["methylcellulose", "CHEMICAL", 115, 130], ["methylcellulose", "CHEMICAL", 115, 130], ["cells", "CELL", 4, 9], ["methylcellulose", "SIMPLE_CHEMICAL", 115, 130], ["tenfold serial virus dilutions", "TREATMENT", 31, 61], ["medium containing 0.9% methylcellulose", "TREATMENT", 92, 130]]], ["Following incubation for 48 h at 39\u00b0C, the cells were fixed with 3% paraformaldehyde, permeabilized with 0.25% Triton X-100, and subsequently incubated with the TW2.3 monoclonal antibody directed to the vaccinia E3L protein (kindly provided by Jonathan Yewdell, NIH, Bethesda, USA) and anti-mouse IgG conjugated to horseradish peroxidase (DAKO).", [["cells", "ANATOMY", 43, 48], ["Triton X-100", "CHEMICAL", 111, 123], ["paraformaldehyde", "CHEMICAL", 68, 84], ["cells", "CELL", 43, 48], ["paraformaldehyde", "SIMPLE_CHEMICAL", 68, 84], ["Triton X-100", "SIMPLE_CHEMICAL", 111, 123], ["vaccinia", "ORGANISM", 203, 211], ["E3L", "GENE_OR_GENE_PRODUCT", 212, 215], ["anti-mouse IgG conjugated to horseradish peroxidase", "GENE_OR_GENE_PRODUCT", 286, 337], ["DAKO", "GENE_OR_GENE_PRODUCT", 339, 343], ["TW2.3 monoclonal antibody", "PROTEIN", 161, 186], ["vaccinia E3L protein", "PROTEIN", 203, 223], ["anti-mouse IgG", "PROTEIN", 286, 300], ["horseradish peroxidase", "PROTEIN", 315, 337], ["DAKO", "PROTEIN", 339, 343], ["anti-mouse", "SPECIES", 286, 296], ["horseradish", "SPECIES", 315, 326], ["3% paraformaldehyde", "TREATMENT", 65, 84], ["0.25% Triton", "TREATMENT", 105, 117], ["the TW2.3 monoclonal antibody", "TREATMENT", 157, 186], ["the vaccinia E3L protein", "TREATMENT", 199, 223], ["anti-mouse IgG", "TREATMENT", 286, 300]]], ["Infected cell foci were visualized with the AEC peroxidase substrate and expressed as plaque-forming units per milliliter (pfu/ml).", [["cell foci", "ANATOMY", 9, 18], ["plaque", "ANATOMY", 86, 92], ["cell foci", "CELL", 9, 18], ["AEC peroxidase", "GENE_OR_GENE_PRODUCT", 44, 58], ["AEC peroxidase substrate", "PROTEIN", 44, 68], ["Infected cell foci", "PROBLEM", 0, 18], ["the AEC peroxidase substrate", "TEST", 40, 68], ["cell foci", "OBSERVATION", 9, 18], ["plaque", "OBSERVATION", 86, 92]]], ["Using this assay, the final VSV replicon particle preparations proved to be free of MVA-T7.Bioassays for determining antiviral activity ::: Materials and MethodsSerial twofold or fourfold dilutions of type I IFN were prepared with cell culture medium containing 5% FBS.", [["cell", "ANATOMY", 231, 235], ["FBS", "ANATOMY", 265, 268], ["VSV", "ORGANISM", 28, 31], ["type I IFN", "GENE_OR_GENE_PRODUCT", 201, 211], ["cell", "CELL", 231, 235], ["FBS", "ORGANISM_SUBSTANCE", 265, 268], ["type I IFN", "PROTEIN", 201, 211], ["VSV", "SPECIES", 28, 31], ["this assay", "TEST", 6, 16], ["the final VSV replicon particle preparations", "TREATMENT", 18, 62], ["Materials", "TREATMENT", 140, 149], ["MethodsSerial twofold or fourfold dilutions", "TREATMENT", 154, 197], ["type I IFN", "PROBLEM", 201, 211], ["cell culture medium", "TREATMENT", 231, 250], ["T7", "ANATOMY", 88, 90]]], ["The IFN dilutions (100 \u00b5l) were added in quadruplicates to confluent cells grown in 96-wells (5\u00d7104 cells/well) and incubated for either 1, 2, 4, or 20 hours at 39\u00b0C (DF-1 cells) or 37\u00b0C (all other cell lines).", [["cells", "ANATOMY", 69, 74], ["cells", "ANATOMY", 100, 105], ["DF-1 cells", "ANATOMY", 167, 177], ["cell lines", "ANATOMY", 198, 208], ["IFN", "CHEMICAL", 4, 7], ["cells", "CELL", 69, 74], ["cells", "CELL", 100, 105], ["DF-1 cells", "CELL", 167, 177], ["cell lines", "CELL", 198, 208], ["IFN", "PROTEIN", 4, 7], ["confluent cells", "CELL_LINE", 59, 74], ["5\u00d7104 cells", "CELL_LINE", 94, 105], ["The IFN dilutions", "TREATMENT", 0, 17], ["confluent cells", "TEST", 59, 74], ["DF", "TEST", 167, 169], ["confluent", "OBSERVATION_MODIFIER", 59, 68], ["cell lines", "OBSERVATION", 198, 208]]], ["The cells were infected with VSV\u0394G(Luc)-infected cell lysates.", [["cells", "ANATOMY", 4, 9], ["cell lysates", "ANATOMY", 49, 61], ["cells", "CELL", 4, 9], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 29, 34], ["Luc", "GENE_OR_GENE_PRODUCT", 35, 38], ["cell lysates", "CELL", 49, 61], ["infected cell lysates", "PROBLEM", 40, 61], ["infected", "OBSERVATION", 15, 23], ["infected cell lysates", "OBSERVATION", 40, 61]]], ["RLU+IFN represents the RLU values from IFN-treated cells and RLU\u2212IFN the readings taken from reference cells, which had not received any type I IFN.Bioassays for determining antiviral activity ::: Materials and MethodsA conventional type I IFN bioassay was performed by incubating 96-well cell cultures for 20 hours with twofold dilutions of type I IFN as described above.", [["cells", "ANATOMY", 51, 56], ["cells", "ANATOMY", 103, 108], ["cell cultures", "ANATOMY", 289, 302], ["IFN", "CHEMICAL", 39, 42], ["RLU+IFN", "GENE_OR_GENE_PRODUCT", 0, 7], ["IFN", "GENE_OR_GENE_PRODUCT", 39, 42], ["cells", "CELL", 51, 56], ["RLU\u2212IFN", "GENE_OR_GENE_PRODUCT", 61, 68], ["cells", "CELL", 103, 108], ["type I IFN", "GENE_OR_GENE_PRODUCT", 137, 147], ["cell cultures", "CELL", 289, 302], ["type I IFN", "GENE_OR_GENE_PRODUCT", 342, 352], ["RLU", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 4, 7], ["IFN-treated cells", "CELL_LINE", 39, 56], ["RLU", "PROTEIN", 61, 64], ["IFN", "PROTEIN", 65, 68], ["reference cells", "CELL_TYPE", 93, 108], ["type I IFN", "PROTEIN", 137, 147], ["IFN", "PROTEIN", 240, 243], ["96-well cell cultures", "CELL_LINE", 281, 302], ["type I IFN", "PROTEIN", 342, 352], ["RLU", "TEST", 0, 3], ["IFN", "PROBLEM", 4, 7], ["the RLU values", "TEST", 19, 33], ["IFN-treated cells", "TREATMENT", 39, 56], ["RLU\u2212IFN", "TREATMENT", 61, 68], ["Materials", "TREATMENT", 197, 206], ["MethodsA conventional type I IFN bioassay", "TREATMENT", 211, 252], ["type I IFN", "PROBLEM", 342, 352], ["IFN", "OBSERVATION", 4, 7]]], ["The cells were infected with propagation-competent VSV (m.o.i. of 1 pfu/cell) and incubated until a cytopathic effect (CPE) was evident in mock-treated control cells.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 72, 76], ["cells", "ANATOMY", 160, 165], ["cells", "CELL", 4, 9], ["VSV", "ORGANISM", 51, 54], ["cell", "CELL", 72, 76], ["cells", "CELL", 160, 165], ["mock-treated control cells", "CELL_LINE", 139, 165], ["VSV", "SPECIES", 51, 54], ["a cytopathic effect", "PROBLEM", 98, 117], ["CPE", "PROBLEM", 119, 122], ["infected", "OBSERVATION", 15, 23]]], ["The cells were washed twice with PBS and stained for 1 h with 0.1% crystal violet in 10% formalin.", [["cells", "ANATOMY", 4, 9], ["formalin", "CHEMICAL", 89, 97], ["formalin", "CHEMICAL", 89, 97], ["cells", "CELL", 4, 9], ["formalin", "SIMPLE_CHEMICAL", 89, 97], ["PBS", "TREATMENT", 33, 36], ["0.1% crystal violet", "TREATMENT", 62, 81]]], ["The plates were washed with tap water to remove excess crystal violet and dried.", [["The plates", "TREATMENT", 0, 10], ["tap water", "TREATMENT", 28, 37], ["excess crystal violet", "TREATMENT", 48, 69], ["plates", "OBSERVATION_MODIFIER", 4, 10], ["crystal violet", "OBSERVATION", 55, 69]]], ["The dye was dissolved by adding 100 \u00b5l of 70% ethanol to each well.", [["ethanol", "CHEMICAL", 46, 53], ["ethanol", "CHEMICAL", 46, 53], ["dye", "SIMPLE_CHEMICAL", 4, 7], ["ethanol", "SIMPLE_CHEMICAL", 46, 53], ["The dye", "TREATMENT", 0, 7]]], ["The absorbance of crystal violet at 595 nm was determined with a microplate reader.", [["crystal violet", "PROBLEM", 18, 32], ["a microplate reader", "TREATMENT", 63, 82], ["absorbance", "OBSERVATION_MODIFIER", 4, 14], ["crystal violet", "OBSERVATION", 18, 32]]], ["The IFN titer was calculated as the reciprocal of the last IFN dilution causing 50% inhibition of virus-induced CPE (50 % reduction of absorbance at 595 nm compared to mock-infected cells) and was expressed as IFN units per volume.", [["cells", "ANATOMY", 182, 187], ["IFN", "CHEMICAL", 59, 62], ["CPE", "CHEMICAL", 112, 115], ["IFN", "GENE_OR_GENE_PRODUCT", 4, 7], ["cells", "CELL", 182, 187], ["IFN", "PROTEIN", 4, 7], ["IFN", "PROTEIN", 59, 62], ["IFN", "PROTEIN", 210, 213], ["The IFN titer", "TEST", 0, 13], ["the last IFN dilution", "TREATMENT", 50, 71], ["virus", "PROBLEM", 98, 103], ["induced CPE", "PROBLEM", 104, 115], ["absorbance", "TEST", 135, 145]]], ["Alternatively, antiviral activity was calculated according to the following formula: Antiviral activity (%) = (OD595+IFN \u2013 OD595\u2212IFN)\u00d7100/(OD595Mock \u2013 OD595\u2212IFN).", [["IFN", "PROTEIN", 117, 120], ["OD595", "PROTEIN", 123, 128], ["IFN", "PROTEIN", 129, 132], ["IFN", "PROTEIN", 157, 160], ["antiviral activity", "PROBLEM", 15, 33], ["Antiviral activity", "TREATMENT", 85, 103], ["IFN", "TREATMENT", 117, 120]]], ["OD595+IFN and OD595\u2212IFN represent the absorbance of IFN-treated and non-treated cells following infection with VSV and staining with crystal violet, respectively.", [["cells", "ANATOMY", 80, 85], ["OD595", "CHEMICAL", 0, 5], ["OD595", "CHEMICAL", 14, 19], ["IFN", "CHEMICAL", 52, 55], ["infection", "DISEASE", 96, 105], ["OD595", "CHEMICAL", 0, 5], ["OD595+IFN", "GENE_OR_GENE_PRODUCT", 0, 9], ["OD595\u2212IFN", "GENE_OR_GENE_PRODUCT", 14, 23], ["IFN", "GENE_OR_GENE_PRODUCT", 52, 55], ["cells", "CELL", 80, 85], ["VSV", "ORGANISM", 111, 114], ["OD595", "PROTEIN", 0, 5], ["IFN", "PROTEIN", 6, 9], ["OD595", "PROTEIN", 14, 19], ["IFN", "PROTEIN", 20, 23], ["IFN-treated and non-treated cells", "CELL_LINE", 52, 85], ["VSV", "SPECIES", 111, 114], ["IFN", "TREATMENT", 6, 9], ["IFN", "TREATMENT", 20, 23], ["the absorbance of IFN", "PROBLEM", 34, 55], ["non-treated cells", "PROBLEM", 68, 85], ["infection", "PROBLEM", 96, 105], ["VSV", "PROBLEM", 111, 114], ["crystal violet", "TREATMENT", 133, 147], ["absorbance", "OBSERVATION_MODIFIER", 38, 48], ["infection", "OBSERVATION", 96, 105]]], ["OD595Mock denotes the absorbance of non-infected cells.Statistical analysis ::: Materials and MethodsMean values and standard deviation were calculated.", [["cells", "ANATOMY", 49, 54], ["OD595Mock", "SIMPLE_CHEMICAL", 0, 9], ["cells", "CELL", 49, 54], ["OD595Mock", "PROTEIN", 0, 9], ["non-infected cells", "CELL_TYPE", 36, 54], ["non-infected cells", "PROBLEM", 36, 54], ["MethodsMean values", "TEST", 94, 112], ["standard deviation", "TEST", 117, 135], ["absorbance", "OBSERVATION_MODIFIER", 22, 32], ["non-infected cells", "OBSERVATION", 36, 54]]], ["Statistical analysis was performed using the paired Student's t-test.", [["Statistical analysis", "TEST", 0, 20], ["the paired Student's t-test", "TEST", 41, 68]]], ["P<0.05 was considered significant.Generation of the VSV\u0394G(Luc), was propagated on BHK-G43 helper cells which express the VSV G protein in an inducible manner [23].", [["BHK-G43 helper cells", "ANATOMY", 82, 102], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 52, 57], ["Luc", "GENE_OR_GENE_PRODUCT", 58, 61], ["BHK-G43 helper cells", "CELL", 82, 102], ["VSV G protein", "GENE_OR_GENE_PRODUCT", 121, 134], ["VSV\u0394G", "DNA", 52, 57], ["Luc", "PROTEIN", 58, 61], ["BHK-G43 helper cells", "CELL_LINE", 82, 102], ["VSV G protein", "PROTEIN", 121, 134], ["VSV", "SPECIES", 121, 124], ["BHK", "TEST", 82, 85], ["the VSV G protein", "TEST", 117, 134]]], ["Up to 109 virus replicon particles (VRP) were released into the cell culture supernatant 24 h post infection (data not shown).", [["cell", "ANATOMY", 64, 68], ["supernatant", "ANATOMY", 77, 88], ["VRP", "CHEMICAL", 36, 39], ["infection", "DISEASE", 99, 108], ["VRP", "ORGANISM", 36, 39], ["cell", "CELL", 64, 68], ["virus replicon particles", "TREATMENT", 10, 34], ["the cell culture", "TEST", 60, 76], ["infection", "PROBLEM", 99, 108], ["infection", "OBSERVATION", 99, 108]]], ["Several mammalian and avian cells were found to be susceptible to infection with the VRPs in line with previous observations on the very broad cell tropism of VSV [29].", [["cells", "ANATOMY", 28, 33], ["cell", "ANATOMY", 143, 147], ["infection", "DISEASE", 66, 75], ["avian", "ORGANISM", 22, 27], ["cells", "CELL", 28, 33], ["cell", "CELL", 143, 147], ["VSV", "ORGANISM", 159, 162], ["mammalian and avian cells", "CELL_TYPE", 8, 33], ["VRPs", "DNA", 85, 89], ["VSV", "SPECIES", 159, 162], ["Several mammalian and avian cells", "PROBLEM", 0, 33], ["infection", "PROBLEM", 66, 75], ["the VRPs in line", "TREATMENT", 81, 97], ["avian cells", "OBSERVATION", 22, 33], ["infection", "OBSERVATION", 66, 75]]], ["Infected cells were readily detected (5 to 6 h post infection) by means of GFP reporter expression (Fig. 1b).", [["cells", "ANATOMY", 9, 14], ["infection", "DISEASE", 52, 61], ["cells", "CELL", 9, 14], ["GFP", "GENE_OR_GENE_PRODUCT", 75, 78], ["GFP reporter", "DNA", 75, 87], ["Infected cells", "PROBLEM", 0, 14], ["infection", "PROBLEM", 52, 61], ["cells", "OBSERVATION", 9, 14]]], ["However, non-helper cells were unable to complement the VSV G deletion and thus could not produce infectious progeny virus.", [["non-helper cells", "ANATOMY", 9, 25], ["non-helper cells", "CELL", 9, 25], ["VSV", "ORGANISM", 56, 59], ["G", "GENE_OR_GENE_PRODUCT", 60, 61], ["progeny virus", "ORGANISM", 109, 122], ["non-helper cells", "CELL_TYPE", 9, 25], ["VSV G deletion", "DNA", 56, 70], ["VSV", "SPECIES", 56, 59], ["non-helper cells", "PROBLEM", 9, 25], ["the VSV G deletion", "PROBLEM", 52, 70], ["infectious progeny virus", "PROBLEM", 98, 122], ["infectious", "OBSERVATION_MODIFIER", 98, 108]]], ["Importantly, VSV\u0394G(Luc) replicon ::: ResultsInfection of BHK-21 cells with VSV\u0394G(Luc)-infected cells depends on the replication/transcription levels of the RNA replicon.", [["BHK-21 cells", "ANATOMY", 57, 69], ["cells", "ANATOMY", 95, 100], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 13, 18], ["Luc", "GENE_OR_GENE_PRODUCT", 19, 22], ["BHK-21 cells", "CELL", 57, 69], ["VSV\u0394G(Luc)", "GENE_OR_GENE_PRODUCT", 75, 85], ["cells", "CELL", 95, 100], ["VSV\u0394G(Luc) replicon", "DNA", 13, 32], ["BHK-21 cells", "CELL_LINE", 57, 69], ["VSV\u0394G(Luc)-infected cells", "CELL_LINE", 75, 100], ["BHK", "TEST", 57, 60], ["VSV\u0394G", "TEST", 75, 80], ["infected cells", "PROBLEM", 86, 100], ["the replication", "TREATMENT", 112, 127], ["the RNA replicon", "TREATMENT", 152, 168], ["infected cells", "OBSERVATION", 86, 100], ["RNA replicon", "OBSERVATION", 156, 168]]], ["Thus, a reduction in viral genome replication as a consequence of type IFN action should lead to correspondingly lower luciferase levels.", [["type IFN", "GENE_OR_GENE_PRODUCT", 66, 74], ["luciferase", "GENE_OR_GENE_PRODUCT", 119, 129], ["viral genome", "DNA", 21, 33], ["IFN", "PROTEIN", 71, 74], ["luciferase", "PROTEIN", 119, 129], ["a reduction", "TREATMENT", 6, 17], ["viral genome replication", "TREATMENT", 21, 45], ["type IFN action", "PROBLEM", 66, 81], ["correspondingly lower luciferase levels", "PROBLEM", 97, 136], ["reduction", "OBSERVATION_MODIFIER", 8, 17], ["viral genome replication", "OBSERVATION", 21, 45]]], ["To test this hypothesis, normal human dermal fibroblasts (NHDF) were incubated for various time periods with serial dilutions of human IFN-\u03b2 before infection with VSV\u0394G(Luc) was also used to quantify the activities of porcine and chicken IFN-\u03b1.", [["dermal fibroblasts", "ANATOMY", 38, 56], ["NHDF", "ANATOMY", 58, 62], ["infection", "DISEASE", 148, 157], ["human", "ORGANISM", 32, 37], ["dermal fibroblasts", "CELL", 38, 56], ["NHDF", "CELL", 58, 62], ["human", "ORGANISM", 129, 134], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 135, 140], ["VSV\u0394G", "SIMPLE_CHEMICAL", 163, 168], ["Luc", "ORGANISM", 169, 172], ["porcine", "ORGANISM", 218, 225], ["chicken", "ORGANISM", 230, 237], ["normal human dermal fibroblasts", "CELL_TYPE", 25, 56], ["NHDF", "CELL_TYPE", 58, 62], ["human IFN-\u03b2", "PROTEIN", 129, 140], ["IFN", "PROTEIN", 238, 241], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 129, 134], ["porcine", "SPECIES", 218, 225], ["chicken", "SPECIES", 230, 237], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 129, 134], ["porcine", "SPECIES", 218, 225], ["chicken", "SPECIES", 230, 237], ["serial dilutions", "TREATMENT", 109, 125], ["human IFN", "TREATMENT", 129, 138], ["infection", "PROBLEM", 148, 157], ["VSV\u0394G(Luc", "TREATMENT", 163, 172], ["porcine and chicken IFN", "TREATMENT", 218, 241], ["dermal fibroblasts", "OBSERVATION", 38, 56]]], ["While the dose response curve of chicken IFN-\u03b1 on DF-1 chicken fibroblasts (Fig. 2b) was similar to the one of human IFN-\u03b2 on NHDF (Fig. 2a), porcine IFN-\u03b1 showed a different kinetics on PK-15 porcine kidney cells.", [["DF-1 chicken fibroblasts", "ANATOMY", 50, 74], ["kidney cells", "ANATOMY", 201, 213], ["chicken", "ORGANISM", 33, 40], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 41, 46], ["DF-1 chicken fibroblasts", "CELL", 50, 74], ["Fig. 2b", "CELL", 76, 83], ["human", "ORGANISM", 111, 116], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 117, 122], ["NHDF", "SIMPLE_CHEMICAL", 126, 130], ["porcine", "ORGANISM", 142, 149], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 150, 155], ["PK-15 porcine kidney cells", "CELL", 187, 213], ["chicken IFN-\u03b1", "PROTEIN", 33, 46], ["DF-1 chicken fibroblasts", "CELL_LINE", 50, 74], ["human IFN-\u03b2", "PROTEIN", 111, 122], ["NHDF", "PROTEIN", 126, 130], ["porcine IFN-\u03b1", "PROTEIN", 142, 155], ["PK-15 porcine kidney cells", "CELL_LINE", 187, 213], ["chicken", "SPECIES", 33, 40], ["chicken", "SPECIES", 55, 62], ["human", "SPECIES", 111, 116], ["porcine", "SPECIES", 193, 200], ["chicken", "SPECIES", 33, 40], ["chicken", "SPECIES", 55, 62], ["human", "SPECIES", 111, 116], ["chicken IFN", "TREATMENT", 33, 44], ["DF", "PROBLEM", 50, 52], ["human IFN", "TREATMENT", 111, 120], ["porcine IFN", "TEST", 142, 153], ["a different kinetics", "PROBLEM", 163, 183], ["PK", "TEST", 187, 189], ["porcine kidney cells", "TREATMENT", 193, 213], ["kidney", "ANATOMY", 201, 207]]], ["In these cells, a full antiviral state was accomplished only after 20 hours of treatment indicating that PK-15 cells respond rather slowly to the action of type I IFN (Fig. 2c).", [["cells", "ANATOMY", 9, 14], ["PK-15 cells", "ANATOMY", 105, 116], ["cells", "CELL", 9, 14], ["PK-15 cells", "CELL", 105, 116], ["type I IFN", "GENE_OR_GENE_PRODUCT", 156, 166], ["PK-15 cells", "CELL_LINE", 105, 116], ["type I IFN", "PROTEIN", 156, 166], ["treatment", "TREATMENT", 79, 88], ["PK", "TEST", 105, 107]]], ["Thus, the assay is applicable to type I IFN from different species but may perform differentially on distinct cell types.Quantification of type I IFN antiviral activity ::: ResultsTo further evaluate the bioassay, samples containing type I IFN of unknown activity were tested against a commercial IFN-\u03b2 standard and the results were compared with those obtained with a conventional IFN bioassay based on VSV cytotoxicity.", [["cell", "ANATOMY", 110, 114], ["samples", "ANATOMY", 214, 221], ["type I IFN", "GENE_OR_GENE_PRODUCT", 33, 43], ["cell", "CELL", 110, 114], ["type I IFN", "GENE_OR_GENE_PRODUCT", 139, 149], ["type I IFN", "GENE_OR_GENE_PRODUCT", 233, 243], ["VSV", "ORGANISM", 404, 407], ["type I IFN", "PROTEIN", 33, 43], ["IFN", "PROTEIN", 146, 149], ["type I IFN", "PROTEIN", 233, 243], ["IFN", "PROTEIN", 297, 300], ["IFN", "PROTEIN", 382, 385], ["VSV", "SPECIES", 404, 407], ["the assay", "TEST", 6, 15], ["type I IFN", "PROBLEM", 33, 43], ["different species", "PROBLEM", 49, 66], ["the bioassay", "TEST", 200, 212], ["a conventional IFN bioassay", "TEST", 367, 394], ["VSV cytotoxicity", "TREATMENT", 404, 420], ["distinct cell types", "OBSERVATION", 101, 120]]], ["Human type I IFN was induced in NHDF human fibroblasts following infection with VSVMq was inactivated for 30 min with 0.1 M HCl to avoid any interference with the bioassay (see also the section on thermal and pH stability of IFN).", [["NHDF", "ANATOMY", 32, 36], ["fibroblasts", "ANATOMY", 43, 54], ["infection", "DISEASE", 65, 74], ["VSVMq", "CHEMICAL", 80, 85], ["HCl", "CHEMICAL", 124, 127], ["HCl", "CHEMICAL", 124, 127], ["Human", "ORGANISM", 0, 5], ["type I IFN", "GENE_OR_GENE_PRODUCT", 6, 16], ["NHDF", "CELL", 32, 36], ["human", "ORGANISM", 37, 42], ["fibroblasts", "CELL", 43, 54], ["VSVMq", "SIMPLE_CHEMICAL", 80, 85], ["Human type I IFN", "PROTEIN", 0, 16], ["NHDF human fibroblasts", "CELL_LINE", 32, 54], ["IFN", "PROTEIN", 225, 228], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 37, 42], ["Human type I", "SPECIES", 0, 12], ["human", "SPECIES", 37, 42], ["VSVMq", "SPECIES", 80, 85], ["Human type I IFN", "PROBLEM", 0, 16], ["infection", "PROBLEM", 65, 74], ["VSVMq", "TREATMENT", 80, 85], ["any interference with the bioassay", "PROBLEM", 137, 171], ["infection", "OBSERVATION", 65, 74]]], ["When the VSV\u0394G(Luc) (Fig. 4a).", [["VSV\u0394G(Luc)", "DNA", 9, 19]]], ["In contrast, untreated cells or cells that had received type I IFN from a different species were not protected and showed GFP expression accordingly.", [["cells", "ANATOMY", 23, 28], ["cells", "ANATOMY", 32, 37], ["cells", "CELL", 23, 28], ["cells", "CELL", 32, 37], ["type I IFN", "GENE_OR_GENE_PRODUCT", 56, 66], ["GFP", "GENE_OR_GENE_PRODUCT", 122, 125], ["untreated cells", "CELL_TYPE", 13, 28], ["type I IFN", "PROTEIN", 56, 66], ["GFP", "PROTEIN", 122, 125], ["untreated cells or cells", "PROBLEM", 13, 37], ["type I IFN", "PROBLEM", 56, 66], ["a different species", "PROBLEM", 72, 91], ["untreated cells", "OBSERVATION", 13, 28]]], ["To compare the effects of different concentrations of homologous and heterologous type I IFN on human cells, we treated NHDF for 20 hours with serial dilutions of human, porcine, and murine type I IFN prior to infection with VSV\u0394G(Luc) bioassay.", [["cells", "ANATOMY", 102, 107], ["NHDF", "ANATOMY", 120, 124], ["NHDF", "CHEMICAL", 120, 124], ["infection", "DISEASE", 210, 219], ["type I IFN", "GENE_OR_GENE_PRODUCT", 82, 92], ["human", "ORGANISM", 96, 101], ["cells", "CELL", 102, 107], ["NHDF", "SIMPLE_CHEMICAL", 120, 124], ["human", "ORGANISM", 163, 168], ["porcine", "ORGANISM", 170, 177], ["murine", "ORGANISM", 183, 189], ["type I IFN", "GENE_OR_GENE_PRODUCT", 190, 200], ["Luc", "ORGANISM", 231, 234], ["heterologous type I IFN", "PROTEIN", 69, 92], ["human cells", "CELL_TYPE", 96, 107], ["murine type I IFN", "PROTEIN", 183, 200], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 163, 168], ["porcine", "SPECIES", 170, 177], ["murine", "SPECIES", 183, 189], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 163, 168], ["porcine", "SPECIES", 170, 177], ["different concentrations of homologous", "TREATMENT", 26, 64], ["heterologous type I IFN on human cells", "PROBLEM", 69, 107], ["serial dilutions of human, porcine, and murine type I IFN", "TREATMENT", 143, 200], ["infection", "PROBLEM", 210, 219]]], ["The antiviral activity of human IFN-\u03b2 was fully maintained when the cytokine was incubated for 30 min at 50\u00b0C (Fig. 5a).", [["human", "ORGANISM", 26, 31], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 32, 37], ["human IFN-\u03b2", "PROTEIN", 26, 37], ["cytokine", "PROTEIN", 68, 76], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["human IFN", "TREATMENT", 26, 35], ["antiviral activity", "OBSERVATION", 4, 22]]], ["At 70\u00b0C, the activity of human IFN-\u03b2 dropped to 83% (p = 0.0017).", [["human", "ORGANISM", 25, 30], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 31, 36], ["human IFN-\u03b2", "PROTEIN", 25, 36], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["human IFN", "TEST", 25, 34]]], ["Incubation at higher temperatures (80\u00b0C and 90\u00b0C) affected the activity more drastically, although some activity was still left at these temperatures.", [["Incubation", "TREATMENT", 0, 10]]], ["Only when human IFN-\u03b2 was heated to 100\u00b0C for 30 min, activity was completely abolished.", [["human", "ORGANISM", 10, 15], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 16, 21], ["human IFN-\u03b2", "PROTEIN", 10, 21], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15]]], ["In contrast to human IFN-\u03b2, porcine IFN-\u03b1 was completely inactivated at 70\u00b0C (p<0.0001), whereas human IFN-\u03bb (IL-29), a type III IFN, showed even higher residual activity at 80\u00b0C and 90\u00b0C (p<0.001), suggesting that these cytokines have different physicochemical properties.Thermal and pH stability of type I and type III IFN ::: ResultsTo study the sensitivity of type I and type III IFNs to conditions of extreme pH, human IFN-\u03b2 and human IFN-\u03bb were treated for 30 min with either 0.1 M HCl, 0.1 M NaOH or H2O, adjusted to neutral pH, and assayed on NHDF and Calu-3 cells, respectively.", [["NHDF", "ANATOMY", 551, 555], ["Calu-3 cells", "ANATOMY", 560, 572], ["HCl", "CHEMICAL", 488, 491], ["NaOH", "CHEMICAL", 499, 503], ["H2O", "CHEMICAL", 507, 510], ["HCl", "CHEMICAL", 488, 491], ["NaOH", "CHEMICAL", 499, 503], ["H2O", "CHEMICAL", 507, 510], ["human", "ORGANISM", 15, 20], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 21, 26], ["porcine", "ORGANISM", 28, 35], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 36, 41], ["human", "ORGANISM", 97, 102], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 103, 108], ["IL-29", "GENE_OR_GENE_PRODUCT", 110, 115], ["type III IFN", "GENE_OR_GENE_PRODUCT", 120, 132], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 375, 388], ["human", "ORGANISM", 418, 423], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 424, 429], ["human", "ORGANISM", 434, 439], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 440, 445], ["H2O", "SIMPLE_CHEMICAL", 507, 510], ["NHDF", "CELL", 551, 555], ["Calu-3 cells", "CELL", 560, 572], ["human IFN-\u03b2", "PROTEIN", 15, 26], ["porcine IFN-\u03b1", "PROTEIN", 28, 41], ["human IFN-\u03bb (IL-29", "PROTEIN", 97, 115], ["type III IFN", "PROTEIN", 120, 132], ["cytokines", "PROTEIN", 221, 230], ["IFN", "PROTEIN", 321, 324], ["type I and type III IFNs", "PROTEIN", 364, 388], ["human IFN-\u03b2", "PROTEIN", 418, 429], ["human IFN-\u03bb", "PROTEIN", 434, 445], ["NHDF", "CELL_TYPE", 551, 555], ["Calu-3 cells", "CELL_LINE", 560, 572], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 418, 423], ["human", "SPECIES", 434, 439], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 418, 423], ["human", "SPECIES", 434, 439], ["porcine IFN", "TEST", 28, 39], ["human IFN", "TEST", 97, 106], ["IL", "TEST", 110, 112], ["a type III IFN", "TEST", 118, 132], ["higher residual activity", "PROBLEM", 146, 170], ["these cytokines", "PROBLEM", 215, 230], ["type I and type III IFNs", "PROBLEM", 364, 388], ["extreme pH", "PROBLEM", 406, 416], ["human IFN", "TEST", 418, 427], ["human IFN", "TREATMENT", 434, 443], ["H2O", "TREATMENT", 507, 510], ["neutral pH", "TEST", 524, 534], ["NHDF", "TEST", 551, 555], ["higher", "OBSERVATION_MODIFIER", 146, 152], ["residual activity", "OBSERVATION", 153, 170], ["physicochemical properties", "OBSERVATION", 246, 272], ["pH stability", "OBSERVATION_MODIFIER", 285, 297]]], ["It turned out that the antiviral activity of human IFN-\u03b2 was not significantly affected by acid (p>0.05) (Fig. 5b), confirming the previously noted acid-stability of type I IFNs [31].", [["human", "ORGANISM", 45, 50], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 51, 56], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 166, 177], ["human IFN-\u03b2", "PROTEIN", 45, 56], ["type I IFNs", "PROTEIN", 166, 177], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["human IFN", "TEST", 45, 54], ["type I IFNs", "PROBLEM", 166, 177]]], ["IFN-\u03bb showed similar properties as antiviral activity was maintained following treatment with 0.1 M HCl (Fig. 5c).", [["HCl", "CHEMICAL", 100, 103], ["HCl", "CHEMICAL", 100, 103], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN", "PROTEIN", 0, 3], ["\u03bb", "PROTEIN", 4, 5], ["IFN", "TEST", 0, 3], ["antiviral activity", "TREATMENT", 35, 53], ["treatment", "TREATMENT", 79, 88]]], ["In contrast, alkaline treatment significantly reduced the activity of IFN-\u03bb (p<0.05 for the 250 \u2212 1 ng/ml range), whereas IFN-\u03b2 was not affected (p>0.05) (Fig. 5b).", [["alkaline", "SIMPLE_CHEMICAL", 13, 21], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 70, 75], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 122, 127], ["IFN", "PROTEIN", 70, 73], ["IFN", "PROTEIN", 122, 125], ["alkaline treatment", "TREATMENT", 13, 31], ["IFN", "TEST", 70, 73], ["IFN", "TEST", 122, 125]]], ["Thus, treatment with acid may be employed to inactivate virus in a test sample without affecting the activity of type I and type III IFNs.", [["sample", "ANATOMY", 72, 78], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 124, 137], ["type I and type III IFNs", "PROTEIN", 113, 137], ["acid", "TREATMENT", 21, 25], ["virus", "PROBLEM", 56, 61], ["a test sample", "TEST", 65, 78], ["type I and type III IFNs", "PROBLEM", 113, 137]]], ["On the other hand, alkaline may be used to differentiate between type I and type III IFNs.DiscussionConventional bioassays take advantage of the antiviral activity of type I IFN to measure the inhibition of virus-induced cytopathic effects in cell culture [14].", [["cell", "ANATOMY", 243, 247], ["alkaline", "SIMPLE_CHEMICAL", 19, 27], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 76, 89], ["type I IFN", "GENE_OR_GENE_PRODUCT", 167, 177], ["cell", "CELL", 243, 247], ["type I and type III IFNs", "PROTEIN", 65, 89], ["type I IFN", "PROTEIN", 167, 177], ["alkaline", "TREATMENT", 19, 27], ["type I and type III IFNs", "PROBLEM", 65, 89], ["Conventional bioassays", "TREATMENT", 100, 122], ["the antiviral activity of type I IFN", "TREATMENT", 141, 177], ["the inhibition of virus", "PROBLEM", 189, 212], ["cytopathic effects", "PROBLEM", 221, 239], ["cell culture", "TEST", 243, 255], ["cytopathic", "OBSERVATION_MODIFIER", 221, 231]]], ["In this study, we presented an improved bioassay by employing a recombinant VSV replicon equipped with two reporter proteins.", [["VSV", "ORGANISM", 76, 79], ["reporter proteins", "PROTEIN", 107, 124], ["VSV", "SPECIES", 76, 79], ["this study", "TEST", 3, 13], ["a recombinant VSV replicon", "TREATMENT", 62, 88]]], ["This assay proved to be advantageous over the conventional assay with respect to biosafety, sensitivity, and time requirements.DiscussionThe use of cytopathic viruses in conventional type I IFN bioassays makes appropriate biosafety measures necessary to reduce the risk of unwanted virus transmission and infection.", [["infection", "DISEASE", 305, 314], ["This assay", "TEST", 0, 10], ["sensitivity", "TEST", 92, 103], ["cytopathic viruses", "PROBLEM", 148, 166], ["conventional type I IFN bioassays", "TREATMENT", 170, 203], ["appropriate biosafety measures", "TREATMENT", 210, 240], ["unwanted virus transmission", "PROBLEM", 273, 300], ["infection", "PROBLEM", 305, 314], ["infection", "OBSERVATION", 305, 314]]], ["In this regard, the VSV\u0394G(Luc) is propagated on helper cells providing the G glycoprotein in trans[23].", [["helper cells", "ANATOMY", 48, 60], ["VSV\u0394G", "GENE_OR_GENE_PRODUCT", 20, 25], ["Luc", "GENE_OR_GENE_PRODUCT", 26, 29], ["helper cells", "CELL", 48, 60], ["G glycoprotein", "GENE_OR_GENE_PRODUCT", 75, 89], ["VSV\u0394G", "DNA", 20, 25], ["Luc", "PROTEIN", 26, 29], ["helper cells", "CELL_TYPE", 48, 60], ["G glycoprotein", "PROTEIN", 75, 89], ["helper cells", "TREATMENT", 48, 60], ["the G glycoprotein in trans", "TREATMENT", 71, 98]]], ["The replicon particles produced on these cells can run a single cycle of infection but cannot produce any infectious progeny [28].", [["cells", "ANATOMY", 41, 46], ["infection", "DISEASE", 73, 82], ["cells", "CELL", 41, 46], ["The replicon particles", "TREATMENT", 0, 22], ["infection", "PROBLEM", 73, 82], ["replicon particles", "OBSERVATION", 4, 22], ["infection", "OBSERVATION", 73, 82]]], ["Another aspect contributing to biosafety is that the RNA replicon replicates exclusively in the cytosol and does not produce cDNA intermediates.", [["cytosol", "ANATOMY", 96, 103], ["cytosol", "CELLULAR_COMPONENT", 96, 103], ["the RNA replicon", "TREATMENT", 49, 65], ["biosafety", "OBSERVATION", 31, 40]]], ["Thus, in the case of an accidental infection any risk of recombination with or integration into host chromosomal DNA can be excluded.DiscussionVirus preparations that are used for IFN bioassays must not contain any type I IFN which may distort the results.", [["chromosomal", "ANATOMY", 101, 112], ["infection", "DISEASE", 35, 44], ["chromosomal", "CELLULAR_COMPONENT", 101, 112], ["DNA", "CELLULAR_COMPONENT", 113, 116], ["type I IFN", "GENE_OR_GENE_PRODUCT", 215, 225], ["host chromosomal DNA", "DNA", 96, 116], ["IFN", "PROTEIN", 180, 183], ["type I IFN", "PROTEIN", 215, 225], ["an accidental infection", "PROBLEM", 21, 44], ["integration into host chromosomal DNA", "PROBLEM", 79, 116], ["DiscussionVirus preparations", "TREATMENT", 133, 161], ["IFN bioassays", "TREATMENT", 180, 193], ["infection", "OBSERVATION", 35, 44], ["can be excluded", "UNCERTAINTY", 117, 132]]], ["In addition, the viruses should not induce IFN in infected reporter cells to assure that the effects measured are solely due to the exogenous IFN added.", [["cells", "ANATOMY", 68, 73], ["IFN", "CHEMICAL", 142, 145], ["IFN", "GENE_OR_GENE_PRODUCT", 43, 46], ["cells", "CELL", 68, 73], ["IFN", "GENE_OR_GENE_PRODUCT", 142, 145], ["IFN", "PROTEIN", 43, 46], ["infected reporter cells", "CELL_TYPE", 50, 73], ["IFN", "PROTEIN", 142, 145], ["the viruses", "PROBLEM", 13, 24], ["IFN in infected reporter cells", "PROBLEM", 43, 73], ["the exogenous IFN", "TREATMENT", 128, 145], ["viruses", "OBSERVATION", 17, 24]]], ["Both criteria are fulfilled for VSV\u0394G(Luc) for 5 hours was sufficient to suppress firefly reporter expression by 50%, even though the effective dose was further lowered with longer incubation times.", [["VSV\u0394G", "PROTEIN", 32, 37], ["Luc", "PROTEIN", 38, 41]]], ["While DF-1 fibroblasts responded to chicken IFN-\u03b1 with dose response kinetics similar to the one observed with human IFN-\u03b2 on NHDF, PK-15 cells responded to porcine type I IFN in a much slower way.", [["DF-1 fibroblasts", "ANATOMY", 6, 22], ["NHDF", "ANATOMY", 126, 130], ["PK-15 cells", "ANATOMY", 132, 143], ["DF-1 fibroblasts", "CELL", 6, 22], ["chicken", "ORGANISM", 36, 43], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 44, 49], ["human", "ORGANISM", 111, 116], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 117, 122], ["NHDF", "CELL", 126, 130], ["PK-15 cells", "CELL", 132, 143], ["porcine", "ORGANISM", 157, 164], ["type I IFN", "GENE_OR_GENE_PRODUCT", 165, 175], ["DF-1 fibroblasts", "CELL_LINE", 6, 22], ["chicken IFN-\u03b1", "PROTEIN", 36, 49], ["human IFN-\u03b2", "PROTEIN", 111, 122], ["PK-15 cells", "CELL_LINE", 132, 143], ["porcine type I IFN", "PROTEIN", 157, 175], ["chicken", "SPECIES", 36, 43], ["human", "SPECIES", 111, 116], ["chicken", "SPECIES", 36, 43], ["human", "SPECIES", 111, 116], ["fibroblasts", "PROBLEM", 11, 22], ["chicken IFN", "TREATMENT", 36, 47], ["dose response kinetics", "PROBLEM", 55, 77], ["human IFN", "TREATMENT", 111, 120], ["NHDF", "TREATMENT", 126, 130], ["PK", "TEST", 132, 134]]], ["Thus, compared to conventional bioassays VSV\u0394G(Luc) replicon assay, it was possible to quantify the antiviral activity of IFN-\u03bb (Il-29), a type III IFN.", [["VSV\u0394G", "SIMPLE_CHEMICAL", 41, 46], ["Luc", "GENE_OR_GENE_PRODUCT", 47, 50], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 122, 127], ["Il-29", "GENE_OR_GENE_PRODUCT", 129, 134], ["type III IFN", "GENE_OR_GENE_PRODUCT", 139, 151], ["IFN", "PROTEIN", 122, 125], ["\u03bb", "PROTEIN", 126, 127], ["Il-29", "PROTEIN", 129, 134], ["type III IFN", "PROTEIN", 139, 151], ["conventional bioassays", "TEST", 18, 40], ["replicon assay", "TEST", 52, 66], ["IFN", "TEST", 122, 125], ["Il", "TEST", 129, 131], ["antiviral activity", "OBSERVATION", 100, 118]]], ["This raises the important question of how to distinguish between different antiviral cytokines?", [["antiviral cytokines", "PROTEIN", 75, 94], ["different antiviral cytokines", "TREATMENT", 65, 94], ["antiviral cytokines", "OBSERVATION", 75, 94]]], ["Certainly, neutralizing antibodies may be employed to specify the antiviral cytokine present in the sample.", [["sample", "ANATOMY", 100, 106], ["neutralizing antibodies", "PROTEIN", 11, 34], ["antiviral cytokine", "PROTEIN", 66, 84], ["neutralizing antibodies", "TREATMENT", 11, 34], ["the antiviral cytokine", "TREATMENT", 62, 84]]], ["In addition, the extraordinary acid-stability of type I IFNs may be used to differentiate them from acid-labile cytokines such as type II IFNs [35].", [["type I IFNs", "GENE_OR_GENE_PRODUCT", 49, 60], ["type II IFNs", "GENE_OR_GENE_PRODUCT", 130, 142], ["type I IFNs", "PROTEIN", 49, 60], ["acid-labile cytokines", "PROTEIN", 100, 121], ["type II IFNs", "PROTEIN", 130, 142], ["type I IFNs", "PROBLEM", 49, 60], ["acid-labile cytokines", "PROBLEM", 100, 121], ["type II IFNs", "PROBLEM", 130, 142]]], ["However, acid may not be used to distinguish between type I and type III IFNs as IFN-\u03bb proved to be acid-stable as well.", [["type III IFNs", "GENE_OR_GENE_PRODUCT", 64, 77], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 81, 86], ["type I and type III IFNs", "PROTEIN", 53, 77], ["IFN", "PROTEIN", 81, 84], ["\u03bb", "PROTEIN", 85, 86], ["type I and type III IFNs", "PROBLEM", 53, 77], ["IFN", "TEST", 81, 84]]], ["Since IFN-\u03bb but not IFN-\u03b2 was sensitive to 0.1 M NaOH, treatment with alkaline may be used instead.", [["NaOH", "CHEMICAL", 49, 53], ["NaOH", "CHEMICAL", 49, 53], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 6, 11], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 20, 25], ["NaOH", "SIMPLE_CHEMICAL", 49, 53], ["alkaline", "SIMPLE_CHEMICAL", 70, 78], ["IFN", "PROTEIN", 6, 9], ["\u03bb", "PROTEIN", 10, 11], ["IFN-\u03b2", "PROTEIN", 20, 25], ["IFN", "TEST", 6, 9], ["IFN", "TEST", 20, 23], ["treatment", "TREATMENT", 55, 64], ["alkaline", "TREATMENT", 70, 78]]], ["However, the conditions of treatment still have to be optimized to guarantee the complete inactivation of type III IFNs while maintaining the activity of type I IFNs.DiscussionIn addition to antiviral cytokines, test samples may also contain unknown viruses that potentially interfere with the bioassay.", [["samples", "ANATOMY", 217, 224], ["type III IFNs", "GENE_OR_GENE_PRODUCT", 106, 119], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 154, 165], ["type III IFNs", "PROTEIN", 106, 119], ["type I IFNs", "PROTEIN", 154, 165], ["antiviral cytokines", "PROTEIN", 191, 210], ["treatment", "TREATMENT", 27, 36], ["type III IFNs", "TREATMENT", 106, 119], ["antiviral cytokines", "TREATMENT", 191, 210], ["test samples", "TEST", 212, 224], ["unknown viruses", "PROBLEM", 242, 257], ["viruses", "OBSERVATION", 250, 257]]], ["Treatment with heat or acid may be used to inactivate these viruses without affecting the bioactivity of type I and type III IFNs.", [["type III IFNs", "GENE_OR_GENE_PRODUCT", 116, 129], ["type I and type III IFNs", "PROTEIN", 105, 129], ["heat or acid", "TREATMENT", 15, 27], ["these viruses", "PROBLEM", 54, 67], ["type I and type III IFNs", "PROBLEM", 105, 129]]], ["However, as heat-inactivated influenza viruses still may be able to induce type I IFN [36], virus inactivation by acid may be more convenient.DiscussionThe correct and reliable determination of type I IFN biological activity is an important issue.", [["influenza viruses", "DISEASE", 29, 46], ["influenza viruses", "ORGANISM", 29, 46], ["type I IFN", "GENE_OR_GENE_PRODUCT", 75, 85], ["type I IFN", "GENE_OR_GENE_PRODUCT", 194, 204], ["IFN", "PROTEIN", 201, 204], ["inactivated influenza viruses", "PROBLEM", 17, 46], ["type I IFN", "PROBLEM", 75, 85], ["virus inactivation", "TREATMENT", 92, 110], ["type I IFN biological activity", "PROBLEM", 194, 224]]], ["The new bioassay presented in this study represents an attractive alternative to conventional type I IFN bioassays that work with cytotoxic live viruses.", [["this study", "TEST", 30, 40], ["conventional type I IFN bioassays", "PROBLEM", 81, 114], ["cytotoxic live viruses", "PROBLEM", 130, 152], ["new", "OBSERVATION_MODIFIER", 4, 7], ["bioassay", "OBSERVATION", 8, 16]]], ["VSV*\u0394G(Luc) is easily produced and handled under BSL-1 conditions.", [["VSV", "ORGANISM", 0, 3], ["\u0394G", "GENE_OR_GENE_PRODUCT", 4, 6], ["Luc", "GENE_OR_GENE_PRODUCT", 7, 10], ["VSV", "SPECIES", 0, 3]]], ["The activity of the replicon can be easily determined and standardized taking advantage of the two reporter proteins.", [["reporter proteins", "PROTEIN", 99, 116], ["the replicon", "TREATMENT", 16, 28]]], ["Finally, the proven sensitivity, rapidity, and accurateness of the assay recommends it for the determination of type I IFN from a number of mammalian and avian species.", [["type I IFN", "GENE_OR_GENE_PRODUCT", 112, 122], ["avian", "ORGANISM", 154, 159], ["type I IFN", "PROTEIN", 112, 122], ["rapidity", "TEST", 33, 41], ["the assay", "TEST", 63, 72], ["type I IFN", "PROBLEM", 112, 122], ["mammalian and avian species", "PROBLEM", 140, 167], ["avian species", "OBSERVATION", 154, 167]]], ["Finally, the test may be further developed to quantify the antiviral activity of other cytokines such as type II and type III IFNs.", [["type III IFNs", "GENE_OR_GENE_PRODUCT", 117, 130], ["cytokines", "PROTEIN", 87, 96], ["type II and type III IFNs", "PROTEIN", 105, 130], ["the test", "TEST", 9, 17], ["other cytokines", "PROBLEM", 81, 96], ["type II and type III IFNs", "PROBLEM", 105, 130]]]]}